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Abstract 
Colorectal cancer (CRC) is one of the most common cancers worldwide with over a million new cases 
each year, and evidence implicates chronic inflammation as a risk factor for developing CRC. 
Inflammatory conditions place stresses on bacteria composing the human gut microbiota and alter 
the composition of the gut microbiota in favour of pathobiont Escherichia coli (E. coli), with resultant 
expansion of these bacteria increasing their interactions with the gut mucosa. Mucosa-associated  
E. coli have been found in high numbers within intestinal tissue taken from IBD and CRC patients. 
Pro-inflammatory cytokines such as cyclooxygenase-2 (COX-2) are commonly implicated in 
inflammatory disease, and can be released upon tissue damage or following infection. COX-2-driven 
prostaglandin E2 (PGE2) increases are believed to activate the cancer-related Wnt signalling pathway, 
with accumulation and subsequent nuclear translocation of the key Wnt protein β-catenin aiding 
proliferation, migration and metastasis. With COX-2 implicated in CRC development and progression 
and a cascade for COX-2 and PGE2 stimulating cancer cell growth via Wnt activation, mucosa-
associated E. coli infection could lead to sustained increases in Wnt signalling. In addition, as mucosa-
associated E. coli strains isolated from CRC patients can survive and replicate within human 
macrophages and increase COX-2 and PGE2 secretion, this could enhance their tumourigenic effects. 
The aim of this project was to characterise the effects of mucosa-associated E. coli isolates from CRC 
and IBD patients on the activation of the Wnt signalling pathway both in vitro and in vivo.  We first 
used CRC cell lines and human macrophage cells to assess the effects of mucosa-associated E. coli 
infections. We show consistent increases in total and nuclear localised β-catenin at both the gene and 
protein level in vitro, and have shown that this correlates with increased COX-2 gene and protein 
levels. Downstream Wnt transcription was shown following infection, and this was inhibited by the 
addition of a COX-2 inhibitor. We also showed increased release of PGE2 from macrophages infected 
with mucosa-associated E. coli, which could be a contributing factor in driving the Wnt response in 
neighbouring intestinal epithelial cells. To investigate these effects in vivo, we used colonic tissue from 
V 
 
a germ-free Il10-/- mouse model of CRC mucosa-associated E. coli infection to determine COX-2 and 
Wnt pathway activation. Following mono-association of germ-free Il10-/- mice with a CRC mucosa-
associated E. coli isolate, significant increases in COX-2 and β-catenin protein expression and increased 
levels of β-catenin nuclear localisation were observed. 
To further investigate changes in COX-2 and Wnt signalling, we used a fosmid library of 968 clones 
created from the fragmented DNA of another mucosa-associated E. coli isolate from a CRC patient to 
confirm up-regulation of COX-2 gene expression following infection of CRC cells with fosmid clones. 
We identified 12 fosmid clones showing confirmed COX-2 gene expression increases, and sequenced 
the DNA content of all 12 fosmid clones to find common genes or operons that may be contributing 
towards these expression changes. Sequencing showed similarities in DNA content, with particularly 
common homology in two fosmids containing genes involved in growth and survival, particularly in 
high-stress inflammatory conditions. This data may aid identification of genes or operons that 
contribute to the induction of COX-2 and Wnt signalling observed in vitro and in vivo. 
We were also able to develop a 3D organotypic cell culture using a series of colorectal cell lines at 
different key stages of malignant transformation in the adenoma-carcinoma pathway. Successful 3D 
aggregate cultures were achieved, and data obtained from infecting these aggregates would suggest 
that this method of culture is suitable for studying mucosa-associated E. coli-host epithelium 
interactions, and confirmed data previously obtained by infection of 2D monolayer CRC cell cultures 
and those responses seen in an in vivo gut infection model. 
Our study supports the hypothesis that mucosa-associated E. coli isolates from CRC and IBD patients 
can activate the Wnt signalling pathway both in vitro and in vivo, and provides further evidence 
towards mucosa-associated E. coli isolates upregulating pro-inflammatory COX-2 and PGE2 release in 
the gut. This suggests translational effects that might be seen in patients, which indicates a role for 
mucosa-associated E. coli, in the development and progression of colorectal cancer via increased Wnt 
signalling. 
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1.1 Introduction to colorectal cancer 
Colorectal cancer (CRC) is one of the most common cancers worldwide with over a million new cases 
each year. Incidence rates differ geographically, with the lowest rates in less developed regions such 
as Africa and Central America, with the highest in more developed regions such as Australasia, Europe 
and North America (Gellad and Provenzale, 2010). CRC contributes to approximately 600,000 deaths 
worldwide each year, making it the fourth most common cause of death from cancer (Ferlay et al., 
2010), with more than 1.1 million deaths per year expected by 2030 (Arnold et al., 2017). 
The majority of CRC cases are now known to originate from colonic polyps, masses of hyper-
proliferating epithelial cells lining the colon, before progressing into carcinomas (Williams et al., 2013). 
Adenomatous polyps account for half of all colorectal polyps, with the amount and size of polyps 
present being indicators of increased risk of development of CRC (Williams et al., 2013). Some new 
cases occur in those with a family history of CRC – previous adenomatous polyps or CRC, or 
inflammatory bowel disease (IBD) that predisposes to CRC (Winawer et al., 1997, Fearon, 1995), but 
at least 70% of all new CRC cases occur with no known predisposing factors, known as sporadic CRC. 
Familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC) account 
for the majority of highly penetrant, high-risk hereditary cases. FAP is attributed to APC gene 
mutations, associated with abnormal proliferative Wnt signalling, causing individuals to develop 
adenomatous polyps throughout the colon. These individuals have an almost 100% chance of 
developing colorectal cancer (Dunlop et al., 2002). HNPCC is a disorder caused by mutations of DNA 
mismatch repair (MMR) genes causing abnormal functioning, which increases both the risk and 
penetrance of CRC (Balmana et al., 2013). Colectomy is recommended as a form of prophylaxis for 
those considered high risk for CRC, but this leaves the rectum intact with patients at an increased risk 
for rectal cancer development (Van Cutsem et al., 2009b), so adjuvant therapies are required. 
With between 70% and 95% of CRC cases being sporadic – occurring with no known predisposing 
factors – the approach to chemoprevention and treatment becomes much more convoluted (Butler 
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and Roberts-Thomson, 2004). Sporadic CRC can involve a number of different genetic alterations 
caused by mutations and epigenetic changes (Dubois, 2014). The classic examples of genetic alteration 
are mutations of the KRAS oncogene at the early adenoma stage leading to increased MAPK signalling, 
p53 tumour suppressor mutations shown to facilitate malignancy, and again mutations of the APC 
gene as an initiating event. APC mutations are common to both hereditary and sporadic forms of CRC, 
causing deregulated Wnt signalling, highlighting a common link. 
Due to a lack of known predisposing factors in sporadic cases they are currently treated similar to 
hereditary cases, where colectomy can be used as a prophylactic or resection treatment followed by 
suppression of secondary sites using adjuvant therapy. With sporadic forms of CRC accounting for the 
majority of cases, a lot of effort is going into understanding the molecular events sustaining it as well 
as the relatively recent implications of chronic inflammation. 
Chronic inflammation is a risk factor for developing CRC, with inflammatory bowel diseases (IBD), 
ulcerative colitis and Crohn’s disease, associated with an increased risk of CRC (Renz et al., 2013, Eaden 
et al., 2001, Ohman, 1982, Jess et al., 2005). The risk associated with IBD is thought to be genetically 
acquired, but IBD-associated cancers differ from sporadic and hereditary cases in that they typically 
arise due to lack of proper differentiation of epithelial cells from a flat mucosa (Rhodes and Campbell, 
2002). Both APC and p53 mutations are present in both IBD-associated and sporadic CRC cases at 
different stages of CRC progression, suggesting biological features of IBD-associated and sporadic CRC 
overlap (see Figure 1.3). Altered Wnt signalling due to APC mutations occurs late in the sequence from 
dysplasia to cancer. The genetic alterations seen in common sporadic and IBD-associated CRC cases 
are widely similar, but these changes have been shown to occur at different stages of carcinogenesis 
(Rhodes and Campbell, 2002). 
1.2 Staging and treatment of colorectal cancer 
Current clinically recommended treatments for CRC focus on preventing the hyper-proliferation of 
intestinal epithelial cells. Advances in the treatment of primary CRC have significantly reduced CRC-
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related deaths, and advances in the treatment of advanced and metastatic CRC has significantly 
improved disease-free survival (Winawer et al., 2003, Recondo et al., 2014). However, the lack of 
distinction between treatment of patients at high risk due to hereditary disease, sporadic cases linked 
to genetic abnormalities and patients at increased risk associated with inflammatory bowel disease 
(IBD) is concerning. The next step forward for adjuvant therapy for CRC is treatment focussed on 
smaller patient groups and individualised therapies using a more translational approach, where 
diagnosis and treatment regimens take into account novel molecular staging as well as traditional 
pathological and clinical staging. 
Current clinical guidelines for CRC treatment are based on associated risk stratification and the 
effectiveness of current screening techniques (Winawer et al., 2003), including colonoscopy, faecal 
occult blood testing, rectal examination, sigmoidoscopy, barium enemas, virtual colonoscopy and 
stool DNA. Surveillance guidelines for high-risk patients are also in place aiming to reduce the number 
of new and recurring CRC cases, with regular colonoscopy being performed in order to identify CRC 
and any metastases as early as possible (Eaden et al., 2002, Newcomb et al., 1992, Winawer et al., 
1997). Diagnosis of colonic adenocarcinoma currently requires confirmation using histopathology of 
tissue samples taken via colonoscopy/sigmoidoscopy (Van Cutsem et al., 2009b). It is also 
recommended that risk factors including hereditary predisposition and biopsy location should be 
documented and considered when deciding on treatment (Siriwardana et al., 2009). Staging  of CRC is 
done according to the TNM system along with the Dukes’ stage using a number of techniques including 
clinical examination, blood counts, liver and renal function tests, X-ray and CT-scans of the chest, 
abdomen and pelvis and a colonoscopy of the entire colon (Van Cutsem et al., 2009b). 
Survival rates for CRC have been steadily increasing, with estimates from the US National Cancer 
database showing 5-year survival rates of 63.9–93.2% depending on stage of progression (Van Cutsem 
et al., 2009b). Colonoscopy alone is now believed to lower mortality rates due to colorectal cancer by 
as much as 40% (Bertagnolli et al., 2006), and our understanding of the underlying molecular biology 
of CRC is leading to the development of novel and better-targeted therapies. 
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Colectomy remains the most effective way of managing CRC, where a wide resection removes the 
primary tumour site along with any localised lymph nodes (Van Cutsem et al., 2009b). Following 
surgery, adjuvant therapy is dependent on the staging of cancers and treatments have been steadily 
improving. For more than 40 years, the drug 5-fluorouracil (5-FU) was used to target cell division in 
hyper-proliferative cells in the treatment of both metastatic and adjuvant colorectal cancers with only 
a small survival benefit (Arnold and Schmoll, 2005). For primary CRC, options for adjuvant treatment 
now include 5-FU combinations with leucovorin (5-FU/LV), also known as folinic acid, leucovorin and 
oxaliplatin (FOLFOX), as well as other chemotherapy agents including irinotecan and capecitabine, all 
of which act to inhibit DNA replication and enhance the effects of 5-FU (Arnold and Schmoll, 2005, 
Bauer and Spitz, 1998, Van Cutsem et al., 2009b). FOLFOX has been shown to significantly improve 
disease free survival (DFS) in stage II and III colon cancer and improves also the overall survival in stage 
III colon cancer, and is now the standard adjuvant treatment for stage III colon cancer, and results 
suggest patients with stage II colon cancer also see an improved DFS (Van Cutsem et al., 2009b). 
Adjuvant treatment for advanced CRC also includes FOLFOX and a combination of 5-FU/LV and 
irinotecan or capecitabine. 
Additional treatments targeting upregulated pro-metastatic factors, such as vascular endothelial 
growth factor (VEGF) and epidermal growth factor receptor (EGFR), are now suggested for 
consideration in patients with metastatic CRC (Van Cutsem et al., 2009a). Antibodies for VEGF such as 
bevacizumab, and for EGFR such as cetuximab and panitumumab are now being successfully 
investigated as adjuvant therapies (Arnold and Schmoll, 2005, Van Cutsem et al., 2009b). Another 
combination therapy of capecitabine plus oxaliplatin (XELOX) is also fast becoming an effective first-
line treatment for metastatic CRC (Cassidy et al., 2011, Cassidy et al., 2004). 
Other treatment regimens now consider non-steroidal anti-inflammatory drugs (NSAIDs) such as 
sulindac for post-surgery chemoprevention in high-risk patients (Kim et al., 2014). This follows earlier 
studies in human colorectal cancer cell lines suggesting a role for inflammation in disease 
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development and progression (Liggett et al., 2014, Williams et al., 1999a, Flis and Splwinski, 2009) and 
in vivo models (Chiu et al., 1997).  
However, even with survival rates now increasing for both primary and advanced CRC there is a severe 
lack of more effective treatments, which highlights the need for more innovative approaches for 
diagnosis and therapy. Development of novel chemopreventative agents are beginning to give 
promising results (Serafino et al., 2014), and further combination therapies will likely lead to 
improvement in colorectal cancer treatment. However, the variety of current and future treatment 
options requires translational research to identify those treatments that will be beneficial for specific 
patient groups and individuals (Arnold and Schmoll, 2005). Specific features and molecular/genetic 
markers are becoming more of a focus due to our improved understanding of the molecular biology 
of CRC, and it is hoped this will obtain maximal benefit for each therapeutic option available to smaller 
patient groups and individualised therapies in the future. 
One area of therapeutic potential is to target common changes in molecular biology seen in colorectal 
cancers. An early study helped to identify adenomas as the starting point for most colorectal 
carcinomas, and outlined some common genetic alterations and loss of functions at various stages of 
cancer development (Vogelstein et al., 1988). A comprehensive review of gene mutations in CRC 
revealed many prominent oncogenes and tumour-suppressor genes associated with CRC are the APC, 
KRAS, and TP53 genes, as well as a wider assortment of genes mutated in subsets of CRC cases now 
being implicated (Fearon, 1995). 
We are yet to fully understand the significance of individual and collective genetic and epigenetic 
defects in CRC (Fearon, 1995). However, gene sequencing, functional genetic studies, and intricate 
murine models of CRC using mutations in some of these genes, particularly APC, have provided further 
insight into how oncogenes and tumour-suppressors co-operate, with co-existence of mutations 
found within individual CRC tumours (Jackstadt and Sansom, 2016, Phesse et al., 2017). Deletion of 
Apc in mouse models has revealed insights into the mechanism of early tumourigenesis, while 
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truncations that closely mimic those seen in human CRC have been shown to drive changes in 
expression of other cell markers, such as Leucine-rich repeat-containing G-protein coupled receptor 5 
(Lgr5) and Axin. Some of the more recent findings have been reported to be fundamental changes in 
concepts on intestinal homeostasis, and have allowed further insights into the impact of deleting 
genes such as Apc (Jackstadt and Sansom, 2016). These developments have allowed a more intricate 
look at molecular staging of colorectal cancers and better identification of tumour subclasses, 
progression markers and prediction of disease outcome (Eschrich et al., 2005). Molecular staging 
based on gene expression at the time of diagnosis could predict the behavioural direction of cancers, 
which has some promise in predicting the long-term outcome of individual cases. 
Better characterization of the involvement of oncogenes through to protein expression and post-
translational modifications, as well as the epigenetic impact of environmental factors, will be 
important in furthering the understanding of the biology of CRC progression, particularly in sporadic 
and IBD-associated CRC. Recent studies showing the complex interactions between diet and 
environmental agents, the gut flora, and inflammation associated with increased risk of CRC go some 
way towards improving the treatment of CRC through improving our understanding of the 
development of carcinomas (Bongers et al., 2014, Peterson et al., 2008). 
1.3 The adenoma-carcinoma sequence 
Normal epithelial cells of the gut mucosa progressively transform into a benign state of adenoma, 
before becoming neoplastic and evolving into invasive carcinoma, eventually leading to metastatic 
cancer (Hanahan and Weinberg, 2011). This is now stage characterised as the adenoma-carcinoma 
sequence. CRC can develop from normal colonic tissues, with a single layer of epithelial cells forming 
the gut mucosal barrier protecting a variety of colonic tissues from the vast contents of the gut 
(Marshman et al., 2002). The colonic mucosa contains deep pockets called the crypts of Lieberkuhn. 
Highly proliferative pluripotent stem cells are responsible for regeneration of the epithelial layer and 
can migrate throughout the crypts, differentiating into several specialised functional cell types to form 
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the mature gut mucosa (Gregorieff and Clevers, 2005, Merlos-Suárez et al., van de Wetering et al., 
2002). Goblet cells are responsible for the production of mucins to protect the epithelium from gut 
bacteria, whilst colonic enterocytes are absorptive cells allowing nutritional absorption via the colon. 
Paneth cells produce bactericidal compounds protecting the epithelial barrier from commensal and 
pathogenic bacteria present in the gut. The entire process of epithelial renewal takes approximately 
3–5 days (Hirata et al., 2013, Potten and Loeffler, 1990) but depends on a specific order of molecular 
signalling events to occur normally. 
Assuming normal development and proliferation of intestinal stem cells, differentiation and migration 
occur in a coordinated manner toward the intestinal lumen, forming a complex but conserved 
arrangement of intestinal cells. However, upon mutation, the normal process of differentiation, 
proliferation, migration and apoptosis are disrupted. Recently, a 'Big Bang' model has been described. 
After the initial transformation, colorectal tumours are said to grow predominantly as a single 
expansion populated by numerous intermixed sub-clones, with alterations arising early during growth. 
This opens up to increasing numbers of mutations and gene copy numbers over time. Colorectal 
tumour profiling revealed the absence of intra-tumour heterogeneity in most cases, with most 
detectable heterogeneity originating from early alterations. This model allows a quantitative 
framework to interpret tumour growth dynamics and predict early malignant potential with significant 
clinical implications (Sottoriva et al., 2015). 
During initial transformation, the epithelial gut mucosa first harbours a small bundle of abnormally 
proliferating cells creating an adenoma, but these cells remain in situ, with no extension into deeper 
tissues. As the tumour begins to invade deeper into the intestinal tissues of the submucosa, muscular 
propria and serosa, the tumour extends towards regional lymph nodes and large blood vessels. Once 
cancerous cells reach the lymph nodes, it becomes much more dangerous, dropping the 5-year 
survival rate substantially. Cancer cells that move into blood vessels can cause metastasis, which 
usually leads to death within 5-years of detection (Newcomb et al., 1992). Clinical recommendations 
for treatment of primary CRC following detection concentrate on pathological staging of the adenoma-
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carcinoma sequence according to the TNM and modified Dukes’ stage systems distinguishing 
according to the degree of extension of adenomatous polyps from its origin (Van Cutsem et al., 2009b, 
Newcomb et al., 1992). As seen in Figure 1.3, the adenoma-carcinoma sequence in sporadic and IBD-
associated cases is influenced by the molecular biology of CRC, which can be shaped by environmental 
factors as well as genetic predispositions. 
The differences between these two forms of CRC lie in the stage of progression in which common 
mutations occur. In IBD-associated cases, p53 mutations occur early in progression with APC 
mutations occurring much later, whereas sporadic cases are commonly associated with much earlier 
APC mutations with p53 mutations occurring towards the latter stages of progression. It is also 
interesting that there is a difference in cancer phenotype, where IBD-associated CRC is linked with flat 
tumours, compared to the polyp-associated tumours in sporadic CRC (Rhodes and Campbell, 2002). 
These differences may in part be explained by the differing contributions of inflammatory modulators 
in the development of dysplasia and progression to carcinoma in these two sequences. 
 
 
Figure 1.3. The adenoma-carcinoma sequence for sporadic and IBD-associated CRC. Typical 
mutations of APC, K-ras and p53 genes, and microsatellite instability are shown at suggested stages 
of progression. The impact of environmental factors indicated at the beginning of IBD-associated and 
throughout sporadic CRC. The potential impact of bacteria (dotted line) is suggested from adenoma 
(sporadic) or low-grade dysplasia (IBD) to carcinoma. Adapted from (Rhodes and Campbell, 2002). 
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1.4 The impact of chronic inflammation in the gut 
The inflammatory response involves a number of signalling pathways responsible for regulating the 
expression of inflammatory mediators. Our knowledge of signalling in inflammation has improved 
considerably, with a particular focus on the study of various interleukin and tumour necrosis factor 
(TNF) receptor families and the Toll-like microbial pattern recognition receptors (TLRs), which are 
considered key contributors (Lawrence, 2009). It has been suggested that the effects of inflammatory 
signalling can depend on the method of cytokine signalling recognition, and the complex processes of 
cytokine recognition involved in inflammation has been extensively studied.  
Pro-inflammatory cytokines such as interleukins, tumour necrosis factor alpha (TNF-α), nitric oxide 
(NO) and cyclooxygenase-2 (COX-2) are all commonly implicated in inflammatory disease, and can be 
released upon tissue damage or following infection (Bartchewsky et al., 2009, Anderson et al., 1996, 
Laflamme et al., 1999, Tak and Firestein, 2001). Both TNF-α and COX-2 have come into focus in recent 
years as driving forces for the recruitment and activation of inflammatory cells (Karin et al., 2006). By 
blocking key inflammatory mediators associated with TNF-α and COX-2 release, it is possible to 
attenuate the inflammatory response, so these inflammatory cytokines now established as important 
therapeutic targets in chronic inflammatory diseases (Karin et al., 2006, Nakamura et al., 2009). 
Chronic inflammatory signalling as a result of tissue damage and/or infection that goes unnoticed or 
uncorrected can increase risk of chronic inflammatory diseases. Chronic inflammation is often 
implicated in altering key cancer signalling pathways; one example of this is chronic TNF-α and COX-2 
release mediating response via NFκB signalling (Paik et al., 2002, Lawrence, 2009). Activation of the 
canonical NF-κB pathway in response to inflammatory cytokines has shown to be important in the 
pathogenesis of chronic inflammatory diseases such as rheumatoid arthrtitis (RA) and IBD (Tak and 
Firestein, 2001). NF-κB activation is thought to play a complex but pivotal role in chronic and acute 
inflammatory diseases as well as in cancer (Hoesel and Schmid, 2013), and this has led to the 
development of anti-inflammatory drugs targeting NF-κB (Karin et al., 2004).  
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With an array of inflammatory molecules involved in different pathways linking inflammatory 
signalling with cancer signalling, the impact of inflammation could be a key factor in the development 
and progression of a number of cancers. IBD-associated CRC is an excellent example of the influence 
of chronic inflammation in the increased risk of cancer development. 
IBD consists of ulcerative colitis (UC) affecting the colon and rectum, and Crohn’s disease (CD) affecting 
any part of the gastro-intestinal tract. These have many overlapping genetic factors and clinical 
features, and the risk of developing cancers is equivalent in both conditions when there is a similar 
extent and duration of colonic disease (Ekbom et al., 1990a). Patients with CD-associated colon cancer 
and UC-associated colon cancer show marked similarity in terms of median duration of IBD before 
cancer, age at cancer, and presence of dysplasia (features of malignancy without evidence of tissue 
invasion) (Choi and Zelig, 1994). In both UC and CD, strong associations exist between the duration 
and extent of mucosal inflammation and the cancer risk. 
The association between cancer risk and inflammation is not straightforward, but there are clear 
associations between cancer risk and disease extent and duration in patients with colitis extending 
proximal to the rectum (Ekbom et al., 1990b). In CD, there is a convincing association between 
inflammation and cancer at various sites. Small bowel CD comes with an increased risk for small bowel 
cancer, which is otherwise a rare phenomenon (Collier et al., 1985). Murine models have allowed 
insights into the impact of inflammation on colorectal carcinogenesis. For example, in Apc-mutant 
mice, activation of the cytokine-stimulated pathway mediated by the first member of the class of 
cytokine receptors, glycoprotein 130 (gp130), associated Janus kinases (Jaks), and the transcription 
factor Stat3 (signal transducer and activator of transcription 3) was required for tumourigenesis via 
the Wnt pathway (Phesse et al., 2014). Partial genetic and pharmacological inhibition of the gp130-
Jak-Stat3 pathway was shown to prevent Wnt–mediated tumour growth. 
With many clinical and epidemiological studies suggesting an association between infectious agents 
and chronic inflammatory disorders and cancer (Karin et al., 2006), it is reasonable to assume that the 
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increased risk of colorectal cancer in IBD patients is a result of the disease rather than an inherited 
phenomenon, and can be associated with the site, extent and duration of inflammation. 
IBD-associated CRC therefore serves as an exemplary model of inflammation-associated cancer, but 
this correlation also provides important insights into the understanding of sporadic CRC pathogenesis. 
With chronic inflammation being a strong factor in the risk of development and progression of CRC in 
IBD patients, it was suggested that other factors may be involved. 
A key aspect of CRC pathogenesis is an intestinal epithelial barrier that can be compromised by 
microbial toxins, environmental factors or genetic predispositions. This point towards another factor 
in disease risk alluded to in Figure 1, which is the involvement of bacteria. Both IBD-associated and 
sporadic CRC are now presumed to result in part from an altered host response to the normal 
intestinal bacterial flora (Shanahan, 2001), known as the gut microbiota. This led to the question of 
whether this can result in changes of bacterial composition in the gut and whether this can contribute 
to disease progression.  
1.5 The gut microbiota 
Bacteria are an important component of the human body, colonising the majority of epithelial 
surfaces. The community of bacteria and other microorganisms living within the human body are 
collectively known as the ‘microbiota’. There are 10 times more cells comprising the microbiota than 
the number of cells in the human body, and approximately 70% of these are localised in the intestine 
(Compare and Nardone, 2011). Most of the microbiota consists of bacteria with much smaller 
numbers of Archaea, Eukarya and viruses, and we now know that more than 1,000 bacterial species 
can be found in the human intestine (Qin et al., 2010). A symbiotic relationship between the host and 
microbiota means that intestinal bacteria can be beneficial to intestinal health. 
The human microbiota becomes established in stages. From childbirth and subsequent weaning, the 
increasing diversity of the microbiota occurs over the first couple of years and once established, by 
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around 3 years old, the microbiota typically remains constant over time (Ursell et al., 2012, Albenberg 
and Wu, 2014). The majority of bacteria in the gut microbiota belong to four common phyla: 
Bacteroidetes (e.g. Bacteroides), Firmicutes (e.g. Clostridium, Enterococcus and Streptococcus), 
Actinobacteria (e.g. Bifidobacterium) and Proteobacteria (e.g. Escherichia coli), with approximately 
95% Bacteroidetes or Firmicutes (Siezen and Kleerebezem, 2011, Cotillard et al., 2013). However, 
numerous studies have shown that this composition can be altered. 
Microbiota transplantation gave insights into the impact of environmental factors on bacterial 
composition, suggesting that our gut microbial composition reflects the bacteria we are exposed to 
from birth as well as what is now known as habitat effects, where specific bacteria are able to colonise 
at different sites of the gut (Rawls et al., 2006). 
The production of mucus is also indicated as an important factor influencing the pattern of microbial 
colonization of different regions of the gut (Peterson et al., 2008). An important part of the host-
bacterial interactions is the limit of interactions between the two, so it is then important that the 
intestinal microbiota is kept at a distance from intestinal epithelial cells to minimise the likelihood of 
bacterial invasion (Brown et al., 2013). Innate immune strategies are in place to keep much of the 
microbial community within the lumen of the intestinal tract and limit invasion of pathogenic bacteria. 
Specialised functional cells such as goblet cells are responsible for the production of mucins and 
Paneth cells producing bactericidal compounds help protect the epithelial barrier from commensal 
and pathogenic bacteria (Kamada et al., 2013). The mucus layer, antimicrobial peptides (AMPs) and 
innate lymphoid cells (ILCs) help to avoid bacterial invasion whilst promoting mutualistic interactions 
(Brown et al., 2013). Microbial signals can also induce the production of interleukins such as IL-22, and 
immunoglobulins such as IgA to aid in barrier function (Brown et al., 2013).  
Studies focussing on mouse colonic mucus show two distinct layers of mucus with similar protein 
composition and mucin-2-glycoprotein (MUC2) as the major structural component (Johansson et al., 
2008). However, proteolytic cleavage of MUC2 affects the shape and density of the mucus. The inner 
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layer is densely packed and attached to the epithelium, and this layer is devoid of any bacteria. The 
outer layer contains cleaved MUC2 glycoproteins, making it much less dense and is often colonized by 
bacteria. This was confirmed using MUC2-/- mice, where bacteria are in direct contact with epithelial 
cells far down in the crypts, which led to inflammation and cancer development (Johansson et al., 
2008). 
Deregulation of mucin production has therefore provided an important link between inflammation 
and cancer, and mucins have been identified as attractive therapeutic targets (Kufe, 2009). Ulcerative 
colitis, a form of IBD, is characterised by marked inflammation, superficial mucosal ulceration, 
infiltration of neutrophils, and depletion of goblet cell mucins. The extent of disease in patients with 
ulcerative colitis is associated with decreased MUC2 production, which suggests that the mucosal 
barrier is important in the pathogenesis of this form of IBD. However, the role of MUC2 as a tumour 
suppressor appears paradoxical, with reports that MUC2 can be expressed at increased levels in gastric 
(Leteurtre et al., 2006), pancreatic (Takikita et al., 2009) and ovarian (Hirabayashi et al., 2008) 
carcinoma and can vary depending on progression. A recent study highlighted the fact that DNA 
methylation and histone modification of MUC2 may play an important role in carcinogenesis, and 
concluded that further studies of the epigenetics of mucin gene expression are required in order to 
fully understand the relationship between mucin expression (Yonezawa et al., 2008). 
Other studies have focussed on the nutrients available to the gut microbiota and how this might affect 
microbial composition. For example, diets rich in carbohydrates can benefit certain members of the 
gut microbiota, such as Bacteroides (Hooper et al., 1999), where these bacteria can be found 
assembled on food particles and mucus. These changes in composition can become more pronounced 
when the diet is also depleted of complex polysaccharides (Sonnenburg et al., 2005). 
Complex control mechanisms help to ensure the symbiotic relationship, with crosstalk on a cellular 
level between intestinal epithelial cells, immune cells and the microbiota, representing a fundamental 
feature of intestinal homeostasis. However, these control mechanisms can fail, leading to a change in 
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the relationship between bacteria and epithelial cells lining the intestines. Factors including age, 
genetics, and diet may influence microbiome composition, and of these diet is the easiest to modify 
and presents the simplest route for therapeutic intervention (Wu et al., 2011). 
Epigenetic environmental and lifestyle factors are becoming increasingly prominent in research 
focussing on microbiota composition. Diet has previously been shown to affect cellular processes like 
apoptosis in colorectal cancer, which can both limit or increase burden and/or progression of 
colorectal cancer (Bellamy et al., 1995). 
The symbiotic relationship between microbiota and gut can also be changed pathologically, where 
obesity, diabetes, atherosclerosis and IBD have all been implicated as factors affecting microbial 
composition, and the relationship between alterations in the microbiota and development of 
intestinal disease such as IBD and colorectal cancer is now becoming more of a key focus. Evidence 
for the preferential localisation of some tumours in specific areas of the intestine suggests that non-
genetic factors such as changes in the microbiome play an important role in their development 
(Bongers et al., 2014). 
1.6 The human gut microbiota under inflammatory conditions 
Development of tumours associated with local changes in epithelial barrier function, bacterial 
invasion, production of antimicrobials, and increased expression of several inflammatory factors 
indicate that tumours can be driven by the interplay between genetic and epigenetic changes in the 
host, chronic inflammatory responses and a host-specific microbiota. 
Inflammatory conditions can place abnormal stresses on bacteria in the human gut. Under chronic 
inflammatory conditions, such as those seen in IBD in both Crohn’s disease and ulcerative colitis 
patients, the faecal microbiota commonly shows reduced bacterial diversity. This is most pronounced 
in Crohn’s disease where a reduction in Firmicutes can be observed alongside an increase in 
Proteobacteria such as Escherichia coli (E. coli) (Hold et al., 2014). 
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Animal models of IBD have been found to result in similar changes in the microbiota, particularly 
reduced diversity. One of the most typical and most used mouse models in these types of studies is 
the colitis model induced by dextran sodium sulphate (DSS). Use of these models has shown that there 
is marked disturbance of the mucosal barrier, with a loss of colonic adherent mucus. The faecal 
microbiota also shows a reduction in bacterial diversity, with increases in numbers of some of the 
more robust species. One example of this is increased Enterobacteriaceae, such as E. coli (Nagalingam 
and Lynch, 2012). 
Similar changes were seen in mouse models of infective gastroenteritis, using Citrobacter rodentium 
and Campylobacter jejuni infections, as well as chemically and genetically induced models of intestinal 
inflammation to demonstrate host-mediated inflammation. Bacterial infection, a chemical trigger 
such as dextran sodium sulphate (DSS), and genetic pre-dispositions such as interleukin-10-(Il-10)-
deficiency, known to play a key role in defence against infection of epithelial cells and used in many 
murine models, markedly alters the colonic microbial community (Lupp et al., 2007). It therefore 
seems likely that many alterations in faecal microbiota seen in IBD could be a consequence of 
inflammation, and that this is indicative of the gut microbiota as a whole. 
While IBD could be influenced by the intestinal microbiota, the difficulty in culturing these complex 
microorganisms has precluded the formal identification of specific bacteria involved in disease. 
Several studies have attempted to characterise the gut microbiota using molecular 16S metagenomic 
sequencing, with one study revealing the composition of the human distal intestinal microbiota in 
both normal and IBD conditions. 
In the normal distal intestine, the two predominant phyla, Firmicutes and Bacteroidetes, make up the 
majority of microbiota with lesser contributions from Proteobacteria and Actinobacteria, and minor 
contributions from Fusobacteria, Verrucomicrobia, and Cyanobacteria (Arthur and Jobin, 2011). A 
study of relative abundance of bacterial phyla in the small intestine and colon showed that 
Proteobacteria and Firmicutes can be found at increased levels in IBD patients (Figure 1.6) (Peterson 
17 
 
et al., 2008). Changes in bacterial composition in favour of these bacteria can lead to an increase in 
opportunistic pathogens. 
Studies focussing on the mucosa-associated microbiota have generated more dramatic differences 
than study of faecal microbiota between health and IBD, particularly in Crohn’s disease. This is the 
case for the mucosa-associated E. coli that have been found more commonly in mucosal biopsies from 
the ileum and colon of patients with Crohn’s disease (Darfeuille-Michaud et al., 1998, Martin et al., 
2004). In colonic biopsies, many of these bacteria are present within the adherent mucus (Swidsinski 
et al., 2002), although there is also evidence of intracellular E. coli from study of gentamicin-treated 
and subsequently lysed mucosal samples (Martin et al., 2004).  
A recent study of both mucosal and faecal samples from newly-diagnosed paediatric cases prior to 
treatment has given further clarification, showing clear compositional differentiation between Crohn’s 
disease and controls in mucosal samples and faecal samples (Gevers et al., 2014), again including 
increased numbers of E. coli, as well as Veillonella spp., Haemophilus spp. and Fusobacteria, alongside 
reduced numbers of a range of bacteria, including Faecalibacterium prausnitzii. 
It is now believed that many of the changes in microbiota composition seen in IBD, including an 
increase in E. coli, may be at least in part secondary to chronic inflammation. With development of 
tumours driven by the interplay between genetic changes in the host, chronic inflammatory responses 
and a host-specific microbiota, it seemed understandable that studies into the gut microbiota in CRC 
would suggest bacteria as a contributing factor. 
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Figure 1.6. IBD Bacterial phyla identified in the human gut microbiota. Under normal conditions, 
Firmicutes and Bacteroidetes predominate throughout the gut. In patients with IBD, substantial 
increases in Proteobacteria are shown throughout the small intestine and colon, suggesting chronic gut 
inflammation can alter the composition of the gut microbiota. No data was provided for the microbiota 
of the descending colon in IBD.  Adapted from (Peterson et al., 2008). 
 
1.7 The human gut microbiota in colorectal cancer 
Several studies implicate microbial dysbiosis in the development of colorectal adenomas and CRC (Wu 
et al., 2013, Zhu et al., 2014, Chen et al., 2012, Sobhani et al., 2011), with some intriguing similarities 
between the microbiota in colorectal cancer and in Crohn’s disease. In colorectal cancer, and in 
patients with colonic adenomas, there is tendency for the faecal microbiota to show reduced diversity, 
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a higher proportion of Proteobacteria and a lower proportion of Bacteroidetes (Dulal and Keku, 2014). 
Again, study of the mucosa-associated microbiota reveals changes that may be missed by study of 
faecal microbiota, including increases in mucosa-associated E. coli and Fusobacterium nucleatum. 
Mucosa-associated E. coli in colon cancers also show some of the adherent, invasive phenotypic 
features of E. coli associated with colorectal disease (Martin et al., 2004). 
It is becoming increasingly likely that the microbiota plays a significant part in the pathogenesis of 
colorectal cancer, and a recent study characterising the gut microbiome in healthy, adenoma, and 
carcinoma patients representing various stages of colorectal cancer development has added extra 
weight to this theory (Zackular et al., 2014). Analysis of stool samples confirmed a similar 
enrichment/depletion of bacterial populations associated with adenomas and carcinomas to that of 
previous studies. Inclusion of gut microbiome significantly improved the ability to differentiate 
between clinical groups in comparison to risk factors such as age and race alone. This demonstrates 
the feasibility of using the composition of the gut microbiome to determine the necessity to screen 
for pre-cancerous and cancerous lesions in colorectal disease alongside standard clinical screening. 
More studies using stool markers along with linkage to dietary data and individual health information 
could aid the development of more targeted therapies that could be given based on individual 
screening cases. 
The composition and functional stability of the human gut microbiota given the variety of 
environmental exposures are not well defined. Alterations in bacterial community composition 
associated with adenomas may be a contributory cause of CRC, and these findings could lead to 
strategies to manipulate the microbiota to prevent colorectal adenomas and cancer as well as to 
identify individuals at high risk (Shen et al., 2010, Dulal and Keku, 2014). The role of the intestinal 
microbiota is being studied as a major factor in the impact of innate immune sensors and their 
associated signalling in protecting or promoting the development of colorectal cancer via 
inflammation and proliferation. 
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With the gastrointestinal tract colonised by thousands of bacterial species, this complex microbial 
community carries a diverse microbial genome with the potential to influence intestinal homeostasis. 
The relationship between innate sensors, the microbiota and development of colitis-associated 
colorectal cancer indicate that microbial composition may impact the status of various pathologic 
conditions including IBD and colorectal cancer (Arthur and Jobin, 2011). 
The microbiota has previously been linked to innate (Clarke et al., 2010) and adaptive immunity 
(Chervonsky, 2010), gastrointestinal development (Hooper, 2004), invasion and angiogenesis 
(Stappenbeck et al., 2002). Due to gut bacteria being implicated in a number of steps of disease 
progression in CRC, it is easy to see the varying ways in which bacteria can influence colorectal disease. 
The major route in which bacterial infection can aid progression of CRC is via inflammatory pathway. 
One important feature of IECs in protection against possible bacterial infection is the expression of 
Toll-like receptors (TLRs) at the cell surface (Arthur and Jobin, 2011). TLRs can recognise and be 
activated by specific features of bacterial pathogens, such as cell-surface lipopolysaccharides and 
proteins, and play an important role in inflammation and tissue regeneration via the myeloid 
differentiation primary response gene 88 (MyD88). 
TLR expression in IECs varies, with low levels of TLR2 and TLR4 expression in colonic tissue, abundant 
TLR3 expression in the small intestine and colon, and TLR5 expression predominantly in the colon. 
Activation of TLR signalling results in the expression of antimicrobial peptides and the production of 
prostaglandins and cytokines as a protective mechanism to stop bacterial colonization of IECs. This 
includes the induction of cyclooxygenase expression, which can promote epithelial cell proliferation, 
whilst interleukins are also responsible for regulating TLR signalling by decreasing TLR expression in 
IECs. These mechanisms help to establish a microorganism-induced programme of epithelial cell 
homeostasis and aid the repair of the intestinal epithelial barrier. However, TLR signalling can have 
cancer-promoting effects, which is best established in the colon where there is constant interaction 
between gut microbiota and intestinal epithelial cells (Arthur and Jobin, 2011, Pradere et al., 2014). 
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Excessive TLR signalling due to the invasion and colonisation of bacteria and the resulting chronic 
inflammation can lead to over-exuberant repair responses associated with the development of colon 
cancer. Although inflammation is controlled by numerous mediators and pathways, several systems, 
such as TLR signalling, can function as key upstream regulators (Pradere et al., 2014). Dysregulation of 
protective mechanisms such as TLR signalling helps to explain how bacterial infections of the gut could 
promote colorectal cancer. A mouse model of gastric cancer has shown that Stat3 directly up-
regulates epithelial expression of TLR2 in gastric tumours, where genetic and therapeutic targeting of 
TLR2 inhibited gastric tumorigenesis, but didn't affect inflammation (Tye et al., 2012). This suggests 
TLR activation may also regulate cancer growth in an inflammation-independent manner. 
Another key protection pathway is the recognition of peptidoglycan by nucleotide-binding 
oligomerisation domain–containing protein-1 (Nod1), which has been shown to be crucial for 
maintaining a basal level of immune activation in mouse knock-out studies (Clarke et al., 2010). Gram-
positive bacteria in the gut microbiota are a rich source of peptidoglycan known to prime the innate 
immune system, which enhances bacterial killing via neutrophils. Nod1 predominantly recognises 
meso-diaminopimelic acid (mesoDAP)-containing peptidoglycan found primarily in Gram-negative 
bacteria. NOD1 knock-out leads to a reduction in the ability to kill Gram-positive bacteria, allowing 
better survival and more opportunity to colonise within the gut (Lysenko et al., 2007). Genetic 
polymorphisms in NOD1 and NOD2 are associated with increased risk of gastric cancers, particularly 
in the case of H. pylori infection, which suggests they play important roles in promoting the 
development of gastric cancers (Wang et al., 2012a). However, while these changes offer insights into 
mechanisms of microbial infection control, and demonstrates the importance of Nod1 in neutrophil-
mediated clearance of bacteria in vivo, there is as yet little evidence convincingly implicating NOD1 
polymorphisms in colorectal cancers. 
Any changes in the control of microbial composition can influence the human microbiota, with altered 
microbiota known to influence our gastrointestinal health as well as our susceptibility to disease 
(Kamada et al., 2013). The final composition and diversity of our microbiota is partially determined by 
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environmental factors, highlighted by the vast differences of the adult microbiota compared to that 
at birth (Greer and O'Keefe, 2011). With environmental and lifestyle factors significantly altering 
microbial function, extensive research now indicates that a westernised diet low in complex 
carbohydrates and overuse of antibiotics and underuse can lead to an intensified inflammatory 
potential. Chronic inflammation due to microbial composition can cause increased risk of certain 
diseases. There has been a rise in cases of inflammatory bowel disease that has been linked to 
impaired beneficial bacterial exposure and education of the gut immune system (Greer and O'Keefe, 
2011), and current research highlights a complicated relationship between the gut microbiota and 
immunity, inflammation and carcinogenesis. 
Recent research has focused on better understanding the interplay between chronic inflammation 
and development of cancer, with IBD-associated cases at the forefront, with a number of 
inflammatory, proliferative and immune signalling pathways now linked to the microbiota and 
development of colorectal cancer (Arthur and Jobin, 2011). TLRs are known to trigger signalling 
pathways leading to the expression of various genes including growth factors and inflammatory 
mediators, thus amplifying inflammation and promoting carcinogenesis. Microbial enzymes can also 
process dietary pro-carcinogens to their biologically active forms (Figure 1.7). 
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Figure 1.7. Composition of the intestinal microbiota can influence inflammatory signalling and 
carcinogenesis. The intestinal microbiota promotes inflammation and neoplasia via signatures 
recognised by TLRs. TLRs trigger downstream signalling pathways leading to the expression of various 
genes, including inflammatory mediators and growth factors to amplify inflammation and promote 
neoplasia. Bacterial enzymes can also cause activation of pro-carcinogens to their biologically active 
form to elicit further neoplastic changes. Adapted from (Arthur and Jobin, 2011). 
 
With carcinogenesis known to be induced via both inflammatory signalling and carcinogenic 
metabolites of bacteria in the gut, the intricate mechanisms within these pathways could be targeted 
for novel therapies, reducing the effects brought about by bacterial infection, but for this to be 
possible more insight into specific bacteria and their associated pathogenic characteristics is 
necessary. Inflammation has been shown to promote CRC in patients with colitis, and the microbiota 
has been identified as a target of inflammation affecting the progression of CRC. One study using high 
throughput sequencing revealed that inflammation modifies composition of the gut microbiota in 
colitis-susceptible Il10−/− mice, and showed the promotion of invasive carcinoma following mono-
24 
 
association with E. coli NC101 expressing the genotoxin-encoding polyketide synthase (pks) 
pathogenicity island (Arthur et al., 2012). These types of studies suggest a contributory and possibly 
key role played by infection-induced inflammation in colorectal carcinogenesis. 
Recent evidence suggests a correlation between Gram-negative Proteobacteria found adhered to the 
adult gut mucosa. A number of bacteria have been implicated as risk factors and causes of 
gastrointestinal cancers via chronic infection and inflammation.  For example, E. coli have a higher 
presence in the gut microbiota under inflammatory conditions and some strains have the arsenal to 
become opportunistic pathogens, adhering to and invading intestinal epithelial cells (Martin et al., 
2004). Preventative and adjuvant therapies interfering with inflammatory pathways as well as 
downstream signalling events, such as Wnt signalling, triggered by infections could help to minimise 
the risks posed by bacteria such as E. coli in colorectal disease. However, our limited understanding of 
the role of bacteria in colorectal disease meant that more information was required before looking 
into potential therapies. 
1.8 The role of E. coli in colorectal disease 
In inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease (CD), the composition 
of the intestinal microbiota can be compromised over a number of years; there is even evidence to 
suggest that gut bacteria may play a role in the onset of IBD (Chassaing and Darfeuille–Michaud, 2011). 
In many cases, E. coli have been the focus, with independent studies reporting increased numbers of 
intestinal E. coli in patients. Increased numbers of E. coli have been found in the ileum of CD patients 
(Darfeuille-Michaud et al., 1998), and data also suggests a preferential increase in the concentration 
of Bacteroides, and in particular E. coli, in the gut of IBD patients (Swidsinski et al., 1998). 
It is therefore believed that the chronic inflammatory conditions in the intestine of CD patients can 
change bacterial composition to favour those capable of surviving the conditions. This can increase 
risk of bacterial infection by these bacteria – a phenomenon supported by data showing an increase 
in mucosa-associated and intra-mucosal bacteria, again primarily E. coli, in Crohn’s disease as well as 
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colon cancer patients (Martin et al., 2004). These studies support a central role for mucosa-adherent 
bacteria, in particular E. coli, in the pathogenesis of Crohn’s disease and colon cancer. However, the 
mechanisms by which these bacteria are involved in Crohn’s disease and colon cancer are not fully 
understood. 
It has also been shown that Crohn’s disease-associated E. coli can translocate across intestinal M-cells. 
E. coli translocation was shown to be increased across M-cell monolayer cultures, generated by co-
culture of Caco-2 and Raji-B cell lines in Ussing chambers, in comparison to using parent Caco-2 
monolayer cultures, with electron microscopy also confirming E. coli located within M-cells (Roberts 
et al., 2010). Interestingly, the same study also showed how soluble plant fibres and emulsifiers can 
affect this translocation, highlighting the impact of environmental factors such as diet on potential 
infection, particularly in those at increased risk. The results suggest that an increase in number of E. 
coli residing within the intestine can increase the risk of infection, inflammation and colon cancers. If 
this is indeed the case, a better understanding of the role of these bacteria in carcinogenesis, in 
particular in the case of intestinal epithelial cells, is essential. 
A study investigating changes in the gut microbiota that may contribute to colorectal cancer found an 
altered composition of the colonic-adherent microbiota in Il-10 deficient mice, causing an imbalance 
in intestinal bacteria, or ‘dysbiosis’, with a reported 100-fold increase E. coli (Arthur et al., 2012). The 
study also reported that mice colonized solely with E. coli harbouring the pks pathogenicity island 
developed invasive adenocarcinoma after azoxymethane treatment. The pks pathogenicity island is 
able to synthesise a genotoxin known as colibactin, suggesting that E. coli may exert DNA damage 
independent of inflammation, due to the absence of the anti-inflammatory cytokine Il-10. However, 
the role of other cytokines, such as tumour necrosis factor (TNF) and Il-12 in these models, were not 
assessed and may still be involved (Scheinin et al., 2003). 
The increased abundance of E. coli in the gut has long been linked to carcinogenesis. A study detected 
bacteria in 90% and 93% of adenoma and carcinoma biopsy specimens, respectively. In addition, 
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partially intracellular E. coli were found in 87% of patients with adenoma and carcinoma compared to 
none in control samples. It was therefore concluded that the colonic mucosa of patients with 
colorectal carcinoma but not normal colonic mucosa was colonised by intracellular E. coli (Swidsinski 
et al., 1998). 
Infection-induced hyper-proliferation of epithelial cells, either via inflammatory cytokines or 
independent of them, seems to be a common theme in most gut-associated cancers. One aspect that 
seems to stand out is the impact of bacterial composition in carcinogenesis, with dysbiosis being a 
consistency. If changes in the microbiota are involved in cancer development, the colon should be a 
major site of action, and inflammation will play a significant role. Therefore, it should not be surprising 
that the risk of cancer in inflammatory bowel diseases is considerably higher if the disease affects the 
colon rather than the small intestine (Bienz and Clevers, 2000). 
With evidence of E. coli found within gut tissues in Crohn’s disease and colon cancer, the 
characteristics responsible for their ability to adhere to and invade these tissues have been recently 
investigated. A study identifying a number of genes contributing to the adhesive and invasive 
characteristics of CRC-associated E. coli isolates also identified genes that could be involved in 
colorectal carcinogenesis (Prorok-Hamon et al., 2014). Mucosa-associated E. coli isolates were found 
to commonly express lpfA and fimH. These genes are now known to be involved in M-cell 
translocation, which is likely to be the initial route for invasion in vivo. Isolates from Crohn’s disease 
and CRC patients showed increased prevalence of afimbrial adhesion (afa). This increased presence 
also correlated with increased adherence to and invasion of intestinal epithelial cells, as well as 
increased VEGF expression known to aid angiogenesis and, therefore, development and progression 
of cancer. 
As mentioned earlier, colonic mucosal E. coli from IBD and CRC patients more commonly express the 
pks pathogenicity island responsible for the formation of colibactin (Arthur et al., 2012). Interestingly, 
E. coli expressing both afaC and lpfA were common in Crohn’s disease and CRC patients, whereas E. 
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coli expressing both afaC and pks were common in patients with CRC and ulcerative colitis (Prorok-
Hamon et al., 2014). This suggests that the presence of the pks island isn’t the sole determinant of 
CRC development, and that adherence and invasion characteristics may be contributing to 
carcinogenesis. All isolates, however, were found to express the htrA gene, encoding the stress protein 
HtrA, and the dsbA gene, encoding the oxido-reductase enzyme DsbA, both of which have previously 
been shown to be essential for intracellular replication within macrophages (Bringer et al., 2005, 
Bringer et al., 2007). These characteristics are thought to be phenotypic of a collective group of 
bacteria now termed 'adherent and invasive E. coli' (AIEC), associated with IBD and CRC. 
1.9 Adherent and invasive E. coli (AIEC) 
It has been demonstrated that, under IBD and CRC inflammatory conditions, increased numbers of 
pathogenic E. coli are found within the microbiota (Chassaing et al., 2011, Hold et al., 2014, Rhodes 
and Campbell, 2002). Martin et al. showed these E. coli can adhere to and invade the gut mucosa, 
hence the term AIEC. This effect was shown to be pronounced in IBD and CRC patients, with altered 
mucosal glycosylation said to affect mucosal bacterial adherence (Martin et al., 2004). The mucosa-
associated microbiome also shows reduced biodiversity, with E. coli dominating (Tawfik et al., 2014), 
which further supports E. coli invasion into the mucosa in IBD and CRC patients. 
Adhesion and invasion are believed to be dependent, in part, on the expression of type 1 pili (FimH) 
on the bacterial surface, long polar fimbriae promoting mucosal translocation, and carcinoembryonic 
antigen-related cell adhesion molecule 6 (CEACAM6) glycoprotein on the apical surface of intestinal 
epithelial cells (Barnich et al., 2007, Prorok-Hamon et al., 2014, Tawfik et al., 2014). CEACAM6 acts as 
a receptor for AIEC adhesion and is abnormally expressed by intestinal epithelial cells in CD patients 
(Darfeuille-Michaud and Colombel, 2008). CEACAM6 has also been a focus for involvement in anoikis, 
an apoptotic mechanism of cell death, and its contribution in pancreatic carcinogenesis (Duxbury et 
al., 2004). Malignant cells are often able to escape anoikis, contributing to an ability to form 
metastases. CEACAM6 expression varies between pancreatic cancer cell lines, with over-expression 
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associated with greater anoikis-resistance and in vivo metastasis. CEACAM6 gene silencing promotes 
anoikis, reversing any acquired anoikis resistance, and was found to inhibit metastasis in pancreatic 
adenocarcinoma (Duxbury et al., 2004). 
With both CEACAM glycoproteins associated with adhesion and invasion and overexpressed in many 
cancers, it has been identified as a therapeutic target. The effects of monoclonal antibodies have been 
evaluated using migration, invasion and adhesion assays in vitro using a panel of human pancreatic, 
breast, and colonic cancer cell lines, and in the GW-39 human colonic micrometastasis in vivo model 
(Blumenthal et al., 2005). These antibodies were effective at inhibiting cell migration, invasion and cell 
penetration through an extracellular matrix (ECM). Adhesion of tumour cells added to endothelial cells 
within the in vivo micrometastasis model was significantly decreased by up to 58%.  
Mucosa-associated E. coli strains able to adhere to and invade the intestinal mucosa have been 
isolated from CRC and IBD patients but not from control patients (without IBD). However, there is still 
little understanding of the molecular effects of mucosa-associated E. coli within the gut mucosa, or 
whether these are in fact impacting on carcinogenesis. Investigating whether these E. coli also possess 
the ability to activate key cancer-promoting proteins within intestinal epithelial cells will give a better 
understanding of the development, growth and spread of colonic tumours. 
Evidence would suggest these changes may have a significant role in carcinogenesis via inflammatory 
signalling, meaning it would be important to reduce the inflammatory effects of E. coli within the gut 
mucosa by removing or killing these bacteria. However, AIEC have been shown to be resistant to killing 
by mucosal macrophages, which has shown to be important in disease pathogenesis (Tawfik et al., 
2014) and virulence, adherence and invasive factors are believed to be responsible. It has been 
suggested that further investigation to identify and characterise virulence, adherence and invasive 
factors supporting AIEC survival could give insights into novel and targeted AIEC treatments (Tawfik et 
al., 2014). Additionally, novel factors may be present that increase their pathogenicity and contribute 
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to cancer burden. Finding and evaluating other factors expressed by mucosa-associated AIEC that may 
be potentially contributing to carcinogenesis is an important step. 
1.10 Possible mechanisms of colorectal cancer development involving E. coli  
One of the key factors already shown to contribute to the carcinogenicity of mucosa-associated  
E. coli is the pks pathogenicity island. Several members of the Enterobacteriaceae family, including 
Escherichia coli, Klebsiella pneumonia and Enterobacter aerogenes, are known to harbour the pks 
pathogenicity island encoding colibactin (Putze et al., 2009). Deletion of the pks pathogenicity island 
from E. coli NC101 decreased tumour multiplicity and invasion in AOM-treated Il10−/− mice without 
altering intestinal inflammation (Arthur et al., 2012), thus highlighting the importance of this 
pathogenicity island in carcinogenesis. AIEC containing the pks pathogenicity island were found in a 
significantly high percentage of inflammatory bowel disease and CRC patients, again suggesting that 
colitis can promote tumorigenesis by altering microbial composition and induce the expansion of 
microorganisms with genotoxic capabilities. 
The suggested effects of colibactin on the host immune response as well as the impact on cancer 
development have recently been identified as a therapeutic target. The pks-encoded enzyme ClbP is 
an atypical peptidase that contributes to the synthesis of colibactin. ClbP has been identified as a 
therapeutic target, with key features of ClbP analysed using bacterial fractionation and Western-
blotting (Cougnoux et al., 2012). This revealed the docking of ClbP to the bacterial inner membrane 
via a C-terminal domain harbouring three transmembrane helices (Figure 1.10). 
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Figure 1.10. The role of the ClbP enzyme in colibactin maturation. Membrane-bound ClbP enzyme 
activity contributes to the synthesis and maturation of the genotoxin colibactin. Negatively-charged 
residues in the catalytic domain of ClbP allow docking to the bacterial membrane. The transfer of pre-
colibactin into the extracellular matrix (periplasm) via an efflux pump enables its maturation via ClbP 
into the bioactive form, colibactin. Adapted from (Cougnoux et al., 2012). 
 
The complete sequence of the C-terminal domain was found to be necessary for ClbP bioactivity 
(Cougnoux et al., 2012). This study was able to identify key features of ClbP bioactivity, including 
association with the bacterial inner membrane, the exposition of its enzymatic domain in the bacterial 
periplasm and key residues of the enzymatic domain. These findings give insights into colibactin 
synthesis and will aid the design of inhibitors targeting the production of colibactin in bacteria 
containing pks pathogenicity islands. 
The effect of colibactin has also been studied for impact in metastatic CRC, giving a completely 
different mechanism of carcinogenesis for colibactin. Transient contact of a few malignant cells with 
colibactin-producing E. coli increased tumour growth in a xenograft mouse model, and this growth 
was sustained by the accompanied production of GM-CSF (granulocyte macrophage colony-
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stimulating factor) and fibroblast growth factor (Dalmasso et al., 2014). An additional consequence 
of pks-expressing E. coli was the induced alteration of p53 SUMOylation, an essential post-
translational modification in eukaryotic cells. Small, ubiquitin-like modifier (SUMO) is believed to be 
involved in the nuclear export of p53 to allow tumour suppression (Santiago et al., 2013), so 
alterations in the process could be another contributing factor to pathogenicity. 
The underlying mechanisms for this process are thought to involve the induction of microRNAs 
(miRNAs) – a class of highly conserved and endogenous non-coding RNAs regulating the expression of 
target genes at the post-transcriptional level (Xu et al., 2013). For example, expression of one specific 
miRNA known as miR-20a-5p has been shown to aid production of sentrin/SUMO-specific protease 1 
(SENP1) important in the regulation of the SUMOylation process, thus disrupting gene transcription. 
The expression of SENP1, miR-20a-5p and growth factors have been observed in a CRC mouse model 
and in human biopsies that are found colonized by pks-expressing E. coli (Xu et al., 2013). This data 
reveals a new mechanism of carcinogenesis following infection with pks-expressing  E. coli, with 
production of growth factors promoting proliferation of uninfected cells and subsequent tumour 
growth. This again gives insight into where the pks pathogenicity island shows therapeutic potential, 
and opens up research into the role of miRNAs in bacterial carcinogenesis. 
The many links between bacteria and colonic disease such as CRC is well documented, with the 
pathogenicity of bacteria such as E. coli becoming a key focus. Bacterial invasion has now been linked 
with a variety of human cancers occurring principally via inflammatory pathways. Understanding the 
link between chronic inflammatory processes and events that drive carcinogenesis could be important 
in helping the design of novel strategies to prevent CRC. 
Another mechanism affecting gut pathogenicity is disruption of the innate immunity in the gut, with 
intestinal epithelial cells and underlying macrophages normally able to keep potential pathogens 
under control, maintaining mucosal homeostasis. One major factor involved in innate immunity of the 
intestinal mucosa is nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB; (Jarry et al., 
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2014). NF-κB, known to be involved in the increased expression of many genes of inflammatory and 
immune responses, can be upregulated in response to microorganisms and lipopolysaccharides (La 
Ferla et al., 2004), and is known to be involved in inflammatory disease. 
NF-κB is considered a crucial factor in maintaining chronic inflammation. Normally, NF-κB-containing 
complexes are sequestered in the cytosol in the inactive form due to their association with inhibitory 
proteins. Activation of the canonical pathway causes nuclear translocation of NF-κB (Scheidereit, 
2006) where it induces target gene transcription including pro-inflammatory cytokines such as TNF-α 
(Jarry et al., 2014). Release of these inflammatory cytokines have been shown to be associated with 
increased risk of disease. 
A 3D model of human intestinal mucosa explant culture has been used to explore the effects of the 
mucosa-associated E. coli strain LF82, associated with Crohn’s disease, on NF-κB signalling. Results 
showed that LF82 E. coli enter and survive within intestinal epithelial cells and macrophages without 
altering the mucosal architecture. LF82 E. coli were able to activate NF-κB signalling in epithelial cells, 
NF-κB/p65 nuclear translocation, and TNF-α secretion. In addition, NF-κB activation was said to be 
crucial for the maintenance of epithelial homeostasis upon LF82 infection, with activation of NF-κB 
also demonstrated in situ in macrophages and intestinal epithelial cells in the inflamed mucosa from 
IBD patients (Rogler et al., 1998). With activation of NF-κB also seen in absorptive epithelial 
enterocytes in response to various E. coli, its role in the response of intestinal epithelial cells to 
bacterial infections, particularly E. coli, could be crucial (Savkovic et al., 1997, Elewaut et al., 1999).  
These molecular mechanisms of pathogenicity following E. coli adherence and invasion of intestinal 
epithelial cells such as NF-κB activation are of major interest, with various immune factors, receptors 
such as TLRs and cytokine receptors thought to be involved. Good examples of these are interleukin-
1 receptors and TNF receptors typically associated with the canonical NF-κB pathway (Rahman and 
McFadden, 2011, May and Ghosh, 1997, Le Negrate, 2012). It has been suggested that 
enteropathogenic E. coli (EPEC) can activate or suppress NF-κB depending on TLR signalling. Increased 
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TNF-α promoter activity in cells can be stimulated by bacterial isolates from IBD patients, suggesting 
TNF-α plays an important role in NF-κB-induced inflammation caused by E. coli strains associated with 
inflammatory disease (La Ferla et al., 2004, Wang and Hardwidge, 2012). 
An experimental murine cancer metastasis model, in which mouse adenocarcinoma cells are injected 
into the tail vein of BALB/c mice to generate lung metastases, and whose growth is stimulated in 
response to injection of bacterial lipopolysaccharide (LPS), was used to investigate the role of NF-κB 
in inflammation-induced tumour growth. Results showed that LPS-induced metastatic growth 
response depended on both TNF-α production and NF-κB activation in tumour cells. In addition, 
inhibition of NF-κB in both colon and mammary carcinoma cells converts the LPS-induced growth 
response to LPS-induced tumour regression (Luo et al., 2004). 
Molecular mechanisms linking bacterial infections, inflammation and cancer indicate certain strains 
of E. coli as a risk factor for CRC patients following the acquisition of virulence factors. One of these 
factors is a protein toxin named cytotoxic necrotizing factor 1 (CNF1) (Travaglione et al., 2008), which 
is reported to induce a long-lasting activation of NF-kB, as well as COX-2 expression, to protect 
epithelial cells from apoptosis and promote cellular motility. As cancer may arise through dysfunction 
of similar regulatory systems, E. coli infections associated with different virulence factors could 
contribute to tumour development in a similar fashion via other signalling pathways not yet proven in 
the E. coli-influenced colorectal disease. 
1.11 Activation of Wnt signalling 
Significant increases in COX-2 expression and activity, heavily involved in prostaglandin E2 (PGE2) 
synthesis, have been observed where cancer-associated E. coli have been studied in the context of 
CRC (Raisch et al., 2014, Abdallah Hajj Hussein et al., 2012, Lew et al., 2002). Studies of both CRC 
animal models and human CRC have shown a long-standing association with increased PGE2 synthesis, 
and  investigation of PGE2 synthesis in the gut mucosa using mucosal biopsy specimens obtained 
during diagnostic colonoscopies show its role in the adenoma-carcinoma sequence (Pugh and Thomas, 
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1994). Intestinal polyps and adenocarcinomas were found to synthesise more PGE2 than normal 
colonic tissues, but there was no difference found between polyps and adenocarcinomas. However, 
mucosal samples from colorectal cancer patients were found to synthesise more PGE2 than both 
control and polyp-associated mucosa. These results suggested colorectal carcinogenesis via the 
adenoma-carcinoma sequence could be associated with a progressive increase in PGE2 synthesis. 
Canonical Wnt signalling typically begins when a Wnt ligand binds to a cell membrane spanning 
Frizzled (Fz) family receptor and/or low-density lipoprotein receptor-related proteins 5 or 6 (Flanagan 
et al., 2015a). Upon binding and subsequent activation, the cytoplasmic protein Dishevelled (Dsh) is 
recruited and activated. Activated Dsh associated with axin, causing inhibition of glycogen synthase 
kinase 3 (GSK3β). GSK3β normally phosphorylates the tumour suppressor APC, which acts as a 
negative regulator by phosphorylating β-catenin; GSK3β has also been shown to phosphorylate β-
catenin directly. Phosphorylation of β-catenin is normally followed by its degradation within the 
proteasome. Inhibition of GSK3β or APC activity therefore allows β-catenin to accumulate in the 
cytoplasm, increasing chances of localisation to the nucleus (Coste et al., 2007, Kaler et al., 2012, 
MacDonald et al., 2009). The completion of this signalling cascade is dependent on the nuclear 
localisation of the protein β-catenin. Upon entering the nucleus, β-catenin activates transcription of 
downstream target genes via the lymphoid enhancer-binding factor 1 (LEF1) and T cell factors (TCF) 1, 
3 and 4, with TCF4 reported to be responsible for Wnt-signalling in CRC (Van der Flier et al., 2007). 
Subsequent cellular responses associated with cancer, such as proliferation, adhesion and migration, 
occur following gene transduction via these TCF/LEF transcription factors. 
Cyclooxygenase-2 (COX-2) and PGE2 have been shown to stimulate colon cancer cell growth via the 
heterotrimeric guanine nucleotide-binding protein (G protein)–coupled receptor, EP2, by a signalling 
pathway involving the activation of phosphoinositide 3-kinase (PI3K) and the protein kinase Akt 
(Figure 1.11; Castellone et al., 2005). This has since been suggested to lead to the activation of the 
canonical Wnt signalling pathway, which may provide a new molecular framework for the future 
evaluation of E. coli infection in inflammation-associated colorectal cancer (Castellone et al., 2005). 
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Figure 1.11. Activation of the Wnt signalling pathway by cyclooxygenase-2. In the basal state (left 
panel), the GSK-3β and axin protein complex promotes b-catenin phosphorylation, leading to ubiquitin-
dependent degradation of β-catenin in the proteasome. Overexpression of COX-2 leads to increased 
production of PGE2, which can activate EP2 receptors coupled to G proteins of the Gs family (right 
panel). Activation leads to the exchange of GDP for GTP, causing the alpha subunit of Gs protein to 
bind to axin. This promotes the release of GSK-3β from the inhibitory complex, with stimulation of the 
PI3K-Akt signalling route causing phosphorylation and further inactivation of GSK-3β. These events 
stabilise β-catenin nuclear translocation and lead to the expression of growth-promoting genes 
regulated by the TCF/LEF transcription factors. Adapted from (Castellone et al., 2005). 
 
 
Basal Wnt signalling COX-2-induced Wnt signalling 
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Wnt signalling through β-catenin is required for homeostasis and regeneration of the adult intestinal 
epithelium (Phesse et al., 2014). However, inappropriate levels of accumulated β-catenin in adult 
tissues are associated with development of a wide variety of cancers. Most sporadic colorectal cancers 
as well as familial adenomatous polyposis are linked to Wnt signalling, and in particular the loss of 
function of APC found in the majority of sporadic colorectal cancers (Kaler et al., 2012). β-catenin is 
frequently mutated in liver cancers and in some gastric adenocarcinomas (Coste et al., 2007). APC and 
β-catenin mutations both lead to stabilization of β-catenin and constitutive β-catenin/TCF 
transcriptional activity. 
Disrupted Wnt signalling is currently considered as a major risk factor for colorectal cancer, but it is 
not the only contributor or requirement for tumour initiation and progression (Coste et al., 2007). 
Many studies have since focused on epigenetic changes in colorectal cancer and how environmental 
factors such as diet can influence colorectal cancer via changes in gene-expression. Epigenetic 
inactivation of inhibitors of the Wnt/β-catenin pathway is said to be associated with a tumour-
favourable phenotypic outcome. Gene silencing through both DNA methylation and histone 
modification can cause loss of function of Wnt regulators such as SFRPs (Secreted frizzled-related 
proteins) and Dickkopf Wnt Pathway Inhibitor 3 (DKK3), as well as regulatory Wnt ligands such as 
Wnt5A, contributing to abberant Wnt signalling (Serman et al., 2014, Galamb, et al., 2016). Evaluation 
of the effects of E. coli in a similar context could reveal further links between bacteria and Wnt 
signalling. An interruption of normal Wnt signalling has been confirmed following H. pylori infection, 
with β-catenin identified as a specific host molecule influencing gastric carcinogenesis in conjunction 
with H. pylori infection (Polk and Peek, 2010). Nuclear accumulation of β-catenin has been shown to 
be increased in gastric adenomas compared with non-transformed gastric mucosa, which suggests 
that irregular Wnt-signalling precedes the development of gastric cancer. 
Increased Wnt signalling has also been identified in intestinal cells following infection with S. 
typhimurium. This Salmonella was shown to upregulate several genes implicated in Wnt signalling (Liu 
et al., 2010). A Salmonella protein, AvrA, has been identified that modulates Wnt signalling, modifying 
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β-catenin, increasing total β-catenin expression, and activating Wnt/β-catenin transcriptional activity 
in intestinal epithelial cells. There is an increase in the number of stem cells and proliferative epithelial 
cells in vivo in intestine infected with Salmonella expressing AvrA. An interesting point was made 
linking Wnt pathway activation and of Notch pathway signalling, with noted modulation of Jagged1. 
Normally found at the base of crypts in the small intestine, Jagged1 was found distributed diffusely 
throughout crypts following Salmonella infection (Liu et al., 2010). 
Enterotoxigenic Bacteroides fragilis (ETBF) has emerged globally as a cause of human diarrheal disease 
often accompanied by colitis (Housseau and Sears, 2010). Up to 35% of studied populations can carry 
ETBF without symptoms, which led to a hypothesis towards a secreted toxin. ETBF is now known to 
secrete the B. fragilis toxin (BFT), known to bind to colonic epithelial cells and stimulate cleavage of 
the tumour suppressor protein, E-cadherin (Rhee et al., 2009). E-cadherin cleavage can increase 
permeability of the intestinal epithelial barrier causing activation of the β-catenin/Wnt pathway and 
subsequent activation of c-Myc, inducing increased proliferation of colonic epithelial cells (Wu et al., 
2003). BFT was also reported to be able to activate the NFκB pathway and induce the secretion of 
inflammatory cytokines, leading to the conclusion that ETBF are pro-inflammatory, oncogenic colonic 
bacteria. These examples show the influence of bacteria on both stem cells and epithelial cells 
throughout the gut, and show how bacterial infection can be linked to carcinogenesis. Important 
mechanisms by which bacterial agents may induce carcinogenesis include chronic infection, immune 
evasion and immune suppression. Bacterial infections can induce the release of cytokines such as 
reactive oxygen species, interleukins and cyclooxygenases from inflammatory cells, which can 
contribute to carcinogenic and mutagenic changes. Chronic stimulation of these substances has been 
shown to contribute to carcinogenesis (Mager, 2006). 
Fusobacterium nucleatum infection, associated with colorectal cancer (CRC), is linked to adherence 
and invasion and induction of oncogenic and inflammatory responses to stimulate growth of CRC cells. 
Fusobacterium nucleatum infection is believed to occur through its unique FadA adhesin, which has 
been shown to bind to the protein E-cadherin, which can activate β-catenin signalling (Rubinstein et 
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al., 2013). The FadA gene levels in the colon tissue from patients with adenomas and adenocarcinomas 
are 10–100 times higher compared to normal individuals and this increased FadA expression in CRC 
correlates with increased expression of oncogenic and inflammatory genes. With similar traits to AIEC, 
it is possible that AIEC virulence factors could influence Wnt signalling in a similar manner. This 
suggests a mechanism by which bacteria can drive Wnt signalling and CRC, and these virulence factors 
could be a potential diagnostic and therapeutic target in CRC. 
Recently, Frizzled receptors have been established as physiologically relevant receptors for colonic 
epithelial damage following in vivo infection with Clostridium difficile (C. difficile). The C. difficile toxin 
B (TcdB) is a critical virulence factor that causes diseases associated with C. difficile infection. TcdB has 
been shown to bind to a conserved binding site known as the cysteine-rich domain, with the highest 
affinity towards Frizzled receptors 1, 2 and 7 (Tao, et al., 2016). Interestingly, rather than activate 
these receptors, TcdB was shown to compete with Wnt ligands for binding, thus blocking Wnt 
signalling. Frizzled receptor knock-out in both in vitro and in vivo disease models showed less 
susceptibility to TcdB-induced tissue damage, suggesting that some bacteria can also negatively 
regulate the Wnt pathway (Tao, et al., 2016). 
With a substantial body of evidence supporting the role of bacteria, particularly with a strong role for 
E. coli, in inflammation and intestinal disease, the inclusion of standard IBD and cancer therapies based 
on bacterial infections seems almost inevitable. Mucosa-associated E. coli have been shown to be able 
to produce an array of effects associated with many inflammatory and cancer pathways. Further 
investigation into these abilities, and potential involvement of additional cancer-promoting effects, 
may allow targeted treatment of bacterial contributors, or even combination therapies. This could be 
a reasonable approach to targeting this phenomenon, even solely based on current knowledge, in 
order to minimise the cancer risk now associated with E. coli infections. 
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1.12 Minimising the effects of mucosa-associated E. coli in colorectal disease 
With several possible pathways available for E. coli to impact inflammation of the gut and increase the 
risk of colorectal disease, there is a strong need to understand and prevent this potential impact. This 
means that further studies are required to assess these pathways in order to understand where novel 
therapies could be introduced. 
Limiting potentially pathogenic host-bacterial interactions is an important step. If the intestinal 
microbiota is kept at a distance from intestinal epithelial cells, it may be possible to minimise the 
likelihood of bacterial invasion (Brown et al., 2013). The mucus layer, antimicrobial peptides (AMPs) 
and innate lymphoid cells (ILCs) are just some factors helping gut tissue to avoid bacterial invasion 
whilst promoting mutualistic interactions with bacteria (Brown et al., 2013). However, it is possible 
that additional therapies focussing on bacterial interactions would be beneficial, and could prevent 
invasion of bacteria such as E. coli, and these studies are now being conducted. 
One particular focus has been on antibiotic treatment of mucosa-associated E. coli in Crohn’s disease. 
There is evidence of metronidazole with azathioprine and ornidazole treatment as prophylaxis limiting 
the postoperative recurrence of Crohn's disease, which could be beneficial in preventing IBD 
progression into CRC (D'Haens et al., 2008, Rutgeerts et al., 2005). Quinolone-based antibiotic 
regimens have also been effective in targeting intra-macrophage AIEC isolates in vitro (Subramanian 
et al., 2008), and antibiotic combination therapies such as ciprofloxacin, tetracycline, and 
trimethoprim could prove clinically relevant and reduce the risk of drug resistance, a problem that has 
been previously highlighted using Crohn’s AIEC isolates (Dogan et al., 2013). However, drug-drug 
interactions could be a problem with combination antibiotics, meaning that alternative strategies 
maybe be necessary. Nitroimidazole compounds have shown efficacy in Crohn's disease, decreasing 
recurrence rates in operated patients. The use of metronidazole and ciprofloxacin is now also 
recommended in perianal disease. A major problem has been the appearance of adverse systemic 
effects limiting the long-term use of antibiotics as a preventative Crohn's disease therapy. However, 
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rifaximin, a semi-synthetic derivative of rifamycin, has given some promising results in inducing 
remission of CD with an excellent safety profile (Scribano and Prantera, 2013). 
Studies suggest that targeting prostaglandin production can reduce the incidence of colorectal 
adenomas, colorectal cancer, and deaths from colorectal cancer. Recent studies are now being used 
to help explain the beneficial effects of non-steroidal anti-inflammatory drugs (NSAIDs) in animal 
models and human disease. With bacterial infections associated with increased inflammation and 
cyclooxygenase/prostaglandin production, the impact of infections in CRC, in particular IBD-associated 
CRC could be minimised by preventing inflammatory signalling. 
COX-2 is overexpressed in early and advanced CRC tissues and indicates a poor prognosis (Brown and 
DuBois, 2005). Long-term intake of compounds inhibiting cyclooxygenases has been shown to reduce 
the overall relative risk for developing colorectal cancer (Gupta and Dubois, 2001), with selective COX-
2 inhibitors now approved for use as therapy in patients with familial polyposis (Brown and DuBois, 
2005). Their role is currently being evaluated for use in wider populations. Importantly, some selective 
COX-2 inhibitors appear to be relatively safe, which is important to allow large-scale clinical testing in 
healthy people (Dannenberg et al., 2001). Initial clinical trials using selective COX-2 inhibitors such as 
celecoxib have shown anti-tumour activity in patients with familial adenomatous polyposis and in 
preventing sporadic colorectal adenomas (Bertagnolli et al., 2006). Another study showed that use of 
celecoxib by patients at high risk for CRC was shown to significantly reduce adenoma burden detected, 
thus confirming that celecoxib can be used to prevent pre-malignant adenomas (Bertagnolli et al., 
2006). Rofecoxib, another selective COX-2 inhibitor, was also found to reduce adenoma recurrence as 
well as the risk of advanced adenomas (Baron et al., 2006). Rofecoxib treatment was, however, 
associated with significant upper gastrointestinal events and serious thrombotic cardiovascular 
events; therefore, rofecoxib would unlikely be an attractive therapy. 
Clinical studies suggest that regular use of aspirin may also decrease the risk of colorectal adenomas, 
the precursors to most colorectal cancers (Baron et al., 2003). A randomized trial of aspirin using 
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patients with previous colorectal cancer aimed to reduce recurrence of colorectal adenomas. The 
study was terminated early when statistically significant results were reported during interim analysis 
where adenomas were found in 17% of patients receiving aspirin and 27% of patients in the placebo 
group; the number of adenomas was also lower in the aspirin group, as was the time to the detection 
of a first adenoma was. Daily use of aspirin is associated with significant reduction in the incidence of 
colorectal adenomas in patients with previous colorectal cancer (Sandler et al., 2003). 
Another method of reducing the downstream effects of prostaglandins would be to limit interactions 
with receptors. The predominant prostaglandin species in benign and malignant colorectal tumours is 
PGE2, which is known to acts via four EP receptors, termed EP1 to EP4 (Hull et al., 2004). EP receptors 
have been identified as potential targets for prevention of a variety of cancers, including skin 
(Rundhaug et al., 2011), breast (Reader et al., 2011) and non-small cell lung cancer (NSCLC) (Gray et 
al., 2009). 
Signalling through EP receptors has been linked to several cancer signalling pathways. EP2 receptor 
activation leads to GSK-3 phosphorylation, and subsequent inactivation (Fang et al., 2000), which has 
been linked to increased β-catenin/TCF transcriptional activity, however the relevance of EP2/EP4 
receptor–induced β-catenin up-regulation in colorectal epithelial cells, which already contain only 
mutant APC, remains to be determined (Hull et al., 2004). EP4 receptor signalling can also lead to ERK 
signalling, with EP1 receptor activation and signalling also shown to activate ERK signalling in human 
colorectal cancer cells. With several studies showing that PGE2 levels significantly increased in benign 
and malignant human and rodent colorectal tumours (Yang et al., 1998, Pugh and Thomas, 1994, Chiu 
et al., 1997) it would be beneficial to look at these receptors as a therapeutic target for colorectal 
cancers. 
1.13 The important role of COX-2 and VEGF in colorectal disease 
The role of COX-2 in CRC development and progression has been widely reported, with expression 
now an independent predictor of poor prognosis (Ogino et al., 2008). Recently, cancer-associated E. 
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coli strains have been shown to increase cyclooxygenase-2 (COX-2) expression and subsequent 
prostaglandin-E2 (PGE2) secretion from human macrophages due to their ability to survive and 
replicate within macrophages (Raisch et al., 2015). As previously described, COX-2 and PGE2 have the 
ability to stimulate colon cancer cell growth via activation of the G protein–coupled receptor EP2, 
which leads to activation of the Wnt signalling pathway via the inactivation of glycogen synthase 
kinase 3β (GSK3β), thus allowing the accumulation and increased nuclear localisation of β-catenin 
(Castellone et al., 2005). Alongside adherence and invasion factors, COX-2 induction associated with 
strains taken from CRC patients could be another important factor in determining the role of these 
bacteria in the development and progression of CRC. 
Prostaglandin production is fast becoming a key focus in CRC diagnosis and treatment. Increased 
expression of prostaglandin-endoperoxide synthase 2 (PTGS2), also known as COX-2, leads to an 
increase in prostaglandin E2 (PGE2) production, promoting cancer cell growth via EP2 receptor-
mediated signalling (Castellone et al., 2005). COX-2 targeted inhibition using NSAIDs such as aspirin 
reduces CRC incidence and improves clinical outcome following CRC surgery (Tougeron et al., 2014). 
There is now evidence suggesting that inhibition of COX-2 using NSAIDs can down-regulate 
phosphatidylinositol 3-kinase (PI3K) signalling activity (Liao et al., 2012), which plays a major role in 
cell proliferation, adhesion, survival, and motility in many human cancers (Samuels et al., 2004). 
Activating mutations in the PI3K signalling pathway are now believed to be potential biomarkers for 
CRC, meaning that regular use of aspirin following CRC diagnosis is only associated with longer survival 
among CRC patients with aberrant PI3K signalling (Liao et al., 2012).  
Another key modulator appears to be vascular endothelial growth factor (VEGF). Increases in VEGF 
gene and protein expression are widely conserved across most cancers, and is considered to be 
involved in metastasis and angiogenesis of colorectal cancer. Increases in VEGFA gene expression 
following mucosa-associated E. coli infection has been previously confirmed using real-time PCR 
(Prorok-Hamon et al., 2014), whilst citing previous links between inflammation and E. coli infections 
43 
 
leading to increases in VEGF and cancer progression (Cane et al., 2010, Waldner et al., 2010). 
Interestingly, interventions that either reduces the colonisation of gut tissues by these bacteria or 
block their interaction with the mucosa may have preventive or therapeutic effects in colon cancer 
and CD were suggested following this study. This further implicates the importance of the mucosa-
association of these E. coli strains in the development and progression of CRC. 
With antibodies against VEGF now being successfully investigated in advanced and metastatic 
colorectal cancer trials as adjuvant therapies, and with VEGF being induced by E. coli invasion in 
epithelial cells (Prorok-Hamon et al., 2014) this could reduce the impact of bacteria-induced CRC 
pathogenesis. Both VEGF and increased microvessel density (MVD) have been associated with greater 
incidence of CRC metastases and decreased survival, with meta-analysis performed on twenty studies 
focussing on VEGF and MVD. Increased levels of VEGF were associated with unfavourable survival, 
with a 4-fold increase in the rate of distant metastases. Similar analysis on studies for MVD showed 
that patients with high MVD expression in tumours again had poorer overall survival and disease 
prognosis. Results from this study demonstrate a strong indication of using VEGF and MVD as future 
prognostic biomarkers for CRC patients (Wang et al., 2014). Increased VEGF expression has recently 
been associated with the presence of the afimbrial adhesin operon in mucosa-associated E. coli in CD 
and colon cancer, correlating with diffuse adherence to and invasion of intestinal epithelial cells 
(Prorok-Hamon et al., 2014). The specific identification of VEGF expression in this case further 
supports the inclusion of VEGF as a future biomarker and a potential target for reducing the effects of 
mucosa-associated E. coli in CD and colon cancer. 
Given the wider implications of COX-2 and VEGF in CRC, and the conserved nature of their increases 
following mucosa-associated E. coli infections, this became a clear focus for our project going 
forwards. 
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1.14 Modelling bacterial infections in vitro and in vivo 
New models are currently being explored for the diagnosis of primary and metastatic colorectal 
cancer, which has represented one of the big challenges in the clinical management of patients. For 
example, the detection of circulating tumour cells is becoming a promising addition to current 
detection techniques, and testing this model experimentally as well as clinically has demonstrated its 
use as a relatively reliable prognosis tool to determine progression-free survival in metastatic CRC 
patients (Barbazan et al., 2012). If bacteria are shown to impact the development and progression of 
CRC, it would be beneficial to be able to model these effects in a similar way before trying to 
implement then clinically. 
When choosing in vivo models for investigating the effects of bacterial infections in the development 
and progression of CRC, it is beneficial to consider the typical microbial composition given its 
implications in promoting and progressing intestinal disease. The murine microbiota is remarkably 
similar to that of the human gut, so studies performed in murine models in vivo will likely have 
translational implications relevant to the human disease (Arthur and Jobin, 2011). 
There is also a necessary requirement to use better in vitro models to improve the translational 
approach to CRC treatment, with a number of advanced in vitro models now being pursued. The 
multicellular spheroid (MCS) model is an in vitro model highly representative of the avascular region 
of solid tumours, which reflects the micro-environmental conditions of tumours in vivo. This model is 
considered the most appropriate model for studying drug resistance, and has been used to compare 
the chemo-sensitivity of CRC cell line DLD-1 to 5-fluorouracil (5-FU) and differential protein expression 
in the 3D MCS model and 2D monolayers. The expression levels of several proteins such as p-mTOR 
decreased upon 5-FU exposure in 2D monolayers, while its level was higher in the 3D MCS model. The 
differential expression between the 3D MCS model and 2D monolayers suggests differences in 
signalling mechanisms in solid tumour microenvironments compared to traditional cell culture 
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methods for CRC cells, and this has been shown to be important in the modelling of existing CRC 
treatments (Lee et al., 2014).  
A recent study developed a novel tumour model that permitted direct in situ visualization of E. coli in 
a 3D environment with epithelial-like B16.F10 melanoma cells (Elliott et al., 2011) to study 
proliferation and transport behaviours of E. coli in three-dimensional (3D) tumour environment. The 
findings from studies such as this will become increasingly useful for developing novel strategies to 
study the effect of bacteria in 3D tumour environments, and the impact of pathogenic bacteria in 
progressing CRC. 
1.15 The potential impact of mucosa-associated E. coli on Wnt signalling 
Increasing evidence suggests that constituents in the gut microbiota and chronic inflammation are 
involved in colorectal cancer (CRC) development. Gut inflammation creates an environment that 
supports tumour development by altering microbial composition. The dysbiotic microbiota is thought 
to contribute to the initiation and progression of CRC and our understanding of the microbiota could 
be essential for the management of colorectal disease (Perez-Chanona and Jobin, 2014). The contrast 
between the beneficial and detrimental roles of the microbiota during initiation, progression, and 
treatment of cancer further highlight the link between bacteria and cancer, and suggests that the 
microbiota could be considered as a key factor in the development and progression of colorectal 
disease. 
With resultant expansion of, and contact with, specific bacteria such as E. coli, CRC has been associated 
with increased numbers of mucosal bacteria, particularly adherent and invasive mucosa-associated E. 
coli. A convincing body of evidence supports the influence of these E. coli in development and 
progression of CRC, with chronic infections highly likely to lead to the typical repercussions of chronic 
inflammatory disease. This promotion and progression of cancer is likely to be aided by pathogenicity 
and virulence factors. Disruption of cellular signalling pathways controlling inflammation and 
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tumorigenesis may also be involved, with preliminary data showing that AIEC can upregulate epithelial 
pro-inflammatory COX-2 and PGE2 release. 
The correlation between AIEC infection and cytokine production, particularly COX-2, in CRC patients 
suggests the need for additional investigation in order for therapeutic interventions to be better 
implemented, and the use of anti-inflammatory agents similar to those tested in clinical trials could 
limit the inflammatory driving force of COX-2 and prostaglandin production, thus potentially reducing 
proliferative and angiogenic effects, as well as risk of metastases. 
High numbers of E. coli have been shown in the microbiota and within gut tissue in IBD and CRC 
patients. The impact of a number of factors are indicated for the progression of IBD-associated and 
sporadic CRC, and the potential impact of bacteria is suggested from as early as adenoma (sporadic) 
or low-grade dysplasia (IBD) through to carcinoma (see Figure 1.3). Our focus on the impact of E. coli 
in the development and progression of colorectal carcinogenesis stems from the accumulated data 
implicating E. coli in disease. With a number of pathogenic and virulence factors already highlighted 
as a potential link between E. coli and carcinogenesis, we wanted to be able to investigate this further, 
with a particular focus on pathways already heavily implicated in colorectal disease.  
Due to the promising link between COX-2 and colorectal disease, and the suggested link between COX-
2 and Wnt signalling, we chose to focus our efforts on this relationship, particularly looking at any 
impact on β-catenin activity. Wnt signalling helps regulate cell cycle and cell growth, whilst also playing 
a crucial role in colorectal tumorigenesis, so investigating whether AIEC possess ability to activate key 
cancer-promoting proteins within epithelial cells lining the bowel may allow further insight into the 
development, growth and spread of colorectal tumours. We therefore look to characterise Wnt 
signalling as a mechanism for malignant development in the intestinal epithelium following AIEC 
infection. 
It is already evident that preventative measures limiting the availability of E. coli surface adhesion 
molecules could be achieved by targeting adherence factors; if pathogenic E. coli strains are unable to 
47 
 
adhere to epithelial cells in the gut, virulence and invasive factors are effectively nullified. However, 
to be able to target specific pathogenic factors carried by AIEC would require a better understanding 
of the factors involved specifically in development and progression of CRC. By using a combination of 
in vitro and in vivo techniques, including the introduction and implementation of novel three-
dimensional colorectal cultures, further research into the impact of E. coli in CRC could add a more 
definitive insight into the translational effects of chronic infection, and where we could look to prevent 
these effects in the future. 
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Chapter 2: 
Hypothesis 
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2.1 Hypothesis 
Wnt signalling is a mechanism for malignant development in the intestinal epithelium following 
mucosa-associated E. coli infection. 
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Chapter 3: 
Aims 
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3.1 Aims 
1. To characterise the effects of mucosa-associated E. coli isolates from CRC and IBD patients on 
the activation of the Wnt signalling pathway in vitro using human CRC cell lines. 
2. To evaluate the inflammatory response of human macrophage cells following treatment with 
mucosa-associated E. coli isolates from IBD and CRC patients. 
3. To investigate the effects of mucosa-associated E. coli isolates from CRC and IBD patients on 
the activation of the Wnt signalling pathway in vivo using a germ-free Il10-/- mouse model of 
CRC mucosa-associated E. coli infection. 
4. To sequence and analyse the DNA content of fosmid clones confirmed to up-regulate PTGS2 
(COX-2) gene expression in vitro in order to find common genes or operons responsible for or 
contributing towards expression changes. 
5. To develop a 3D organotypic cell culture using a series of colorectal cell-lines at different 
stages of malignant transformation in the adenoma-carcinoma pathway. 
6. To investigate the effects of mucosa-associated E. coli infection of 3D organotypic cell cultures 
on COX-2 expression and Wnt pathway activation. 
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Chapter 4: 
Materials and Methods 
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4.1 Mammalian Cell Culture and Cell Line Maintenance 
4.1.1 Cell Line Propagation and Maintenance 
All cells were propagated from liquid nitrogen-stored stocks. Vials of frozen cells were thawed for 2 
minutes at 37°C in a water bath before being added to the appropriate cell media as recommended 
by the European Collection of Animal Cell Cultures (ECACC) at the Public Health Laboratory Service 
(Wiltshire, UK). Cell suspensions were then centrifuged (300 x g) for 5 minutes forming a pellet to 
remove the 10% v/v dimethyl sulfoxide (DMSO, Sigma Aldrich; Poole, UK) used in cell freezing media. 
Cell pellets were resuspended in cell media and added to 25 cm2 cell culture flasks and incubated at 
37°C in a humidified atmosphere of 5% CO2, 95% air. 
For cell passage, media was removed and cells were washed with sterile 1X phosphate-buffered saline 
(PBS; Sigma Aldrich) at pH 7.4 pre-warmed to 37°C in a water bath. Cells were then detached by 
treatment with 1X trypsin-ethylenediaminetetraacetic acid (EDTA) solution, containing 0.25% (v/v) 
trypsin and 0.02% (w/v) EDTA (both Sigma Aldrich) in PBS pre-warmed to 37°C. Following detachment, 
trypsin was removed and washed out by the addition of an equal volume of foetal bovine serum (FBS)-
containing cell media (10% FBS). The cell suspension was then mixed thoroughly and split at an 
appropriate ratio (between 1:3 and 1:20 depending on the cell type) into new cell culture flasks with 
fresh cell media. 
4.1.2 Monolayer Culture of SW480 Colonocytes 
The adherent human colonic epithelial cell line SW480 was derived from a Duke's type B colorectal 
adenocarcinoma removed from a 50-year-old male patient (Leibovitz et al., 1976). SW480 is one of 
the best characterized of the large number of established colorectal cancer cell lines, with numerous 
biochemical and genetic properties of this cell line previously reported (Yang et al., 2006). This cell line 
was selected for use due to high basal Wnt signalling activity driven by an APC protein truncated at 
residue 1338 and therefore lacking the Axin binding domains (Yang et al., 2006), as well as c-Myc 
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amplification and point mutations of the KRAS and TP53 genes (Rochette et al., 2005, Ahmed et al., 
2013). 
The SW480 cell line (#87092801, ECACC) was maintained at 20-90% confluence in complete 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma Aldrich) supplemented with 10% (v/v) FBS 
(Invitrogen; Paisley, UK), 100 U/mL penicillin and 100 µg/mL streptomycin (Sigma Aldrich). Cells were 
maintained at 37°C in a humidified atmosphere of 5% CO2, 95% air. 
4.1.3 Monolayer Culture of DLD-1 Colonocytes 
The adherent human colonic epithelial cancer cell line DLD-1 was derived from a Dukes' type C 
colorectal adenocarcinoma removed from a 45-year-old male patient (Dexter et al., 1981). Again, this 
cell line was selected for use due to high basal Wnt signalling activity driven by APC truncated at 
residue 1427 in DLD-1 cells, again resulting in loss of axin binding domains (Yang et al., 2006). DLD-1 
cells also present with point mutations of the KRAS and TP53 genes, as well as PIK3CA gene mutation 
(Ahmed et al., 2013). 
The DLD-1 cell line (#90102540, ECACC) was maintained at 20-90% confluence in complete DMEM 
supplemented with 10% (v/v) FBS (Invitrogen), 100 U/mL penicillin and 100 µg/mL streptomycin 
(Sigma Aldrich). Cells were maintained at 37°C in a humidified atmosphere of 5% CO2, 95% air. 
4.1.4 Monolayer Culture of Stably Transfected HeLa TCF/LEF Luciferase Reporter Cells 
The Human cervix epitheloid carcinoma HeLa cell line (Lucey et al., 2009) stably transfected with pTA-
TCF/LEF-luciferase reporter vector (which contains 6 repeats of TCF/LEF binding sites, a minimal 
promoter upstream of the firefly luciferase coding region firefly luciferase) was bought commercially 
(#SL-0022-FP; Signosis, USA). This was used as a reporter system to monitor TCF/LEF transcription 
downstream of β-catenin nuclear translocation. Cells were maintained at 20-90% confluence in DMEM 
supplemented with 10% (v/v) FBS (Invitrogen), 100 U/mL penicillin and 100 µg/mL streptomycin 
(Sigma Aldrich) at 37°C in a humidified atmosphere of 5% CO2, 95% air. 
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4.1.5 Monolayer Culture of AA/C1 and AA/C1/SB Colonocytes 
The premalignant human colonic epithelial cell line PC/AA and experimentally-transformed AA/C1 and 
AA/C1/SB cells were kindly donated by Professor Chris Paraskeva (University of Bristol, UK). The PC/AA 
cell line, established from a premalignant adenoma taken from a patient with familial adenomatous 
polyposis, was immortalised following in vitro passaging in combination with mouse NIH-3T3 
fibroblast cells grown in collagen-coated flasks and used to produce clonogenic variants AA/C1 and 
AA/C1/SB (Williams et al., 1990, Paraskeva et al., 1988).  Briefly, PC/AA cells were transformed into 
AA/C1 under standard culture conditions but in the absence of NIH-3T3 feeder cells and collagen-
coating, with AA/C1 cells then transformed into AA/C1/SB cells following continued treatment with  
1 mM sodium butyrate. AA/C1 cells remained non-tumourigenic, whereas AA/C1/SB cells showed 
tumourigenicity in nude mice, showing similar traits to adenoma and carcinoma cells, respectively 
(Williams et al., 1990). 
Both AA/C1 and AA/C1/SB cells required DMEM supplemented with 20% v/v FBS (Invitrogen), 2 mM 
L-glutamine (Sigma Aldrich), 100 U/mL penicillin and 100 µg/mL streptomycin (Sigma Aldrich), 1 µg/mL 
hydrocortisone sodium succinate (Sigma Aldrich) and 0.2 units/mL human insulin (Sigma Aldrich). Cells 
were maintained at 20-90% confluence in 25 cm2 plastic tissue culture flasks at 37°C in a humidified 
atmosphere of 5% CO2, 95% air. 
4.1.6 Monolayer Culture of THP-1 Blood Monocytes 
The human peripheral blood monocyte suspension cell line THP-1 (#88081201, ECACC) was originally 
derived from the peripheral blood of a 1 year old male with acute monocytic leukaemia (Tsuchiya et 
al., 1980). THP-1 cells were maintained at approximately 20-80% density suspended in RPMI-1640 
(Sigma Aldrich) supplemented with 10% (v/v) FBS (Invitrogen), 50 µM 2-mercaptoethanol, 100 U/mL 
penicillin and 100 µg/mL streptomycin (Sigma Aldrich) at 37°C in a humidified atmosphere of 5% CO2, 
95% air. 
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THP-1 monocytes can be differentiated into macrophage-like cells. THP-1 monocytes were 
differentiated into macrophages by treatment with 20 ng/mL phorbol myristate acetate (PMA) for 3 
days. Enhanced differentiation of PMA-treated cells was also tested by removing the PMA-containing 
media and incubating the cells in fresh media for a further 5 days (Daigneault et al., 2010). These cells 
were used to investigate the interactions between macrophage cells and mucosa-associated E. coli 
isolated from patients with IBD and CRC using a PGE2 enzyme-linked immuno-sorbent assay (ELISA) 
similar to that used in a previous study (Raisch et al., 2015). 
4.2 Three Dimensional Organotypic Cell Culture 
The development of a three-dimensional (3D) organotypic colonic tissue model using cells grown in 
vitro was established to mimic that of the host colonic tissue. This model was developed using the 
Rotary Cell Culture System (RCCS; Synthecon, US) as shown in Figure 4.2.1, and was used to develop 
colonic organotypic tissue cultures to investigate the adenoma-carcinoma sequence, as well as to 
assess the effect of E. coli infection on Wnt signalling. 
 
 
 
 
Figure 4.2.1 Rotary cell culture system (RCCS) setup. The annotated image shows a typical RCCS 
setup using a 50 mL disposable culture vessels. The RCCS culture system (left) would be placed inside 
the incubator, with the control box (right) placed outside and linked via cable. 
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Briefly, colonocytes were added directly into 10 ml or 50 ml disposable vessels, or seeded onto 
diethylaminoethyl (DEAE) cellulose (Cytodex-1; C0646, Sigma-Aldrich) and collagen (Cytodex-3; 
C3275, Sigma-Aldrich) micro-carrier beads before being added to a rotary cell culture vessel, or were 
and attached to the RCCS before initiating rotation. SW480 colonocytes were used for initial testing, 
before also using the DLD-1 cell line and AA/C1/SB colonocytes. SW480 and DLD-1 cells were 
maintained in complete DMEM supplemented with 10% (v/v) FBS and 100 U/mL penicillin and 100 
µg/mL streptomycin at 37°C in a humidified atmosphere of 5% CO2 and 95% air, with AA/C1/SB also 
requiring 2 mM L-glutamine, 1 µg/ml hydrocortisone sodium succinate and 0.2 units/ml human insulin 
as used in monolayer culture. 
Media was changed 72-96 hours after seeding, and then every 48 hours until cell aggregates were 
harvested. Periodic sampling following media changes allowed monitoring of cell aggregation, viability 
and morphology, as well as cell interaction with Cytodex-1 and Cytodex-3 coated cross-linked dextran 
micro-carrier beads using light microscopy (Figure 4.2.2). These micro-carriers were selected due to 
the high surface area to volume ratio and the specific bead coatings, which mimic the surface tension 
and adhesive surface for epithelial colonocytes in vivo (Goh et al., 2013). 
 
20x20x
Figure 4.2.2 SW480 cells adhered to Cytodex-1 and Cytodex-3 microcarrier beads. Images show 
SW480 colonocytes adhered to Cytodex-1 (left) and Cytodex-3 (right) cross-linked dextran micro-carrier 
beads as viewed under light microscopy at 20x magnification. 
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Following cell culture using the RCCS, harvested cell aggregates were plated for E. coli treatment 
experiments or used to assess aggregate structure using haematoxylin and eosin (H&E) staining and 
immunohistochemistry (IHC). The use of this system for infection assays have been previously 
reported (Carvalho et al., 2005, Barrila et al., 2010). 
4.3 Histological Processing 
Organotypic 3D cell aggregates were washed and stored in sterile phosphate buffered saline (PBS; 
pH7.4) overnight to allow the aggregates to settle; this helped to avoid loss of harvested aggregates 
from processing cassettes. Cell aggregates were then suspended in 500 µL sterile Histogel (Thermo; 
Paisley, UK) heated until liquid, and left to cool until set solid. The Histogel cell suspension was then 
placed in histological processing cassettes. Cell aggregates were then processed overnight (see Table 
4.3) using a Shandon 2LE tissue processor (Thermo Shandon; Runcorn, UK). 
 
Table 4.3. Histological processing schedule for Histogel-suspended cell aggregates. 
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Cell aggregates were embedded within the histological processing cassettes using Surgipath Formula 
R paraffin wax (Leica; Milton Keynes, UK) in a Shandon Histocentre embedding system (Thermo 
Shandon; Runcorn, UK). For sectioning of the cell aggregates, the paraffin wax blocks containing the 
aggregates were cooled on ice for 30 minutes. Blocks were then sectioned by microtome at a thickness 
of 4 µm and floated in a heated water bath before adhering to glass slides; for immunohistochemistry, 
3-aminoprpyltriethoxylsilane (APTS; 98-100%) coated slides were used (Fisher Scientific; 
Loughborough, UK). Slide-mounted sections were then dried in an oven at 37°C overnight. 
4.4 Bacterial Cell Culture 
4.4.1 Bacterial Strains 
E. coli strains used were previously isolated from the colorectal mucosa of patients with CD, UC and 
CRC (Martin et al., 2004). Briefly, this study had used human colorectal biopsy specimens washed in 
sterile saline and treated with dithiothreitol (DTT) solution to remove the overlying mucus layer. The 
resultant DTT solution was plated onto MacConkey agar and incubated at 37°C for 24 hours, with 
bacterial growth designated as mucus-associated. Following DTT treatment, biopsy specimens were 
then either treated with sterile saline or gentamicin (50 µg/mL) – the latter to kill any extracellular 
bacteria. Supernatant from the saline-treated biopsies were plated, with growth designated as 
mucosa-associated bacteria. Those biopsy specimens treated with gentamicin were lysed with sterile 
distilled water and plated onto MacConkey agar, with bacterial growth on these plates designated as 
being intracellular. Selected colonies were Gram stained; Gram-negative rods were further 
characterised using API bacterial identification tests (Bio-Merieux; Marcy L’Etoile, France) and pulsed-
field gel electrophoresis (PFGE). Individual isolates (including those identified as E. coli) were stored 
as frozen cultures at -80 °C on Protect beads (#D535; Lab M, Manchester, UK). For the E. coli isolates 
used in this project, a number of relevant adhesion and invasion characteristics/virulence factors have 
been previously identified (Martin et al., 2004, Prorok-Hamon et al., 2014, Arthur et al., 2012); these 
are summarised in Table 4.4.1. Strains were selected in order to cover different characteristics 
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associated with intestinal disease. The non-pathogenic E. coli K12 (#10798; ATCC), isolated from a 
stool sample of a patient convalescent from diphtheria (Bachmann, 1972), was used as a negative 
control throughout the project as a negative control, with no reported implications in intestinal 
inflammation or carcinogenesis. 
 
 
 
 
 
4.4.2 Bacterial Growth and Culture 
Individual E. coli strains were grown on solid culture on Luria Bertoni (LB) agar (5.0 g tryptone, 2.5 g 
yeast extract, 5.0 g sodium chloride, 7.5 g agar, 0.5 L Elga purified water) and incubated at 37°C 
overnight. Bacto™ agar, Bacto™ tryptone and Bacto™ yeast extract were supplied by BD Biosciences 
(Oxford, UK), with sodium chloride supplied by Sigma Aldrich. Following incubation, single colonies 
were removed from solid agar culture and suspended in sterile phosphate buffered saline (PBS, pH 
7.4). The bacterial culture was centrifuged at 1,000 x g for 5 minutes and washed before being 
resuspended in sterile PBS or the appropriate assay culture medium before measuring absorbance 
(OD600nm); average absorbance from 3 readings of suspension culture was used to estimate bacterial 
numbers in liquid cultures (OD600nm = 0.6 equivalent to approx. 3 x 108 bacteria). 
Table 4.4.1. Summary of adhesion and invasion characteristics and virulence factors associated with 
E. coli strains isolated from patients. Adapted from Martin et al. 2004; Subramanian et al. 2008; Arthur 
et al. 2012; Prorok-Hamon et al. 2014. 
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4.4.3 Fragmented E. coli HM358 DNA fosmid library of clones 
A fosmid library of clones was previously created using the fragmented DNA from E. coli HM358 by 
Professor J. Marchesi at University College Cork (see (Prorok-Hamon et al., 2014). Fosmid clones were 
grown from frozen stocks in liquid-phase culture using LB broth (5.0 g tryptone, 2.5 g yeast extract, 
5.0 g sodium chloride, 0.5 L Elga purified water) at 37°C overnight. 
Briefly, LB broth was added to deep-well 96 well plates (500 µL per well), with one clone grown in each 
well.  Plates were sealed using a slotted 96-well rubber seal to allow aerobic growth while eliminating 
the risk of cross-contamination and incubated at 37°C overnight. Following incubation, 200 µL samples 
were taken from 3 wells of each plate and diluted in 1800 µL PBS before measuring absorbance 
(OD600nm). Average absorbance was used to estimate bacterial numbers in liquid cultures. These 
fosmid clones were used to screen for changes in cyclooxygenase-2 (PTGS2) gene expression in 
response to infection. 
4.4.4 Bacterial Fosmid DNA Extraction and Purification 
Fosmid DNA was extracted and purified from clones of the fragmented E. coli HM358 fosmid library 
showing >2-fold up-regulation of PTGS2. Extraction and purification of fosmid DNA was completed 
using the Plasmid Midi kit (Qiagen; Manchester, UK) following manufacturer guidelines. 
This purification protocol uses a modified alkaline lysis procedure followed by the binding of DNA to 
resin under appropriate salt and pH conditions, with RNA, proteins and other impurities removed and 
DNA eluted.  Briefly, selected clones were grown in a starter culture of LB broth under vigorous shaking 
conditions overnight at 37°C. The starter culture was then diluted 1/500 and left overnight under the 
same conditions. Cells were then pelleted by centrifugation at 1,000 x g for 15 minutes and lysed using 
Buffer P1 in combination with RNase A to remove and RNA contamination. Cell lysate was washed 
before precipitation of genomic DNA, proteins and cell debris. The precipitate was centrifuged at 
1,000 x g for 30 minutes and supernatant containing plasmid DNA removed. Supernatant containing 
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plasmid DNA was bound to a pre-treated resin by gravity flow and washed with Buffer QC to remove 
any contaminants. The DNA was then eluted using Buffer QF, precipitated using isopropanol and 
centrifuged at 1,000 x g for 30 minutes. After removing the supernatant, the DNA pellet was washed 
in 70% ethanol and centrifuged at 1,000 x g for 10 minutes. The pellet was then air-dried for 10 
minutes and DNA dissolved in Tris-EDTA buffer at pH 8.0 (10 mM Tris and 1 mM EDTA in distilled 
water; Sigma Aldrich). 
4.5 Mammalian Cell Infections 
In order to ensure consistent and accurate determinations of numbers of bacteria cells to use in 
mammalian cell infections, optical density curves were generated in order to estimate multiplicity of 
infection (MOI; Figure 4.5). Prior to cell infection, bacteria were removed from solid phase cultures, 
washed 3 times and re-suspended using sterile phosphate-buffered saline (PBS, pH 7.4). Cultures were 
then measured for absorbance (OD600nm) to determine volumes of bacterial suspension to achieve the 
required MOI for the assay. 
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Figure 4.5. Optical density curves for mucosa-associated and non-pathogenic E. coli isolates. 
Dilutions of mucosa-associated E. coli isolates HM358 (A) and HM605 (B) and non-pathogenic E. coli 
K12 (C) were measured for absorbance (OD600nm) and used to calculate colony forming units (N=1, 
n=3). 
 
A. 
B. 
C. 
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4.6 Quantitative PCR (qPCR) 
4.6.1 RNA Extraction 
SW-480, DLD-1 and AA/C1/SB cells were treated with E. coli isolates (MOI: 10) for up to 4 hours before 
lysis using Buffer RLT (Qiagen). RNA was extracted and purified using the RNeasy Kit (Qiagen). Briefly, 
lysed cell samples were homogenised using QIAshredder spin columns (Qiagen) and centrifuged for 2 
minutes (13,000 x g) and transferred into spin columns. The homogenised samples were mixed with 
70% ethanol and centrifuged for 15 seconds (13,000 x g). The sample then undergoes a series of 
additions that are applied to the spin column to bind RNA to the membrane and wash away any 
contaminants. High-quality RNA was then eluted in 50 µL RNase-free water and stored at -80°C. Before 
use, the concentration of RNA in each sample was quantified by absorbance spectrophotometry at a 
wavelength of 260nm using a Nanodrop Lite (Thermo Scientific; Loughborough, UK); RNA purity was 
also assessed by the 260/280 nm absorbance ratio, where an absorbance of ≥1.8 was considered 
adequate for use in qPCR. 
4.6.2 Complementary DNA (cDNA) Synthesis 
Random Hexamer cDNA synthesis was performed with 400 ng purified RNA from individual samples 
using a Transcriptor First Strand Kit (Roche; Welwyn Garden City, UK) as per the manufacturer’s 
instructions. Briefly, RNA was incubated with random hexamer primers for 10 minutes at 65°C in a 
heat block before cooling on ice. Samples were then incubated with reverse transcriptase component 
mixture at 25°C for 10 minutes then 50°C for 60 minutes; the reaction was then stopped by incubation 
at 85°C for 5 minutes, with resulting cDNA stored at -20°C overnight.  
4.6.3 RT2 Wnt Signalling Target Gene PCR Array 
cDNA (400 ng) was added to a 96-well Human Wnt Signaling Targets RT2 Profiler PCR Array plate 
(SABiosciences; Manchester, UK) containing primers, specific to 84 Wnt target genes and 5 house-
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keeping genes, and SYBR Green Mastermix. Real-time PCR (RT-PCR) assay was run using the 
LightCycler 480 (Roche) with the program outlined in Table 4.6.3, and absolute quantification 
completed using LightCycler 480 software (version 1.5). Analysis was then completed using the RT2 
Profiler PCR Array Data Analysis software (version 3.5, SABiosciences; 
http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). 
 
Table 4.6.3. RT-PCR program for quantification using LightCycler 480. 
 
 
4.6.4 Taqman qPCR 
Real-time PCR (RT-PCR) was run with primers designed using the ProbeFinder system (Roche) and 
matched to the correct probe in the Human Universal ProbeLibrary (Roche). The concentration of each 
primer and probe was normalised (Table 4.6.4) for use in routine assays following optimisation. RT-
PCR was run in 96-well format using TaqMan detection (LightCycler 480 Probes Master; 
#04902343001, Roche) and absolute quantification completed using the LightCycler 480 (Roche). 
Analysis was completed in Microsoft Excel (version Excel 2013), with target genes normalised to levels 
of beta-Actin (ACTB) or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) house-keeping genes. 
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Table 4.6.4. Primer, probe and LightCycler 480 Probes Master assay conditions. 
 
 
 
 
 
 
4.7 Protein determination using the Bradford Assay 
Protein concentration of cell lysate was determined for use in immunoblots using the Bradford assay. 
Bovine serum albumin (BSA; Sigma Aldrich) protein was diluted in distilled water to create a standard 
curve from 0-2 mg/mL. BSA standards were then added in triplicate to a clear-bottomed 96-well plate 
alongside samples of cell lysate of unknown protein concentration diluted 1:10 (e.g. 2 µL in 18 µL 
distilled water), also in triplicate. After warming to room temperature, 250 µL Bradford reagent (Sigma 
Aldrich) was added to each well and incubated at room temperature for 30 minutes on a shaker. 
Following incubation, light absorbance at 595 nm was measured using the Tecan Sunrise plate reader 
(Tecan Group, Switzerland). A standard curve was plotted in Microsoft Excel using mean absorbance 
of known BSA standards. A linear trend line was added and line equation obtained, with the y-axis 
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intercept set as the mean absorbance for wells containing water only (0 mg/mL BSA). The standard 
curve line equation was then used to calculate unknown protein concentrations. 
4.8 Immunoblotting 
SW-480 and DLD-1 cells were treated with E. coli isolates (MOI:10) for up to 4 hours before lysis using 
radio-immunoprecipitation assay (RIPA) buffer containing 50mM Tris-HCl, pH 7.4, 150mM NaCl, 1mM 
EDTA, 1mM phenylmethylsulfonyl fluoride (PMSF), 1mM sodium fluoride, 1mM sodium 
orthovanadate, 1 µg/mL protease inhibitor cocktail (#P8340); all were obtained from Sigma Aldrich. 
Protein concentrations for lysate samples were determined by Bradford assay. Protein samples of 
known concentration were then loaded onto SDS-polyacrylamide gels (Table 4.8) alongside the 
Precision Plus Protein Kaleidoscope marker (#1610375, BioRad, UK). 
Gels were run using a Mini-PROTEAN® Tetra Vertical Electrophoresis system (#1658005, BioRad) for 
30 minutes at 50 V, then another 90 minutes at 100 V, with protein transferred using electroblotting 
for 60 minutes at 100 V onto nitrocellulose membrane. Membranes were incubated in blocking buffer 
(1% w/v BSA in PBS) before incubation with primary antibodies; monoclonal mouse anti-human β-
catenin E-5 (#sc-7963, Santa Cruz via Insight Bio; Wembley, UK), monoclonal mouse anti-human 
cyclooxygenase-2 D-5 (#sc-514489, Santa Cruz) and monoclonal mouse anti-human pan-actin Ab-5 
(#MS1295, Thermo) were used. Membranes were developed using SuperSignal West Dura solution 
(#34075, Thermo) and measured for luminescent signal using a ChemiDoc system (BioRad). 
Densitometry was performed using ImageLab software (version 4.1, BioRad) measuring band 
intensities and normalising to the untreated control. Results were calculated as fold-change relative 
to untreated controls (designated as 1.0 fold-change). Immunoblot band intensities for COX-2 and β-
catenin protein were then normalised to levels of pan-actin. 
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Table 4.8. Ingredients for polyacrylamide running and stacking gels. 
 
 
4.9 Cellular immunofluorescence studies to examine β-catenin nuclear localisation 
SW480 and DLD-1 cells were fixed to 13 mm glass coverslips in a 12-well plate tissue culture plate 
(Corning, UK) at a cell density of 10,000 cells per well in 2 mL growth medium. After 48 hours, cells 
were gently washed with sterile PBS (pH 7.4). Cells were then cultured overnight in serum-free 
medium before being treated with E. coli isolates for 4 hours. 
Following E. coli treatment, cells were washed with sterile PBS and incubated overnight in serum-free 
DMEM containing 50 μg/mL gentamicin (Sigma Aldrich) to enable visualisation of the β-catenin 
nuclear localisation effect of intracellular isolates, with prostaglandin E2 (1 µM) treatment also left 
overnight as a positive control for β-catenin nuclear localisation. Cells were fixed using 100% methanol 
at -20˚C for 15 minutes before washing using sterile PBS. Cells were then permeabilised using PBS 
containing 5% w/v BSA and 1% v/v triton X-100 for 30 min, followed by three washes using sterile PBS. 
Blocking was then completed using PBS containing 5% w/v BSA overnight at 4 °C. Cells were incubated 
with primary mouse monoclonal IgG antibody for human β-catenin E-5 (#sc-7963, Santa Cruz) for 1 
hour. Secondary fluorescein isothiocyanate (FITC) conjugated anti-mouse IgG antibody was then 
applied to slides in the dark for 1 hour before coverslips were mounted using Vectashield (VectorLabs, 
Peterborough) containing 4',6-diamidino-2-phenylindole (DAPI) to stain cell nuclei. After mounting, 
images were captured using AQM Advance software (version 6.0, Kinetic Imaging, UK) using a 
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fluorescence microscope (DAPI, excitation 405nm, emission 460nm; FITC, excitation 450nm, emission 
535nm) and quantified using ImageJ 1.48v (NIH, USA; https://imagej.nih.gov/ij/download.html). 
4.9.1 Using ImageJ to examine β-catenin nuclear localization 
A user protocol was developed to be able to use ImageJ to quantify nuclear and cytoplasmic FITC 
staining indicating β-catenin localisation within each cell (for full user protocol, see Appendix 1). 
Briefly, each image containing DAPI and FITC overlay capture was opened in ImageJ, with colour 
channels split into red, green and blue channels. The channel images are transformed into greyscale, 
with the blue (DAPI) and green (FITC) channels retained and red channel discarded. Background 
fluorescence was then removed for both image channels. A pixel radius was set for each image as 50.0 
pixels. 
4.9.2 Defining nuclear and cytoplasmic regions of interest within ImageJ 
In order to define nuclear regions of interest (ROIs), an untreated control image was used. Following 
channel splitting and removal of background fluorescence, the DAPI image was duplicated and used 
to define the ‘max/min’ greyscale thresholds. Image masks were then created to define nuclear ROIs, 
with dark pixel outliers removed (pixel radius of 2.0, and threshold of 10.0 used to remove dark pixel 
outliers). Following outlier removal, the mask particles were analysed; for dark stained nuclei, a 
maximum pixel size (250.0) minus ‘infinity’ (250-Infinity) was used, with any measure of circularity 
(0.00-1.00) included. This nuclear ROI was then added to the ROI manager, with the image mask shown 
to contain numbered nuclear ROIs. To define cytoplasmic ROIs, the green FITC image channel was 
duplicated and masked in the same way in order to define ‘max/min’ greyscale thresholds, this time 
using an inverted image showing FITC-staining as white pixels. The duplicated greyscale image was 
then matched to the FITC-staining of the unaltered image. Once matched, this threshold was then set 
for every subsequent image, including images of cell treated with E. coli. Nuclear staining was then 
removed using the thresholds set for nuclear ROIs, creating a new masked pixel image showing only 
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greyscale cytoplasmic staining. Image masks for nuclear and cytoplasmic staining were then saved and 
used to quantify ROIs. 
4.9.3 Quantification of nuclear and cytoplasmic ROIs 
The ROIs were quantified using the within the analysis section of ImageJ. This produces a ‘Mean gray 
value’, plus other measurements such as standard deviation, with labels for cytoplasmic and nuclear 
ROIs also displayed alongside the result. The results are then automatically exported as a table, which 
was used to quantify cytoplasmic and nuclear β-catenin staining. Cytoplasmic and nuclear ROI results 
were used to calculate a mean cytoplasmic and nuclear stain for all cells within each image, which was 
then used to give a ratio for ‘nuclear:cytoplasmic’ staining by dividing your mean nuclear stain by the 
mean cytoplasmic stain. These ratios were then used to compare β-catenin nuclear localisation in 
untreated control and cells treated with E. coli isolates (normalised to untreated controls). The ratios 
for nuclear:cytoplasmic staining for SW480 and DLD-1 cells were then plotted using Microsoft Excel. 
4.10 HeLa cell TCF/LEF luciferase reporter assay 
The established and commercially-available TCF/LEF luciferase reporter HeLa cell line stably 
transfected with a pTA-TCF/LEF-luciferase reporter vector contains 6 repeats of the TCF/LEF binding 
sites upstream of the firefly luciferase coding region (#SL-0022-NP-SIG; Signosis via Stratech Scientific, 
UK). These cells were used as a reporter system, monitoring the activation of β-catenin activity 
triggered by mucosa-associated E. coli infection. 
Briefly, cells were seeded at a cell density of 10,000 cells/well in a clear bottom 96-well plate and 
incubated in serum-free DMEM overnight. Cells were then treated with E. coli isolates (MOI:10) for 4 
hours. Following treatment, cells were incubated overnight in serum-free DMEM containing 50 μg/mL 
gentamicin (Sigma Aldrich) to allow any β-catenin nuclear localisation and subsequent transcription 
caused by intracellular bacteria before lysis using Passive Lysis Buffer (#E-1941, Promega; 
Southampton, UK); light microscopy was used to confirm complete cell lysis before transferring the 
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cell lysate to a white-walled 96-well plate (#3917, Corning). The lysate was then incubated with 
luciferase substrate (LUC100; Signosis, US), and the plate read immediately for luminescence at 550 
nm using a luminometer (Tecan Infinite 200 Pro; Tecan UK Ltd, Reading, UK). Analysis was completed 
to give fold change data, with 10 mM lithium chloride (LiCl) used as a positive control (as 
recommended by the manufacturers), and 100 mM LiCl to induce cell death as a negative background 
luminescence control. 
4.11 Prostaglandin E2 enzyme-linked immuno-sorbent assay (ELISA) 
The Prostaglandin E2 (PGE2) Express ELISA (#500141, Cayman Chemicals via Cambridge Bioscience; 
Cambridge, UK) was used to measure levels of PGE2 in cell supernatant from human THP-1 monocyte-
derived macrophage cells treated with E. coli isolates. This assay is based on competition between 
PGE2 and a PGE2-acetylcholinesterase conjugate (PGE2 tracer) for a PGE2 monoclonal antibody; any 
PGE2-antibody complex formation is bound to a goat anti-mouse IgG attached to the well of the assay 
plate. Following washing, 200 µL Ellman’s reagent, containing the substrate for acetylcholinesterase, 
is added to each well, with the product of the enzymatic reaction having a yellow colour that absorbs 
strongly at 412 nm. 
Briefly, THP-1 monocytes at a cell density of 1x106 cells in a 25 cm2 flask were differentiated into 
macrophages by treatment with 20 ng/mL phorbol myristate acetate (PMA) overnight before E. coli 
treatment for 4 hours. Following treatment, cell supernatant and bacteria in suspension were 
removed and cells were incubated in serum-free RPMI-1640 containing 50 μg/mL gentamicin 
overnight. Cell supernatant was then removed for use in assay. Briefly, samples of cell supernatant 
were incubated with PGE2 antibody and a tracer dye (supplied by manufacturer) in a plate coated with 
goat anti-mouse IgG (all included in the assay kit) for 1 hour. Wells were then washed before signal 
development using Ellman’s reagent for 90 minutes. The plate was then read for absorbance at 405-
420 nm using a Tecan Sunrise (Tecan). Absorbance measurements were compared to those obtained 
using PGE2 standards (0 pg/mL – 2000 pg/mL; included in the assay kit). 
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4.12 In vivo modelling of mucosa-associated E. coli infection 
4.12.1 Animal ethics 
Animal models of intestinal inflammation and CRC are indispensable for our understanding of the 
pathogenesis of IBD and CRC in humans. Procedures were performed with ethical approval under 
appropriate UK Home Office and overseas institutional licences.  
Wild-type C57BL/6 mice were maintained under specific pathogen-free conditions in the new 
Biomedical Services Unit (University of Liverpool), with wild-type controls sourced from either Charles 
River (Margate, UK) or the Walter and Eliza Hall Institute (WEHI). Dextran sodium sulphate (DSS) 
colitis-induction studies were performed under Home Office project licence 70/8457 held by Professor 
Mark Pritchard (Cellular & Molecular Physiology, University of Liverpool). Animals received 2% w/v 
DSS (MP Biomedicals, UK) in drinking water for 5 days followed by up to 16 days recovery, with body 
weight and severity of colitis assessed by Dr Carrie Duckworth (Cellular & Molecular Physiology, 
University of Liverpool) and scored using well established protocols (Wirtz et al., 2007, Burkitt et al., 
2015, Williams et al., 2016). 
Apc mutant AhCre mouse studies, recommended for modelling CRC, were performed by Dr John 
Jenkins and Dr Cleberson Quieroz (Gastroenterology Research Unit, University of Liverpool). The Apc 
mutations induced in this model were the removal of the Apc gene using a loxP-flanked Apc allele 
(Apcflox/flox), causing accumulation and subsequent nuclear localisation of β-catenin (Sansom et al., 
2004), as well as mice harbouring one wild-type Apc allele and one Apc allele mutated at codon 850 
(Apcmin⁄+). 
4.12.2 Germ-free Il10-/- 129/SvEv mouse mono-association model 
Mouse colonic tissue was kindly donated by Dr Janelle Arthur (University of North Carolina-Chapel Hill,  
USA). Experimental work utilising this tissue was completed with the aim of gaining insights into how 
in vitro changes could translate in vivo. Germ-free Il10-/- 129SvEv strain mice (n=17) were mono-
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associated with E. coli HM44 for 6 weeks at the gnotobiotic facility at University of North Carolina 
(Table 4.12.2) with local ethical approval. Mice were colonized using cotton swabs soaked in an 
overnight culture of HM44 grown in Luria Broth from a glycerol stock. Stool pellets were collected at 
the conclusion of the experiment and plated on eosin-methylene blue agar plates (a selective stain for 
Gram-negative bacteria) to demonstrate E. coli colonisation (see Figure 4.12.2; courtesy of Dr Janelle 
Arthur). Colonic tissue was obtained from HM44 mono-associated mice (n=15 of 17) and germ-free 
controls (n=5). Tissue was formalin-fixed and paraffin-embedded before microtome-sectioning and 
processing. Dr Janelle Arthur (UNC-Chapel Hill, USA), had noted higher levels of inflammation and 
vascularisation of the colonic tissue of HM44 mono-associated mice (data not shown). 
 
Table 4.12.2. Details of Germ-free Il10-/- 129/SvEv mice colonised with E. coli HM44. 
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4.12.3 Haematoxylin and Eosin (H&E) Staining 
Microtome-sectioned tissue was mounted on glass slides and placed in a slide rack. Tissue was de-
waxed in xylene for 10 minutes before rehydration (2 minutes in 100% ethanol, 2 minutes in 90% 
ethanol, 2 minutes in 70% ethanol and 2 minutes in water). Slides were then placed in Gill no.1 
haematoxylin (Sigma-Aldrich) for 3 minutes before running under tap water for 10 minutes. Slides 
were then placed in eosin (Sigma-Aldrich) for 3 minutes, then put immediately in water for 2 minutes 
before dehydration (20 dips in 70%, 90% and 100% ethanol). Slides were then transferred into xylene 
for 10 minutes and mounted onto glass coverslips (22x50mm) using DPX Mountant (Sigma Aldrich). 
Figure 4.12.2. E. coli colonisation of HM44 mono-associated mice. Stool pellets collected at the 
conclusion of the experiment were plated on eosin-methylene blue agar plates to demonstrate  
E. coli colonisation. Image courtesy of Dr Janelle Arthur. 
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4.12.4 Immunohistochemistry 
Microtome-sectioned tissue was processed for incubation with primary antibodies. 
Immunohistochemistry for cyclooxygenase-2 (COX-2) and β-catenin was performed using a 1:400 
dilution of the COX-2 antibody (#ab15191, Abcam; Cambridge, UK) and 1:50 dilution of the β-catenin 
antibody (#610154, BD Biosciences); these dilutions were decided following antibody titration tests 
using available tissue. Heat-induced antigen retrieval was performed in citric acid buffer (pH 6.4). 
Images were captured using SPOT Image Capture Software (SPOT Imaging Solutions) on a light 
microscope (Leica, Germany); 5 images per slide were taken to ensure adequate coverage of the tissue 
section. Total epithelial and nuclear staining was evaluated using the IHC Profiler and ImmunoRatio 
plugins for ImageJ 1.48v. Scoring for total epithelial staining was done using the modified HSCORE 
method. 
4.13 Statistics 
N indicates number of independent experiments, whilst n indicates assay treatment replicates within 
an experiment. Tests for normality and equality of variances of control and treatment groups were 
performed using Shapiro-Wilk test and Levene’s test respectively. Where appropriate, statistical 
analysis for independent two-sample studies was performed using Students’ unpaired T test or non-
parametric Mann–Whitney U test. For multiple treatment analyses, one way analysis of variance 
(ANOVA) or non-parametric Kruskal-Wallis ANOVA was performed as appropriate followed by pair-
wise comparison of treatment means. All statistical analyses were completed using StatsDirect v2.6.2 
software (Sale, UK). Differences were considered significant when P<0.05. Data is expressed as mean 
± SEM except for in vivo scoring data, where median and interquartile ranges are stated. 
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Chapter 5: 
Characterising in vitro changes in Wnt signalling 
following infection with mucosa-associated E. coli 
isolates from inflammatory bowel disease and 
colorectal cancer patients 
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5.1 Introduction 
A growing body of evidence suggests that a change in the composition of gut bacterial communities 
in cases of chronic inflammation has a role in inflammatory bowel disease (IBD) and colorectal cancer 
(CRC) pathogenesis. Among the many changes in bacterial composition associated with colonic 
disease, an increased abundance of Gram-negative bacteria Enterobacteriaceae has been shown, with 
high numbers of E. coli found in colonic tissue biopsies taken from patients with IBD and CRC (Martin 
et al., 2004, Swidsinski et al., 1998, Viljoen et al., 2015). Mucosa-associated E. coli isolated from IBD 
and CRC patient biopsy tissue have been found to possess a number of virulence factors that increase 
their adherence and invasion to, and that enhance their genotoxic and angiogenic potential within, 
the colonic epithelium (Prorok-Hamon et al., 2014). 
Similar mucosa associated E. coli strains have demonstrated an ability to survive and replicate within 
macrophages (Raisch et al., 2014). Macrophages are believed to be the predominant tumour-
infiltrating cells that integrate signals present in the tumour microenvironment, leading to the 
secretion of molecules that support cancer progression. Elevated levels of cyclooxygenase-2 (COX-2) 
and prostaglandin E2 (PGE2) can orchestrate the pro-cancer role of these macrophages, with COX-2 
found elevated in the majority of adenomas and adenocarcinomas. Therefore, survival of these E. coli 
within epithelial and macrophage cells has been suggested as a driving factor in the development and 
progression of CRC. 
Several bacteria have strong association with cancer in the gut, with the key example being 
Helicobacter pylori infection and increased risk of gastric cancer development (Polk and Peek, 2010). 
A number of mechanisms have been suggested to support gastric adenocarcinoma development (Kim 
et al., 2011), one of which is an increase in Wnt signalling via β-catenin accumulation in the epithelial 
cell nucleus as shown in animal models of gastric cancer (Polk and Peek, 2010). Similarly, other 
bacteria and bacterial products have been suggested to have an ability to activate the Wnt signalling 
pathway. In studies where human colonic cells were treated with Salmonella typhimurium (Liu et al., 
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2010) or the Bacteroides fragilis enterotoxin (Compare and Nardone, 2011), increased Wnt signalling 
was shown as defined by  high levels of β-catenin nuclear localisation. 
One suggested mechanism for the increase in Wnt signalling is increased levels of COX-2 enzyme 
leading to an increase in nuclear localisation of β-catenin (Castellone et al., 2005). In this scenario, 
bacteria with an ability to invade and survive within the gut mucosa cause increased, sustained release 
of inflammatory cytokines. This cytokine-induced release of cyclooxygenase 2 (COX-2) has been 
suggested to be an important factor, where high levels of COX-2 causes an increase in prostaglandin 
E2 (PGE2) that binds to the prostaglandin E2 (EP2) receptors (Williams et al., 1999b). Once activated, 
the EP2 receptor causes the release of β-catenin from critical interacting partners axin and 
adenomatous polyposis coli (APC). With increased, sustained levels of COX-2, β-catenin accumulates 
in the cytoplasm, and translocates to the nucleus to induce downstream responses such as cell 
proliferation, invasion and migration. 
With a number of bacteria already shown to increase Wnt signalling, it was understandable to predict 
that mucosa-associated E. coli, originally isolated in increased numbers from the mucosa of IBD and 
CRC patients, may have a similar effect. In this chapter, the role of these bacteria on Wnt signalling in 
vitro was investigated, with a particular focus on characterising the steps involved and the potential 
impact on the pathogenesis of colorectal cancer. 
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5.2 Hypothesis 
Mucosa-associated E. coli play a role in increasing Wnt/β-catenin signalling and this is a key 
mechanism contributing to the development and progression of colorectal cancer. 
5.3 Aims 
1. To characterise the effects of mucosa-associated E. coli isolates from CRC and IBD patients on 
the activation of the Wnt signalling pathway in vitro using human CRC cell lines. 
2. To evaluate the inflammatory response of human macrophage cells following treatment with 
mucosa-associated E. coli isolates from IBD and CRC patients. 
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5.4 Methods 
An initial screen investigating Wnt-related gene expression using a Human Wnt Signalling Targets RT2 
Profiler PCR array containing 84 Wnt-relevant genes was completed using human CRC cell lines, 
SW480 and DLD-1, treated for 4 hours (MOI:10) with E. coli isolates HM44 and HM358 previously 
isolated from colonic mucosal biopsies from CRC patients, as well as with a non-pathogenic reference 
E. coli strain K12 (see Chapter 4.4.1) used as a negative control (see Chapter 4.6.3). Changes in Wnt-
related gene expression found to be common to both cell lines and CRC E. coli isolates were then 
followed up for further evaluation using additional qPCR. Translation of these changes were 
investigated at protein level by immunoblotting (see Chapter 4.8) and by immunofluorescence 
detection of β-catenin nuclear localisation (see Chapter 4.9). 
The downstream effect of an increase in E. coli-induced β–catenin protein changes was assessed using 
HeLa cells stably transfected with firefly luciferase reporter vector under the control of TCF/LEF 
transcription factor activity. Briefly, cells were treated with E. coli isolates from IBD and CRC patients 
for 4 hours (MOI:10) before overnight incubation in gentamicin-containing media. Cells were then 
lysed before addition of a luciferase substrate and luminescent signal measured using a luminometer 
(550 nm; for full details see Chapter 4.10). 
Given that similar CRC mucosa-associated E. coli have been shown to survive and replicate within 
macrophages, increase COX-2 gene (PTGS2) expression and cause subsequent PGE2 release using THP-
1 monocyte-differentiated macrophage cells (Raisch et al., 2015), we examined for the ability of our 
own IBD and CRC E. coli isolates to effect PGE2 release from the same cell-line (see Chapter 4.11). 
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5.5 Results 
5.5.1 Wnt-related gene expression is altered following CRC E. coli infection 
To begin the study, we sought to identify early Wnt-related targets that could be impacted by 
intestinal cell infection by mucosa-associated E. coli from CRC patients. The Human Wnt Signalling 
Targets RT2 Profiler PCR Array plate (SABiosciences) covering 84 Wnt signalling and target genes was 
used to gain an insight into the effect of CRC mucosa-associated E. coli infection on Wnt target gene 
expression. Significant changes in gene expression were observed following infection of SW-480 and 
DLD-1 colorectal cancer cells with CRC mucosa-associated E. coli isolates, HM44 and HM358, 
compared to uninfected controls (Figure 5.5.1.1).  
A total of 12 genes were up-regulated more than 2-fold and 9 genes down-regulated more than 2-fold 
following infection of SW480 and DLD-1 cells with both CRC E. coli isolates (Figure 5.5.1.2; N=3 arrays 
per treatment). These altered genes play roles in proliferation, invasion, angiogenesis and migration. 
Only 3 genes were found to be commonly upregulated in response to both E. coli strains in both cell 
lines – the inflammatory and cell cycle regulating prostaglandin synthase-2 (PTGS2) gene encoding 
COX2; the FOSL1 gene encoding Fos-like antigen 1 involved in cell proliferation and linked to bacterial 
infection; and VEGF-A encoding vascular endothelial growth factor-A involved in migration and 
angiogenesis (see Table 5.5.1). Other notable upregulated genes include those encoding transcription 
factor c-Myc, MYC, and connective tissue growth factor Wnt-inducible-signalling pathway protein 1, 
WISP1. Significant down-regulation of inhibitory Wnt genes such as WISP2 was also shown, but with 
no common changes in WISP2 expression observed between cell lines. 
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A. B. 
C. D. 
Figure 5.5.1.1. Wnt signalling target gene array profiling: changes in Wnt target gene expression 
following infection with mucosa-associated E. coli. Scatterplots show log10 expression of Wnt 
signalling target genes normalised to house-keeping gene GAPDH for SW480 (A and B) and DLD-1 (C 
and D) cells infected with E. coli HM44 and HM358 for 4 hours (MOI:10) before lysis (N=3 arrays per 
treatment). A total of 12 genes were up-regulated (red) and 9 genes down-regulated (green) more than 
2-fold. 
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Figure 5.5.1.2. Wnt signalling target gene array profiling: changes in Wnt target gene 
expression following infection with mucosa-associated E. coli. Graphs show Wnt target gene up- 
and down-regulation following 4h infection with E. coli HM44 (grey) and HM358 (black) in comparison 
to untreated controls, normalised to GAPDH; (A) SW480 genes upregulated, (B) SW480 genes 
downregulated, (C) DLD1 genes upregulated, (D) DLD1 genes downregulated (N=3 arrays per 
treatment; Unpaired T-test: *P<0.05, **P<0.01, ***P<0.001). Genes included in graphs showed >2 fold 
change in one or both of the two cell lines tested. The unpaired T-test was completed using RT2 
Profiler PCR Array Data analysis software version 3.5 (available from  
http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). 
A. SW480 (upregulated) B. SW480 (downregulated) 
C. DLD1 (upregulation) D. DLD1 (downregulated) 
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Table 5.5.1. Wnt signalling target gene array profiling: changes in Wnt target gene expression 
following infection with mucosa-associated E. coli. Table shows data for up-regulated (red) and 
down-regulated (green) expression of Wnt signalling target genes following 4h infection of (A) SW480 
and (B) DLD1 cells with E. coli HM44, HM358 and K12 (SW480 only) in comparison to untreated 
controls and normalised to expression of house-keeping gene GAPDH (N=3 arrays per treatment). 
Unpaired T-test completed using RT2 Profiler PCR Array Data analysis software version 3.5 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). 
A. 
B. 
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The Human Wnt Signalling Targets RT2 Profiler PCR array was also conducted for SW480 cells infected 
with non-pathogenic E. coli K12, originally isolated from the stool of a convalescent diphtheria patient. 
Results showed only one gene to be significantly up-regulated; this was the FGF20 gene which encodes 
fibroblast growth factor 20 (P=0.045), which was shown to be down-regulated following infection with 
the two CRC-associated E. coli strains (see Table 5.5.1A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.1.3. Wnt signalling target gene array profiling: changes in Wnt target gene 
expression following infection with mucosa-associated CRC E. coli isolates HM44 and HM358 
and non-pathogenic E. coli K12. Graphs show Wnt target gene up-regulation (A) and down-
regulation (B) following 4h infection with HM44 (grey) and HM358 (black), with HM44 and HM358 
comparison to E. coli K12 controls, normalised to GAPDH. Genes included in graphs showed >2 fold 
change following treatment with E. coli HM44 and/or HM358 in one or both of the two cell lines tested 
(N=3 arrays; Unpaired T-test; *P<0.05 **P<0.01 ***P<0.001). 
A. SW480 (upregulated) 
B. SW480 (downregulated) 
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As the same Wnt gene effects were not shown following E. coli K12 infection, gene responses following 
infection with CRC-associated E. coli strains was then compared to those seen following infection with 
E. coli K12 (Figure 5.5.1.3). Significant differences in responses to infection suggested that induction 
of Wnt signalling was likely specific to infection with the CRC mucosa-associated E. coli strains. This 
observation was therefore followed up in later experiments where changes in protein levels were 
evaluated.  
5.5.2 Time-dependent PTGS2 and CTNNB1 gene up-regulation assessed by Taqman qPCR 
The COX-2 encoding gene, PTGS2, was commonly up-regulated in both SW480 and DLD-1 cell lines 
following infection with both CRC mucosa-associated strains HM44 and HM358. COX-2 up-regulation 
has been previously linked to increases in Wnt signalling (Castellone et al., 2005). These changes were 
subsequently confirmed by qPCR for PTGS2 along with increased expression of the gene encoding β-
catenin, CTNNB1, as a surrogate for Wnt pathway activation (Figure 5.5.2; N=3, n=3). 
Using an infection time-course, we were able to see significant increase in PTGS2 and CTNNB1 
expression following 2 hour (2h) and 4 hour (4h) infections of SW480 and DLD-1 cells with CRC mucosa-
associated E. coli HM44 and HM358 (MOI: 10) compared to untreated controls from the same time-
point. SW480 cells infected with E. coli HM44 and HM358 for 2h resulted in significant 2.7 ± 0.6 fold 
(P<0.05, Unpaired T-test) and 4.4 ± 0.8 fold (P<0.01) PTGS2 upregulation respectively, whilst infection 
over 4h produced 8.1 ± 0.8 fold (P<0.001) and 9.2 ± 1.0 fold (P<0.001) levels of upregulation. Probing 
for CTNNB1 expression showed a similar pattern; infection for 2h resulted in 0.9 ± 0.1 fold and 1.7 ± 
0.3 fold changes, whilst infections over 4h showed significant 1.5 ± 0.2 fold (P<0.05) and 1.7 ± 0.2 fold 
(P<0.01) levels of CTNNB1 up-regulation.  
Similar results for both PTGS2 and CTNNB1 expression were also seen in DLD1 cells infected with E. 
coli HM44 and HM358. DLD-1 cells infected for 2h resulted in 4.8 ± 2.0 fold (P<0.05) and 4.3 ± 2.1 fold 
up-regulation of PTGS2 respectively, whilst infection with the same strains over 4h resulted in  
6.7 ± 0.6 fold (P<0.001) and 11.4 ± 1.5 fold (P<0.001) upregulation of PTGS2. CTNNB1 expression 
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following 2h infection was not seen to be significant increased (0.8 ± 0.3 fold changes using both 
strains), but was significantly enhanced following infection for 4h with 3.1 ± 1.0 fold (P<0.05) and  
4.0 ± 1.5 fold (P<0.05) upregulation respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.2. Time-dependent upregulation of human PTGS2 and CTNNB1 genes following 
mucosa-associated E. coli treatment as assessed by Taqman qPCR. Graphs show fold-change 
data for PTGS2 (COX-2) and CTNNB1 (β-catenin) gene expression following E. coli HM44 and HM358 
infections for 2h and 4h in SW480 (A and B) and DLD1 (C and D) cells. Ct values were originally 
compared to those of untreated control samples before being normalised to GAPDH expression (N=3, 
n=3; Unpaired T-test; *P<0.05, **P<0.01, ***P<0.001). 
A. SW480 - 2h B. SW480 - 4h 
C. DLD1 - 2h D. DLD1 - 4h 
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5.5.3 Time-dependent increase in COX-2 and β-catenin protein expression in response to 
CRC mucosa-associated E. coli infection 
Immunoblots were used to confirm that the increased gene expression of PTGS2 and CTNNB1 
following CRC mucosa-associated E. coli infection translated into changes in protein levels of COX-2 
and β-catenin respectively (Figure 5.5.3.1). Results show that CRC mucosa-associated E. coli infection 
increases expression of β-catenin in a time-dependent manner, and that this correlated with increased 
COX-2 protein expression in both SW480 and DLD-1 CRC cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
Figure 5.5.3.1. COX2 and β-catenin immunoblots using CRC cells left untreated and following 
infection with E. coli HM44 and HM358. Immunoblots show β-actin control (43 kDa), COX-2 (69 kDa) 
and β-catenin (92 kDa) protein in (A) SW480 and (B) DLD1 cells untreated and following E. coli infection 
(HM44 and HM358). The infection time-course was carried out over a period of 4 hours (N=2, n=2). 
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SW480 cells infected with E. coli HM44 and HM358 for 4h gave significant 5.7 ± 0.7 fold and 2.8 ± 0.0 
fold respective increases in COX-2 protein levels compared to non-infected controls (both P<0.01) 
(Figure 5.5.3.2A). The HM44 and HM358 infections also resulted in significant 2.6 ± 0.1 fold (P<0.001) 
and 1.8 ± 0.2 fold (P<0.05) increases in β-catenin protein levels respectively (Figure 5.5.3.2B). Similar 
results were observed using DLD-1 cells, where the 4h infection with both E. coli strains again resulted 
in the highest fold-changes in both COX-2 and β-catenin protein expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.3.2. Increased COX2 and β-catenin protein levels in CRC cells following infection 
with E. coli HM44 and HM358. Immunoblots using lysates from SW480 and DLD1 cells left 
untreated and infected with E. coli HM44 and HM358 were analysed by densitometry. Protein levels 
for COX-2 and β-catenin in SW480 cells (A and B) and DLD1 cells (C and D) were shown to increase 
in a time-dependent manner following infection. COX-2 and β-catenin densitometry was normalised 
to changes in β-actin. Fold change was compared to untreated samples at 0h (N=2, n=2) (Unpaired 
T-test; *P<0.05, **P<0.01, ***P<0.001). 
A.      SW480 - COX2 B. SW480 - β-catenin 
C. DLD1 - COX2 D. DLD1 - β-catenin 
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Following the findings that total COX-2 and β-catenin protein levels were significantly increased 
following CRC-associated E. coli HM44 and HM358 infection of colonocytes, the effects of other 
mucosa-associated E. coli strains were investigated. Another CRC mucosa-associated isolate, HM545, 
an isolate from a CD patient HM605, and the non-pathogenic E. coli K12 strain were used to infect 
SW480 and DLD1 cells in comparison to infection with CRC mucosa-associated isolates HM44 and 
HM358 (Figure 5.5.3.3) (N=2 experiments, n=2 replicates). 
 
 
 
 
Densitometry results indicated that non-pathogenic E. coli K12 effected the smallest fold increase in 
β-catenin in both cell-lines tested (1.15 ± 0.05 fold and 1.14 ± 0.04 fold in SW480 and DLD-1 cells 
respectively). Results for E. coli HM44 and HM358 were similar to those seen previously (see Figure 
5.5.3.2), with SW480 cells showing a slightly lower fold change in these experiments. CRC mucosa-
associated E. coli HM545 showed 1.15 ± 0.06 fold (P=0.0670) and 1.15 ± 0.03 fold (0.0474) changes in 
Figure 5.5.3.3. Changes in β-catenin protein levels in CRC cells following infection with CD and 
CRC mucosa-associated and non-pathogenic E. coli isolates. Immunoblots using lysates from 
SW480 and DLD1 cells and infected with E. coli HM44, HM358, HM545, HM605 and K12 for 4h were 
analysed by densitometry. Densitometry for β-catenin was normalised to β-actin levels. Fold change 
was statistically compared to E. coli K12 infected samples (N=2, n=2; Unpaired T-test, *P<0.05). 
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SW480 and DLD-1 cells, respectively, with CD-associated E. coli HM605 effecting 1.31 ± 0.08 fold 
(P=0.1296) and 1.19 ± 0.03 fold (P=0.0955) changes. These results would suggest that increases in 
COX-2 and β-catenin gene expression following CRC-associated E. coli infection translate into protein 
expression. However, the smaller increases in β-catenin protein expression obtained following 
infection with E. coli HM545 and CD-associated E. coli HM605 hinted towards a lesser impact on Wnt 
signalling with some isolates. This suggested that the trait may be shared by other inflamed mucosa-
associated E. coli, rather than just those strains isolated from CRC patients, but that the extent of the 
impact on Wnt signalling may show variation. This was followed up by including more CD and UC 
isolates in later downstream Wnt signalling experiments (see Section 5.5.5). 
5.5.4 Mucosa-associated E. coli isolates increase nuclear localisation of β-catenin in CRC  
cell-lines  
Development of a Quantitative Immunofluorescent Cell Imaging Assay 
Following the increases observed in both CTNNB1 gene and β-catenin protein expression in response 
to CRC mucosa-associated E. coli infection, it was important to assess the extent of nuclear localisation 
of β-catenin following infection with these E. coli. To do this, SW480 and DLD-1 cells were treated with 
E. coli isolates from CRC patients (HM44, HM358 and HM545), as well as the colonic mucosa-
associated E. coli isolate from a Crohn's disease patient HM605. Cells infected for 4h were fixed to 
glass coverslips and assessed for nuclear localisation of β-catenin.  DAPI stain was utilised to identify 
the cell nucleus. Separate high-power field images (5 images per slide) split into FITC (β-catenin) and 
DAPI (nucleus) channels were then taken and used to produce a DAPI/FITC composite or overlay 
image. This allowed analysis of each image for both nuclear and cytoplasmic localisation. An 
automated system of image analysis was developed using the public domain image analysis software 
Image J (v1.45s, National Institutes of Health, Bethesda, Maryland, USA) as previously published 
(Noursadeghi et al., 2008) in order to remove bias and subjectivity, and negate the impact of using 
92 
 
staining intensity as the sole measure to be quantified. High-quality staining was achieved in both 
SW480 and DLD-1 cells, which can be seen in Figures 5.5.4.1 and 5.5.4.2 respectively. 
An automated scoring technique was developed and initially employed for DAPI/FITC composite 
images of both untreated SW-480 and DLD-1 cells. The same thresholds were then applied to cells 
treated with E. coli isolates. The full optimised protocol for scoring can be found in Chapter 4.9 and 
Appendix 1. Briefly, each composite image was split into channels showing green (FITC) and blue 
(DAPI). Background fluorescence was the removed using a radius of 50.0 pixels. Regions of interest 
(ROI’s) were then defined for nuclear and cytoplasmic cell regions to measure the extent of β-catenin 
immunofluorescence in these regions. A ratio of nuclear:cytoplasmic signal was then calculated for 
each treatment condition and compared to E. coli K12 infected controls. 
Increased β-catenin nuclear localisation in response to mucosa-associated E. coli infection 
Localisation of β-catenin was assessed by scoring both nuclear and cytoplasmic FITC-staining, allowing 
a ratio of nuclear:cytoplasmic β-catenin to be calculated for both SW480 and DLD-1 cells (Figures 
5.5.4.1 and 5.5.4.2). Importantly, significantly increased nuclear localisation was shown to occur 
following infection with either CRC or CD mucosa-associated E. coli (N=3, n=2). 
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Figure 5.5.4.1. Localisation of β-catenin in SW480 CRC cells following mucosa-associated E. coli 
infection shown by immunofluorescence. DAPI nuclear staining and FITC-labelling of β-catenin in 
SW480 cells was shown following infection with mucosa-associated E. coli strains associated with CRC 
(HM44 and HM358) and CD (HM605) and non-pathogenic E. coli K12 (N=3, n=2; 5 images per slide). 
PGE2 (1μM) known to cause β-catenin nuclear localisation was used as a positive control. 
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Figure 5.5.4.2. Localisation of β-catenin in DLD1 CRC cells following mucosa-associated E. coli 
infection shown by immunofluorescence. DAPI nuclear staining and FITC-labelling of β-catenin in 
DLD1 cells was shown following infection with mucosa-associated E. coli strains associated with CRC 
(HM44 and HM358) and CD (HM605) and non-pathogenic E. coli K12 (N=3, n=2; 5 images per slide). 
PGE2 (1μM) known to cause β-catenin nuclear localisation was used as a positive control. 
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Treatment of SW480 cells with CRC mucosa-associated E. coli HM44 led to a significant 2.3 ± 0.2 fold 
increase in β-catenin nuclear localisation (P<0.001; ANOVA), a response similar in magnitude to that 
seen following treatment with 1μM PGE2 (2.4 ± 0.3 fold; P<0.001). Likewise, infection of SW480 cells 
with E. coli HM358 also resulted in a significant 1.8 ± 0.2 fold (P<0.01) increase in β-catenin nuclear 
localisation (Figure 5.5.4.3). CD mucosa-associated E. coli HM605 also effected a 1.5 ± 0.1 fold (P<0.01) 
increase nuclear localisation of β-catenin. In addition, E. coli K12 did not cause any nuclear localisation 
of β-catenin (0.9 ± 0.1 fold change) compared to untreated controls. Similar results were seen using 
DLD-1 cells with significant increases in β-catenin nuclear localisation again observed following 
infection with mucosa-associated E. coli strains HM44, HM358 and HM605. 
 
 
 
 
 
Figure 5.5.4.3. Increased nuclear localisation of β-catenin in CRC cells following mucosa-
associated E. coli infections shown. A ratio of nuclear:cytoplasmic localisation of FITC-labelled β-
catenin was assessed in SW480 and DLD1 cells. Increased nuclear localisation was shown following 
infection with mucosa-associated E. coli strains from CRC (HM44 and HM358) and Crohn’s disease 
(HM605) patient colonic mucosa, compared to non-pathogenic E. coli K12 (N=3, n=2; 5 images per 
slide; *P<0.05, **P<0.01, ***P<0.001; ANOVA). Prostaglandin-E2 (1 μM) was used as a positive control. 
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This assessment of nuclear localisation suggests that the observed mucosa-associated E. coli infection 
induced increases in gene and protein expression do indeed translate to increased nuclear 
translocation of β-catenin. It was then speculated that downstream Wnt transcriptional activity would 
likely also be increased following infection with mucosa-associated E. coli isolates also. 
5.5.5 Increased HeLa cell TCF/LEF luciferase activity as a marker for Wnt transcription 
The downstream effect of β-catenin nuclear localisation following mucosa-associated E. coli infection 
on Wnt transcription was assessed using an established TCF/LEF luciferase reporter stable HeLa cell 
line (Signosis, USA).  As TCF/LEF transcription factor are the major end point mediators of Wnt 
signalling, downstream of β-catenin movement into the nucleus, the activity of the luminescent Firefly 
luciferase protein under the control of TCF/LEF transcription is considered a good reporter of Wnt 
signalling in the nucleus. 
As recommended by the manufacturer, 10 mM lithium chloride (LiCl) was used as a positive control 
for enhancement of luciferase activity in these cells, as well as use of PGE2 to be consistent with 
previous experiments (Figure 5.5.5A). In this assay, 10 μM PGE2 was used as it gave a more consistent 
and robust signal over 1µM used in previous experiments. A negative control of 100 mM LiCl was also 
included. This dose was seen to effect cell rounding during optimisation studies allowing only a 
baseline signal response to be observed. 
Overall, we were able to observe significant 1.5 to 2.6 fold increases in luciferase activity following 
treatment with CRC-associated E. coli isolates HM44, HM358 and HM545, CD-associated isolates 
HM95 and HM605 and UC-associated isolates HM250 and HM251, in comparison to E. coli K12 
treatment (Figure 5.5.5B; all P<0.001; ANOVA). A similar 2-fold increase in luciferase activity was 
observed using 10 µM prostaglandin-E2 (P<0.001), with the non-pathogenic E. coli K12 strain only 
producing a minimal 1.09±0.01 fold change compared to untreated controls (P<0.05; all N=2, n=6). 
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5.5.6 Inhibition of mucosa-associated E. coli-induced Wnt transcription using COX inhibitors 
With consistently increased levels of luciferase activity (indicating increased TCF/LEF transcription) 
following infection with mucosa-associated E. coli, and with the ability to screen multiple wells in this 
assay system, this assay was exploited to assess the impact of COX-2 activity in Wnt transcription. 
Initially, cyclooxygenase inhibitors aspirin, diclofenac and indomethacin were tested for their ability 
to block PGE2-induced Wnt transcriptional activity over 24 hours using the TCF/LEF HeLa cell luciferase 
reporter assay. Each inhibitor was added at the same time as addition of PGE2. 
Results showed an approximate 3-fold increase in luciferase activity with 10 µM PGE2 in the presence 
of no inhibitor (i.e. dH2O vehicle control only), with lower levels of luciferase activity observed 
following treatment with increasing concentrations of each inhibitor. The highest level of inhibition 
observed of the three cyclooxygenase inhibitors selected was using 100 µM diclofenac, showing  
FIGURE 5.5.5. Increased Wnt transcription in cervical HeLa cells following mucosa-associated 
E. coli treatment. Cervical HeLa cell TCF/LEF luciferase reporter assay showed increased TCF/LEF 
transcription following treatment with mucosa-associated E. coli HM44, HM358 and HM545 from CRC, 
HM95 and HM605 from Crohn’s disease (CD), and HM250 and HM251 from ulcerative colitis (UC) 
patients, compared to E. coli K12 (N=2, n=6; *P<0.05, **P<0.01, ***P<0.001; ANOVA). 
A. B. 
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95.3 ± 3.3 % inhibition of PGE2-induced luciferase activity compared to only 22.5 ± 1.4 % and 46.8 ± 
4.8 % inhibition with 100 µM aspirin and indomethacin, respectively (Figure 5.5.6.1B; N=1, n=3). 
Diclofenac at a concentration of 100 µM was then used in combination with E. coli HM545 and HM605 
treatment for 4 hours; these isolates were chosen to represent mucosa-associated E. coli from CRC 
and IBD patients as they gave the highest increases of luciferase activity. We were able to show 
consistent, significant inhibition of mucosa-associated E. coli-induced TCF/LEF transcription following 
co-treatment using diclofenac (Figure 5.5.6.2). Treatment with E. coli HM545 and HM605 along gave 
1.5 ± 0.1 fold (P<0.01) and 1.7 ± 0.1 fold (P<0.001) increases, respectively, reduced to 0.9 ± 0.1 fold 
(P<0.01) and 1.0 ± 0.1 fold (P<0.001) changes in combination with diclofenac, respectively. These 
results were similar to those seen with prostaglandin-E2 treatment, where a 2.0 ± 0.1 fold (P<0.001) 
increase was reduced to a 1.2 ± 0.1 fold (P<0.001) change with diclofenac treatment. Cell phenotype 
was altered slightly, with cells becoming more rounded under the microscope following treatment 
with diclofenac (100 µM). Cell growth and cell viability were not quantified. 
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Figure 5.5.6.1. Effect of cyclooxygenase (COX) inhibition on increased Wnt transcription in 
HeLa TCF/LEF luciferase reporter cells following PGE2 treatment. Prostaglandin-E2 (10 μM) was 
used to stimulate Wnt transcription in cervical HeLa cell TCF/LEF luciferase reporter assay in 
combination with cyclooxygenase inhibitors diclofenac (Dic), aspirin (Asp) and indomethacin (Ind) at 0, 
1, 10 and 100 μM. Results show (A) a reduction in PGE2 induced Wnt transcription with increasing 
concentrations of COX inhibitor, with (B) the highest % inhibition seen at 100 μM 
(diclofenac>indomethacin>aspirin; N=1 assays, n=3 wells). 
 
 
A. 
B. 
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Assessment of luciferase activity linked to TCF/LEF transcription using this method would suggest that 
Wnt transcription induced by mucosa-associated E. coli treatment translates from increased nuclear 
β-catenin localisation. Results also suggest that cyclooxygenase activity contributes significantly to 
increased Wnt transcription. 
5.5.7 Mucosa-associated E. coli treatment of THP-1 monocyte-derived macrophage cells 
results in increased release of prostaglandin-E2 
A recently published study showed CRC E. coli promoting COX-2 and PGE2 expression as well as their 
survival within human macrophages (Raisch et al., 2015). The authors reported significant changes 
Figure 5.5.6.2. Cyclooxygenase (COX) inhibition significantly reduces Wnt transcription induced 
following mucosa-associated E. coli infection for 4h. COX inhibitor diclofenac (100 μM) showed 
inhibition of increased TCF/LEF transcription caused by treatment of cells with PGE2 (10 μM) and 
mucosa-associated E. coli HM545 and HM605 (N=2, n=6; *P<0.05, **P<0.01, ***P<0.001). 
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only with CRC-associated E. coli and not with commensal or non-pathogenic E. coli strains, with this 
induction requiring live bacteria; the changes were not associated with production of the genotoxin 
colibactin. The study used human THP-1 monocytes differentiated into macrophages with 20 ng/ml 
phorbol myristate acetate (PMA) treatment for 72 hours. Considering the inhibition of mucosa-
associated E. coli-induced Wnt transcription following co-treatment with COX inhibitor diclofenac, 
increased PGE2 expression and survival within human macrophages, and the involvement of COX-2 in 
malignant development, we examined the ability of our own mucosa-associated E. coli isolates to 
affect PGE2 release in the same way. 
In addition, another study had shown that removal of PMA over a period of 5 days (termed reduced 
PMA treatment) produced cells with more macrophage-like morphology (Daigneault et al., 2010). 
Hence, we used this method to confirm the initial differentiation following PMA treatment (Figure 
5.5.7.1). Using light microscopy, we were able to observe larger macrophage cells showing a wider 
coverage of the cell culture plate surface, with more pronounced finger-like projections visible 
following reduced PMA treatment. Cell growth was not quantified. 
We assessed the amount of PGE2 produced following treatment of these monocyte-derived 
macrophage cells with CRC and IBD mucosa-associated E. coli isolates using both PMA and reduced 
PMA differentiation approach (Figure 5.5.7.2A and 5.5.7.2B, respectively). The amount of PGE2 
production was assessed in the same way as the study conducted by Raisch et al. (2015) using cell 
culture supernatant and assay by enzyme-linked immunosorbent (ELISA) assay. E. coli LF82, known to 
persist in macrophage cell lines and increase COX-2 expression (Raisch et al., 2015), and E. coli K12 
were used as positive and negative controls, respectively. The PGE2 concentration was then assessed 
for each treatment compared to known standards.  
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Pre-treatment PMA treated (24h) PMA treated (72h) Reduced PMA (5d)
Monocytes in 
suspension
Fully-adherent 
macrophages
Figure 5.5.7.1. Morphology changes of THP-1 monocytes when differentiated into macrophages. 
THP-1 monocytes were incubated with 20ng/ml phorbol myristate acetate (PMA) for 72 hours, before 
removal of PMA and incubation for a further 5 days (reduced PMA). Images from left to right show THP-
1 monocytes before PMA treatment, 24 hours and 72 hours after treatment, and 5 days after the removal 
of PMA. Cells are seen to increase in size 24 hours after PMA treatment and show full adherence after 
72 hours. The reduced PMA image shows a more macrophage-like morphology, with larger and more 
pronounced finger-like projections, whilst remaining fully adherent (N=2, 3 images time point). 
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 A. 
Figure 5.5.7.2. Mucosa-associated E. coli induce increases in prostaglandin-E2 secretion in 
monocyte-derived macrophage cells. Prostaglandin-E2 (PGE2) release was measured using the 
supernatant of THP-1 monocyte-derived macrophage cells treated with CRC mucosa-associated 
(HM44, HM358 and HM545), CD mucosa-associated (HM605, HM615, HM95) and UC mucosa-
associated (HM250 and HM251) E. coli isolates, and E. coli K12. PGE2 release was measured in THP-
1 cells differentiated using (A) PMA treatment for 72 hours well (N=2, n=3; *P<0.05, **P<0.01; ANOVA), 
and (B) following PMA-reduction treatment for another 5 days (N=1, n=3). 
 
B. 
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We were able to show significantly increased concentrations of PGE2 in the supernatant of cells 
infected with both CRC-associated E. coli isolates HM44 (2.4 ± 0.4 fold; P<0.05) and HM545 (3.8 ± 2.1 
fold; P<0.01), as well as with the CD-associated isolate HM605 (2.3 ± 0.8 fold; P<0.001) in comparison 
to E. coli K12 treatment. UC-associated isolate HM251 also showed a 1.7 ± 0.2 fold increase, with the 
positive control LF82 showing a 1.5 ± 0.1 fold increase. Non-pathogenic E. coli K12 gave a 1.6 ± 0.1 fold 
change in comparison to untreated controls. 
Both CRC and IBD associated E. coli isolates induced high levels of PGE2 secretion, similar to those 
previously reported in THP-1 monocyte-differentiated macrophages as per Raisch et al. (2015). Lower 
levels of PGE2 secretion were shown in cells differentiated using the reduced PMA method; the basal 
level of PGE2 secretion in untreated cells and following treatment with HM44 and HM605 isolates was 
much lower than when using the standard PMA differentiation method. However, treatment with E. 
coli HM44 and HM605 caused similar fold increases in macrophages differentiated using either the 
standard PMA treatment for 72 hours or following reduction in PMA levels for a further 5 days, 
showing a 2.5 to 3.5 fold increase in all cases. 
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5.6 Discussion 
Wnt signalling target gene array reveals commonly upregulated genes in response to infection with 
CRC mucosa-associated E. coli 
Our first insights into the Wnt-specific effects of mucosa-associated bacteria taken from CRC patients 
came from the use of a real-time PCR (RT-PCR) array quantifying changes in expression of Wnt target 
genes following the infection of CRC cell lines SW480 and DLD-1. We observed that a number of key 
genes associated with Wnt signalling were up-regulated, with many of the gene changes highlighted 
previously implicated in development, progression and/or spread of CRC. 
We observed a significant increase in vascular endothelial growth factor A (VEGFA) gene expression 
in response to infection with CRC-associated E. coli strains HM44 and HM358 in both CRC cell lines 
studied. Increase in VEGF gene and VEGF protein expression is widely conserved across most cancers 
studied, and considered to be a key change promoting angiogenesis and metastasis of colorectal 
cancer. Increase in VEGF-A gene expression following mucosa-associated E. coli infection has been 
previously shown using real-time PCR and correlates to possession of the afimbrial adhesin by these 
CRC isolates (Prorok-Hamon et al., 2014). This also supports previous association between Afa-
expressing diffuse adherent E. coli (DAEC) infection and inflammation leading to increases in VEGF and 
induction of epithelial mesenchymal transition (EMT) important in colorectal cancer progression (Cane 
et al., 2010, Waldner et al., 2010). Interventions that either reduce colonisation of intestine by these 
bacteria or block their interaction with the mucosa were suggested following this study as likely having 
significant preventive or therapeutic benefit in both colon cancer and CD. This further implicates 
perhaps the importance of the mucosa-association of these E. coli strains in the development and 
progression of CRC. 
Another important finding from the Wnt signalling target gene array was the observation that there 
was significant up-regulation of the COX-2 gene, PTGS2, following infection with both CRC-associated 
E. coli strains, again seen in both CRC cell lines used. The role of COX-2 in CRC development and 
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progression has been widely reported, with expression of COX-2 now an independent predictor of 
poor prognosis in CRC (Ogino et al., 2008). Recently, cancer mucosa-associated E. coli strains have 
been shown to increase COX-2 expression and enhance subsequent PGE2 secretion from human 
macrophages, likely due to their ability to survive and replicate within the macrophage 
phagolysosomes (Raisch et al., 2015). As previously described, COX-2 and PGE2 have the ability to 
stimulate colon cancer cell growth via activation of the G protein-coupled receptor EP2, which leads 
to activation of the Wnt signalling pathway via the inactivation of glycogen synthase kinase 3β 
(GSK3β), thus allowing the accumulation and increased nuclear localisation of β-catenin (Castellone et 
al., 2005). Alongside adherence and invasion factors, COX-2 induction associated with E. coli isolated 
from CRC patient mucosae could be another important fact in establishing a significant role for these 
bacteria in the development and progression of CRC. 
Given the wider implications of COX-2 and VEGF in CRC, and the conserved nature of the observed 
increases in both following infection of intestinal epithelial cells with CRC and inflamed mucosa-
associated E. coli, this became a clear focus for the project going forwards. Moreover, other key gene 
array changes observed in response to both CRC E. coli isolates also provide further insight into the 
molecular events associated with Wnt signal pathway activation following infection. 
This includes significant increase in WISP1 gene expression seen, following infection of SW480 cells 
with both CRC-associated E. coli HM44 and HM358 (P<0.05). However, this effect was notably not 
replicated following infection of DLD-1 cells with these isolates. WNT1 inducible signalling pathway 
protein 1 (WISP1) is a cysteine rich protein secreted into the extracellular matrix to modulate cellular 
responses such as cell growth, differentiation and survival (Berschneider and Konigshoff, 2011). The 
role of WISP1 is inconsistent across different cancers but, importantly, an overexpression of WISP1 
has been shown in colorectal cancer patients (Pennica et al., 1998, Davies et al., 2010). It has been 
suggested that modulation of WISP1 could represent a novel approach to treating cancers in a tissue 
specific manner, but that further in vivo studies would be necessary to determine the therapeutic 
potential of WISP1 modulation within these tissues (Berschneider and Konigshoff, 2011). Additionally, 
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the down-regulation of inhibitory Wnt genes such as WISP2 suggests a reduction in normal regulation 
of Wnt signalling. WISP2 protein expression is known to control invasion, with WISP2 knockout 
previously been shown to significantly increase Caco-2 CRC cell invasion and motility (Frewer et al., 
2013). In addition, the same study showed up-regulation of matrix metalloproteinases (MMPs), 
indicating that WISP2 likely regulates invasion and motility through MMPs. We also showed up-
regulation of MMP7 and MMP9 in SW480 cells following infection with CRC mucosa-associated E. coli 
isolates. MMP7 protein is known to be highly expressed in advanced colorectal adenomatous polyps 
showing evidence of severe dysplasia and involved in progressing colorectal adenomas to a malignant 
stage (Qasim et al., 2013). Our findings of WISP2 gene down-regulation and up-regulation of MMP 
genes in colonocytes following CRC mucosa-associated E. coli may add weight to the impact on 
malignant development in the colon as previously suggested. 
Another key finding was the upregulation of the JAG1 gene encoded Jagged-1 protein in response to 
infection of colonocytes with the CRC mucosa-associated E. coli. Jagged-1 protein is normally found at 
the base of intestinal crypts and plays an important role in activation of Notch signalling, promoting a 
cancer stem cell phenotype in CRC cells (Lu et al., 2013). Jagged-1 has also previously been found to 
be distributed diffusely throughout crypts following Salmonella Typhimurium infection, a bacterium 
known to activate Wnt signalling (Liu et al., 2010). As also seen for our CRC mucosa-associated E. coli 
strains in this study, upregulated expression of FOSL1 gene encoding the FOS-like antigen-1 (FOSL1) 
transcription factor, has also previously been associated with intestinal S. Typhimurium infection 
(Hannemann et al., 2013). FOS-like antigen-1 plays a key role in enhancing cellular proliferation and 
migration (key factors in CRC development/progression) by forming dimers with members of the Jun 
family of proteins to generate the activator protein-1 (AP-1) transcription factor (Verde et al., 2007).  
The varied roles of these Wnt target genes and their associated proteins could be important in 
determining the chronic effect of Wnt signalling induced by CRC-associated E. coli infections. Taking 
this a step further, with significant up-regulation of a number of these genes associated with Gram-
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negative bacterial infection, it is possible these genes and their associated protein products would 
likely be of therapeutic interest in limiting the development and progression of CRC. 
Following the Wnt signalling target gene array studies, we went on to confirm the observed up-
regulation of both COX-2 (PTGS-2) gene and β catenin (CTNNB1) gene expression by Taqman qPCR 
using Roche Human Universal Probe Library primers designed specifically to recognise the PTGS2 and 
CTNNB1 gene transcripts. Here we investigated mRNA abundance following 2h and 4 h infection of 
SW480 and DLD-1 cells with CRC mucosa-associated E. coli HM44 and HM358. The results using this 
technique were consistent with the Wnt RT2 PCR array, thus further confirming increases observed in 
expression of these genes. We observed a time-dependent increase of PTGS-2 gene expression, as 
well as the expression of the CTNNB1 gene encoding β-catenin, at both 2 and 4 h, with 4h infection of 
both cell lines using either HM44 or HM358 E. coli strains, resulting in the largest fold increases in 
comparison to uninfected controls. The observed increases in gene expression also converted to time-
dependent increases of both COX-2 and β-catenin protein expression respectively, with the highest 
levels of protein expression observed following 4h post infection.  
Differences observed between CRC cell lines 
Results from the Wnt signalling gene profiling array, alongside confirmatory real time qPCR and 
subsequent analysis of protein level changes, suggested some potential signalling differences between 
SW480 and DLD-1 cells. Both CRC cell lines are known to have high basal levels of Wnt signalling (Yang 
et al., 2006). One possible explanation for the difference between SW480 and DLD1 cell Wnt/β-catenin 
signalling pathway activity might be differing levels of β-catenin phosphorylation (Yang et al., 2006). 
It has been suggested that differences in β-catenin phosphorylation may be a consequence of loss in 
a key phosphatase binding site, likely due to the differences in site of APC truncation across a variety 
of CRC cell lines (Sadot et al., 2002). For example, SW480 colon cancer cells harbour a truncation in 
APC at position 1338 and show high levels of phospho-β-catenin, whereas HT29 cells harbour 
truncation in APC at position 1555 and accumulate non-phosphorylated β-catenin. This suggests the 
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1338-1555 amino acid region of APC is likely involved in the differential regulation of the de-
phosphorylation and degradation of phospho-β-catenin. It would be interesting to examine CRC 
mucosa-associated E. coli-infected HT29 cell responses in the same way as we have examined for in 
SW480 and DLD1 cells so as to check for any differences in these protein levels and associated 
signalling. 
Whilst high basal levels of Wnt signalling makes these cell lines a useful model for this study, larger 
increases in Wnt signalling could be masked in comparison to other CRC cell lines such as HT-29. CRC 
mucosa-associated E. coli isolates may have a similar if not bigger impact in intestinal epithelial cells 
with lower levels of basal Wnt activity and those earlier in the intestinal adenoma-carcinoma 
sequence. On the other hand, lower levels of basal Wnt signalling might also make for difficulty in 
detection of changes in Wnt signalling target gene and protein expression more difficult. 
Nuclear β-catenin translocation in CRC cells 
A previously described, validated technique for the quantitative analysis of nuclear translocation of 
NFκB in primary human macrophages (Noursadeghi et al., 2008) was successfully adapted here to 
quantify cytoplasmic and nuclear localisation of β-catenin. Here we used a monoclonal IgG antibody 
recognising β-catenin E-5, followed by FITC-conjugated anti-mouse IgG antibody amplification, to 
show increase in nuclear translocation of β-catenin in colonocytes following infection with CRC 
mucosa-associated E. coli isolates (combined with DAPI to define the cell nucleus). We were also able 
to show similar increased nuclear translocation of β-catenin with LiCl and PGE2 treatment. 
Quantification using ImageJ, as described in the study of Noursadeghi et al. (2008), allowed us to 
differentiate levels of nuclear and cytoplasmic staining to generate a stain localisation ratio. Without 
this, the results would have relied on staining intensity, which is notoriously difficult to interpret. 
The observed increase in nuclear β-catenin localisation in response to CRC mucosa-associated E. coli 
infection was similar in both SW480 and DLD-1 cells but with DLD-1 cells showing a lower level/pattern 
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of increase. This supports earlier observations where changes in both β-catenin gene and protein 
expression in DLD-1 cells were also less pronounced than those seen in SW480 cells. 
Use of TCF/LEF signalling in HeLa cells as a model for assessing increased Wnt transcription 
TCF/LEF activity induces transcription of Wnt target genes by binding promoters of downstream target 
genes involved in cell proliferation, survival and migration (Morin et al., 1997, van de Wetering et al., 
2002).  Results obtained here in this study using the luciferase-reporter HeLa cell line obtained from 
Signosis show that this phenomenon may occur in cells without high basal Wnt activity. Data obtained 
suggest that mucosa-associated E. coli isolates taken from CRC and IBD (CD and UC) patients all 
possess ability to increase Wnt transcription via TCF/LEF transcription factors, further confirming the 
movement of β-catenin to the epithelial cell nucleus. Again, the lack of induction of Wnt 
transcriptional activity by the non-pathogenic non-invasive E. coli K12 suggests this could be specific 
to CRC/inflamed mucosa-associated E. coli known to invade intestinal epithelial cells in vitro (Martin 
et al., 2004) and observed to be intraepithelial within CRC tissue (Swidsinski et al., 1998). The results 
obtained using the luciferase-reporter HeLa cell line supported those observations previously seen in 
mucosa-associated E. coli inoculated CRC cells assessed using the Wnt RT2 PCR array, qPCR and 
immunoblot analyses. 
COX inhibition reduces mucosa-associated E. coli-induced Wnt transcriptional activity 
Another key outcome from this study that was obtained using the HeLa TCF/LEF-luciferase reporter 
cells was that inhibition of Wnt transcription could be seen using several cyclooxygenase (COX) 
inhibitors. The chemopreventative effects of diclofenac (Kaur and Sanyal, 2010, Kaur Saini and Nath 
Sanyal, 2010), aspirin (Menzel et al., 2002, Tougeron et al., 2014) and indomethacin (Xu and Zhang, 
2005, Wang and Zhang, 2005) in colorectal cancer have been extensively studied both in vitro and in 
vivo.  Both diclofenac and aspirin have also been reported to have potential, even proven, 
chemotherapeutic action in patients (Ng et al., 2015). In this study, COX inhibitor treatment resulted 
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in observed decreases in Wnt transcriptional activity of PGE2-treated HeLa TCF/LEF-luciferase reporter 
cells, with diclofenac showing the highest levels of inhibition; diclofenac>indomethacin>aspirin at 
concentrations selected for initial testing based on previous key studies (Botting, 2006, Din et al., 
2004).  Following this, we tested diclofenac (100μM) in HeLa TCF/LEF-luciferase reporter cells infected 
with mucosa-associated E. coli strains HM545 (CRC) and HM605 (CD), strains which were selected as 
they gave consistently higher fold changes in activity of Wnt/β-catenin signalling pathway in the 
cultured cells. Diclofenac (100μM) was shown to significantly inhibit the increased signalling seen in 
cells infected with HM545 and HM605 in the absence of diclofenac. The high concentration of 
diclofenac caused some cell rounding (indicative of possible increased cell toxicity) as has also been 
noted with COX inhibitors in other studies (Din et al., 2004, Inoue et al., 2013), which might explain 
the lower levels of luciferase activity seen in uninfected controls treated with diclofenac. However, 
these apparent changes in cell viability were not significantly impacted with COX inhibitor treatments 
used in our study, as shown by the lack of significant changes between uninfected controls with and 
without inhibitor in HeLa TCF/LEF-luciferase reporter cells. 
It has been suggested that diclofenac could also attenuate Wnt signalling via the nuclear factor kappa-
B (NFκB) pathway (Cho et al., 2005). Indomethacin has also been shown to re-localise β-catenin from 
the nucleus and cytoplasm to the plasma membrane thus decreasing Wnt/β-catenin signalling 
(Kapitanovic et al., 2006). Our results demonstrating Wnt pathway activation by CRC and IBD mucosa-
associated E. coli alongside evidence that Wnt pathway attenuation following the use of COX inhibitors 
suggest that mucosa-associated E. coli mono-association/infection studies promoting tumourigenesis 
in vivo (Arthur et al., 2012) focussing on the effect of COX-2 inhibitors or Wnt signal pathway inhibitors 
would be of high scientific interest. 
The impact of COX-2 inhibitors here points towards regulation of Wnt activity via reduced signalling 
by the EP2 receptor, as COX-2 and subsequent PGE2 increases are believed to increase Wnt activity via 
binding to the EP2 receptor (Castellone et al., 2005). However, although COX-2 inhibitors significantly 
decreased Wnt transcription, other potential changes in receptor numbers or release of Wnt ligands 
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has not been assessed, and may contributing to Wnt regulation here. Significant alteration of Wnt 
ligand release and Frizzled receptors following E. coli and/or COX-2 inhibitor treatment could impact 
Wnt transcription. Therefore, it would be interesting to investigate the impact of Wnt ligand release 
following these treatments using immunoblotting and ELISA, as well as assessing the impact of Frizzled 
receptor inhibitors/antibodies, such as OMP-185 used successfully in preclinical models (Zhang and 
Hao, 2015), alone and in combination with COX-2 inhibitors. 
Increased PGE2 secretion from monocyte-derived macrophages 
The recruitment of macrophages following an infection is a key mechanism of protection. 
Macrophages are a predominant stromal component of both murine and human tumours supporting 
key processes involved in cancer development and progression via production of key oncogenic 
factors such as COX-2 (Raisch et al., 2015). If tumour-infiltrating macrophages are unable to kill 
mucosa-associated/invading bacteria this may lead to intraphagolysome residence of these 
pathogenic bacteria within intestinal tissue, with genotoxic, angiogenic and pro-inflammatory 
potential (Subramanian et al., 2008, Arthur et al., 2012, Prorok-Hamon et al., 2014). E. coli have been 
isolated from macrophages in CD, and persistence within the macrophage phagolysosome may 
provide stimulus for inflammation (Bringer et al., 2007, Mpofu et al., 2007, Subramanian et al., 2008). 
The results from the present study confirm those of similar studies (Raisch et al., 2015), with human 
monocyte-derived macrophages infected with pathogenic E. coli showing increased production and 
release of COX-2. These results would suggest that macrophage activity, or survival of bacteria within 
macrophages, contributes to increased levels of Wnt signalling in nearby tissues, particularly given the 
link between COX-2 signalling and Wnt signalling shown throughout. 
CD and CRC mucosa-associated E. coli appear to be adapted to an intracellular lifestyle within the low 
pH, low nutrient, high oxidative stress environment of the macrophage phagolysosome (Bringer et al., 
2005, Bringer et al., 2007, Tawfik et al., 2014). Intracellular survival and replication of these particular 
E. coli has also been shown to be similar whether phagocytosed by macrophages isolated from CD or 
113 
 
healthy non-inflamed intestine control patients (Flanagan et al., 2015b).  This study also showed that 
the macrophage intraphagolysosome alkalinizing drug hydroxychloroquine (HCQ) promoted killing of 
phagocytosed mucosa-associated E. coli and also enhanced the efficacy of antibiotics targeting 
bacteria with an intracellular lifestyle, such as doxycycline and ciprofloxacin (Flanagan et al., 2015b). 
This study further identified that supplementation with vitamin D, to enhance macrophage function, 
also supported killing of these E. coli strains. This would suggest future animal studies to see whether 
targeting CRC mucosa-associated E. coli with combination HCQ/antibiotics and/or vitamin D 
supplementation reduced Wnt signal pathway activation and carcinogenesis in vivo.  Later human 
preventative trials might then be warranted. 
The role of COX-2 in CRC is already supported by its elevated expression found in 50% of adenomas 
and 85% of adenocarcinomas, its association with worse survival among CRC patients, and the 
efficiency of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXIBs) to 
reduce the occurrence of sporadic CRC. The results obtained in this study and in the Raisch et al. (2015) 
study suggest that bacteria residing within macrophages could contribute to progression of CRC, 
including proliferation and survival of cancer cells, angiogenesis, immunosuppression, invasion, and 
metastasis (Raisch et al., 2015). The increased release of PGE2 could be another major contributing 
factor in driving the Wnt response in neighbouring intestinal epithelial cells. 
Summary 
We have been able to show increases in total and nuclear localised β-catenin at both the gene protein 
level in vitro following infection with mucosa-associated E. coli isolates from IBD and CRC patients, and 
have shown that this correlates with COX-2 gene and protein levels. While this part of the study does 
not elude to why this happens, it does suggest an effect that is specific to mucosa-associated E. coli 
strains with the ability to adhere to and invade intestinal epithelial cells. 
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Chapter 6: 
Increased expression of cyclooxygenase-2 and  
β-catenin in vivo following mono-association of 
Il10-/- germ-free mice with CRC E. coli HM44 
indicates translation of increased Wnt signalling 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
6.1 Introduction 
With a wide role of COX-2 in CRC development and progression reported (Brown and DuBois, 2005, 
Ogino et al., 2008), and a cascade suggested for the role of COX-2 and prostaglandin-E2 (PGE2) in 
stimulating cancer cell growth via Wnt activation (Castellone et al., 2005), it is highly possible that 
COX-2 induction following chronic bacterial infection of colonic cells could lead to sustained increases 
in Wnt signalling in vivo. 
COX-2-driven PGE2 increases are believed to activate the G protein-coupled receptor EP2 leading to 
phosphoinositide 3-kinase (PI3K) activation of the Wnt signalling pathway via the inactivation of 
glycogen synthase kinase 3β (GSK3β). The subsequent accumulation of β-catenin in the cytoplasm and 
nuclear translocation following infection of colonic cells with mucosa-associated E. coli could aid 
proliferation, migration and metastasis. With gut inflammation able to alter the composition of the 
gut microbiota in favour of pathogenic mucosa-associated E. coli (Darfeuille-Michaud et al., 1998, 
Swidsinski et al., 1998, Martin et al., 2004), this could create an environment that supports tumour 
development by resultant expansion of, and contact with, these bacteria. 
In addition, as CRC-associated E. coli strains can survive and replicate within human macrophages, as 
well as increase COX-2 expression and subsequent PGE2 secretion (Raisch et al., 2015), the impact of 
mucosa-associated E. coli survival and PGE2 increases shown in the present study could enhance the 
tumourigenic effect of these infections in vivo.  
We have so far been able to characterise upregulation of Wnt signalling target genes alongside 
increases in COX-2 and β-catenin, at both mRNA and protein level, following in vitro infection of CRC 
cell lines with mucosa-associated E. coli. The existing link between COX-2 and β-catenin previously 
reported (Castellone et al., 2005) and shown here using in vitro infection models would suggest 
translation into an in vivo infection model. 
The Il10 knock-out (Il10-/-) model removes anti-inflammatory Il-10 as an innate defence mechanism, 
allowing a direct look at the effect of CRC mucosa-associated E. coli HM44 infection of an otherwise 
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germ-free gut. This model has been previously used to show that colitis in mice can promote 
tumorigenesis by altering microbial composition and inducing the expansion of microorganisms with 
genotoxic capabilities (Arthur et al., 2012). Similar germ-free studies have revealed a key role for the 
microbiota in driving CRC, particularly where changes in microbial composition can influence the 
development of colitis-associated CRC (Arthur and Jobin, 2011). Therefore, we investigated this effect 
in vivo using a germ-free Il10 knock-out (Il10-/-) mouse model mono-associated with the mucosa-
associated E. coli HM44, a clinical isolate from a CRC patient (Martin et al., 2004).  
Other in vivo model studies assessing the effects of bacteria such as H. pylori have also shown links 
between increased COX-2 and β-catenin expression and tumor development (Oshima and Oshima, 
2010). Similarly, H. felis infections have shown activation of Wnt signalling through activation of PI3K 
and AKT, leading to the phosphorylation and inactivation of GSK3β, allowing β-catenin to accumulate 
in the cytosol and translocate to the nucleus (Oguma et al., 2008). This has been attributed to multiple 
H. pylori cancer-associated determinant factors reported to influence β-catenin activation, and is 
consistent with other reports investigating β-catenin activation caused by infection with bacteria such 
as Salmonella typhimurium and Bacteroides fragilis (Polk and Peek, 2010). 
Any similar alterations in β-catenin signalling following mono-association with mucosa-associated E. 
coli HM44 would suggest that the effects previously seen in vitro could translate into increased risk of 
cancer development in disease-relevant animal models, further implicating the potential for these 
bacteria to cause human disease. By investigating the effects of HM44 mono-association on COX-2 
protein expression, this could also be important in further establishing the link between increased 
COX-2 and β-catenin signalling. 
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6.2 Hypothesis 
Increase in COX-2 and Wnt signalling following mucosa-associated E. coli infection of human CRC cells 
observed in vitro translates to changes in vivo following CRC mucosa-associated E. coli HM44 mono-
association of a germ-free Il10-/- mouse model. 
6.3 Aims 
• To investigate by immunohistochemistry (IHC) whether COX-2 and Wnt pathway activation 
are initiated in vivo using a germ-free Il10-/- mouse model of CRC mucosa-associated E. coli 
infection. 
• To confirm the in vitro link between COX-2 upregulation and increased Wnt signalling in vivo 
using the same germ-free Il10-/- mouse model of mucosa-associated E. coli infection. 
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6.4 Methods 
The COX-2 and β-catenin IHC protocols were initially optimised using intestinal tissue obtained from 
wild-type C57BL/6 mice where colitis had been induced with dextran-sodium sulphate (DSS) (Melgar 
et al., 2005), that results in significant upregulation of COX-2 (Singh et al., 2010), and from AhCre+ 
Apcfl/fl mice (a novel inducible Ahcre transgenic line in conjunction with a loxP-flanked Apc allele), 
where Cre Apcfl/fl induction by β-napthoflavone results in significant nuclear translocation of  
β-catenin (Sansom et al., 2004). 
Mono-association studies used gut tissue from germ-free Il10-/- 129SvEv strain mice mono-associated 
with E. coli HM44 for 6 weeks (n=15) or those mice uninfected (n=5). Mono-association was carried 
out at the gnotobiotic facility at NC State University (University of North Carolina Chapel Hill, USA); all 
animal infection and tissue/bundling/processing work was completed by Dr Janelle Arthur with 
protocols previously well established (Arthur et al., 2012). Briefly, strain mice were mono-associated 
for 6 weeks. Germ-free Il10-/- 129SvEv mice were colonized using cotton swabs soaked in an overnight 
culture of CRC mucosa-associated E. coli HM44 grown in LB broth from a -80oC glycerol stock – a 
common colonization procedure used in the NC State gnotobiotic facilities, where mouse health was 
continuously monitored. Stool pellets were collected at the conclusion of the experiment and plated 
to demonstrate colonization. Colonic tissue was taken from HM44 mono-associated mice (n=15) and 
germ-free controls (n=5) before fixing and paraffin wax embedding (see Chapter 4.3). 
Paraffin wax embedded tissue was microtome-sectioned and processed for incubation with primary 
antibodies. Heat-induced antigen retrieval was performed in citric acid buffer (pH 6.4) before bovine 
serum albumin (BSA) blocking. Immunohistochemistry for COX-2 and β-catenin was performed using 
a 1:400 dilution of the COX-2 antibody (#ab15191, Abcam) and 1:50 dilution of the β-catenin antibody 
(#610154, BD Biosciences). Slides were then incubated in haematoxylin before being fixed with DPX 
mountant – a mixture of distyrene, plasticizer and xylene – to enable visualisation and quantification 
of cellular localisation. 
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Images were captured (5 random fields of view) using SPOT Image Capture Software (SPOT Imaging 
Solutions) on a light microscope (Leica). Total epithelial and nuclear staining was evaluated using the 
IHC Profiler and ImmunoRatio plugins for ImageJ 1.48v, respectively. Scoring for total epithelial 
staining, quantified using the IHC Profiler plugin, was done using the Modified HSCORE method 
(Varghese et al., 2014), with a maximum achievable score of 300 and a minimum score of 0 (arbitrary 
units). Comparison of nuclear and cytoplasmic β-catenin staining, quantified using ImmunoRatio, was 
performed calculating ratios of nuclear and total staining in tissue sections following published 
techniques (Tuominen et al., 2010, Sundara Rajan et al., 2014). 
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6.5 Results 
6.5.1 Optimisation of IHC conditions for detection of COX-2 and β-catenin protein 
Before submitting the germ-free Il10-/- model tissue slides for IHC, a number of steps were completed 
in order to optimise the IHC protocol (see Section 4.12.3), for both COX-2 and β-catenin detection, 
and to validate the scoring technique. The COX-2 IHC protocol was optimised using gut tissue from a 
wild-type C57BL/6 DSS-induced colitis mouse model (Melgar et al., 2005); this tissue was kindly 
generated and donated by Dr Carrie Duckworth and Miss Stephanie James (Cellular and Molecular 
Physiology, University of Liverpool). 
The β-catenin IHC protocol was optimised using small intestinal tissue section slides obtained from 
AhCre+ Apcfl/fl and ApcMin/+ mice, kindly donated by Dr John Jenkins and Dr Cleberson Quieroz 
(Gastroenterology Research Unit, University of Liverpool), a gift from the late Professor Alan Clarke 
(University of Cardiff). The mutation induced in the AhCre+ Apcfl/fl model was the removal of the Apc 
gene using a loxP-flanked Apc allele following β-napthoflavone treatment, causing accumulation and 
subsequent nuclear localisation of β-catenin (Sansom et al., 2004). Nuclear localisation observed in 
these tissues were compared to that of colonic sections from tissue of six-month old ApcMin⁄+ mice 
harbouring one wild-type Apc allele and one Apc allele mutated at codon 850 (Su et al., 1992). Images 
of immuno-stained tissue were used to validate the scoring techniques of Modified HSCORE and 
ImmunoRatio for use with the germ-free Il10-/- mono-association model tissue. 
The developed IHC staining protocol used an anti-mouse COX-2 antibody (#ab15191, Abcam) 
previously used successfully with mouse tissue (Miyoshi et al., 2012, Nilsson et al., 2012). This antibody 
was recommended for use at 1:200 to 1:1000 by the manufacturer, with an in-house protocol 
developed for similar mouse model tissue at a 1:400 dilution. To confirm this dilution was suitable for 
use, a titration was completed using 1:200, 1:400 and 1:800 dilutions on spare small intestinal tissue 
made available from the DSS-induced colitis mouse model (Figure 6.5.1.1). 
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The tissue was taken from a mouse at day 7 of DSS treatment; at this stage of treatment, a high level 
of inflammation (Melgar et al., 2005) should allow for detectable COX-2 protein levels. From image 
analysis of antibody treated tissue sections, it was shown that the 1:400 dilution allowed detection of 
suitable levels of COX-2 protein for this particular tissue without showing any noticeable non-specific 
binding. 
 
 
Following the titration of the anti-mouse COX-2 antibody, a 1:400 dilution was used for detection of 
COX-2 expression in intestinal tissue from mice at different stages of DSS treatment. The aim of this 
Figure 6.5.1.1 Titration of anti-mouse cyclooxygenase-2 (COX-2) antibody. Images show C57BL/6 
mouse small intestinal tissue sections taken from a mouse at day 7 of DSS-induced colitis development, 
with COX-2 protein and cell nucleus immuno-stained using diaminobenzene (DAB) and haematoxylin, 
respectively. Tissue sections were incubated with 1:200, 1:400 and 1:800 dilutions of anti-mouse COX-
2 antibody, as well as a no-antibody control (Negative control) and a primary IgG control (Isotype 
control). Sections (n=3) were imaged at 40x magnification (3 random fields per section). 
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was to ensure that differences in COX-2 levels could be effectively visualised, with higher levels 
expected following inflammation caused by DSS treatment. 
Tissue isolated from mice at an early stage of DSS-induced colitis, day 1 to day 4, showed minimal 
levels of COX-2 expression, with expression seen to increase as the model progressed to day 7 through 
day 9. The tissue taken from mice at day 10 and day 11 following DSS treatment showed decreased 
expression of COX-2, with levels seen to be similar to that of the earlier stages of DSS-induced colitis; 
this is believed to be in line with the recovery stage, normally observed around 12 days after DSS 
treatment in this particular model (Melgar et al., 2005). Example images can be seen in Figure 6.5.1.2. 
The expression of β-catenin in intestinal tissues of Apc mutant AhCre+ Apcfl/fl and ApcMin⁄+ mice were 
assessed using conditions pre-defined by Dr John Jenkins and Dr Cleberson Quieroz (University of 
Liverpool; unpublished data); an antibody dilution of 1:50 was used solely. Due to the nature of the 
mutations in both the Apcfl/fl and ApcMin⁄+ models, it was expected that the total expression and nuclear 
localisation of β-catenin would be observed to be higher in the Apcfl/fl tissue; this was confirmed by 
DAB staining these antibody-treated tissues (Figure 6.5.1.3). 
COX-2 staining in the Apc mutant mouse intestines was much less evident when compared to β-
catenin, which is indicative of the lower expression levels these gut tissues. However, the detection 
levels were deemed acceptable to submit these tissues for validation of the automated scoring system 
that was to be used for the germ-free Il10-/- model tissue imaging. 
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Figure 6.5.1.2. Cyclooxygenase-2 (COX-2) levels in DSS-induced colitis. Images show small 
intestinal tissue sections taken from C57BL/6 mice following 1, 4, 7 and 11 days of 2% w/v DSS 
treatment (N=1), with COX-2 protein antibody immuno-histochemical staining using diaminobenzene 
(DAB) and cell nucleus staining with haematoxylin, respectively. Tissue sections were incubated with a 
1:400 dilution of anti-mouse COX-2 antibody, with sections (n=3) imaged at 25x magnification (3 random 
fields per section). 
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6.5.2 Optimisation of tissue IHC imaging of germ-free Il10-/- mice using ImageJ 
Germ-free Il10-/- mice on a 129SvEv background were colonised with E. coli HM44 by Dr Janelle Arthur 
at the gnotobiotic facility at NC State University using methods previously described (Arthur et al., 
2012). Mice were colonised with E. coli HM44 on 8/2/2012 in order of mouse number (see Chapter 
4.12; Table 4.12.2). It was noted on 2/3/2012 that the majority of mice had ruffled fur and irregular 
stool was found in all cages. On 16/3/2012, two of the colonised mice were found dead with mouse 
#2 appearing to be of ill health (possibly linked to the large abscesses); subsequently, all other mice 
Figure 6.5.1.3. β-catenin expression in Apc mutant mice. Images show intestinal tissue sections 
taken from AhCre+ Apcfl/fl and ApcMin/+ mice (N=1); with β-catenin protein detected by IHC with specific 
antibody and diaminobenzene (DAB) stain and cell nucleus staining with haematoxylin, respectively. 
Sections of intestinal tissue were incubated with a 1:50 dilution of anti-mouse β-catenin antibody, with 
sections (n=3 sections for each strain) imaged at 25x magnification. AhCre+ Apcfl/fl small intestinal tissue 
shows high levels of DAB staining, with lower levels seen in the ApcMin/+ colonic tissue (3 random image 
fields per section). 
Apcfl/fl 
ApcMin/+ 
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were sacrificed on 3/19/12. Microtome-sectioned bundled gut tissue from these mice was kindly 
donated for IHC use in the current study. 
Following IHC, images were taken at 4x, 10x, 25x and 40x magnification on a light microscope (Leica). 
Images were scrutinised optically to determine the extent of total staining, as well as the localisation 
of nuclear and cytoplasmic staining (Figure 6.5.2.1). Using anti mouse COX-2 antibody stained tissue 
(1:400 dilution), it was concluded that the 25x magnification should be used for quantification of 
immuno-staining. Optical visualisation at lower 4x and 10x magnifications did not allow for clear 
distinction between individual cells, nor clear distinction of absence or presence of nuclear staining, 
and moreover seemed to show greater variation in light intensity both across and between images; 
the latter of these issues was likely a problem caused by microscope or the image acquisition software 
at the time of testing. Imaging at 25x and 40x both gave better consistency in light intensity, avoiding 
light rings seen at lower magnification, and ability to distinguish localisation of staining. As the 25x 
magnification gave a better coverage of tissue, allowing more cells to be incorporated into the scoring, 
it was decided that the 25x magnification would be used going forward. 
The process of quantifying or scoring within ImageJ required the removal of any possible contaminants 
that might influence results; an example of this would be cell debris stained by DAB that could be 
misinterpreted as tissue specific staining within the automated scoring system; these edits can be 
performed within ImageJ by selecting and clearing unwanted sections of tissue or debris (Figure 
6.5.2.2). 
Following optimisation of tissue processing and imaging, it was necessary to be able to validate the 
automated method of scoring; as tissue from the optimisation step had already been processed and 
imaging completed, it was decided that these images be used for validation. 
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Figure 6.5.2.1. Cyclooxygenase-2 (COX-2) colonic tissue protein expression in germ-free and 
HM44 mono-associated Il10-/- 129SvEv mice. Images show germ-free and HM44 mono-associated 
Il10-/- 129SvEv mouse colonic tissue with COX-2 protein detected by IHC with specific antibody and 
diaminobenzene (DAB) stain and cell nucleus staining with haematoxylin, respectively. Tissue sections 
were imaged at 4x, 10x, 25x and 40x magnification. 
Figure 6.5.2.2. Image editing within ImageJ (version 1.48). Unedited and edited image of a gut 
tissue section taken from a HM44 mono-associated Il10-/- mouse (mouse #3, image 4). Tissue had 
been immuno-stained to show β-catenin expression, i.e. with antibody specific staining of protein 
detected using diaminobenzene (DAB), and cell nucleus staining with haematoxylin, respectively. 
Tissue was imaged at 40x magnification. 
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6.5.3 Validation of the Modified HSCORE quantification method using ImageJ 
The ImageJ plugin IHC Profiler was used to analyse tissue immuno-staining. IHC Profiler allows scoring 
of DAB detection staining on an arbitrary scale using staining categorised by percentage of positive 
and negative staining. Following splitting of the image into haematoxylin and DAB detection stain 
recognition, we were able to clear either the empty and/or unwanted areas, such as non-epithelial 
cells for β-catenin scoring and/or cell debris, to prepare the image for scoring. IHC Profiler was then 
used to analyse images based on both the intensity and distribution of DAB detection reagent staining. 
The IHC localisation was scored in a semi-quantitative fashion; each image was processed using the 
IHC Profiler, with staining automatically recorded as percentages of positively stained target cells in 
each of five intensity categories; these were denoted as negative (no staining), low positive (weak but 
detectable above control), positive (distinct staining) and high positive (strong staining). For each 
tissue, a value designated as the HSCORE was derived by summing the percentages of cells staining at 
each intensity multiplied by the weighted intensity of staining: 
Modified HSCORE calculation 
HSCORE value = (%Negative x 0) + (%Low Positive x 1) + (%Positive x 2) + (%High Positive x 3) 
Using this calculation, the scale of Modified HSCORE value would be between 0–300, with a score of 
0 achieved where 100% of the tissue staining for one image was categorised as negative and a score 
of 300 achieved where 100% of the tissue staining was categorised as high positive. This system was 
validated using images of COX-2 and β-catenin immuno-stained tissue from the DSS-induced colitis 
and the AhCre+ Apcfl/fl mouse models, respectively. Images of DSS-induced colitis mouse model tissue 
at days 7 and 11, along with Apcfl/fl and ApcMin/+ intestinal tissues, were processed as described by 
Varghese et al. (2014) and a score obtained for each image (Varghese et al., 2014). Following imaging 
and automated processing of COX-2 IHC processed intestinal tissue, DSS-induced colitis mice at day 7 
following DSS treatment achieved a modified HSCORE of 38.5 ± 5.6, whereas tissue from day 11 
achieved a lower score of 17.9 ± 6.5 (N=1, n=3 sections; 3 images per slide). Following imaging of  
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β-catenin IHC processed tissue, the AhCre+ Apcfl/fl small intestinal tissue achieved a score of 113.4 ± 
3.0, compared to 47.4±2.9 for ApcMin/+ colon tissue; N=1, n=3 sections; 3 images per slide (Figure 6.5.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
Apc(flox/flox) Apc(min/+)
M
od
ifi
ed
 H
SC
O
R
E
Model tissue
0
5
10
15
20
25
30
35
40
45
50
DSS day 7 DSS day 11
M
od
ifi
ed
 H
SC
O
R
E
Model tissue
Figure 6.5.3. Modified HSCORE validation for quantification of cyclooxygenase-2 (COX-2) and β-
catenin expression in mouse intestinal tissue. Graphs show modified HSCORE quantification of  
(A) COX-2 stained intestinal tissue from C57BL/6 DSS-induced colitis model and (B) β-catenin stained 
intestinal tissue from Apc mutant mice; higher scores were achieved by small intestinal tissue from mice 
at day 7 following 2% w/v DSS treatment and the AhCre+ Apcfl/fl model for COX-2 and β-catenin, 
respectively, with lower scores for small intestinal tissue from mice at day 11 following DSS colitis 
induction and in the colon of ApcMin/+ model. Quantification was completed using images of immuno-
stained tissue sections at 25x magnification, with protein expression determined by IHC and detection 
using diaminobenzene (DAB) stain and cell nucleus staining with haematoxylin, respectively (N=1, n=3; 
3 images per slide). 
B. β-catenin 
A. COX-2 
Apcfl/fl ApcMin/+ 
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6.5.4 Validation of the ImmunoRatio ImageJ plugin for nuclear protein quantification 
Following validation of the modified HSCORE method, Apc mutant mouse gut tissue was used to 
validate the ImmunoRatio scoring system. This has been previously used to assess nuclear localisation 
in tissue sections, and was applied here to assess the extent of β-catenin nuclear localisation. In this 
case, an image of AhCre+ Apcfl/fl tissue at 25x magnification was used to determine threshold cut-offs 
for DAB and haematoxylin staining (Figure 6.5.4), set as -20 for DAB staining and 5 for haematoxylin 
staining. These thresholds were kept consistent for all tissue types in the study. 
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Figure 6.5.4. ImmunoRatio validation for quantification of nuclear DAB staining to indicate β-
catenin expression in mouse tissue. The image was produced by ImageJ as a montage of the 
quantification of DAB staining of AhCre+ Apcfl/fl small intestinal tissue following processing using the 
ImmunoRatio plugin. The graph shows the results of quantification of nuclear DAB staining for both 
AhCre+ Apcfl/fl and ApcMin/+ gut tissue. Quantification was completed using images of immuno-stained 
tissue sections at 25x magnification, with protein expression detected by IHC with specific antibody and 
diaminobenzene (DAB) stain and cell nucleus stained using haematoxylin, respectively (N=1, n=3; 3 
images per slide). 
ApcMin/+ Apcfl/fl 
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By applying set cut-offs for DAB and haematoxylin staining for all images, it was established that Apcfl/fl 
small intestinal tissue had 60.9 ± 3.9 % of β-catenin showing nuclear localisation. This was around a  
2-fold increase that seen in ApcMin/+ colonic tissue, which had 26.9 ± 3.7 % nuclear β-catenin 
localisation (Figure 6.5.4). These results suggested that the ImmunoRatio plugin is a suitable 
automated system to be able to show differences in nuclear β-catenin localisation in murine intestinal 
tissue. Following optimisation/confirmation of the COX-2 and β-catenin antibody dilutions, imaging 
magnification and validation of the automated modified HSCORE and ImmunoRatio scoring systems, 
we implemented these processes to the germ-free Il10-/- mouse tissues with the aim of establishing 
effect of mono-association of these mice with the human CRC mucosa-associated E. coli isolate HM44. 
6.5.5 Increased COX-2 and β-catenin expression in colonic epithelial tissue from HM44 
mono-associated mice 
Germ-free Il10-/-  129/SvEv mice were mono-associated with human mucosa-associated E. coli isolate 
HM44 for 6 weeks (infected, n=15; germ free (GF), n=5). IHC of fixed paraffin wax embedded colonic 
tissue revealed significant increases in mucosal COX-2 protein levels and significant increased total β-
catenin protein levels in the intestinal epithelium, as well as increased nuclear localisation of β-
catenin.  
The median HSCORE for COX-2 staining was 32.2 (IQR 15.6, 56.6) in germ-free control Il10-/- mouse 
intestinal tissue, with a significant increase to 89.9 (IQR 66.0, 100.9) in tissue from E. coli HM44 mono-
associated mice (Figure 6.5.5.1; Mann-Whitney U, P<0.001). Epithelial staining for β-catenin showed 
a median HSCORE of 44.1 (IQR 28.8, 126.0) in germ-free control tissue and 177.2 (IQR 98.8, 184.9) in 
the E. coli HM44 colonised intestinal tissue (Figure 6.5.5.2; P<0.001), while median nuclear localisation 
of β-catenin within the epithelium was scored at 16.7% (IQR 11.5, 45.3) and 62.4% (IQR 42.4, 67.1) 
respectively (Figure 6.5.5.2; P<0.001). 
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Figure 6.5.5.1. Significant increases in cyclooxygenase-2 (COX-2) expression quantification in 
intestinal tissue following in vivo mono-association of germ-free Il10-/- mice with a CRC mucosa-
associated E. coli. IHC images show COX-2 protein expression detected using diaminobenzene 
(DAB) stain and cell nucleus staining with haematoxylin respectively, in (A) germ-free Il10-/- mice and 
(B) mice mono-associated E. coli HM44. (C) Graph shows modified HSCORE quantification of total 
COX-2 protein levels in intestinal tissue, with significantly higher scores observed in mice mono-
associated with HM44 (P<0.001; Mann-Whitney U). Image quantification was completed on sections 
from N=5 germ free mice, and N=15 HM44 mono-associated mice (with n=5 images per section) at 25x 
magnification. 
A. B. 
C. 
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Figure 6.5.5.2. Significant increases in β-catenin expression and nuclear localisation 
quantification in intestinal tissue following in vivo mono-association of germ-free Il10-/- mice 
with a CRC mucosa-associated E. coli. IHC images show β-catenin protein expression detected 
using diaminobenzene (DAB) stain and cell nucleus staining with haematoxylin respectively, in in 
(A) germ-free Il10-/- mice and (B) mice mono-associated E. coli HM44. Graphs show modified 
HSCORE and % nuclear DAB staining quantification for (C) total β-catenin expression and (D) 
nuclear localisation in intestinal tissue. Significantly higher scores/staining were seen in tissue taken 
from HM44 mono-associated mice (both P<0.001; Mann-Whitney U). Image quantification was 
completed on sections from N=5 germ free mice, and N=15 HM44 mono-associated mice (with n=5 
images per section) at 25x magnification. 
A. 
B. 
C. D. 
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Mean and confidence interval data show an approximate 2-fold significant increase (P<0.001) in COX-
2 staining E. coli HM44 colonised intestinal tissue (mean 78.7; 95%CI 71.0, 86.4) compared to germ-
free control Il10-/- mice (mean 38.6; 95%CI 27.4, 49.8). A similar 2-fold significant increase (P<0.001) 
was also observed for total β-catenin staining in E. coli HM44 colonised tissue (mean 146.0; 95%CI 
130.4, 161.5) compared to germ-free tissue (mean 71.8; 95%CI 50.9, 92.7). Nuclear localisation of β-
catenin was also shown to significantly elevated, again around 2-fold (P<0.001) in E. coli HM44 
colonised tissue (mean 51.6%; 95%CI 45.4, 57.8) compared to controls (mean 25.8; 95%CI 18.1, 33.6). 
The staining intensity, along with the final HSCORE values, for both COX-2 and β-catenin, in intestinal 
tissue sections from the murine model systems used (DSS-induced colitis and Apc mutants) were 
assessed and confirmed by two independent experimenters, Dr Carrie Duckworth and Dr John Jenkins 
(University of Liverpool), both with vast experience of murine and human histopathology (and 
specifically IHC for COX-2 and β-catenin). A random selection of images were also confirmed to 
correlate with automated HSCORE values attributed to tissues from both germ-free and HM44 mono-
associated Il10-/- mice. 
Haematoxylin and eosin staining was also processed by Dr Janelle Arthur and reviewed by animal 
pathology expert, Dr Jonathan Williams, University of Liverpool (now at Department of Pathology and 
Pathogen Biology, Royal Veterinary College, North Mymms AL9 7TA, UK). Imaging of germ-free mice 
showed normal colonic folds of proximal colon with relatively few goblet cells, with thin mucosa seen 
in some small areas (Figure 6.5.5.3). In comparison, E. coli HM44 mono-associated mice showed 
infiltration of neutrophils, lymphocytes and plasma cells in the lamina propria, areas of crypt mitosis, 
and extravasated erythrocytes indicating possible minimal haemorrhage. Some images also showed 
thinning of the crypts, neutrophils undergoing epithelial exocytosis, and single cell apoptosis/necrosis, 
with possible micro-erosions.  
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In summary, automated quantification of IHC processed intestinal tissue suggests that HM44 mono-
association of germ-free Il10-/- mice caused an approximate 2-fold increase in both COX-2 and Wnt 
pathway activation (i.e. nuclear localisation of β-catenin), and these increases were seen to be highly 
significant. Further work remains to fully determine phenotypic changes and development of 
hyperplasia and/or tumours, with early observations of the gut epithelial environment showing 
inflammatory infiltrate and crypt mitosis, suggesting a proliferative state of crypt cells. This remains 
to be quantified. 
 
Figure 6.5.5.3. H&E imaging of intestinal tissue following in vivo mono-association of germ-free 
Il10-/- mice with a CRC mucosa-associated E. coli. H&E histology of germ-free Il10-/- mice and mice 
mono-associated with E. coli HM44 was completed by Dr Janelle Arthur (University of North Carolina 
Chapel Hill, USA) and reviewed by Dr Jonathan Williams (University of Liverpool). Images shown were 
captured at 20x and 40x magnification. 
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6.5.6 Discussion 
Following mono-association of germ-free Il10-/- mice with a CRC mucosa-associated E. coli isolate, 
there were significant increases observed in intestinal tissue expression of both COX-2 and β-catenin 
protein, with the latter showing increased levels of nuclear localisation. Nuclear translocation of beta 
catenin leads to significant potential for activation of TCF/Lef Wnt pathway signalling, a key early step 
in colorectal carcinogenesis (Behrens et al., 1996, Morin et al., 1997, Kobayashi et al., 2000). This result 
obtained in vivo validates data obtained in vitro following infection of CRC cell-lines SW480 and DLD-
1 with CRC and IBD mucosa-associated E. coli (see Chapter 5). 
Microbial composition has been found to influence the development of colitis-associated colorectal 
cancer. Studies using germ-free mouse models have revealed a key role for the microbiota in driving 
colorectal cancer with mice raised in germ-free conditions typically devoid of intestinal inflammation 
and tumours (Arthur and Jobin, 2011). Gut bacteria interaction with Toll-like receptors (TLRs) on the 
luminal surface of intestinal epithelial cells (with consequent signalling via MyD88) is a key step in 
experimental CRC pathogenesis (Rakoff-Nahoum and Medzhitov, 2009). Moreover, MyD88-/- mice 
cross-bred onto either ApcMin/+ mice resulted in marked reduction in tumours and mortality (Rakoff-
Nahoum and Medzhitov, 2007). In other susceptible mouse models, the presence of commensal and 
other bacteria facilitates CRC development in comparison with germ-free animals. Examples include, 
the spontaneous CRC that develops in TCR-βchain-p53 double-knockout mice, which does not develop 
if animals are kept under germ-free conditions (Kado et al., 2001), and colonisation of germ-free rats 
with E. coli or Bacteroides spp. increases the number of carcinogen-induced aberrant crypt foci, a 
precursor for CRC (Onoue et al., 1997).   
The IL-10 family of cytokines have been established as playing an essential role in anti-inflammatory 
immune response, with a particular role in defence against infections within epithelial cells (Ouyang 
et al., 2011, Iyer and Cheng, 2012, Couper et al., 2008). The germ-free Il10-/- murine model used in the 
present study has been highlighted by Scheinin et al. (2003) to be important in advancing our 
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understanding of pathogenesis in inflammation-associated bowel diseases and in supporting 
development of new therapeutics for conditions such as Crohn's disease, a bowel disease with 
significant increased risk of CRC, and where mucosa-associated E. coli likely play a key role in this 
condition (Martin et al., 2004, Prorok-Hamon et al., 2014). The removal of this innate defence 
mechanism allows a direct look at the effect of CRC (and IBD) mucosa-associated E. coli infection of 
an otherwise germ-free gut. Using microscopic evaluation of the immuno-stained mouse intestinal 
tissue, we were able to see an increase in both COX-2 and β-catenin protein levels following infection 
solely with an adherent, invasive E. coli HM44 isolated from a patient with CRC (Martin et al., 2004).  
Il10-/- mice that develop colitis in the presence of normal enteric microbiota, do not develop 
inflammation if kept in a germ-free environment, and when given the carcinogen azoxymethane, only 
develop CRC when acquiring a normal gut microbiota following transfer from germ-free conditions, 
with modulation of the microbiota also altering CRC susceptibility (Uronis et al., 2009).  
Germ-free Il10-/- mice have previously been shown to develop colitis after being colonized with other 
specific bacteria, such as Enterococcus faecalis (E. faecalis) (Balish and Warner, 2002). E. faecalis not 
only induced inflammation, primarily in the colon and rectum, but rectal dysplasia and 
adenocarcinoma were also observed in the infected mice (Balish and Warner, 2002). In addition, 
conventional housed Il10-/- mice with a complex-intestinal microbiota actually developed E. faecalis-
induced colitis within 10 to 15 weeks of age and showed more pathology in the caecum (typhlitis) than 
observed with E. faecalis-induced colitis in germ-free Il10-/- mice. In contrast, neither germ-free Il10-/- 
mice nor Il10-/- mice colonized with a pure culture of Candida albicans, E. coli, Lactobacillus casei, L. 
reuteri, L. acidophilus, a Bifidobacterium spp., Lactococcus lactis or a Bacillus spp. developed colitis 
during the 25-30 week study. The authors concluded here that E. faecalis could specifically trigger 
colitis, dysplasia, and carcinoma in a genetically susceptible murine host (Balish and Warner, 2002).  
E. faecalis is also known to produce superoxide, which results in genomic instability, severe 
inflammation and CRC in Il10-/- mice (Wang and Huycke, 2007, Wang et al., 2012c).  
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Mono-association of germ-free Il10-/- mice with a murine AIEC isolate, influenced by intestinal 
inflammation, appears to drive CRC progression in carcinogen-treated mice through the pks 
pathogenicity island (Arthur et al., 2012) encoding for colibactin, a genotoxin shown to induce 
enterocyte DNA damage and promote tumour growth (Cuevas-Ramos et al., 2010, Cougnoux et al., 
2014). An increased prevalence of pks-positive E. coli isolates in colorectal tissue implies a similar 
cancer-promoting role in human CRC (Arthur et al., 2012, Prorok-Hamon et al., 2014).  
However, the CRC mucosa-associated E. coli strain used in this study, HM44, does not harbour the pks 
pathogenicity island encoding for colibactin (Arthur et al., 2012; Prorok-Hamon et al., 2014) but does 
harbour the afa operon, more characteristic of diffuse adherent E. coli (DAEC) isolates (Servin, 2005). 
It has been recently observed that there is increased prevalence of afa-expressing mucosa-associated 
E. coli in CRC, with these isolates showing significant ability to upregulate angiogenic VEGF mRNA 
(Prorok-Hamon et al., 2014). DAEC have also been observed to both increase activity of AKT 
serine/threonine kinase, a molecular link to Wnt signalling, and to enhance nuclear localization of β-
catenin (Anderson and Wong, 2010, Cane et al., 2007). DAEC afimbrial adhesins (Afa/Dr) are also 
known to promote secretion of pro-angiogenic VEGF from epithelial cells and to induce epithelial-
mesenchymal transition (Cane et al., 2010), a potential mechanism for carcinoma progression (Thiery 
et al., 2009). Moreover, VEGF/VEGFR2 signaling is a key molecular link between inflammation and CRC 
promoting epithelial cell proliferation and tumour growth in vivo (Waldner et al., 2010).   
Our ability to quantify the changes in COX-2 and β-catenin protein expression following as little as 6-
weeks of colonisation in vivo in this study could be seen as an important step towards linking mucosa-
associated E. coli infections to an increased risk of CRC development and progression. This is a key 
finding, further supporting showing that inflammation signals and increase in Wnt signalling, could be 
an early event in bacteria-induced colon carcinogenesis. 
For this part of the study, immunohistochemical staining was a powerful tool in being able to visualise 
the changes in expression of COX-2 and β-catenin. The use of DAB staining for nuclear localisation was 
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also important to assess β-catenin nuclear localisation.  However, even with the use of negative 
controls and blocking, absolute quantification using DAB staining intensities can be difficult to 
interpret, comparatively (Rizzardi et al., 2012, de Matos et al., 2010). Other robust techniques such as 
qPCR and immunoblotting can be used alongside IHC to allow more comparisons to be drawn and to 
confirm changes in gene and protein expression. Future analysis using techniques such as these may 
help to strengthen and confirm our findings of COX-2 and β-catenin protein expression changes. 
This use of an automated scoring system to detect levels of COX-2 and β-catenin allowed for a higher 
throughput image quantification in this study, where experimenter bias was also significantly reduced. 
With a pre-determined number of images taken per immuno-stained tissue section and microscopy 
light settings consistent for imaging of both germ-free and HM44 mono-associated Il10-/- murine 
tissues, automating the process of categorising the DAB staining intensity ruled out the maximum 
number of variables that could affect the outcome of this scoring method. High quality results were 
achieved by adapting the HSCORE method – an early approach reported in a breast cancer model 
(McCarty et al., 1986). Due to the limited availability of colonic tissue from the in vivo mono-
association study, we decided first to optimise and validate the HSCORE method of quantification 
before submitting the germ-free Il10-/- model tissue for immunohistochemistry (IHC). Intestinal tissues 
tissue from a wild-type C57BL/6 mouse treated with 2% w/v DSS, typically used to model the 
development of DSS-induced colitis, and with observed upregulation of COX-2 (Singh et al., 2010) was 
first used to validate the HSCORE system for COX-2 staining. The original study utilising this scoring 
technique evaluated the immunohistochemical staining of human tumour tissue using a monoclonal 
anti-oestrogen receptor antibody (McCarty et al., 1986). Immunohistochemical localisation was 
scored in a semi-quantitative fashion incorporating both the intensity and the distribution of specific 
staining (McCarty et al., 1986).  Evaluation of staining in our study, was recorded as percentages of 
positively stained target cells in five intensity categories; these were denoted as 0 (no staining), 1+ 
(weak but detectable above control), 2+ (distinct), 3+ (strong), and 4+ (minimal light transmission 
through stained nucleus). These percentages were used to designate a HSCORE value derived by 
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summing the percentages of cells staining at each intensity multiplied by the weighted intensity of 
staining (McCarty et al., 1986). The method of achieving a final HSCORE value described in the original 
study is similar to that incorporated into the IHC Profiler values of negative, low positive, positive and 
high positive. The IHC Profiler is a plugin for ImageJ, and was also used in our study. This method is 
typically used for scoring protein targets with cytoplasmic and/or nuclear expression (Varghese et al., 
2014), making it suitable for scoring total epithelial levels of COX-2 and β-catenin expression. As 
mentioned previously, the ability to deconvolute the cell nuclear blue haematoxylin stain and the 
brown diaminobenzidine (DAB) stain used to detect COX-2 and β-catenin antibody binding, allowed 
for a more sensitive method of quantification. If such a tissue scoring technique was to be utilised as 
a marker for COX-2 or β-catenin in future studies, it would benefit from a compared to an established 
scoring system using tissue pathology. One such system has been developed for visual analogue 
scoring in order to quantifying immunohistochemical staining, and has been used to compare 
untreated and H. felis-infected C57BL/6 mice (Duckworth et al., 2015). This would enable the 
experimenter to further confirm the suitability of the automated scoring technique. In order to further 
minimise the risk of bias with more valuable tissue, for example limited biopsy tissue being used to 
determine CRC cancer risk, it would be beneficial to introduce an image blinding system, where the 
person evaluating the staining intensity of each image was blinded as to the origin of the tissue. 
Nevertheless, the way in which this scoring system is automated should remove any interference with 
the final scoring outcome. 
Following the validation of the COX-2 protocol, we sought to optimise and validate the HSCORE system 
for β-catenin staining. As previously mentioned, gut tissue obtained from loxP-flanked Apc mutant 
(Apcfl/fl) AhCre mice (Sansom et al., 2004, Su et al., 1992), recommended for modelling CRC (Karim and 
Huso, 2013, Newman et al., 2001), was used to validate the scoring system for β-catenin, but also to 
validate the ImmunoRatio scoring system (described above), which has been previously used to assess 
nuclear localisation in tissue sections (Tuominen et al., 2010, Sundara Rajan et al., 2014). 
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The APC gene codes for the functional tumour-suppressor protein adenomatous polyposis coli, with 
inactivation recognised as a key early event in the development of sporadic colorectal cancers 
(Sansom et al., 2004). APC protein is responsible for targeting β-catenin for degradation; therefore, 
loss of conventional Apc function in these mouse models gives rise to unregulated Wnt signalling, 
leading to increased cell adhesion and migration, loss of cell cycle control, reduced apoptosis and 
chromosomal stability (Bienz and Clevers, 2000, Nathke et al., 1996, Fodde et al., 2001). The loss of 
Apc function in this mouse model meant that gut tissue would be highly valuable for the optimisation 
and validation of the scoring technique that was to be used to assess β-catenin localisation in the 
HM44 mono-association model. 
The Apcfl/fl mutant mouse model, a novel inducible transgenic line in conjunction with a loxP-flanked 
Apc allele, was created by Sansom et al. (2004) using Cre/loxP technology (Sansom et al., 2004) and 
adopted by Dr John Jenkins and Dr Cleberson Quieroz, who kindly donated gut tissue for use in our 
study. Cre recombinase is a tyrosine recombinase enzyme responsible for the excision of any region 
of DNA placed between two loxP sites, with the loxP site genetically targeted around an essential exon 
in a gene, in this case Apc. The resulting mice contain the floxed (flanked by loxP sites) allele in all 
tissues but are phenotypically wildtype. These floxed mice are then bred to Cre expressing transgenic 
animals, where an inducer is required to drive Cre expression in order for gene deletion to occur (Hall 
et al., 2009). In this case, the Cre Apcfl/fl was induced by beta-napthoflavone injectons (Sansom et al., 
2004). 
The multiple intestinal neoplasia mouse model is typically used as a model for familial adenomatous 
polyposis coli (FAP). Mice in this model harbour one wild-type Apc allele and one Apc allele mutated 
at codon 850 (ApcMin⁄+). Due to the mutation, this model displays Apc-driven tumourigenesis in the 
intestine, and investigation of adenomas from both FAP patients and ApcMin⁄+ mice has shown either 
mutation or loss of the wild-type Apc allele in most adenomas (Luo et al., 2009). Adenomas found in 
this mouse model are predominantly localised to the small intestine and are generally benign, 
meaning a lack of progression to invasive colon cancer (Young et al., 2013). 
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Summary 
Significant increases in both COX-2 and β-catenin expression, and in nuclear localisation of β-catenin, 
was shown in murine intestinal tissue mono-associated with a human CRC mucosa-associated E. coli 
isolate HM44. This demonstrates translation of findings seen in vitro, where COX-2 and Wnt signalling 
pathway activation was observed in laboratory cultures CRC cell-lines infected by the same isolate 
(and other similar CRC and IBD mucosa-associated E. coli isolates), into a disease-relevant in vivo 
system. These increases in β-catenin/Wnt pathway activation could impact cell adhesion and 
migration, loss of cell cycle control, reduced apoptosis and chromosomal stability as previously 
reported. Further work remains to fully determine phenotypic changes and development of 
hyperplasia and/or tumours, but early observations of the gut epithelial environment showed 
inflammatory infiltrate and crypt mitosis, suggesting a proliferative state of crypt cells infected with 
CRC-associated E. coli HM44. With a number of factors, both genetic and environmental, causing a 
shift towards increased numbers of these pathogenic bacteria, influenced by intestinal inflammation, 
this could be seen as a possible early driving event in the development and/or progression of 
colorectal cancers. Additional study of other chronic mucosa-associated E. coli infections would be 
beneficial, and could help to build a convincing argument towards the involvement of these specific 
Wnt-activating bacteria in IBD-associated and sporadic CRC.  
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Chapter 7: 
Identification of genomic elements responsible for 
COX-2 up-regulation using a fosmid clone library 
generated from CRC mucosa-associated  
E. coli HM358 
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7.1 Introduction 
With a wide role of cyclooxygenase-2 (COX-2) in CRC development and progression, and a cascade 
suggested for the role of COX-2 and prostaglandin-E2 (PGE2) in stimulating cancer cell growth via Wnt 
activation (Castellone et al., 2005), it is highly possible that COX-2 induction following chronic bacterial 
infection of colonic cells could lead to sustained increases in Wnt signalling in vivo.  
COX-2-driven PGE2 increases are believed to activate the G protein–coupled receptor EP2 leading to 
phosphoinositide 3-kinase (PI3K) activation of the Wnt signalling pathway via the inactivation of 
glycogen synthase kinase 3β (GSK3β). The subsequent accumulation of β-catenin in the cytoplasm and 
its nuclear translocation following infection of colonic cells with mucosa-associated E. coli could 
support cancer cell proliferation, migration and metastasis. With gut inflammation able to alter the 
composition of the microbiota in favour of the adherent, invasive E. coli pathovar (Darfeuille-Michaud 
et al., 1998, Swidsinski et al., 1998, Martin et al., 2004), this could create an environment that also 
favours tumour development and progression, by resultant expansion of, and contact with, these 
mucosa-associated bacteria. In addition, as CRC mucosa-associated E. coli strains can also survive and 
replicate within human mucosal macrophages, leading to further increases in mucosal COX-2 
expression and subsequent PGE2 secretion (Raisch et al., 2015).  
We have so far been able to characterise upregulation of Wnt signalling target genes alongside 
increases in COX-2 and β-catenin at both mRNA and protein level following in vitro infection of CRC 
cell lines with mucosa-associated E. coli isolates, including HM44 and HM358 both isolated from CRC 
patient biopsy tissues. We have also been able to show translation of increased CRC E. coli-induced 
COX-2 and β-catenin protein expression to that observed in vivo in an infection model using germ-free 
Il10-/- mice mono-associated with the CRC mucosa-associated E. coli HM44. 
These results suggest that inflammation-associated and CRC mucosa-associated adherent, invasive  
E. coli may harbour a key virulence factor(s) that support increased COX-2 and Wnt signalling, 
important as possible drivers in the development and/or progression of CRC. Therefore, we aimed to 
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establish whether specific genomic elements could be identified as being responsible for or 
contributing towards these effects in colonic cell lines. To support this, we were fortunate to have 
access to a screening library of 968 clones prepared using sheared gDNA fragments isolated from CRC 
mucosa-associated E. coli HM358, shown to increase COX2 in CRC cell lines in vitro (See Chapter 5) 
randomly inserted into the pCC1Fos fosmid vector transformed to non-pathogenic E. coli EPI300-T1 
(see Figure 7.4). This approach had already successfully been used to identify the afimbrial adhesin 
afa operon, more common to diffusely adherent E. coli (DAEC) (Servin, 2005), showing its role in 
adhesion to, and invasion of epithelial cells, increased VEGF expression (i.e. angiogenic potential), and 
increased prevalence and presence in E. coli isolates from the colorectal mucosae of patients with 
Crohn's disease and CRC (Prorok-Hamon et al., 2014). 
With these mucosa-associated E. coli found in increased numbers within intestinal tissue taken from 
patients with IBD and CRC, a considerable impact could be made by identifying a bacterial gene 
cluster/gene encoding a key virulence factor(s) responsible for, or contributing towards, increased 
mucosal COX-2 and Wnt signal pathway activation, characteristic of inflammation-associated and 
sporadic CRC. 
 
 
 
 
 
 
 
 
 
145 
 
7.2 Hypothesis 
Increases in COX-2 following mucosa-associated E. coli infection of colonocytes, observed in vitro and 
in vivo, are driven by specific genomic elements encoding key virulence factors likely specific to 
mucosa-associated E. coli. 
7.3 Aims 
• To investigate PTGS2 (COX-2) gene expression by RT-PCR following infection of SW480 CRC 
cells with 968 library clones each containing a fosmid harbouring a functional fragment of 
gDNA from the CRC mucosa-associated E. coli HM358 (known in vitro to upregulate COX2).  
• To sequence all confirmed PTGS2-inducing fosmid clones to find any common genes/operons 
and identify genomic elements responsible for or contributing towards mucosal COX-2 
expression changes. 
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7.4 Methods 
To identify potential genomic elements involved in activation of COX-2 by CRC mucosa-associated E. 
coli, we used a 968 fosmid clone library previously prepared in E. coli EPI300-T1 using sheared large 
functional fragments of genomic DNA from E. coli HM358, a haemagglutination-positive, adherent, 
invasive CRC isolate (Prorok-Hamon et al., 2014). Briefly, genomic DNA from this isolate was extracted 
using the Genomix Cell/Tissue kit (Talent; Italy) and randomly sheared to create a non-biased fosmid 
library using the CopyControl fosmid library kit (Epicentre; USA). DNA fragments were ligated into the 
pCC1Fos vector and introduced into phage T1-resistant E. coli K-12 derivate EPI300-T1, with 
subsequent clones selected on chloramphenicol (12.5 μg/mL) containing LB agar. 
 
 
Figure 7.4. Production of fosmid library and subsequent induction of clones using 
haemagglutinnating positive (HA+) CRC mucosa-associated E. coli isolate HM358. Adapted from 
Epicentre CopyControl™ Fosmid Library Production (http://www.epibio.com/docs/default-
source/protocols/copycontrol-fosmid-library-production-kit-with-pcc1fos-vector.pdf). 
 
For our study, each of the 968 fosmid library clones were sub-cultured from -80oC stored Protect bead 
stocks, and glycerol stocks generated for long-term storage and SW480 CRC cell infections in a 96 well 
format. Briefly, liquid LB broth was prepared (5g sodium chloride, 5g tryptone, 2.5g yeast extract and 
500 mL Elga-purified dionised water), with 500 μL added to each well of a deep 96-well plate (Sigma 
Aldrich; UK). Using a sterile loop, a single Protect bead was added to individual wells of the 96 deep 
well liquid LB plate. The 96-well cultures were covered using a slotted rubber plate lid (Sigma Aldrich) 
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and incubated at 37 °C overnight in a shacking incubator (140 rpm). Culture growth was characterized 
by a cloudy haze in the media and confirmed by conducting optical density (OD600nm) measurement 
using samples from 3 randomly selected wells, before using the same sample to grow clones on LB 
agar; a negative control using LB media supplemented with 500 µg/mL gentamicin (Sigma Aldrich) 
with and without bacteria was used to confirm lack of growth in these cultures. Following growth, 500 
μL of 50% glycerol (100% glycerol in Elga-purified deionised water) was added to each well of bacterial 
culture and gently mixed. Glycerol stocks were stored at -80oC. To recover bacteria from frozen 
glycerol stocks, a sterile loop was used to streak onto LB agar plates and grown overnight.  
For infection studies using SW480 CRC cells, cells of a low passage number (below 20 passages) were 
cultured as monolayers and maintained in DMEM supplemented with 10% FBS at 37˚C. Trypsinised 
cells were diluted to a cell suspension containing 250,000 cells/mL, with 2 mL of culture added to each 
well of clear 12-well cell culture plates (Corning; UK) and incubated overnight at 37 ˚C. Cells were 
infected with each of the 968 fosmid library clones for 4 hours at 37˚C (MOI: 10) for consistency with 
previous in vitro infection studies. Following infection, bacteria-containing media was removed and 
cells washed three times using sterile PBS (pH7.4) before lysis. Lysates were processed for extraction 
of RNA using the Zymo ZR-96 Quick-RNA kit (R1052; Zymo Research, US) following the manufacturers 
protocol. Briefly, each lysate was transferred to the 96-well Silicon-A Plate (supplied) and centrifuged 
at 4500 x g for 5 min. Lysate was then mixed with RNA lysis buffer and washed in Prep and Wash 
buffers (supplied), centrifuged at 4500 x g for 5 min. RNA was then eluted using DNase/RNase free 
water. Eluted RNA was used to synthesise cDNA and stored at -80 ˚C. 
RT-PCR using the cDNA was then used to assess expression of the PTGS2 gene encoding for COX-2 
protein, as in previous in vitro infection studies (see Chapter 5). Results were normalised to the 
expression of β actin gene, ACTB. Positive and negative controls using parent CRC mucosa-associated 
E. coli HM358 infected SW480 cells and non-infected cells respectively, were included in each run, 
with the same RT-PCR and amplification/quantification conditions optimised previously for use in the 
LightCycler 480 (Roche). Analysis of Ct values was then completed. 
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Fosmid library clones up-regulating PTGS2 expression were screened again to confirm activity, this 
time by RT-PCR using cDNA reverse transcribed from extracted total RNA from each infected culture 
using the same RT-PCR conditions. Following confirmation, fosmid DNA from positive clones and the 
parent HM358 strain were each extracted using the QIAfilter Midi kit (Qiagen) following the 
manufacturer's instructions and DNA quantified using Qubit (Thermo) fluorometric quantification 
according to manufacturer's instructions. Extracted fosmid DNA was kindly sequenced using Illumina 
MiSeq technology (Illumina Inc., USA) by Dr Matthew Bull and Professor Julian Marchesi (School of 
Biosciences, Cardiff University). As only 12 fosmids were to be sequenced in this study, a single-index 
approach was used, where only one end of each fragment was indexed. 
Briefly, extracted fosmid DNA was fragmented using dsDNA fragmentase (#M0348L, New England 
BioLabs Inc., USA), and resulting fragments size-selected to approximately 400 bp using Ampure XP 
SPRI beads (Beckman Coulter). Illumina sequencing libraries were prepared using a NEBNext Ultra 
DNA Library Prep Kit (#E7645L, New England BioLabs Inc.), following the manufacturer’s instructions. 
Resulting libraries were quantified using Qubit (Life Technologies) and combined at equimolar 
concentrations for sequencing. Libraries were sequenced on a MiSeq (Illumina Inc.) using a 2x150 
Nano sequencing kit (Illumina Inc.) following manufacturer’s instructions, with sequence analysis tasks 
carried out virtually, hosted by the Cloud Infrastructure for Microbial Bioinformatics (CLIMB; 
http://www.climb.ac.uk/) according to established protocols (Esson et al., 2016, McNally et al., 2016). 
The reads from each fosmid were assembled into contigs using the plasmidSPAdes function of SPAdes 
Genome Assembler software (version 3.8.0; http://bioinf.spbau.ru/spades) as previously reported 
(Antipov et al., 2016). Contigs denoting overlapping sequence data were screened for genomic DNA 
based on sequencing coverage and ordered based on fosmid backbone positioning. Subsequent 
fosmid-only assemblies were then annotated using Prokka annotation software (version 1.11; 
https://github.com/tseemann/prokka) as previously reported (Seemann, 2014). 
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7.5 Results 
7.5.1 Initial screening of fragmented E. coli HM358 fosmid library clones 
Following infection of SW480 cells with each of 968 fosmid library clones of fragmented E. coli HM358 
genome, and subsequent cellular lysis, RNA extraction and cDNA synthesis (4 hours post-infection), 
RT-PCR was completed using primers for COX-2 (PTGS2), as well as β-actin (ACTB) as a house-keeping 
gene, to calculate changes in COX-2 gene expression for each clone of the fosmid library. RNA 
extraction was successful for 842 clone infections (87.0%). 
A cut-off threshold of ≥2-fold change in PTGS2 expression was set to be consistent with previous cut-
off threshold set for the Wnt signalling RT2 PCR array data sets (Chapter 5). Initial screening of fosmid 
clones revealed ≥2-fold up-regulation of COX-2 gene expression caused by 45 clones (5.3%) and ≥2-
fold down-regulation caused by 34 clones (4.0%), with the remaining 763 clones (90.6%) resulting in 
≤2-fold up- or down-regulation considered to have caused no change (Figure 7.5.1); expression change 
s for clones causing ≥2-fold up-regulation is shown in Table 7.5.1 (n=1). 
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Figure 7.5.1. Changes in COX-2 gene expression following infection of SW480 cells with E. coli 
EPI300T1 fosmid library clones from a fragmented E. coli HM358 fosmid library. Graphs show fold 
change data for (A) untreated and HM358 treated controls (n=10) and (B) clones from a fragmented E. coli 
HM358 fosmid library (n=1). Fold change data for the fosmid clones was segregated into those that caused 
≥2-fold up-regulation and ≥2-fold down-regulation, with changes of <2 fold up- or down-regulation 
designated as no change. 
A B 
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Table 7.5.1. Fold change in COX-2 (PTGS2) gene expression for positive clones. 
 
*High Ct value (>30) for ACTB housekeeping gene with no notable change in Ct value for PTGS2 compared to 
untreated controls 
**Low Ct value (<10) for PTGS2 with no notable change in Ct value for ACTB housekeeping gene compared to 
untreated controls 
 
7.5.2 Confirmation RT-PCR of positive clones causing up-regulation of PTGS2  
Initial screening of the 968 fosmid library of clones measured changes in PTGS2 gene expression 
following single infections (n=1); therefore, it was necessary to confirm these findings using a 
secondary screen. This was done by RT-PCR of cDNA reverse-transcribed from extracted total RNA of 
SW480 cells infected with each of the 36 clones showing ≥2-fold up-regulation of PTGS2 and 3 
randomly selected clones showing ≥2-fold down-regulation or no change (n=3). A decision was made 
to not include 9 clones showing ≥2-fold up-regulation in the initial screen due to abnormally high or 
low Ct values for either ACTB or PTGS2; again, this was to ensure consistency with results obtained in 
the Wnt signalling RT2 PCR array data sets. 
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The secondary screen revealed only 12 clones (33.3%) were confirmed to show ≥2-fold up-regulation 
of PTGS2 expression, with 14 clones (38.9%) showing ≥2-fold down-regulation and 10 clones (27.8%) 
considered to have caused no change (Figure 7.5.2; Table 7.5.2); expression changes for clones 
confirmed to show ≥2-fold up-regulation has been shown in Table 7.5.2 (n=3). 
 
A       B 
 
  
 
 
 
Figure 7.5.2. Confirmation of COX-2 (PTGS2) gene up-regulation caused by CRC mucosa-
associated E. coli HM358 and E. coli EPI300T1 fosmid library clones generated from 30-60Kb 
gDNA fragments of E. coli HM358 genome. Graphs show fold change data for  
(A) uninfected and parent E. coli isolate HM358-infected controls (n=6) and (B) clones from a fragmented 
E. coli HM358 fosmid library initially identified as PTGS2 up-regulating (n=3). Confirmation results for 
the fosmid clones were segregated into those that again caused >2-fold up-regulation (Confirmed), those 
that caused between 1.8 to 2.0 fold up-regulation (1.8<x>2.0) and those that caused less than 1.8-fold 
change (Negative). 
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Table 7.5.2. Fold change in COX-2 (PTGS2) gene expression for fosmid clones screened in 
confirmation studies. 
 
 
These results showed that 12 clones from the HM358 fosmid library were confirmed to up-regulate 
PTGS2 gene expression more than 2-fold; this would suggest that these clones may contain specific 
genomic elements inserted within the fosmid that are responsible for the increase observed in COX-2 
following HM358 infection and perhaps as a consequence, Wnt signal pathway activation. To identify 
the genomic elements, we undertook sequence analysis of fosmid DNA isolated from the 12 clones 
confirmed in the secondary screen to up-regulate PTGS2 gene expression. 
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7.5.3 Illumina MiSeq sequencing of fosmid DNA from fosmid library clones generated 
from DNA fragments of E. coli HM358 confirmed to up-regulate PTGS2 gene expression 
Following confirmation of fosmid library clones showing >2-fold up-regulation of PTGS2 expression in 
both the primary screen and secondary confirmatory screen, fosmid DNA was extracted from 12 
positive clones. Fosmid DNA was extracted using QIAfilter Midi kit following the manufacturer's 
instructions, with fosmid DNA from the parent CRC mucosa-associated E. coli HM358 isolate also 
extracted for sequencing. Each sample was then submitted for Qubit fluorimetric quantification of 
DNA content (Table 7.5.3). 
 
Table 7.5.3. Qubit quantification of fosmid DNA from confirmed PTGS2 up-regulating library 
clones and DNA from HM358. 
 
 
Following DNA extraction and quantification, samples were sent to Cardiff University for sequencing 
using the Illumina MiSeq (Illumina Inc., USA). As only 12 fosmids were to be sequenced in this study, 
a single-index approach was used, where only one end of each fragment was indexed. Following 
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sequencing, SPAdes Genome Assembler software (version 3.10.1; http://bioinf.spbau.ru/spades) was 
used for fosmid assembly and Prokka software (version 1.11; https://github.com/tseemann/prokka) 
for rapid prokaryotic genome annotation. Annotation comparisons were then completed using the 
Artemis Comparison Tool (http://www.sanger.ac.uk/science/tools/artemis-comparison-tool-act). 
Here, regions of sequence homology are linked with vertical red (forward match) or blue (reverse 
match) lines (not shown). In all cases, the fosmid operon sequences are shown at the top of the image, 
with the reference backbone sequence at the bottom. 
Of the 12 confirmed positive clones sequenced, some appeared to have common homology. All but 
one clone contained the fosmid vector sequence comprised of the repE, soj and virB operons, which 
were found as a cluster (Figure 7.5.3.2). 
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Figure 7.5.3.2. Sequence alignment of 12 fosmid clones positive for PTGS2 up-regulation. The 
fosmid vector reference sequence of repE, soj and virB operons (red arrows) was identified in 11 of 12 
fosmid clones. Sequences were between 30-50 kDa in 10 of 12 fosmid clones. 
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Fosmid clone 7B12 was found to be around 15 kDa and did not contain the fosmid vector reference 
sequence, suggesting this was an incomplete sequence. Interestingly, clones 2E4 and 6E8 contained 
sequence homology for 15 genomic elements/operons, including yrb, kds, lpt, rpo, pts and glt (Figure 
7.5.3.3). Some of these genomic elements/operons were also found in other PTGS2 up-regulating 
clones, and may be of interest for future studies. 
 
 
 
 
 
 
 
 
 
 
Figure 7.5.3.3. Sequence alignment of fosmid clones 2E4 and 6E8 positive for PTGS2 up-
regulation. The fosmid vector reference sequence of repE, soj and virB operons (red arrows) was 
identified, with the majority of other operons common in both clones (blue arrows) and only 5 additional 
operons in clone 6E8 (grey arrows). The order sequence of the common operons was identical. 
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7.6 Discussion 
By screening clones from the fragmented E. coli HM358 fosmid library using RNA extractions from 
infected CRC cells in vitro, we were unable to identify a common factor associated with increased 
PTGS2 (COX-2) expression. Initial and confirmation screening efforts appeared to identify 12 fosmid 
clones showing increased PTGS2 expression. Subsequent sequencing of these clones using Illumina 
MiSeq showed similarities in DNA content, with particularly common homology in two of these fosmid 
DNA inserts. The fosmid vector sequence of repE, soj and virB operons were used to identify the coding 
region in each clone, with repE and soj encoding replication initiator proteins (Wada et al., 1987, Ogura 
et al., 2003) and virB required for survival and replication (Schmiederer et al., 2001). The operons 
identified following on from the vector sequence were almost identical for the 2E4 and 6E8 clones. 
The following sections highlight their known functions. 
The ispB gene codes for the octaprenyl diphosphate synthase enzyme involved in quinone synthesis 
(Maouche et al., 2016). This gene is essential for normal growth of E. coli (Okada et al., 1997), but to 
date is not known to be associated with virulence. The yrbG gene is believed to play a protective role 
against the lethal action of quinolones (a family of synthetic broad-spectrum antibiotics), with yrbB 
mutations making E. coli more susceptible to quinolone-mediated lethality (Han et al., 2011). YrbB is 
a component of an ABC transport system that maintains lipid asymmetry in the outer membrane of 
Gram-negative bacteria, by preventing surface exposure of phospholipids. It has been suggested that 
these genes may be implicated in cell envelope integrity (Sperandeo et al., 2006). A role for yrbB in 
supporting survival of E. coli in high-stress environments has been shown, with yrbB mutation 
associated with a greater susceptibility to stress-induced killing (including stressors such as UV and 
oxidative damage) than wild-type E. coli, although no difference were seen in response to heat-
induced death (Han et al., 2011). 
The kdsD gene codes for d-Arabinose 5-phosphate isomerase (API), the first enzyme in the 
biosynthetic pathway of 3-deoxy-d-manno-octulosonate (KDO), a unique 8-carbon sugar component 
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of lipopolysaccharides located in the outer leaflet of the outer membrane of Gram-negative bacteria. 
However, presence of the kdsD gene and encoding of API has been reported in E. coli K-12 (Meredith 
and Woodard, 2005), an isolate which was shown to have no impact on PTGS2 expression throughout 
our study. Therefore, the kdsD gene is unlikely to have an important role in driving increased PTGS2 
expression. 
The lpt operon in E. coli codes for the Lpt protein machinery, seven essential proteins (A, B, C, D, E, F, 
and G) which form a complex that constitutes a transporter for lipopolysaccharide (LPS), one of the 
most powerful proinflammatory bacterial virulence factors, engaging transport of LPS from the 
cytoplasm to the outer membrane (Martorana et al., 2014, Bollati et al., 2015). As these are 
considered essential for LPS transport in Gram-negative bacteria, changes in expression (i.e. up-
regulation) in E. coli may affect their ability to survive, which may then enhance their ability to infect 
host cells. This could be a driving factor for PTGS2 expression, but would need to be confirmed either 
by functional studies of insertion of a plasmid containing the lpt operon into a non-PTGS2 inducing E. 
coli (gain of function study) or through use of transposon mutagenesis (Goryshin et al., 2000) to create 
insertional knockout of lpt operon genes in the parent CRC mucosa-associated PTGS2-inducing E. coli 
HM358 (loss of function study). This could then be followed up by mono-association of germ free mice 
with HM358 and the isogenic knockout strain 
In E. coli, the phosphoenolpyruvate-carbohydrate phosphotransferase system (PTS), coded for by the 
pts gene family, is responsible for the transport and phosphorylation of sugars, such as glucose. PTS is 
believed to play an important role in controlling the preferential utilisation of glucose (Escalante et 
al., 2012, Plumbridge, 2002). Earlier studies also reported PTS as being a well characterized system 
mediating information transfer from the external medium to multiple targets inside the cell (De Reuse 
et al., 1989). Again, this growth and survival mechanism may be enhanced in clones shown to up-
regulate PTGS2 expression, and may aid COX-2 signalling changes. 
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The gltB and gltD operons are responsible for the synthesis of glutamate synthase enzyme. Under 
nitrogen-rich conditions, this can be used to form glutamate and glutamine (Kumar and Shimizu, 
2010). Some E. coli mutants that are deficient in glutamate synthase activity have difficulty growing 
with nitrogen sources other than ammonia, suggesting this enzyme is important in bacterial growth 
in nitrogen-rich conditions. Increases in nitrogen metabolism have been shown in IBD, where the 
microbiome begins to respond and compensate to gut inflammation driven oxidative stress (Morgan 
et al., 2012). The Morgan et al. study reported an increase in glutathione transport gene abundance 
in UC and CD and an increase in glutathione metabolism gene abundance in UC. Inflammatory 
cascades aid the production of highly reactive oxygen and nitrogen metabolites, which have been 
found greatly increased in active IBD. Monocytes in the lamina propia also release homocysteine 
during inflammation, which further contributes to oxidative stress (Morgan et al., 2012). These may 
reflect a mechanism by which the gut microbiome addresses the oxidative stress caused by 
inflammation, where changes in expression of genes responsible for controlling bacterial survival 
under these conditions may become important. 
The Morgan et al. study also highlighted that this type of stress allows entero-haemorrhagic E. coli to 
use nitrogen sources as a competitive advantage under these conditions. The possibility that E. coli 
may be highly represented in IBD because they gain a competitive advantage from inflammation-
induced oxidative and/or acid stress, and that they appear better able to compensate for this through 
metabolism of glutathione has been raised previously (Morgan et al., 2012), and may make presence 
of this genomic element in several of the positive fosmid library clones (from the parent isolate 
HM358) in our study of more interest. 
An additional study has also indicated the elevated expression of rpo genes in response to increased 
gltB and gltD expression (Kumar and Shimizu, 2010). Alternative sigma factor 54 (RpoN), coded for by 
rpo, is an important regulator of stress resistance and virulence genes in many bacterial species. RpoN 
plays a major role in the response of E. coli to nitrogen-limiting conditions. Under such conditions, 
RpoN directs the transcription of several operons/regulators in the nitrogen regulatory response in E. 
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coli (Riordan et al., 2010).  With the rpoN operon found in our study in both the 2E4 and 6E8 fosmid 
library clones, and where gltB and gltD were also identified, this perhaps establishes a further 
association between their presence/expression, and may link further to the impact of nitrogen sources 
in intestinal inflammatory conditions as with the gltB and gltD operons. 
As bacteria have to adapt quickly and efficiently to multiply in response to changes in their 
environment, membrane-linked transport systems, such as those eluded to here, are designed to 
recognise and translocate specific molecules across the cell membrane in order to survive, grow and 
persist. The PTS is a good example of a system specifically designed to transport a large number of 
carbohydrates, and is also one of the best characterized systems mediating information transfer from 
the external medium to multiple targets inside the cell (De Reuse et al., 1989). If mucosa-associated 
E. coli do harness these features for growth and survival better than non-pathogenic strains, 
particularly in higher stress conditions such as inflammation, their ability to infect host cells may be 
improved and may have contributed to the COX-2 and Wnt signaling changes observed both in vitro 
and in vivo. 
Going forwards, it would be interesting to look deeper into those operons/genes shared by PTGS2 up-
regulating fosmid library clones more closely. Once key operons/genes have been identified, it would 
be useful to screen all clones for the presence of this operon using RT-PCR. This was done in the study 
of Prorok-Hamon et al., (2014) where sequence analysis of E. coli HM358 and haemagglutination-
positive fosmid clones were subsequently screened by PCR for a conserved element of the 454-
sequencing identified afimbrial adhesin afa-1 operon (i.e. afaC, encoding an usher protein). 
Subsequent insertion of the identified afa-1 operon into a plasmid and transformation of the non-
pathogenic E. coli EPI300-T1 (K-12) base clone strain, demonstrated that presence of this genomic 
element to confer ability to adhere to, and invade, HEp-2 and I-407 epithelial cells (Prorok-Hamon et 
al., 2014). In the same study, the wild-type strain HM358 showed a greater ability to adhere to, and 
invade into, these cells compared to the afa-1-transfected E. coli K-12 strain, implying that other 
adhesins/invasins might also be involved, as invasion into I-407 cells was seen some afaC-negative 
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mucosa-associated E. coli isolates. This means that any leads stemming from our study may not be the 
only factors involved in inducing COX-2 and Wnt signalling, and could mean a role for several 
genes/proteins working in tandem to elicit these effects. It would also be useful to be able to compare 
the sequence of HM358 (data not available) and other mucosa-associated E. coli isolates from CRC 
and IBD patients and to that of E. coli K12 genome (accession number: U00096.2), with the potential 
to insert any genes/operons of interest from data from our study into a wild-type control, such as E. 
coli K12, to investigate effects on PTGS2 expression in SW480 cells. 
The similarities seen in only two of the fosmid clones was an unexpected result, especially given that 
such similarities were not seen in the use of the fosmid library successfully identifying the afimbrial 
adhesin (afa-1) operon, but also that that the afa-1 operon was seen in 7/8 positive clones (one not 
having sequenced) in the Prorok-Hamon study (Prorok-Hamon et al., 2014). 
Given the COX-2 increases are already shown in vitro (see Chapter 5) and in vivo (see Chapter 6) data 
accumulated in our project, measurement of PTGS2 gene expression changes appeared a logical way 
to screen the fosmid library or clones. However, few assays measuring COX-2 activation on a high-
throughput scale would have been suitable for obtaining a robust signal window in order to efficiently 
identify fosmid clones that up-regulate COX-2. 
Readouts using the stable transfected HeLa TCF/LEF luciferase reporter assay (Signosis, USA), which 
yielded reliable and robust data when characterising the in vitro effects of mucosa-associated E. coli 
(see Chapter 5), was trial screened following infection with the same fosmid library clones identified 
to up-regulate PTGS2 gene expression. The assay readout did not produce any reproducible data sets 
to identify TCF/LEF signalling changes following infection with fosmid clones showing COX-2 gene 
changes (n=3, data not shown); this was despite showing reproducible increases in TCF/LEF signalling 
using several mucosa-associated E. coli, including HM358, as positive controls. However, this could 
again be due to limitations of the primary screen in identifying suitable fosmids. Instead, it may be 
possible to examine the effects on Wnt signalling using qPCR to identify changes in expression of 
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specific Wnt-relevant genes such as Axin2, known to be rapidly induced by the activation of Wnt 
signalling (Jho et al., 2002). Another possibility could be to utilise a PGE2 ELISA (such as that shown in 
the in vitro monocyte-derived macrophage infection assays in Chapter 5) as a screening tool, where 
cells inoculated with each fosmid library clones are lysed and used to quantify host cell production of 
PGE2 released to cell supernatants. Measurement of PGE2 would be a downstream reporter of COX-2 
activity. Use of an ELISA readout for COX-2 has also been used with success in a high-throughput 
screening format (Cuendet et al., 2006). 
Summary 
Future work using this data could identify one or even several genes or operons that establish an 
active factor, or factors, that contribute to the induction of COX-2 and Wnt signalling observed in vitro 
and in vivo experiments described earlier in the project. If mucosa-associated E. coli are to be shown 
to harness any of the operons identified here for growth and survival, particularly in higher stress 
conditions such as inflammation, increase their ability to infect host cells and contribute to COX-2 and 
Wnt signalling changes, these could become potential therapeutic targets. 
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Chapter 8: 
Development of a three-dimensional (3D) cell 
culture method to investigate the effects of 
mucosa-associated E. coli infections 
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8.1 Introduction 
Mucosa-associated E. coli have been found in high numbers within intestinal tissue taken from IBD 
and CRC patients (Martin et al., 2004, Hold et al., 2014, Swidsinski et al., 1998). Results obtained so 
far suggest that colonic mucosa-associated E. coli support increased intestinal COX-2 expression and 
Wnt signalling as a possible early event in the development and/or progression of colorectal cancers. 
We have been able to characterise changes in both COX-2 gene and protein expression and Wnt 
signalling, including increased nuclear translocation of β-catenin, following in vitro infection of CRC 
cell lines with mucosa-associated E. coli, as well as showing the translation of these effects in an in 
vivo infection model using germ-free Il10 knock-out mice mono-associated with HM44, a mucosa-
associated E. coli isolated from a CRC patient. 
With gut inflammation already shown to alter composition of the gut microbiota in favour of 
pathobiont mucosa-associated E. coli (Darfeuille-Michaud et al., 1998, Swidsinski et al., 1998, Martin 
et al., 2004), the resultant expansion of these bacteria would likely increase their interactions with gut 
mucosa. With few studies looking to mimic the intricacies of the parent colonic tissue, opportunities 
to effectively show the translational effects of these interactions in vitro have so far been limited. One 
method of modelling better these interactions is by utilising three-dimensional (3D) organotypic cell 
cultures. Previous development of 3D culture models to study host-pathogen interactions has allowed 
a better platform for studying these interactions as these cultures tend to better replicate the growth 
of cells and tissues in vivo compared to 2D monolayer cultures, particularly in the case of tumour 
formation. One study in particular reported successful use of CRC cell lines formed as 3D organotypic 
cultures to study host interaction with pathogens such as enteropathogenic E. coli (EPEC) and 
enterohaemorrhagic E. coli (EHEC) ((Carvalho et al., 2005). The authors made use of a rotating cell 
culture system (RCCS; Synthecon, USA), originally designed and used by the National Aeronautics and 
Space Administration (NASA) to provide a simulated microgravity environment during certain phases 
of the Shuttle missions, before being made commercially available for the production of 3D cell 
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structures (Jessup et al., 1993). This system has been used extensively to characterise cell behaviour 
and neoplastic transformation in 3D culture using a host of different cell types, including cancer cells 
(Vidyasekar et al., 2015), skeletal muscle cells (Klement et al., 2004) and bacteria (Bergmann and 
Steinert, 2015). 
The RCCS generates low-shear stress and microgravity conditions provide unique advantages for the 
cultivation of mammalian tissues (Jessup et al., 1993). A lack of gravity-induced sedimentation 
supports 3D growth in culture and permits human epithelial cells to grow to high densities. The system 
also allows the use of cell micro-carriers, where cells can adhere to, and undergo cell division on, these 
micro-carriers whilst remaining as aggregates in suspension. This culture method is especially useful 
for allowing natural cell-cell interaction, with growth in the RCCS shown to support morphological 
differentiation of human colon carcinoma cells, particularly in co-culture with human stromal cells to 
create a foundation layer for the neoplastic cells to grow on (Jessup et al., 1993, Jessup et al., 2000). 
With several CRC cell lines, such as HT-29 (Goodwin et al., 1992), Caco-2 (Kaeffer et al., 2002) and HCT-
8 (Carvalho et al., 2005), already having been shown to be suitable for use in this system, our aim was 
to create 3D cultures suitable for infection with mucosa-associated E. coli. For this project, porous 
Cytodex micro-carrier beads were examined for their use as a support for CRC cell growth in the RCCS 
system. Two types of micro-carrier beads coated with collagen and diethylaminoethyl (DEAE) 
cellulose, a positively charged resin, were used to simulate the supportive environment provided to 
epithelial colon cells in vivo. 
Here, RCCS culture was initially developed using the SW480 CRC cell line (successfully used in in vitro 
studies demonstrating mucosa-associated E. coli-induced COX-2 expression and Wnt pathway 
activation – Chapter 5) and then expanded to investigate a late-stage adenoma cell line AA/C1 and 
adenocarcinoma cell line AA/C1/SB, both experimentally-transformed from an epithelial adenoma cell 
line PC/AA (Williams et al., 1990, Paraskeva et al., 1992). By using these cell-lines, we would gain 
insight into the impact of colonic mucosa-associated E. coli infection on cells at key stages of 
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transformation in the colorectal adenoma-carcinoma sequence (Armaghany et al., 2012). 
Development of a 3D organotypic cell culture method using this array of colorectal cell lines would 
also afford us opportunity to investigate the effects of mucosa-associated E. coli infection in a system 
that better mimics chronic pathogenic bacterial infection in patients. With a fully validated culture 
procedure, we would then have an efficient and reliable culture platform available for use in future 
studies. 
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8.2 Hypothesis 
Three-dimensional organotypic cell cultures will allow us to investigate the effects of colonic mucosa-
associated E. coli infection in a system that better mimics the intricacies of bacteria-host interactions 
in vivo. 
8.3 Aims 
• To develop a 3D organotypic cell culture using a series of colorectal cell-lines at different 
stages of malignant transformation in the adenoma-carcinoma pathway. 
• To investigate the action of colonic mucosa-associated E. coli infection of 3D organotypic cell 
cultures on COX-2 expression and Wnt pathway activation. 
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8.4 Methods 
The adherent human colonic epithelial cell lines SW480 and DLD-1, derived from male patients with 
Duke's type B (Leibovitz et al., 1976) and type C (Dexter et al., 1981) colorectal adenocarcinomas, 
respectively, were initially grown as monolayer cultures as previously described (see Section 4.1). Cells 
were maintained in complete Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma Aldrich) 
supplemented with 10% (v/v) fetal bovine serum (FBS) (Invitrogen; Paisley, UK), 100 U/mL penicillin 
and 100 µg/mL streptomycin (Sigma Aldrich, UK) at 37°C in a humidified atmosphere of 5% CO2, 95% 
air until they reached confluency. The epithelial cell line PC/AA and experimentally-transformed 
AA/C1 and AA/C1/SB cells were originally established from a pre-malignant adenoma taken from a 
patient with familial adenomatous polyposis and kindly donated by Professor Chris Paraskeva, 
University of Bristol, UK (Williams et al., 1990, Paraskeva et al., 1992). The AA/C1 and AA/C1/SB cell 
lines were grown and maintained under the same conditions as SW480 and DLD-1 cells, excepting that 
complete DMEM was additionally supplemented with 2 mM L-glutamine (Sigma Aldrich), 1 µg/mL 
hydrocortisone sodium succinate (Sigma Aldrich) and 0.2 U/mL human insulin (Sigma Aldrich). 
Once cell lines had reached around 90% confluency, colonic cell lines were each seeded at the required 
density, for example 1 x 106 cells/vessel, directly into 10 mL and 50 mL vessels and added to the 
Synthecon Rotary Cell Culture System (RCCS) following manufacturer recommendations (Figure 8.4). 
Initiation and maintenance technique, as well as cell density and rotation speed were optimised for 
individual cell lines and culture volumes (see Chapter 8.5). Briefly, cells were maintained in complete 
DMEM, with appropriate supplementary reagents required for specific cell lines, at 37°C in a 
humidified atmosphere of 5% CO2, 95% air. Media was changed 72-96 hours after seeding, then every 
48 hours until cell aggregates were harvested. Periodic sampling of cell aggregates following media 
changes allowed monitoring of cell aggregation and viability using light microscopy. Following culture 
in the RCCS for up to 4 weeks, cell aggregates were harvested and plated for E. coli treatment. Assays 
used the same multiplicity of infection (MOI: 10) as used in earlier 2D monolayer studies; this MOI was 
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estimated based on the initial cell density at the beginning of RCCS culture and rate of replication of 
cells seen in 2D monolayer studies. 
 
 
 
 
 
Cultures were also created using extracellular-matrix-coated (ECM) micro-carrier beads, where cells 
grown in monolayer cultures were trypsinised and incubated with the coated beads before being 
added to a rotary cell culture vessel. In this case, Cytodex beads coated in with diethylaminoethyl 
(DEAE) cellulose (Cytodex-1) and collagen (Cytodex-3) were used (Sigma Aldrich); micro-carrier beads 
were prepared and used following the manufacturer's recommendations. Briefly, Cytodex beads were 
sterilized in 100% ethanol before swelling in excess sterile phosphate-buffered saline (PBS; pH7.4), 
using 50 mL/g of Cytodex beads, for a minimum of 2 hours. The cell-bead suspension was then left to 
settle for 10 minutes; the supernatant PBS was decanted and replaced with 70 % (v/v) ethanol in 
distilled water; the beads were washed twice in this solution and then incubated overnight in 70 % 
(v/v) ethanol in distilled water, using 70–100 mL/g Cytodex beads. Following incubation, the 70% (v/v) 
ethanol solution was removed, with the Cytodex beads then washed three times in sterile PBS (50 
mL/g Cytodex beads). The supernatant PBS was again removed and the beads washed once in the 
Figure 8.4. Rotary cell culture system (RCCS). The annotated image shows a typical RCCS setup 
using a 50 mL disposable culture vessel. The RCCS culture system (left) would be placed inside the 
incubator, with the control box (right) placed outside and linked via cable. 
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appropriate cell culture medium (20–50 mL/g Cytodex beads) before use. Immediately prior to use, 
the supernatant was decanted and the beads briefly rinsed in warm 37 °C cell culture medium (20–50 
mL/g Cytodex beads) before being transferred to the culture vessel via sterile syringe. Periodic 
sampling of cell aggregates following media changes every 2-4 days also allowed monitoring of cell 
growth development on the micro-carrier beads (see Chapter 8.5). 
Following culture and subsequent E. coli treatment, cell aggregates were harvested and fixed using 
4% (w/v) paraformaldehyde (Sigma Aldrich) before being washed and stored in sterile PBS 
(approximately 10 ml) overnight. Cell aggregates from each vessel were then suspended in 500µL 
heated Histogel (Thermo; Paisley, UK) until set, before being placed in histological processing 
cassettes. Cell aggregates were then processed overnight using a Shandon 2LE tissue processor, and 
embedded within the histological processing cassettes using Surgipath Formula R Paraffin (Leica, 
Milton Keynes, UK) in a Shandon Histocentre embedder (Thermo Shandon, Paisley, UK) as previously 
described. For sectioning of the cell aggregates, the embedded wax blocks containing the aggregates 
were cooled for 30 minutes on ice, microtome-sectioned to 4 µm, and floated in a 37°C heated water 
bath before adhering to glass slides; for immunohistochemistry, 3-aminoprpyltriethoxylsilane (APTS) 
coated slides were used (Fisher Scientific). Slide-mounted sections were then air-dried in an oven at 
37 °C overnight. 
Cell aggregates treated with mucosa-associated E. coli (MOI: 10) were assessed by RT-PCR for COX-2 
and β-catenin, as well as by haematoxylin and eosin (H&E) staining and immunohistochemistry (IHC). 
For RT-PCR analysis, RNA was extracted and purified using the RNeasy Kit (Qiagen, Manchester, UK), 
with cDNA subsequently synthesised using the Transcriptor First Strand Kit (Roche, Welwyn Garden 
City, UK). RT-PCR was run with primers designed using the ProbeFinder (Roche) and matched to the 
correct probe (see Table 4.6.4) in the human Universal ProbeLibrary (Roche). RT-PCR was run in 96-
well format using TaqMan detection (LightCycler 480 Probes Master; Roche) using the LightCycler 480 
(Roche) and analysis completed in Microsoft Excel. 
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For H&E staining (see Section 4.12.4), microtome slides were placed in Gill no.1 haematoxylin (Sigma-
Aldrich) for 3 minutes before running under tap water for 10 minutes. Slides were then placed in eosin 
(Sigma-Aldrich) for 3 minutes, and then put immediately in water for 2 minutes before dehydration 
(20 dips sequentially in 70%, 90% and 100% ethanol). For immunohistochemistry (see Section 4.12.4), 
COX-2 (#ab15191; Abcam, UK) and β-catenin (#610154; BD Biosciences) antibodies were used at 1:400 
and 1:50 dilutions, respectively. Heat-induced antigen retrieval was performed in citric acid buffer (pH 
6.4). Slides were mounted onto glass coverslips (22 x 50mm) using DPX Mountant (Sigma Aldrich). 
Images were captured using SPOT Image Capture Software (SPOT Imaging Solutions) on a light 
microscope (Leica; Germany). 
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8.5 Results 
8.5.1 Method development and optimising cell aggregation  
The rotating cell culture system (RCCS) was set up in a suitable CO2 incubator set at 37˚C, 5% CO2 and 
95% air, as recommended by the manufacturer, keeping culture conditions consistent with monolayer 
cultures, with the control box sat above the incubator. Once cells in monolayer culture had reached 
90% confluence, cells were trypsinised and placed in either a 10 mL or 50mL disposable culture vessel. 
During culture initiation and maintenance, additional steps were incorporated to improve ease-of-
use. 
To stabilise the disposable culture vessels, they were placed in a sterile 6-well plate in sterile laminar 
flow conditions. Once in the 6-well plate, the large stopper was removed and small ports opened. 
Tilting the culture vessel at a 45-degree angle for initiation was improved upon by adding a small 
amount of culture medium via the large port, 1 ml to a 10 mL vessel and 5 mL to a 50 mL vessel, before 
adding cells; this stopped the cells accumulating in one area of the vessel. Cell cultures using micro-
carrier beads appeared to have a better distribution of cells and fewer disrupted beads (appearing 
popped or broken under microscopy at day 2) with a pre-incubated of cells and beads for 10-15 
minutes, using approximately 5 mg beads per 1 mL cells, before adding to the vessel. All subsequent 
maintenance steps and sampling was done using the same 6-well plate stabilisation and sterile 
technique. 
It was found that the attachment of 3 mL syringes, containing the appropriate cell medium, to both 
small ports was most suitable for both removing bubbles and sampling. As noted by the manufacturer, 
bubbles tended to develop during maintenance of cultures due to evaporation. These bubbles 
noticeably disrupted the rotation of cultures causing abnormal movement and collision of cell 
aggregates, and this had to be corrected roughly every 2 days. Removal of bubbles was aided by 
rotating the vessel by hand until the bubbles were aligned with one of the small ports, with bubbles 
then removed by introducing new culture medium into the opposite port; approximately 1 mL and 2-
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3 mL of culture was removed for sampling from 10 mL and 50 mL vessels, respectively, to visualise the 
development of cell aggregates. During method development, it was found that rotation speed 
generally had to be increased by around 0.5 rpm following each sampling/maintenance step, with an 
initial rotation speed of approximately 15 rpm found to be most suitable to prevent cell sediment; the 
speed increases were likely required due to the increasing sizes of cell aggregates causing them to 
settle more quickly. 
Several resources had suggested initiating cultures with at least 1 x 106 cells per vessel (Goodwin et 
al., 1992, Carvalho et al., 2005, Kaeffer et al., 1999); 1 x 107 cells were initially added to 50 mL vessels 
due to the larger size. Following several rounds of testing, including initial cell seeding densities of 1 x 
105, 5 x 105, 1 x 106 and 1 x 107 cells per 10 mL vessel and up to a larger density of  
1 x 108 cells per 50 mL vessel, it was found that an initial density of >1 x 106 cells per 10 mL vessel and 
1 x 107 cells per 50 mL vessel produced acceptable levels of aggregation with CRC cell lines. From 
observation during microscopy, lower densities appeared to delay the formation of aggregates and 
caused higher levels of cell anoikis/apoptosis, with higher densities causing the formation of larger 
clumps of multiple aggregates; this was not quantified. Larger clumps may have limited the adherence 
and invasion of capable bacteria during infection due to a smaller accessible surface area. 
Upon harvesting the cell aggregates, the large port was found to cause less disruption of aggregates. 
The vessel was removed from the RCCS and tilted to allow the cells to drop to the bottom of the vessel. 
The smaller ports were then opened (no syringes added), followed by removal of the large stopper, 
with the culture then slowly emptied into a sterile centrifuge tube via the large port. The cell 
aggregates were then allowed to settle, with the supernatant used to wash the vessel to maximise 
yield. 
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8.5.2 Case study: SW480 colonocyte 3D aggregation over 21 days of culture in the RCCS 
8.5.2.1 Aggregation without micro-carrier beads 
Following optimisation of the culture method, two cultures of SW480 cells were maintained over 21 
days to assess growth of aggregates, initially in the absence of micro-carrier beads (Figure 8.5.2.1). 
Three-dimensional (3D) culture was first tested in 10 mL and 50 mL vessels using 1 x 107 cells in both 
vessels; initiation of rotating culture was considered as day 0. On sampling and media replenishment 
on day 2, SW480 cells remained viable upon evaluation by microscopy (see Figure 8.5.2). Most cells at 
this stage were not yet aggregated in either 10 mL or 50 mL vessel, with only few cells aggregating to 
form small clumps. 
At day 4, cells began to form larger clusters in both 10 mL and 50 mL vessels. Interestingly, most, if 
not all, cells began to show signs of spikes/projections from cell membrane. Cells remained viable at 
day 6, with many beginning to incorporate into larger aggregates in 10 mL or 50 mL vessels. The 
spikes/projections noted at day 4 became more pronounced, until around day 10 where they were no 
longer visible, suggesting cells had become more accustomed to the rotational conditions. Samples 
from day 8 and day 10 showed the cells forming multiple clusters in both vessels, with what appeared 
to be growing clusters that had combined to aggregate into numerous, much larger, spherical clusters. 
Large clusters remained in both vessels at day 13 and day 15, with a lower number of large clusters 
obtained from the 10 mL vessel; this could have been due to the settling of these larger clusters in the 
50 mL vessel, and possibly the removal of a higher proportion of cells from the 10 mL vessel during 
earlier sampling. A higher number of smaller spheroids had formed by this point in the 10 mL vessels, 
presumably from small clusters of cells. Cell debris became increasingly noticeable at day 15 with some 
cell rounding observed, mainly in those cells yet to aggregate but this was difficult to see within 
clusters. Between day 15 and day 21, the larger clusters appeared to have darkened areas; at this 
stage, it was presumed that cells were either at a high density or necrotic cell death was beginning to 
occur; cell viability was not quantified. Culture maintenance was ended at day 21. 
175 
 
 
 
 
8.5.2.2 Aggregation with micro-carrier beads 
 
Figure 8.5.2.1. SW480 cell aggregate development from day 0 to day 21. Three representative 
images for each sampling point show the development of SW480 cell aggregates in 3D culture using 
the rotating cell culture system (RCCS). Cell aggregates were grown for 21 days in 10 mL and 50 mL 
vessels, with images captured at 25x (day 2-8) and 10x (day 10-21) magnification upon sampling and 
media replenishment. 
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8.5.2.2 Aggregation with micro-carrier beads 
SW480 cultures were also maintained for 21 days in combination with Cytodex-1 and Cytodex-3 micro-
carrier beads coated with diethylaminoethyl (DEAE) cellulose and collagen, respectively, using 10 mL 
vessels at a cell density of 1 x 107 cells per vessel (Figure 8.5.2.2). Cells appeared to remain viable in 
10 mL vessels in combination with both micro-carriers; although this was not quantified. 
At day 2, most cells remained unattached, but with some cells already noticeably interacting with both 
Cytodex-1 and Cytodex-3 micro-carrier beads. Cell coverage of beads began to improve by day 5, with 
some aggregates beginning to form individually but with most cells still remaining in suspension. From 
day 5 onwards, attached cells appear to spread across the surface of micro-carrier beads; this was 
seen to be more pronounced on Cytodex-1 beads (see Figure 8.5.2.2). Cells also began showing signs 
of elongation or spikes/projections from the cell membrane, but this was not as pronounced as 
without the use of micro-carrier beads. 
From day 7, samples obtained from the cultures were observed to contain cell debris, possibly due to 
damage following impact with rotating beads. Cell projections between attached cells began to spread 
across the Cytodex-1 beads, a phenomenon observed to a lesser extent using Cytodex-3 beads. From 
day 9, beads began to form bonds with neighbouring beads via cells attached to DEAE or collagen 
surfaces, creating considerably larger clustering of micro-carriers; these were readily obtained upon 
sampling from day 12 (see Figure 8.5.2.2). 
Little difference was observed between days 14 and 21 cultures in terms of cell coverage of micro-
carriers, with the appearance of greater levels of gathering cell debris seen from day 14 onwards. Cells 
appeared to project and spread more readily across Cytodex-1 beads coated with DEAE, with up to 20 
cells observed attached to one bead. There was considerable variation in cell coverage between beads 
within the same cultures, with bead size also seen to vary. 
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8.5.2.3 H&E staining of 3D SW480 aggregates without micro-carrier beads 
Figure 8.5.2.2. SW480 CRC cells grown as 3D organotypic cultures using micro-carriers. One 
representative image for each sampling point showing development of SW480 cells growing on (A) 
Cytodex-1 and (B) Cytodex-3 micro-carrier beads coated with diethylaminoethyl (DEAE) cellulose and 
collagen, respectively; images taken at 10x magnification throughout. 
A. 
B. 
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8.5.2.3 H&E staining of 3D SW480 aggregates without micro-carrier beads 
Samples of 3D SW480 cultures, alone and in combination with micro-carriers, were also submitted for 
haematoxylin and eosin (H&E) staining. Unfortunately, it was not possible to retain samples at day 2 
of RCCS culture during histological processing due to the small size of the aggregates. H&E staining of 
sample sections allowed insight into the development of 3D cell aggregates (Figure 8.5.2.3). The early 
stages of 3D cell aggregation (up to day 10) showed most cells intact within the developing aggregate, 
which would suggest growth of a spheroid. This is opposed to the situation observed in the later stages 
of culture (beyond day 10), where most cells at the centre of the aggregate had undergone cell death. 
Cell debris was seen to increasingly accumulate, with only a few layers of cells remaining intact. 
 
8.5.2.4 H&E staining of 3D SW480 aggregates with micro-carrier beads 
 
Figure 8.5.2.3. H&E staining of SW480 cells in 3D culture without micro-carrier beads. 
Representative images show H&E staining of SW480 3D cell aggregates grown over 21 days; development 
of aggregates from day 4 to day 21 are depicted for sections of the outer edges of aggregates, as well as 
central sections of aggregates at day 10 to day 21 of culture. Images were taken at 40x magnification. 
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8.5.2.4 H&E staining of 3D SW480 aggregates with micro-carrier beads 
H&E staining was also completed for cells grown on micro-carrier beads, Cytodex-1 and Cytodex-3 
(Figure 8.5.2.4). However, due to the eosinophilic coatings of the micro-carrier beads H&E staining 
was not compatible, with difficulties in distinguishing cells from micro-carrier coatings observed from 
sample taken at day 4 of culture. 
 
 
 
 
 
 
 
 
 
 
 
Following successful formation of 3D cell aggregates using SW480 cells, both with and without micro-
carriers, the RCCS culture method was then applied to other colonic cells, with the aim of replicating 
and confirming the suitability of this technique to number of different colonic cell lines; this included 
DLD-1 cells and the transformed colorectal adenoma-carcinoma cell lines AA/C1 and AA/C1/SB. 
 
Figure 8.5.2.4. H&E staining of SW480 cells in 3D culture with micro-carrier beads. Representative 
images show H&E staining of SW480 cells grown for 4 days on (A) Cytodex-1 and (B) Cytodex-3 micro-
carrier beads, with (C) outer surface and (D) cross-sectional views of Cytodex-3 beads also shown, with 
strong eosin staining of both Cytodex-1 and Cytodex-3 beads. Images taken at 40x magnification. 
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8.5.3 DLD-1 colonocyte 3D organotypic aggregation in the RCCS  
DLD-1 cells show a high basal level of Wnt pathway activation due to an APC gene truncation. Using 
the RCCS conditions determined for SW480 cells, development of DLD-1 cell aggregates was seen to 
occur at a much faster rate (see Figure 8.5.3). Many of the aggregates observed under microscopy 
appeared to contain large dark areas, suggesting greater intra-aggregate cell death and resultant 
cellular debris. 
 
 
 
 
 
 
 
 
 
 
 
8.5.4 Transformed adenoma-carcinoma cell 3D organotypic aggregation in the RCCS  
Following success of generating functional aggregates up to day 10 of culture with SW480 and DLD-1 
cells, two experimentally transformed cell lines representative within the adenoma-carcinoma 
sequence, AA/C1 and AA/C1/SB, were similarly grown as organotypic 3D cultures for 10 days using the 
Figure 8.5.3. DLD-1 cell aggregate development from day 0 to day 21 without micro-carriers. 
Representative images show the development of DLD-1 3D cell aggregates using RCCS culture. Cell 
aggregates were grown for 21 days in 50 mL vessels, with images captured at 10x (day 2-15) and 5x 
(day 21) magnification upon sampling and media replenishment. 
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RCCS (Figure 8.5.4). AA/C1 cells were found not to be compatible with the RCCS, with substantial cell 
rounding, accumulation of large quantities of cellular debris and lack of aggregation seen by day 6 of 
culture; the AA/C1 3D cultures were therefore terminated early. Conversely, AA/C1/SB cells were seen 
to be compatible with culture in the RCCS, with the appearance of large aggregates observed by 
microscopy (see Figure 8.5.4). 
 
 
 
 
 
 
 
 
 
 
 
Due to the successful compatibility of AA/C1/SB cells in 3D aggregate cultures in the RCCS, these cells, 
along with 3D SW480 aggregates, were used in infection assays using mucosa-associated E. coli. 
Infection of non-tumorigenic human AA/C1/SB colonic cells (derived from the colonic PC/AA adenoma 
Figure 8.5.4. Cell aggregate development testing using AA/C1 and AA/C1/SB cell lines. 
Representative images show the development of AA/C1 and AA/C1/SB cell aggregates in 3D RCCS 
culture. AA/C1 cell aggregate development was terminated after 6 days due to cell rounding and 
appearance of cell debris; AA/C1/SB cells were maintained in culture for 10 days. Images were captured 
at 25x (day 2-6) and 10x (day 10) magnification upon sampling and media replenishment. 
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cell-line) grown as 3D aggregates, allowed us to investigate the impact of these bacteria on Wnt 
activation earlier in the adenoma-carcinoma sequence. 
8.5.5 Infection of 3D organotypic colonic cell aggregates to determine COX-2 expression and 
Wnt activation 
Following the successful development of 3D organotypic aggregates using both SW480 and AA/C1/SB 
cells in the RCCS, these cultures were utilised for infection assays. At this point, we were unaware how 
quickly these 3D aggregates expanded under RCCS conditions, and along with the inevitable loss of 
smaller cell aggregates during media replenishment, it was not possible to establish an accurate 
multiplicity of infection (MOI). For this reason, the initial cell density (1 x 107 cells/vessel) was used to 
establish a MOI of 10. Both the SW480 and AA/C1/SB 3D organotypic cultures were maintained for 10 
days in 10 mL vessels before harvesting for infection with mucosa-associated E. coli for 4 hours in 6-
well plates. Following infection of 3D organotypic aggregates, extraction of cellular RNA allowed for 
synthesis of cDNA, which was then subjected to RT-PCR to quantify COX-2 (PTGS2) and β-catenin 
(CTNNB1) gene expression. 
Mucosa-associated E. coli treatment of SW480 3D organotypic cell aggregates at day 10 for 4 hours 
showed a significant increase in PTGS2 expression, with isolates HM44, HM358 and HM605 giving  
2.82 ± 0.27 (P<0.01; Unpaired T-test), 6.17 ± 0.76 (P<0.01) and 102 ± 3.53 (P<0.001) fold changes, 
respectively (N=2, n=3; Figure 8.5.5.1). Cells treated with non-pathogenic E. coli K12 gave Ct values 
above 40 cycles (as per non-template controls) on all occasions during RT-PCR, thus a fold change 
value could not be given, and other E. coli treatment data were compared to untreated controls. 
Infection of SW480 3D aggregates with the same isolates produced similar results when quantifying 
CTNNB1 expression, with increases from 2.1 to 12.6 fold observed following treatment with HM44 
(P<0.01), HM358 (P<0.001) and HM605 (P=0.1428) compared with non-pathogenic E. coli K12 
treatment (N=2, n=3; Figure 8.5.5.2). 
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Figure 8.5.5.2. Changes in β-catenin (CTNNB1) gene expression in SW480 colonic cells grown as 
3D aggregates without micro-carrier beads. Graph shows mean ± SEM fold change data for SW480 
cells treated with mucosa-associated E. coli isolates HM44, HM358, HM545 and HM605, and non-
pathogenic E. coli K12 (MOI: 10 based on original cell seeding density of 1x107 cells/vessel). Fold change 
data normalised to E. coli K12 treatment (N=2, n=3; **P<0.01, ***P<0.001, Unpaired T-test). 
Figure 8.5.5.1. Changes in COX-2 (PTGS2) gene expression in SW480 colonic cells grown as 3D 
aggregates without micro-carrier beads. Graph shows mean ± SEM fold change data for SW480 cells 
treated with mucosa-associated E. coli isolates HM44, HM358, HM545 and HM605, and untreated 
controls (MOI: 10 based on original cell seeding density of 1x107 cells/vessel). Fold change data 
normalised to untreated controls due to lack of E. coli K12 data (N=2, n=3; **P<0.01, ***P<0.001, 
Unpaired T-test). 
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Following the successful observation of significant increases in COX-2 and β-catenin gene expression 
following mucosa-associated E. coli infection of SW480 3D aggregate cultures, AA/C1/SB 3D 
aggregates grown in the RCCS for 10 days were treated with the same E. coli isolates, and compared 
to E. coli K12 treatments or untreated controls. Results from non-pathogenic E. coli K12 treated 
aggregates were only obtained for CTNNB1 expression. However, as no data were obtained for PTGS2 
expression in response to E. coli K12 due to a lack of Ct values during RT-PCR, untreated controls were 
used for data comparisons. 
Mucosa-associated E. coli treatment of AA/C1/SB 3D cell aggregates showed significant increases in 
PTGS2 (Figure 8.5.5.3) and CTNNB1 (Figure 8.5.5.4) expression using CRC mucosa-associated isolates 
HM44 and HM358, showing 19.19 ± 1.42 (P<0.001) and 7.56 ± 1.36 (P<0.001) fold changes in PTGS2 
expression, and smaller 1.52 ± 0.11 (P=0.0162) and 1.19 ± 0.11 (P=0.3491) fold changes in CTNNB1 
expression, respectively. Conversely, treatment with another CRC mucosa-associated E. coli isolate 
HM545 and CD mucosa-associated E. coli isolate HM605 effected little/no increase in PTGS2 
expression, but significantly increased CTNNB1 expression, with 1.58 ± 0.05 fold (P<0.001) and 1.37 ± 
0.11 fold (P=0.0622) changes confirmed, respectively.  
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Figure 8.5.5.4. Changes in β-catenin (CTNNB1) gene expression in AA/C1/SB colonic cells grown 
as 3D aggregates without micro-carrier beads. Graph shows mean ± SEM fold change data for 
AA/C1/SB cells treated with mucosa-associated E. coli isolates HM44, HM358, HM545 and HM605, and 
non-pathogenic E. coli K12 (MOI: 10 based on original cell seeding density of 1x107 cells/vessel). Fold 
change data was normalised to E. coli K12 treatment data (N=2, n=3; *P<0.05, Unpaired T-test). 
Figure 8.5.5.3. Changes in COX-2 (PTGS2) gene expression in AA/C1/SB colonic cells grown as 
3D aggregates without micro-carrier beads. Graph shows mean ± SEM fold change data for 
AA/C1/SB cells treated with mucosa-associated E. coli isolates HM44, HM358, HM545 and HM605 
(MOI: 10 based on original cell seeding density of 1x107 cells/vessel). Fold change data normalised to 
untreated 3D aggregates due to lack of E. coli K12 data (N=2, n=3; *P<0.05, Unpaired T-test). 
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Data for infection of AA/C1/SB cells in 2D monolayer culture was gathered concurrently to enable 
comparison of RT-PCR data obtained from 3D aggregates (Figure 8.5.5.5). These infection assays 
confirmed data obtained from 3D aggregate infections, with similar patterns of increase in PTGS2 and 
CTNNB1 expression for all mucosa-associated E. coli isolates tested. All mucosa-associated E. coli 
infection data was compared to that from non-pathogenic E. coli K12 treatments. 
Figure 8.5.5.5. Changes in COX-2 (PTGS2) and β-catenin (CTNNB1) gene expression in AA/C1/SB 
colonic cells grown in 2D monolayer culture. Graph shows mean ± SEM fold change data for (A) 
PTGS2 and (B) CTNNB1 gene expression in AA/C1/SB cells treated with mucosa-associated E. coli 
isolates HM44, HM358, HM545 and HM605, and non-pathogenic E. coli K12 (MOI: 10). Fold change data 
was normalised to cell left untreated (N=2, n=3; *P<0.05, **P<0.01, ***P<0.001, Unpaired T-test). 
A. 
B. 
187 
 
8.6 Discussion 
Successful 3D aggregate culture of SW480 and DLD-1 CRC cell lines was achieved using a rotating cell 
culture system (RCCS), alone and using micro-carrier bead supports. Following development, with 
respect to structure and formation of 3D organotypic CRC cell aggregates, as observed by microscopy 
and H&E staining, we decided to follow the example of the Carvalho et al. (2005) in using 3D 
aggregates formed following 10 days of culture in the RCCS for subsequent infection assays. This cut-
off (day 10), limited appearance of large dark areas within SW480 cell aggregates at later stages of 
development (>15 days), shown to be a collection of cellular damage/debris. However, this cut-off 
(day 10), meant that DLD-1 3D cell aggregates were not considered suitable for infection studies as 
appearance of dark centres were seen in these particular 3D cell aggregates before day 10 and likely 
would affect their viability and potential for use in infection studies. Production of more viable of 3D 
organotypic aggregates using DLD-1 cells therefore requires further development/investigation. 
Study of mucosa-associated E. coli infection-induced COX2 and β-catenin gene expression in an 
organotypic system was conducted using the adenocarcinoma SW480 cells and in non-tumorigenic, 
anchorage dependent AA/C1/SB colonic cells (Williams et al., 1990) derived from human colonic 
adenoma cell-line PC/AA (Paraskeva et al., 1988). The early data obtained from infecting these 3D 
organotypic aggregates would suggest that this method of culture is suitable for studying mucosa-
associated E. coli-host epithelium interactions, and confirmed/complemented data previously 
obtained by infection of 2D monolayer CRC cell cultures and those responses seen in an in vivo gut 
infection model (see Chapters 5 and 6, respectively). The RT-PCR data obtained from infection assays 
using SW480 3D cell aggregates showed considerably different fold-change results to those observed 
in monolayer cultures, but exhibited the same trend of increasing COX-2 (PTGS2) and β-catenin 
(CTNNB1) gene expression following treatment with mucosa-associated E. coli. Unfortunately, a lack 
of data for PTGS2 expression induced by infection with E. coli K12 meant that we could not corroborate 
the lack of change in expression of this gene using this non-pathogenic strain observed in 2D SW480 
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cell monolayer cultures. We are unable to explain the inability to obtain a Ct value in the range of 40 
cycles, set as the maximum number of cycles during RT-PCR, using E. coli K12 treatments. It is possible 
that this was due to reagent handling given that results were obtained for CTNNB1 expression using 
the same samples, but the fact that this occurred using N=2 could point elsewhere; this may have also 
contributed to the lack of change in PTGS2 expression following HM545 and HM605 treatment of 
AA/C1/SB cell aggregates. 
The data obtained from non-tumorigenic colonic AA/C1/SB 3D organotypic aggregates was 
particularly interesting. Results suggest that CRC mucosa-associated E. coli treatment can increase 
epithelial COX-2 expression and Wnt/β-catenin pathway activation at the later adenoma stage. 
Judging by review of available literature, this is the first time that changes in these surrogate early 
markers of cancer development have been seen in an anchorage dependant, non-tumorigenic 
adenoma cell line, and points towards the effects of these bacteria earlier in the adenoma-carcinoma 
sequence than originally realised. However, as these are only changes in gene expression, it would 
benefit from showing the impact of these infections on protein expression in these 3D aggregates. The 
studies conducted here would also be supported better from availability of data from cells at even 
earlier stages of the adenoma-carcinoma sequence, such as early passages of the PC/AA adenoma cell 
line (Paraskeva et al., 1988), unfortunately not available for these studies, as well as using primary 
cells or organoid-derived colonocytes from human tissue with no disease association to be able to 
model the impact of these bacteria throughout the development and progression of colonic disease. 
As discussed in the in vitro studies (see Chapter 5), we encountered slow growth of non-tumorigenic 
AA/C1 cells in 2D monolayer culture in preparation for adding to the RCCS for 3D culture. As these 
cells mimic the properties of a later stages of adenoma, this is not a surprising find; but the fact that 
these cells grow slowly in monolayer culture may contribute to the incompatibility of these cells when 
they were eventually added to the RCCS. AA/C1 is described as a late passage clonogenic variant of 
pre-malignant epithelial adenoma cell line PC/AA (Paraskeva et al., 1988), likely representing a later 
stage in tumour progression, i.e. still retaining characteristics of the early adenoma cells but acquiring 
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certain characteristics of cancer cells. AA/C1 had a higher colony forming efficiency than its parent, 
but a lower efficiency than that of subsequent AA/C1/SB variants (Williams et al., 1990, Paraskeva et 
al., 1992). The lower colony forming efficiency and higher anchorage dependency may have 
contributed to the slow growth in monolayer culture, as well as their downfall in 3D aggregate culture 
within the RCCS.  
In contrast, the sodium butyrate transformed AA/C1/SB cells seemed to be much more compatible. 
This was the first time AA/C1/SB 3D cell aggregates have successfully been used to quantify COX-2 and 
β-catenin gene expression. The AA/C1/SB cells obtained from Professor Paraskeva's group for this 
study were non-tumourigenic. It would also be beneficial to investigate the compatibility of the 
subsequent tumorigenic AA/C1/SB10 cell line, generated following treatment of AA/C1/SB cells with 
N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), a chemical carcinogen widely used for to develop 
carcinogenesis in cell and animal models (Lee et al., 2007). This treatment was shown to allow 
anchorage independence and increase tumourigenicity (Williams et al., 1990), and these attributes 
may help the cells to grow quicker and adapt better to culture within the RCCS. 
To be consistent with the earlier in vitro CRC 2D monolayer cell-line studies (see Chapter 5), it would 
be important to confirm the impact of mucosa-associated E. coli on COX-2 and β-catenin protein 
expression in both SW480 and AA/C1/SB 3D cell aggregates. Techniques such as immunoblotting, 
immunofluorescence and IHC could be used to order to confirm the translation of increased gene 
expression in infected aggregates. Considering the RT-PCR data showing increased gene expression in 
3D cell aggregates, it is possible that higher levels of DAB staining in IHC might be seen in these cultures 
treated with mucosa-associated E. coli, particularly in the outer cell layers where bacteria would have 
easier access. The IHC protocol for detecting protein expression, more specifically here for COX-2 and 
β-catenin, would likely have to be optimised for use with 3D organotypic aggregates. 
There are an array of published techniques available to develop 3D organoid and organotypic spheroid 
cultures (Achilli et al., 2012), from the more simplistic and better established low-adherence poly-
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hema cultures through to the less well established, more expensive and convoluted stem-cell derived 
organoid cultures used to model human organ development and human disease (Clevers, 2016). Each 
of these options were considered for use in this study; each system has merits, but the choice of 3D 
organotypic culture using RCCS technique for this particular project was an easy one and allowed us 
to utilise/examine cells at stages within the adenoma-carcinoma sequence.  
There are only a small number of studies that have evaluated the use of the RCCS using colonocytes 
(Goodwin et al., 1992, Carvalho et al., 2005, Kaeffer et al., 1999), but the study by Carvalho et al. 
(2005) was a key study, previously utilising the system to investigate pathogenic E. coli interactions 
using colonic cells. This study used human intestinal epithelial HCT-8 cells within the RCCS, with 
layered cell aggregates developing after only 10 days in culture (Carvalho et al., 2005). This 
aggregation was replicated using the colorectal cell lines in our study. The authors noted that the 
aggregates created in this system expressed normal intestinal tissue markers in patterns that 
suggested greater cellular differentiation than conventionally grown monolayers, produced higher 
levels of disaccharidases and alkaline phosphatase, typical of the normal intestine. Cells also 
developed microvilli and desmosomes, more than that seen when grown as 2D monolayers, again 
representative of normal intestinal tissue. This is an important consideration for this work, and is 
something that still needs to be confirmed using the SW480, DLD-1 and transformed adenoma cell 
lines. However, due to limitations in time, examination of markers of cellular differentiation were not 
undertaken in our project, thus we cannot confirm/add to these findings. Future studies may also be 
further expanded to examining differentiation following co-cultures with micro-carrier beads. The use 
of micro-carrier beads here was seen to be a fast and efficient way of mimicking the basement layers 
known to support epithelial growth without having to develop more complicated systems of co-
cultures. The use of the beads within the culture was a technique to enable a higher yield of 
anchorage-dependent cell aggregates, with Cytodex beads used in this study developed specifically 
for the culture of a wide range of cell types and culture volumes; these were shown to work well with 
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the CRC cell lines used in this study, and further study may show these micro-carriers, to be of 
significant value in modelling the infection of colonic cells.  
The low-shear microgravity conditions created by the RCCS also more closely mimic low-shear 
conditions in the intestine, as created by microvilli (Carvalho et al., 2005), and was an important 
consideration for our study. An additional factor supporting use of the RCCS in our project was that 
there was no observable effect of rotation culture on the bacteria inoculum, with Carvalho et al. 
having previously noted that microgravity culture had no influence on pathogenic E. coli growth nor 
on virulence gene expression as compared with normal gravity conditions, with the exception of 
intimin expression by EHEC, which was found to be elevated. The authors also showed that the 
response of cell aggregates to infection with E. coli under RCCS conditions was similar to infection of 
intact colonic tissue, demonstrated by the appearance of the resultant attaching and effacing lesions 
seen in vivo (Carvalho et al., 2005). Due to limitations in time, we did not examine microgravity effects 
of known adhesion/invasion virulence factors of mucosa-associated E. coli (Prorok-Hamon et al., 2014) 
but this would be an interesting future study to be undertaken. 
Even some of the earliest reports on the use of the RCCS suggested that cells grown in bioreactors 
that simulate aspects of microgravity, or that use actual microgravity conditions, could produce tissues 
in sufficient quantity and quality to simulate in vivo tissues (Jessup et al., 1993). With the right 
conditions, certain cultures could also promote differentiation and neoplastic transformation, and 
that a microgravity environment would not alter the ability of epithelial cells to recognize and 
associate with not only each other but also with constituents of basement membrane and extracellular 
matrix (Jessup et al., 1993). A study by (Laguinge et al., 2004) used Annexin V staining to detect cells 
that may have experienced apoptotic death within 3D cultures, with propidium iodide-Annexin-V used 
alongside FITC to dual-stain these cells. Caspase-3 activity was also assessed by labelling cells with a 
fluorescent probe. Given the appearance of what seemed to be necrotic/apoptotic cell debris in the 
centre of cell aggregates in the absence of micro-carrier beads in our project, it would be interesting 
to investigate the exact nature of cell death and composition of debris within these 3D cultures. 
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The use of 3D organotypic cultures is becoming more prominent and relevant to study infectious 
diseases, especially as monolayer cell line cultures tend to exhibit altered properties due to 
immortalization and two-dimensional growth (Barrila et al., 2010, Herbst-Kralovetz et al., 2013, 
McGowin et al., 2013). A 3-D organotypic model of human intestinal epithelium has been successfully 
used to elucidate the role of key invasion and intracellular replication factors of Salmonella enterica, 
showing similar actions to those seen in infection in vivo (Radtke et al., 2010). Thus, the development 
of 3D organotypic culture models as part of this study, using two CRC cell-lines (SW480 and DLD-1) 
and the non-tumorigenic adenoma cell-line (AA/C1/SB), to study Wnt pathway activation, was another 
important step in building better platforms for the study of the interactions between E. coli and 
colorectal cells in a more parent tissue-like and disease-relevant context. With a limited number of 
representative small animal models available to effectively study these interactions, an organotypic 
culture using colonic cell lines allows fast and efficient development of multi-cellular tissue-like 
structures that mimic human tissues. Human tissue explants can be grown using in vitro organ cultures 
(IVOC), which has been done previously, and provides a complex multicellular environment for the 
study of host–pathogen interactions. However, these culture systems require a laboratory facility that 
has quick access to the collection of biopsy materials and suitable laboratories for the culture of these 
in vitro. IVOC studies are also limited to bacterial-host interactions during the relatively short lifespan 
of the collected biopsy material, whereas the use of human cell lines in a 3D organotypic culture have 
an indefinite lifespan (Carvalho et al., 2005). Use of stem-cell derived organoids offers an alternative 
solution (Clevers, 2016), but would require micro-injection of bacteria into the lumen of cultured 
organoids; this is not required in 3D organotypic culture (Carvalho et al., 2005). 
It is clear that more work remains to be done to test the suitability and compatibility of the 3D 
organotypic cultures tested in this project to study pathogen-host intestinal epithelial interactions and 
signalling. The opportunities to improve upon the technique developed here are exciting, both with 
and without use of different extracellular matrix bearing micro-carrier beads, and co-culture with 
stromal cells (Jessup et al., 1993), including myofibroblasts and macrophages, key players of the 
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surrounding micro-environment driving colonic inflammation and neoplasia (Jessup et al., 1993, Crotti 
et al., 2017). 
Additionally, investigating the effects on Wnt protein expression using immunoblotting would 
strengthen these results further. In the event of recent reports showing other pathways such as 
gp130/Stat3 signalling being rate-limiting, even with increased β-catenin nuclear localisation, (Phesse 
et al., 2015), other assays confirming cell proliferation and migration, as well as assessing cell viability 
and metabolism, during 3D development would be beneficial in confirming increased Wnt signalling 
driving malignant development. Due to the potential killing effect of bacterial infections of human 
cells for longer than 4 hours, development of these assays could include gentamicin treatment after 4 
hours of infection in order to allow a longer window to assess phenotypic changes. 
Summary 
The initial work completed here has allowed further insight into the development of colonic cells using 
a 3D RCCS culture method, but more importantly has hinted towards the impact of mucosa-associated 
E. coli during the adenoma-carcinoma sequence. We have been able to show increases in both COX-2 
and β-catenin gene expression, and future use of this RCCS culture method may show changes in COX2 
protein levels and Wnt pathway activation (changes β-catenin protein expression/nuclear 
localisation). While the application of this 3D infection model has not, as yet, been shown to be 
suitable for all colonic cell types, the development of this culture method using the RCCS brings us a 
step closer to modelling mucosa-associated E. coli infection using a system that in vitro model 
epithelium that better mimics/recapitulates the in vivo complex architecture and biochemical 
intricacies of the parent tissue. 
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Chapter 9: 
General Discussion 
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9.1 Summary of findings and advances in links between E. coli and colorectal cancer 
Increasing evidence suggests that constituents in the gut microbiota and chronic inflammation are 
involved in colorectal cancer (CRC) development, with CRC associated with increased numbers of 
mucosal bacteria, particularly E. coli (Swidsinski et al., 1998, Martin et al., 2004). This likely contributes 
to promotion and progression of cancer by virulence factors that disrupt cellular signalling pathways 
controlling inflammation and tumorigenesis (Prorok-Hamon et al., 2014). Our study provides further 
data supporting the notion that mucosa-associated E. coli isolates can upregulate epithelial pro-
inflammatory COX-2 and PGE2 release, suggested to consistently contribute towards increased Wnt 
activation as measured by numerous methods both in vitro and in vivo. This suggests translational 
effects that might be seen in patients, which indicates a role for mucosa-associated E. coli, in the 
development and progression of colorectal cancer via increased Wnt signalling. 
The aim of the project was to investigate whether specific E. coli isolates taken from IBD and CRC 
patients possess ability to activate key cancer-promoting proteins within epithelial cells lining the 
bowel, including those known to help development, growth and spread of tumours. The main pathway 
under investigation was the canonical Wnt pathway signals through β-catenin. Wnt signalling helps to 
regulate cell cycle and cell growth, whilst also playing a crucial role in colorectal tumorigenesis. 
As described in chapter 5, data obtained early in the project pointed towards Wnt activation following 
infection of human colorectal cell-lines with E. coli isolates taken from CRC patients. CRC-associated 
E. coli HM44 and HM358 were selected for use in initial studies as they had been previously shown to 
have strong cancer-related activity, such as increases in pro-angiogenic VEGF (Prorok-Hamon et al., 
2014). The Wnt gene array panel allowed us to get an insight into where these infections may be 
impacting any Wnt activity in these epithelial cells. We observed the expression of a number of genes 
being upregulated >2 fold, as well as some typically inhibitory genes downregulated >2-fold following 
infection. The expression of genes associated with angiogenic factors (VEGFA and JAG1), cell cycle 
regulators (PTGS2, FOSL1 and MYC) and connective tissue growth factors (WISP1) were all seen to be 
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increased by varying levels following infection with these bacteria, with very noticeable increases seen 
in PTGS2 and VEGFA expression. Given that no significant changes were seen with the non-pathogenic 
E. coli K12, this was seen as a potentially specific effects seen only with CRC bacteria capable of 
adhering to an invading the gut mucosa. 
The PTGS2 gene was commonly up-regulated in CRC cell lines SW480 and DLD-1 throughout the study 
following infection with both HM44 and HM358 strains alongside expression of the gene encoding β-
catenin, CTNNB1, and has been previously linked to increases in Wnt signalling (Castellone et al., 
2005). Immunoblots confirmed increased gene expression of PTGS2 and CTNNB1 translated into 
changes in protein levels of COX-2 and β-catenin, respectively. Results show that CRC mucosa-
associated E. coli infection increases expression of β-catenin in a time-dependent manner, and that 
this correlated with increased expression of COX-2 protein in CRC cell lines. 
Another CRC mucosa-associated isolate, HM545, an isolate taken from a Crohn's Disease (CD) patient, 
HM605, and the non-pathogenic E. coli K12 were then used to infect SW480 and DLD1 cells alongside 
HM44 and HM358. Assessment of nuclear localisation of β-catenin following mucosa-associated E. coli 
infection suggested that increased gene and protein expression seen previously translated to 
increased nuclear translocation. Downstream activation of Wnt transcription via TCF/LEF activity 
induces transcription of Wnt target genes by binding promoters of downstream target genes involved 
in cell proliferation, survival, and migration (Morin et al., 1997, van de Wetering et al., 2002). 
We were able to observe significant increases in luciferase activity coupled to TCF/LEF transcription 
following treatment with CRC, CD and UC mucosa-associated E. coli isolates, with no change following 
non-pathogenic E. coli K12 infection. Diclofenac at a concentration of 100 µM showed consistent, 
significant inhibition of mucosa-associated E. coli-induced TCF/LEF transcription. This would suggest 
that Wnt transcription induced by mucosa-associated E. coli treatment translates from increased 
nuclear β-catenin localisation, and that cyclooxygenase activity contributes significantly to increased 
Wnt transcription. 
197 
 
The existing link between COX-2 and β-catenin suggested translation of these results into an in vivo 
infection model. In chapter 6, we investigated this using a germ-free Il10-/- mouse model mono-
associated with the CRC mucosa-associated E. coli HM44 isolated from a CRC patient. Germ-free  
Il10-/- 129SvEv strain mice were mono-associated with E. coli HM44 for 6 weeks (n=15) or left 
untreated (n=5) at the gnotobiotic facility at NC State University by Dr Janelle Arthur et al. at the as 
previously described (Arthur et al., 2012). Immunohistochemistry for cyclooxygenase-2 and β-catenin 
showed highly significant increases in both COX-2 and β-catenin expression, as well as β-catenin 
nuclear localisation, indicating significant increases in Wnt signalling following mucosa-associated E. 
coli mono-association in vivo. This suggests translational effects into a more disease-relevant model. 
Macrophages resident in the gut epithelium in vivo help to guide an immune response towards 
infection. Upon chronic infection, additional macrophages can be recruited in the form of blood 
monocytes that differentiate into macrophages. A recently published study showed CRC-associated E. 
coli promoting COX-2 and PGE2 expression in human macrophages (Raisch et al., 2015). The authors 
reported significant with CRC-associated E. coli but not with commensal or non-pathogenic E. coli 
strains, with this induction requiring live bacteria; the changes were not associated with colibactin 
production. The study used human blood monocytes differentiated into macrophages, replicating the 
in vivo immune response. 
In chapter 5, we were able to show significantly increased concentrations of PGE2 in the supernatant 
of monocyte-derived macrophage cells infected with CRC mucosa-associated E. coli isolates HM44 and 
HM545, as well as CD mucosa-associated isolate HM605, using the same method of differentiation. 
These results were similar to those reported in the Raisch et al. (2015) study, with both CRC and CD 
associated E. coli isolates inducing significantly higher levels of PGE2 secretion. CRC-associated E. coli 
strains can survive and replicate within human macrophages, as well as increase COX-2 expression and 
subsequent PGE2 secretion (Raisch et al., 2015). Our results support these findings, and expand upon 
them by suggesting that mucosa-associated E. coli from IBD patients also enhance PGE2 secretion 
following infection, which may implicate these E. coli in IBD-associated CRC risk. 
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Significant increases in COX-2 expression and activity, and subsequent PGE2 synthesis, have now been 
observed in numerous studies where cancer-associated E. coli have been studied in the context of CRC 
(Raisch et al., 2014, Abdallah Hajj Hussein et al., 2012, Lew et al., 2002). Both human and animal 
models of CRC have shown a long-standing association with increased PGE2 synthesis, and  
investigation of PGE2 synthesis in the gut mucosa using mucosal biopsy specimens obtained during 
diagnostic colonoscopies show its role in the adenoma-carcinoma sequence (Pugh and Thomas, 1994). 
These results suggested colorectal carcinogenesis via the adenoma-carcinoma sequence could be 
associated with a progressive increase in PGE2 synthesis. As COX-2 and PGE2 have been shown to 
stimulate colon cancer cell growth via activation of the canonical Wnt signalling pathway (Castellone 
et al., 2005), this provides a molecular framework for further evaluation of mucosa-associated E. coli 
infection in inflammation-associated colorectal cancer. 
The use of a non-pathogenic E. coli throughout the study was an important control in being able to 
establish a link between the necessary mucosa-association of E. coli strains and the observed changes 
in Wnt signalling. In this case, E. coli K-12 was used as a control in each assay. This wild-type strain of 
E. coli was isolated from the faeces of a convalescent diphtheria patient and is now frequently used 
as a host strain in gene cloning experiments (Kuhnert et al., 1995). Given the lack of COX-2 and Wnt 
activation in vitro following infection with E. coli K12, it is important to consider whether there may 
be specific bacterial factors prevalent in mucosa-associated strains responsible for these changes. 
The adherent and invasive nature of the mucosa-associated E. coli HM44 and HM358 strains suggests 
it is possible that increased Wnt signalling comes from the increased intracellular survival of these 
strains when compared to non-invasive strains such as E. coli K12. A better understanding of 
phenotypic AIEC characteristics associated with increased Wnt signalling could allow a targeted 
inhibition of the effects of AIEC infection in the activation of COX-2 and/or Wnt signalling. Following 
results in vitro and in vivo showing significant increases in COX-2, we were able to confirm up-
regulated COX-2 gene expression in a number of fosmid clones using the fragmented HM358 fosmid 
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library screen (see chapter 7). Fosmid clones created previously (Prorok-Hamon et al., 2014) were 
screened for changes in COX-2 gene expression using RT-PCR following infection of CRC cells. 
Initial and confirmation screening efforts identified 12 fosmid clones showing common PTGS2 
expression increases. Subsequent sequencing of these clones showed similarities in DNA content, with 
particularly common homology in two of these fosmids. The operons identified following the vector 
sequence were almost identical for the 2E4 and 6E8 clones. A number of genes involved in the growth 
and survival of E. coli, particularly under high-stress inflammatory conditions, were identified, 
including the ispB gene that codes for the octaprenyl diphosphate synthase enzyme involved in 
quinone synthesis (Maouche et al., 2016), and the gltB and gltD operons responsible for the synthesis 
of glutamate synthase (Kumar and Shimizu, 2010). 
If the mucosa-associated E. coli do harness these features for growth and survival better than non-
pathogenic strains, particularly in higher stress conditions such as inflammation, their ability to infect 
host cells may be improved and may have contributed to the signaling changes observed both in vitro 
and in vivo. With further infection modelling and continued identification of key operons/genes, it 
may be possible to confirm the presence of existing and/or novel genes/operons involved in the 
adhesion and invasion of mucosa-associated E. coli and subsequent impact of increased COX-2 and 
Wnt signalling. 
9.2 A new model to investigate the interactions between E. coli and the gut epithelium 
The higher presence of E. coli in the gut microbiota under inflammatory conditions, including strains 
possessing an ability to become opportunistic pathogens that adhere to and invade intestinal 
epithelial cells, implicates them as a risk factors for gastrointestinal cancers via chronic infection and 
inflammation. With inflammatory pathways triggering downstream signalling events, we suggested 
that the ability to model or mimic these interactions in vitro would go some way to being able to 
understand the risks posed by bacteria such as mucosa-associated E. coli in colorectal disease. 
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One of our aims was to mimic these interactions utilising 3D cell cultures. Previous development of 
3D culture models to study host-pathogen interactions by different groups has allowed a better 
platform for studying these interactions, with one study in particular having already reported 
successful use of CRC cell lines to study host-pathogen interactions with E. coli (Carvalho et al., 2005). 
As this study made use of the rotating cell culture system (RCCS), we were able to use this information 
as a template for our own 3D model. 
As described in chapter 8, three-dimensional cultures were created suitable for infection with mucosa-
associated E. coli, including the use of porous micro-carrier beads coated with collagen and 
diethylaminoether (DEAE) as a support for CRC cell growth in the RCCS system, simulating the 
supportive environment in vivo. The RT-PCR data obtained from infection assays using SW480 cell 
aggregates showed considerably different fold-change results to those observed in monolayer 
cultures, but exhibited the same trend of significant increases in COX-2 and β-catenin gene expression 
following treatment with mucosa-associated E. coli. 
Unfortunately, a lack of K12 data for COX-2 gene expression means that we cannot confirm the lack 
of change in expression using this non-pathogenic strain as expected. We are so far unable to explain 
the inability to obtain a Ct value in the range of 40 cycles set in the RT-PCR, considering that this was 
achievable following all other treatments and in previous monolayer treatments using K12. It is 
possible that this was due to reagent handling given that results were obtained for CTNNB1 expression 
using the same samples, but the fact that this occurred using N=2 could point elsewhere; this may 
have also contributed to the lack of change in COX-2 gene expression following HM545 and HM605 
treatment of AA/C1/SB cell aggregates. 
RCCS culture was also attempted using late-stage adenoma cell line AA/C1 and completed using the 
adenocarcinoma cell line AA/C1/SB, experimentally-transformed from epithelial adenoma cell line 
PC/AA (Williams et al., 1990, Paraskeva et al., 1992). The AA/C1/SB aggregates were also successfully 
used in RT-PCR studies, with significant increases in COX-2 and β-catenin gene expression shown 
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following CRC mucosa-associated E. coli infections. This was particularly interesting, as it was the first 
time we had seen the impact of mucosa-associated E. coli infections in these cells when grown as 3D 
aggregates; this may also be the first time these results have been seen in an adenocarcinoma cell 
line, and points towards the effects of these bacteria earlier in the adenoma-carcinoma sequence than 
originally realised. This work allowed further insight into the development of 3D RCCS colonic cell 
cultures, but more importantly hinted towards the impact of mucosa-associated E. coli during the 
adenoma-carcinoma sequence. 
While the application of this 3D infection model hasn’t yet been shown to be suitable for all colonic 
cell types, the development of this technique brings us a step closer to modelling mucosa-associated 
E. coli infections in vitro using a system that better mimics growth in the in vivo state. Several groups 
have been able to establish stem-cell derived gastric organoid systems suitable for infection studies, 
using microinjection of H. pylori (Burkitt et al., 2017, Bartfeld et al., 2015, Schlaermann et al., 2016). 
Future use of organoid cultures for E. coli infection studies would further build on our work, allowing 
a system that better reflects key structural and functional properties of the gut and the impact of 
bacterial infections (Clevers, 2016). 
9.3 Expanding on the relationship between infection, inflammation and cancer 
The inflammatory response is already known to involve a number of signalling pathways responsible 
for regulating the expression of inflammatory mediators. Pro-inflammatory cytokines such as 
interleukins, tumour necrosis factor (TNF)-α, nitric oxide and COX-2, commonly implicated in 
inflammatory disease, are released upon tissue damage or following infection (Bartchewsky et al., 
2009, Anderson et al., 1996, Laflamme et al., 1999, Tak and Firestein, 2001). Both TNF-α and COX-2 
have come into focus in recent years as driving forces for the recruitment and activation of 
inflammatory cells (Karin et al., 2006). By blocking key inflammatory mediators associated with TNF-
α and COX-2 release, it is possible to attenuate the inflammatory response, hence these inflammatory 
cytokines now being established as important therapeutic targets in chronic inflammatory diseases 
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(Karin et al., 2006, Nakamura et al., 2009). Under chronic inflammatory conditions such as in IBD in 
both Crohn’s disease and ulcerative colitis, the faecal microbiota commonly shows reduced bacterial 
diversity. This is most pronounced in Crohn’s disease where a reduction in Firmicutes can be observed 
alongside an increase in Proteobacteria such as E. coli (Hold et al., 2014). Animal models of IBD and 
gastroenteritis have been found to result in similar changes in the microbiota, particularly reduced 
diversity. In a mouse model of colitis, induced by dextran sodium sulphate, there is marked 
disturbance of the mucosal barrier including loss of colonic adherent mucus, where the faecal 
microbiota shows a reduction in diversity and an increase in Enterobacteriaceae such as E. coli 
(Nagalingam and Lynch, 2012). Similar changes are seen in mouse models of infective gastroenteritis 
using Citrobacter rodentium and Campylobacter jejuni infections, as well as chemically and genetically 
induced models of intestinal inflammation to demonstrate that host-mediated inflammation in 
response to an infecting agent, a chemical trigger, or genetic predisposition markedly alters the 
colonic microbial community (Lupp et al., 2007). Our study has shown a consistent increase in 
inflammatory COX-2 signalling both in vitro and in vivo following mucosa-associated E. coli infections, 
which could be contributing to the chronic inflammation seen in colonic disease. 
Other studies focussing on the mucosa-associated microbiota have generated more dramatic 
differences than study of faecal microbiota between health and IBD, particularly in Crohn’s disease. 
This is the case for the mucosa-associated E. coli that have been found more commonly in mucosal 
biopsies from the ileum and colon of patients with Crohn’s disease (Darfeuille-Michaud et al., 1998, 
Martin et al., 2004). In colonic biopsies, many of these bacteria are present within the adherent mucus 
(Swidsinski et al., 2002), although there is also evidence of intracellular E. coli from study of 
gentamicin-treated and subsequently lysed mucosal samples (Martin et al., 2004). The increased 
abundance of E. coli in the gut has long been linked to carcinogenesis. A study detected bacteria in 
90% and 93% of adenoma and carcinoma biopsy specimens, respectively. In addition, partially 
intracellular E. coli were found in 87% of patients with adenoma and carcinoma compared to none in 
control samples. It was therefore concluded that the colonic mucosa of patients with colorectal 
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carcinoma but not normal colonic mucosa was colonised by intracellular E. coli (Swidsinski et al., 
1998). It is now believed that many of the changes in microbiota composition seen in IBD, including 
an increase in E. coli, may be secondary to the inflammation. Mucosa-associated E. coli in colon 
cancers also show some of the adherent, invasive phenotypic features of Crohn’s associated E. coli 
(Martin et al., 2004). The isolates from the Martin et al. study are the same isolates tested throughout 
this study. 
The microbiota has previously been linked to innate (Clarke et al., 2010) and adaptive immunity 
(Chervonsky, 2010), gastrointestinal development (Hooper, 2004), invasion and angiogenesis 
(Stappenbeck et al., 2002). Due to gut bacteria being implicated in a number of steps of disease 
progression in CRC, it is easy to see the varying ways in which bacteria can influence colorectal disease. 
The major route in which bacterial infection can aid progression of CRC is via inflammatory pathway. 
TLR signalling plays an important role in inflammation and tissue regeneration via the myeloid 
differentiation primary response gene 88 (MyD88). Activation of TLR signalling results in the 
expression of antimicrobial peptides and the production of prostaglandins and cytokines as a 
protective mechanism to stop bacterial colonization of IECs. This includes the induction of 
cyclooxygenase expression, which can promote epithelial cell proliferation. Dysregulation of 
protective mechanisms such as TLR signalling helps to explain how bacterial infections of the gut could 
promote colorectal cancer. It is possible that COX-2 increases shown throughout our study could be 
brought on via these pathways. 
Infection-induced hyper-proliferation of epithelial cells, either via inflammatory cytokines or 
independent of them, seems to be a common theme in most gut-associated cancers. One aspect that 
seems to stand out is the impact of bacterial composition in carcinogenesis, with dysbiosis being a 
consistency. With evidence of E. coli found within gut tissues in Crohn’s disease and colon cancer, the 
characteristics responsible for their ability to adhere to and invade these tissues have been recently 
investigated (Prorok-Hamon et al., 2014). Increased presence of E. coli correlated with increased 
adherence to and invasion of intestinal epithelial cells, as well as increased VEGF expression known to 
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aid angiogenesis and, therefore, development and progression of cancer. As mentioned earlier, 
colonic mucosal E. coli from IBD and CRC patients more commonly express the pks pathogenicity island 
responsible for the formation of colibactin (Prorok-Hamon et al., 2014, Arthur et al., 2012). The 
presence of the pks pathogenicity island likely contributes to CRC development, but is unlikely to be 
the sole determinant, and adherence and invasion characteristics may contribute to carcinogenesis. 
To reduce the inflammatory effects of E. coli within the gut mucosa it would beneficial to be able to 
remove or kill these bacteria. However, mucosa-associated AIEC have been shown to be resistant to 
killing by mucosal macrophages, which has shown to be important in disease pathogenesis (Tawfik et 
al., 2014) and virulence, adherence and invasive factors associated with mucosa-associated E. coli are 
believed to be responsible. Further investigation to identify and characterise virulence, adherence and 
invasive factors supporting mucosa-associated E. coli survival could give insights into novel and 
targeted AIEC treatments (Tawfik et al., 2014). 
9.4 Mucosa-associated E. coli increase Wnt signalling similar to other pathogenic bacteria 
Disrupted Wnt signalling is currently considered as a major risk factor for colorectal cancer, but it is 
not the only contributor or requirement for tumour initiation and progression (Coste et al., 2007). 
Many studies have since focused on epigenetic changes in colorectal cancer and how environmental 
factors such as diet can influence colorectal cancer via changes in gene-expression. Evaluation of 
mucosa-associated E. coli in this study has revealed further links between bacteria and Wnt signalling. 
An interruption of normal Wnt signalling has previously been confirmed following H. pylori infection, 
with β-catenin identified as a specific host molecule influencing gastric carcinogenesis in conjunction 
with H. pylori infection (Polk and Peek, 2010). Nuclear accumulation of β-catenin has been shown to 
be increased in gastric adenomas compared with non-transformed gastric mucosa, which suggests 
that irregular Wnt-signalling precedes the development of gastric cancer. Increased Wnt signalling has 
also been identified in intestinal cells following infection with S. typhimurium (Liu et al., 2010).  
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Important mechanisms by which bacterial agents may induce carcinogenesis include chronic infection, 
immune evasion and immune suppression. Bacterial infections can induce the release of cytokines 
such as reactive oxygen species, interleukins and cyclooxygenases from inflammatory cells, which can 
contribute to carcinogenic and mutagenic changes. Chronic stimulation of these substances has been 
shown to contribute to carcinogenesis (Mager, 2006). With a substantial body of evidence supporting 
the role of bacteria, particularly E. coli, in inflammation and intestinal disease, the inclusion of 
standard IBD and cancer therapies based on bacterial infections seems almost inevitable. 
9.5 Potential future impact on CRC treatment 
9.5.1 The need for novel and personalised CRC treatment 
The next step forward for adjuvant therapy for CRC is treatment focussed on smaller patient groups 
and individualised therapies using a more translational approach where diagnosis and treatment 
regimens take into account novel molecular staging as well as traditional pathological and clinical 
staging. Our understanding of the underlying molecular biology of CRC is leading to the development 
of novel and better-targeted therapies. Antibodies against the vascular endothelial growth factor 
(VEGF) such as bevacizumab, and anti-EGFR antibodies such as cetuximab and panitumumab are now 
being successfully investigated as adjuvant therapies (Arnold and Schmoll, 2005, Van Cutsem et al., 
2009b). Treatments using non-steroidal anti-inflammatory drugs (NSAIDs) such as sulindac are now 
considered for post-surgery chemoprevention. in high-risk patients (Kim et al., 2014) following studies 
in human colorectal cancer cell lines (Liggett et al., 2014, Williams et al., 1999a, Flis and Splwinski, 
2009) and in vivo models (Chiu et al., 1997).  
An early study helped to identify adenomas as the starting point for most colorectal carcinomas, 
outlined some common genetic alterations and loss of functions at various stages of cancer 
development (Vogelstein et al., 1988). The 'Big Bang' model now suggests that colorectal tumours 
grow predominantly as a single expansion populated by numerous intermixed sub-clones, with 
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alterations arising early during growth and increasing numbers of mutations and gene copy numbers 
over time. This model allows a quantitative framework to interpret tumour growth dynamics and 
predict early malignant potential with significant clinical implications (Sottoriva et al., 2015). With 
compounding mutations found in both primary and advanced CRC and differences in mutation 
sequences in different forms and stages of CRC (Rhodes and Campbell, 2002), there is a severe lack of 
effective treatments, which highlights the need for more innovative approaches for diagnosis and 
therapy.  
Specific features and molecular/genetic markers are becoming more of a focus due to our improved 
understanding of the molecular biology of CRC, and it is hoped this will obtain maximal benefit for 
each therapeutic option available to smaller patient groups and individualised therapies in the future. 
The main area of therapeutic potential is arguably to target common changes in molecular biology 
seen in colorectal cancers. The impact of mucosa-associated E. coli on cancer-associated signalling 
warrants attention as a therapeutic target. 
9.5.2 Targeting mucosa-associated E. coli in colorectal disease 
One particular focus has been on antibiotic treatment of mucosa-associated E. coli. There is evidence 
of metronidazole with azathioprine and ornidazole treatment as prophylaxis limiting the 
postoperative recurrence of Crohn's disease, which could be beneficial in preventing disease 
progression into CRC (D'Haens et al., 2008, Rutgeerts et al., 2005). Quinolone-based antibiotic 
regimens have also been effective in targeting intra-macrophage E. coli isolates in vitro (Subramanian 
et al., 2008), and antibiotic combination therapies such as ciprofloxacin, tetracycline, and 
trimethoprim could prove clinically relevant and reduce the risk of drug resistance, a problem that has 
been previously highlighted using mucosa-associated E. coli isolates from CD patients (Dogan et al., 
2013). Nitroimidazole compounds have shown efficacy in Crohn's disease, decreasing recurrence rates 
in operated patients. However, one major problem has been the appearance of adverse systemic 
effects limiting the long-term use of antibiotics as a preventative Crohn's disease therapy. Rifaximin, 
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a semi-synthetic derivative of rifamycin, has given some promising results in inducing remission of CD 
with an excellent safety profile (Scribano and Prantera, 2013). 
9.5.3 Targeting inflammatory cyclooxygenases and prostaglandin production 
Studies suggest that targeting prostaglandin production can reduce the incidence of colorectal 
adenomas, colorectal cancer, and deaths from colorectal cancer. Recent results are now being used 
to help explain the beneficial effects of non-steroidal anti-inflammatory drugs (NSAIDs) in animal 
models and human disease. With bacterial infections causing increased cyclooxygenase/prostaglandin 
production, such as those modelled in this study with mucosa-associated E. coli, the impact of 
infections in CRC could be minimised by preventing inflammatory signalling. 
Long-term intake of compounds inhibiting cyclooxygenases has been shown to reduce the overall 
relative risk for developing colorectal cancer (Gupta and Dubois, 2001), with selective COX-2 inhibitors 
now approved for use as therapy in patients with familial polyposis (Brown and DuBois, 2005). Animal 
and human studies suggest that regular use of aspirin may also decrease the risk of colorectal 
adenomas, the precursors to most colorectal cancers (Baron et al., 2003). Daily use of aspirin is 
associated with significant reduction in the incidence of colorectal adenomas in patients with previous 
colorectal cancer (Sandler et al., 2003). 
Another method of reducing the downstream effects of prostaglandins would be to limit interactions 
with receptors. The predominant prostaglandin species in benign and malignant colorectal tumours is 
PGE2, which is known to acts via four EP receptors, termed EP1 to EP4 (Hull et al., 2004). EP receptors 
have been identified as potential targets for prevention of a variety of cancers, including skin 
(Rundhaug et al., 2011), breast (Reader et al., 2011) and non-small cell lung cancer (NSCLC) (Gray et 
al., 2009). Signalling through EP receptors has been linked to several cancer signalling pathways. EP2 
receptor activation leads to GSK-3 phosphorylation, and subsequent inactivation (Fang et al., 2000), 
which has been linked to increased β-catenin/TCF transcriptional activity. 
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The importance of the prostaglandin synthesis pathway and in particular the rate-limiting step 
involving cyclooxygenases in colorectal carcinogenesis is important in the development of novel 
colorectal cancer therapies aimed at bacterial infection. Sustained use of other NSAIDs such as 
celecoxib could permit increased surveillance intervals in the expectation of reduced risks of colorectal 
cancer (Baron et al., 2006). However, the potential toxicities of non-aspirin NSAIDs would need to be 
weighed against their benefits in the context of the risk reduction already provided by periodic 
surveillance colonoscopy and polypectomy, meaning that even proven efficacy of these drugs would 
not automatically justify their wide use for chemoprevention (Baron et al., 2006). 
Prostaglandin production is fast becoming a key focus in CRC diagnosis and treatment. Increased 
expression of COX-2 leads to an increase in prostaglandin E2 (PGE2) production, promoting cancer cell 
growth via EP2 receptor-mediated signalling (Castellone et al., 2005). COX-2 targeted inhibition using 
NSAIDs such as aspirin reduces CRC incidence and improves clinical outcome following CRC surgery 
(Tougeron et al., 2014), and may be beneficial in reducing the downstream effects of mucosa-
associated E. coli infection. 
9.5.4 Targeted inhibition of canonical Wnt signalling 
Since Wnt signalling results in diverse downstream intracellular events including proliferation, 
invasion and angiogenesis, targeted inhibition of Wnt/beta-catenin signalling would be a rational new 
approach for CRC therapy (Qi and Zhu, 2008). The added implications of mucosa-associated E. coli and 
several other bacteria inducing Wnt signalling mean that Wnt targeted therapies could reduce the 
burden brought about by pathogenic bacteria. 
There has been an increase in interest in developing therapeutics targeting Wnt-mediated 
transcription and inactivating Wnt target genes (McDonald and Silver, 2011). Destruxin B (DB) isolated 
from fungus (Metarhizium anisopliae) has been identified for pre-clinical evaluation as a Wnt signalling 
target suppressing progression of colorectal cancer. It has been shown to suppress the proliferation 
of and induced cell cycle arrest in HT29, SW480 and HCT116 cells (Yeh et al., 2012) causing down-
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regulation of β-catenin/Tcf4 transcriptional activity leading to decreased expression of target genes 
and inducing apoptosis in HT29 cells. DB-treated mice consistently demonstrated suppressed β-
catenin expression and increased caspase-3 expression, supports destruxin B as an inhibitor of Wnt 
pathway that may be beneficial in CRC treatment (Yeh et al., 2012). 
An extensive review of small molecule inhibitors reveals the importance of targeting Wnt signalling in 
the future of cancer treatment. A number of compounds are able to inhibit Wnt signalling, such as 
sulindac targeting the Wnt protein Dishevelled, bosutinib targeting Src kinase, ethacrynic acid 
derivatives targeting Lef-1 and a number of compounds targeting β-catenin directly (Voronkov and 
Krauss, 2013). The leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) has also been 
identified as a surface marker of colorectal cancer stem cells. LGR5 expression is known to be 
frequently elevated in human CRC, which has been demonstrated to be associated with CRC initiation 
and progression, and recent findings suggest that LGR5 plays a vital role in CRC pathogenesis and has 
the potential to serve as a diagnostic marker and a therapeutic target for CRC patients (Hsu et al., 
2014). Targeting individual components of the Wnt pathway could be one way of eliminating the 
impact of E. coli-induced Wnt signalling in CRC. However, as Wnt signalling through β-catenin is 
required for homeostasis and regeneration of the adult intestinal epithelium, therapeutic targeting of 
this pathway could be challenging (Phesse et al., 2014). 
Advancements in targeting ligand/receptor interactions in Wnt signalling have also shown promise in 
colorectal cancer. Frizzled 7 (FZD7) is a Wnt receptor commonly up-regulated in a variety of cancers, 
including colorectal cancer, and has been targeted using small molecule inhibitors and antibodies. 
Secreted Frizzled-related proteins (sFRPs) have also been in focus as targets for cancer therapy, with 
peptide fragments of Wnt ligands binding FZD receptors also proposed as potential therapeutic agents 
(Zhang and Hao, 2015, Blagodatski et al., 2014). However, it has been stated that further clinical 
studies of these therapeutic agents targeting ligand/receptor interactions are required to confirm 
their safety in patients (Zhang and Hao, 2015). 
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9.5.5 Targeting downstream of Wnt signalling 
As described in chapter 5, the expression of a number of other downstream Wnt targets were found 
to be increased. For example, the expression of VEGF was found to be increased consistently across 
both SW480 and DLD-1 cell lines. By targeting downstream of Wnt signalling, this would likely be a last 
resort therapy. However, with some already established treatment currently in clinical trials for this is 
a possibility. 
Antibodies against VEGF protein are now being successfully investigated in advanced and metastatic 
colorectal cancer trials as adjuvant therapies, and with VEGF being induced by E. coli invasion in 
epithelial cells (Prorok-Hamon et al., 2014) this could reduce the impact of bacteria-induced CRC 
pathogenesis. Both VEGF and microvessel density (MVD) have been associated with greater incidence 
of CRC metastases and decreased survival. Meta-analysis was performed on twenty studies focussing 
on VEGF and MVD. Increased levels of VEGF were associated with unfavourable survival, with a 4-fold 
increase in the rate of distant metastases. Similar analysis on studies for MVD showed that patients 
with high MVD expression in tumours again had poorer overall survival and disease prognosis. Results 
from this study demonstrate a strong indication of using VEGF and MVD as future prognostic 
biomarkers for CRC patients (Wang et al., 2014). 
Increased VEGF expression has recently been associated with the presence of the afimbrial adhesin 
operon in mucosa-associated E. coli in CD and colon cancer, correlating with diffuse adherence to and 
invasion of intestinal epithelial cells (Prorok-Hamon et al., 2014). The specific identification of VEGF 
expression in this case also supports the inclusion of VEGF as a future biomarker and a potential target 
for reducing the effects of mucosa-associated E. coli in CD and colon cancer. 
9.5.6 Enhancing the defences of the intestinal epithelium 
An important part of the host-bacterial interactions is the limit of interactions between the two, so it 
is then important that the intestinal microbiota is kept at a distance from intestinal epithelial cells to 
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minimise the likelihood of bacterial invasion (Brown et al., 2013). Innate immune strategies are in 
place to keep much of the microbial community within the lumen of the intestinal tract and limit 
invasion of pathogenic bacteria. Specialised functional cells such as goblet cells are responsible for the 
production of mucins and Paneth cells producing bactericidal compounds help protect the epithelial 
barrier from commensal and pathogenic bacteria. The mucus layer, antimicrobial peptides (AMPs) and 
innate lymphoid cells (ILCs) functioning together help to avoid bacterial invasion whilst promoting 
mutualistic interactions. Microbial signals can also induce the production of interleukins such as IL-22, 
and immunoglobulins such as IgA to aid in barrier function (Brown et al., 2013).  
Where obesity, excessive alcohol consumption and high-calorie diets can promote cancer, there is 
evidence indicating that diet also be used a form of preventative therapy. Foods containing folates, 
selenium, vitamin D, dietary fibre, garlic, milk, calcium, spices, vegetables, and fruits are now known 
to be protective against CRC (Aggarwal et al., 2013). Numerous natural agents termed 'nutraceuticals' 
have potential to both prevent and treat CRC. Evidence suggests that food-based compounds could 
be used to suppress growth of CRC. Use in cell culture and animal models has given insights into 
modulation of multiple targets, including transcription factors, growth factors, inflammatory 
pathways, invasion and angiogenesis (Aggarwal et al., 2013). 
Bacterial adherence to intestinal epithelial cells can be inhibited using complex oligosaccharides such 
as those present in bovine submaxillary mucin and soluble edible plant fibres (Martin et al., 2004), 
which therefore have therapeutic potential. Elevated risk of colon cancer has been associated with 
the suppression of microbial fermentation and butyrate production, as butyrate provides fuel for the 
mucosa and is anti-inflammatory and anti-proliferative (Greer and O'Keefe, 2011). A significant 
reduction of butyrate-producing bacteria was found in the gut microbiota of CRC patients, and the 
subsequent increase of opportunistic pathogens was suggested to constitute a major structural 
imbalance of gut microbiota in CRC patients (Wang et al., 2012b). 
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Dietary fibres have been shown to produce butyrate by fermentation in the colon. Like other short-
chain fatty acids, such as propionate, butyrate has anti-cancer properties against colorectal cancer 
cells. Soluble plant fibres have been extensively studied using in vitro and ex vivo human intestinal 
mucosa and animal models. Plantain bananas in particular are able to block the adherence of E. coli 
to gut epithelial cells and block translocation across cultured M cells and Peyer’s patches (Roberts et 
al., 2010, Roberts et al., 2013). This effect has since been termed ‘contrabiotic’ to distinguish it from 
the prebiotic effects of dietary fibres. Clinical trials are now beginning to test natural food-based 
agents for efficacy in human disease, and due to their relative safety and affordability in comparison 
to pharmaceutical drugs, this could provide a novel opportunity for early treatment and even help 
prevent human CRC. The major nutraceuticals and functional foods used to modulate the composition 
of intestinal microbiota are represented by prebiotics, probiotics, polyunsaturated fatty acids, amino 
acids and polyphenols (Magrone and Jirillo, 2013). The cellular and molecular effects of these natural 
products in terms of modulation of the intestinal microbiota and mostly attenuation of the 
inflammatory pathway should not be overlooked in CRC treatment. 
There is now a consistent and convincing body of evidence supporting the protective role of dietary 
fibre against colorectal cancer (Norat et al., 2014). CRC prevention methods now include a fibre-rich 
and meat products poor diet (Perez-Cueto and Verbeke, 2012). With soluble plantain fibres blocking 
the adhesion of intestinal bacteria such as E. coli to the intestinal mucosa and preventing M-cell 
translocation of intestinal pathogens (Roberts et al., 2013), this could represent an important novel 
mechanism by which soluble dietary fibres can promote intestinal health. Dietary fibre taken from the 
medicinal plant Plantago ovato was used in a study to treat patients resected for colorectal cancer 
(Nordgaard et al., 1996). Following increased intake of Plantago ovato dietary fibre, the colonic flora 
was adapted to increase the production of butyrate and increased faecal concentrations of butyrate 
in patients resected for colonic cancer. 
Flavonoids such as isorhamnetin have been shown to aid prevention of CRC. Tumorigenesis studies 
using an inbred FVB/N strain of mice treated with the chemical carcinogen azoxymethane and 
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subsequently exposed to colonic irritant dextran sodium sulphate (DSS) showed dietary isorhamnetin 
decreases mortality, tumour number and tumour burden (Saud et al., 2013). An interesting finding in 
this study was the reduction of DSS-induced inflammation, as well as inhibition of AOM/DSS–induced 
oncogenic c-Src activation and β-catenin nuclear translocation. These observations suggest the 
chemoprotective effects of isorhamnetin in colon cancer are linked to its anti-inflammatory activities 
and an inhibition of oncogenic Src activity and Wnt signalling (Saud et al., 2013). 
Vitamin D supplementation also enhances killing of intracellular AIEC in both murine and human 
macrophages, where it stimulates immune response via cellular production of antimicrobial peptides 
and defensins, making it a good supplement for Crohn’s disease patients. A significant reduction in 
risk of requiring surgery was seen for vitamin D deficient Crohn’s disease patients who normalised 
their vitamin D levels with supplementation (Ananthakrishnan et al., 2013), which could help to reduce 
IBD-associated CRC cases in particular.  
Adherent and invasive E. coli adhesion is believed to be dependent, at least in part, on expression of 
type 1 pili on the bacterial surface and carcinoembryonic antigen-related cell adhesion molecule 6 
(CEACAM6) glycoprotein on the apical surface of intestinal epithelial cells (Barnich et al., 2007). With 
both CEACAM5 and CEACAM6 overexpressed in many cancers associated with adhesion and invasion, 
it has been identified as a therapeutic target. Monoclonal antibodies have been evaluated in 
migration, invasion and adhesion assays in vitro using a panel of human pancreatic, breast, and colonic 
cancer cell lines, and in an in vivo model for human colonic micrometastasis (Blumenthal et al., 2005). 
These antibodies were effective at inhibiting cell migration, invasion and cell penetration through an 
extracellular matrix (ECM). Antibodies and/or inhibitors targeting either CEACAM5 or CEACAM6 could 
reduce cell migration, cell invasion, and cell adhesion, and have anti-metastatic effects. Targeting 
CEACAM6 to reduce the influence of bacterial invasion on colorectal carcinogenesis warrants further 
investigation as a novel therapeutic target. 
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With adverse systemic effects limiting the long-term use of antibiotics as a preventative therapy, it 
would be beneficial to consider targeting the effects of bacterial interactions and limiting interactions 
of mucosa-associated E. coli with the gut mucosa. As mucosa-associated E. coli produce an array of 
effects associated with both inflammatory and cancer pathways, it may be difficult to show successful 
treatment by targeting only one of these mechanisms, meaning combination therapies could be a 
reasonable future approach. 
9.5.7 Targeting the effects of mucosa-associated E. coli infections using immunotherapy 
Immunotherapy is becoming an increasing focus in cancer treatment, and is beginning to be targeted 
in other diseases such as diabetes and infectious diseases. Immunotherapy is used to focus the 
immune response towards particular antigens presented on the surface of specific cells, such as 
tumour cells or infected cells. Increased antigen presentation by these cells can mean a more targeted 
effect at these cells, limiting adverse effects. 
Immune responses typically involve signalling between T cells and antigen presenting cells (APCs) and 
between B cells and T cells. Other accessory signals are necessary, such as the secretion of cytokines 
functioning to further enhance, modify, and skew the responding effector cells. T-cell priming and B-
cell activation can occur in absence of CD40 signals, but many cellular and immune functions are 
defective in the absence of this interaction, showing the importance of this ligand/receptor pair in the 
development of adaptive immunity (Elgueta et al., 2009). 
Macrophages are considered the key type of APC involved in fighting bacterial infections, with 
phagocytosis and destruction of bacteria and presentation of bacteria-derived antigens to T cells. 
However, dendritic cells (DCs) are also capable of phagocytosing particulate antigens, including 
bacteria, so DCs may also be important in initiating an immune response to these mucosa-associated 
E. coli infections. Studies have shown stimulation of immune responses by E. coli and Salmonella typhi, 
with T cell stimulation also shown in vivo. These cells are normally able to process E. coli and 
Salmonella typhi for antigen presentation on the major histocompatibility complex (MHC), which is 
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involved in the control of the adaptive immune response. Data shows that these infections can up-
regulate MHC expression, as well as several co-stimulatory molecules and secretion of cytokines. DCs 
are now believed to  contribute to the immune response to Salmonella infections (Yrlid et al., 2000). 
With mucosa-associated E. coli able to survive within macrophages, it may be possible to try to 
improve the immune response to these bacteria by stimulating DC responses. 
Antigen processing and recognition is a key feature of antibacterial immune responses to intracellular 
bacteria, with both conventional and unconventional T cells known to participate in antibacterial 
protection. We are now beginning to understand the broad spectrum of antigen recognition and 
stimulation of distinct T-cell populations that recognize proteins, lipids and carbohydrates from 
bacterial pathogens to strengthen protective immunity (Kaufmann and Schaible, 2005). Pathogens 
able to exploit antigen presentation may be able to evade immune responses, but so far few 
mechanisms for this have been described in bacterial infections. A new focus on the recognition of 
bacterial infections, particularly for those capable of surviving and replicating within immune cells, 
may help to improve natural immune responses to infection before chronic inflammation is able to 
affect cancer development. 
Another important factor could be the role of bacterial DNA in modulating responses from epithelial 
and antigen-presenting cells. One study has shown in vitro and in vivo treatment with bacterial DNA 
from Bifidobacterium breve and Salmonella enterica can enhance the secretion of cytokines from 
epithelial cells and underlying APCs, as well as inducing cytokine secretion from T cells (Campeau et 
al., 2012). If the bacterial DNA is able to induce a cytokine response in these cells, it is possible that 
certain genes or virulence factors could be found and targeted, either by immunotherapy or a more 
directly targeted drug therapy. 
In conclusion, if mucosa-associated E. coli can survive and replicate within epithelial and macrophage 
cell within the gut mucosa, it seems feasible to try to target these infected cells. As infection of various 
cells with different bacteria has been shown to alter antigen presentation, improved targeting of the 
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immune response towards antigens presented by infected epithelial cells could limit the cancer-
related impact of chronic infections. Immunotherapies using the same antigens to activate a targeted 
response from T and B cells could help to reduce the impact of these infections, and may be worth 
investigating. 
9.6 Implications for future investigation 
While data obtained from our study points towards a clear impact of mucosa-associated E. coli 
infections on inflammatory COX-2 signalling and cancer-related Wnt signalling, further investigation is 
required. The impact of a number of factors involved in our in vitro and in vivo work could be improved 
with more data from additional sources. 
SW480 and DLD-1 cells were selected for use throughout our study, both of which are known to have 
high basal levels of Wnt signalling (Yang et al., 2006). Whilst high basal levels of Wnt signalling makes 
these cell lines a useful model for this study, larger increases in Wnt signalling could be masked in 
comparison to other CRC cell lines such as HT-29. There is potential for mucosa-associated E. coli 
isolates to have a similar impact in intestinal epithelial cells with lower levels of basal Wnt activity and 
those earlier in the intestinal adenoma-carcinoma sequence. Our current in vitro data has focussed 
predominantly on the impact of mucosa-associated E. coli infections of CRC cell lines. Use of cell lines 
earlier in the the adenoma-carcinoma sequence, such as the early-stage adenoma PC/AA and later-
stage adenoma AA/C1 cell lines (Williams et al., 1990, Paraskeva et al., 1992) in monolayer infection 
studies would allow further insight into the impact of mucosa-associated E. coli infections on COX-2 
and β-catenin gene and protein expression earlier in the adenoma-carcinoma sequence. Our results 
demonstrating that Wnt pathway activation by mucosa-associated E. coli can be attenuated with the 
use of COX inhibitors such as diclofenac could also be of high scientific interest, and warrants further 
investigation. 
We have shown significant increases in intestinal tissue expression of both COX-2 and β-catenin 
protein, with the latter showing increased levels of nuclear localisation following mono-association of 
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germ-free Il10-/- mice with CRC mucosa-associated E. coli isolate HM44. It has been reported that 
germ-free Il10-/- mice nor Il10-/- mice colonized with pure cultures of non-pathogenic E. coli, as well as 
other bacteria such as a Bifidobacterium spp. and a Bacillus spp. developed colitis did not develop 
colitis, dysplasia or carcinoma (Balish and Warner, 2002). It would therefore be beneficial to 
investigate changes in COX-2 and β-catenin protein expression following mono-association of the 
same germ-free Il10-/- mice used in our study with other mucosa-associate E. coli as well as non-
pathogenic E. coli K12, to confirm the effect is specific to mucosa-associated E. coli. 
The IHC Profiler was used in our study to achieve a final HSCORE value to quantify expression of both 
COX-2 and β-catenin protein. As this method is typically used for scoring protein targets with 
cytoplasmic and/or nuclear expression (Varghese et al., 2014), it was deemed suitable for scoring total 
epithelial levels of COX-2 and β-catenin expression. If such a tissue scoring technique was to be utilised 
as a marker for COX-2 or β-catenin in future studies, it would benefit from a comparison to an 
established scoring system using tissue pathology. One such system has been developed for visual 
analogue scoring in order to quantifying IHC staining, and has been used to compare untreated and 
H. felis-infected C57BL/6 mice (Duckworth et al., 2015). This would enable the experimenter to further 
confirm the suitability of the automated scoring technique. In order to further minimise the risk of 
bias with more valuable tissue, for example limited biopsy tissue being used to determine CRC cancer 
risk, it would be beneficial to introduce an image blinding system, where the person evaluating the 
staining intensity of each image was blinded as to the origin of the tissue. 
It remains clear that more works is yet to be done to test the suitability and compatibility of different 
CRC cell lines for 3D culture using the RCCS, with micro-carrier beads as well as in co-cultures with 
other supportive cells, such as human fibroblasts and stromal cells. With a fully validated culture 
procedure, we would then have an efficient and reliable culture platform available for use in future 
studies. In chapter 8, we show changes in COX-2 and β-catenin gene expression. However, we would 
benefit from showing the impact of these infections on protein expression, as well as nuclear 
translocation. We would also benefit from data using cells at an earlier stage of the adenoma-
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carcinoma sequence in the RCCS, as well as regular colonic cells with no disease association to model 
the impact of these bacteria throughout the development and progression of colonic disease. 
Following initial results from sequencing the fosmids confirmed to up-regulate COX-2 gene expression, 
it would be interesting to look into the genes/operons shared by fosmid clones up-regulating COX-2 
gene expression more closely. Once key genes/operons have been identified, it would be useful to 
screen all clones for the presence of this operon. Similar to the Prorok-Hamon et al. (2014) study, 
where sequence analysis of E. coli HM358 and haemagglutination-positive fosmid clones revealed afa-
1 as an adhesion and invasion factor (Prorok-Hamon et al., 2014), further investigation may confirm 
the presence of existing and/or novel genes/operons involved in the adhesion and invasion of mucosa-
associated E. coli and subsequent impact of increased COX-2 and Wnt signalling. 
Our study has focussed on the impact of mucosa-associated E. coli infections on COX-2 and Wnt 
signalling due to existing links between these E. coli strains and gut infections (Martin et al., 2004, 
Darfeuille-Michaud et al., 1998), and links between inflammatory signalling and Wnt signalling 
(Castellone et al., 2005). However, other signalling pathways are likely to be involved in disease 
pathogenesis implicated with mucosa-associated E. coli infections. Chronic inflammatory signalling as 
a result of tissue damage and/or infection is often implicated in altering key cancer signalling 
pathways. One example of this is chronic TNF-α and COX-2 release mediating response via NF-κB 
signalling (Paik et al., 2002, Lawrence, 2009). Activation of the canonical NF-κB pathway in response 
to inflammatory cytokines has shown to be important in the pathogenesis of chronic inflammatory 
diseases such as rheumatoid arthritis and IBD (Tak and Firestein, 2001). The NF-κB pathway is also 
believed to be important in intestinal innate immunity within intestinal epithelial cells and underlying 
macrophages rapidly available to keep potential pathogens under control, as well as in maintaining 
mucosal homeostasis (Jarry et al., 2014). NF-κB is known to be involved in the increased expression of 
many genes of inflammatory and immune responses and can be upregulated in response to 
microorganisms and lipopolysaccharides and is considered a crucial factor in maintaining chronic 
inflammation (La Ferla et al., 2004). Normally, NF-κB-containing complexes are sequestered in the 
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cytosol in inactive form due to their association with inhibitory proteins. Activation of the canonical 
pathway causes nuclear translocation of NF-κB (Scheidereit, 2006) where it induces target gene 
transcription including pro-inflammatory cytokines such as TNF-α (Jarry et al., 2014). 
Activation of NF-κB has also been demonstrated in situ in macrophages and in intestinal epithelial cells 
in the inflamed mucosa from IBD patients (Rogler et al., 1998). With the activation of NF-κB seen in 
enterocytes in response to various E. coli, its role in the response of intestinal epithelial cells to 
bacterial infections, particularly E. coli, could be crucial (Savkovic et al., 1997, Elewaut et al., 1999). 
Increased TNF-α promoter activity in cells stimulated with bacterial isolates from IBD patients suggests 
TNF-α plays an important role in inflammation caused by E. coli strains associated with inflammatory 
disease (La Ferla et al., 2004, Wang and Hardwidge, 2012). In addition, inhibition of NF-κB in both 
colon and mammary carcinoma cells converts the LPS-induced growth response to LPS-induced 
tumour regression (Luo et al., 2004). 
Molecular mechanisms that link bacterial infections, inflammation and cancer, indicate that certain 
strains of E. coli as a risk factor for patients with colon cancer following the acquisition of virulence 
factors. One of these factors is a protein toxin named cytotoxic necrotizing factor 1 (CNF1) 
(Travaglione et al., 2008), which is reported to induce a long-lasting activation of the transcription 
factor NF-kB and COX2 expression, as well as protect epithelial cells from apoptosis and promote 
cellular motility. As cancer may arise through dysfunction of similar regulatory systems, it seems likely 
that other E. coli infections associated with virulence factors could contribute to tumour development 
in a similar fashion. 
It would also be beneficial to investigate similar effects of other pathogenic bacteria found in increased 
numbers in inflammatory gut conditions. Several studies implicate microbial dysbiosis in the 
development of colorectal adenomas and CRC (Wu et al., 2013, Zhu et al., 2014, Chen et al., 2012, 
Sobhani et al., 2011). Another recent study characterising the gut microbiome in healthy, adenoma, 
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and carcinoma patients representing various stages of colorectal cancer development has added extra 
weight to this theory (Zackular et al., 2014). 
Alterations in bacterial community composition associated with adenomas may be a contributory 
cause of CRC, and these findings could lead to strategies to manipulate the microbiota to prevent 
colorectal adenomas and cancer as well as to identify individuals at high risk (Shen et al., 2010, Dulal 
and Keku, 2014). Study of the mucosa-associated microbiota has revealed changes including increases 
in mucosa-associated E. coli as well as Fusobacterium nucleatum (F. nucleatum). Infection with  
F. nucleatum is associated with colorectal cancer (CRC) and linked to adherence, invasion and 
induction of oncogenic and inflammatory responses to stimulate growth of CRC cells. F. nucleatum 
infection is believed to occur through its unique FadA adhesin, which has been shown to bind to E-
cadherin, activating β-catenin signalling (Rubinstein et al., 2013). With similar traits to mucosa-
associated E. coli, it is possible that similar virulence factors could influence Wnt signalling in a similar 
manner. This suggests further investigation into other similar bacteria would be beneficial, and could 
be key in identifying other mechanisms by which bacteria can drive Wnt signalling and CRC.  
These additions to current in vitro and in vivo data could be important in identifying virulence factors 
and other driving forces affecting cancer-associated signalling, particularly Wnt signalling, and could 
be a potential diagnostic and therapeutic CRC target. Further investigation into the ability of mucosa-
associated E. coli to activate cancer-promoting proteins within intestinal epithelial cells will improve 
our understanding of the potential impact of development, growth and spread of colonic tumours. 
Recent reports of a rate-limiting effect of gp130/Stat3 on Wnt signalling, even where β-catenin nuclear 
localisation is increased (Phesse et al., 2015), would suggest other assays confirming proliferation and 
migration using colorectal cells and tissue, as well as assessing cell viability and metabolism, would be 
beneficial in confirming increased Wnt signalling driving phenotypic changes and impacting malignant 
development. 
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9.7 Final conclusions 
The aim of this project was to investigate whether specific mucosa-associated E. coli isolates taken 
from IBD and CRC patients possess ability to activate key cancer-promoting proteins within epithelial 
cells lining the bowel, including those known to help development, growth and spread of tumours. 
The main pathway under investigation was the canonical Wnt pathway signalling through β-catenin, 
which helps to regulate cell cycle and cell growth, whilst also playing a crucial role in colorectal 
tumorigenesis. 
Data obtained throughout the project has pointed towards Wnt activation through β-catenin following 
infection of human colorectal cell-lines with mucosa-associated E. coli isolates taken from IBD and CRC 
patients. This has been shown consistently alongside increases in COX-2 signalling following infection 
of cell lines in vitro and germ-free Il10-/- mice. Importantly, these changes have not been replicated 
following non-pathogenic E. coli K12 infection, which suggests that this impact if conserved for 
mucosa-associated isolates. The use of a fosmid clone library has allowed us to sequence fosmid 
clones confirmed to up-regulate COX-2 gene expression, which leads us closer to the identification the 
factors that might be contributing towards these changes. We have also sought to establish a novel 
infection model making use of 3D cell aggregates, and have confirmed changes in COX-2 and β-catenin 
gene expression in mucosa-associated E. coli infected aggregates. 
The data obtained from this project adds expands on the relationship between bacterial infection, 
inflammation and cancer, with a focus on mucosa-associated E. coli that are already shown to be more 
prevalent under colorectal disease conditions. This project has shown that mucosa-associated E. coli 
can increase Wnt signalling similar to other pathogenic bacteria, and that this could have future impact 
on CRC treatment focussed on limiting the inflammatory and cancer-promoting effects of mucosa-
associated E. coli infection. 
 
222 
 
References 
 
 
 
 
 
 
 
 
 
 
 
 
223 
 
ABDALLAH HAJJ HUSSEIN, I., FREUND, J. N., REIMUND, J. M., SHAMS, A., YAMINE, M., LEONE, A. & 
JURJUS, A. R. 2012. Enteropathogenic e.coli sustains iodoacetamide-induced ulcerative 
colitis-like colitis in rats: modulation of IL-1beta, IL-6, TNF-alpha, COX-2, and apoptosisi. J Biol 
Regul Homeost Agents, 26, 515-26. 
ACHILLI, T. M., MEYER, J. & MORGAN, J. R. 2012. Advances in the formation, use and understanding 
of multi-cellular spheroids. Expert Opin Biol Ther, 12, 1347-60. 
AGGARWAL, B., PRASAD, S., SUNG, B., KRISHNAN, S. & GUHA, S. 2013. Prevention and Treatment of 
Colorectal Cancer by Natural Agents From Mother Nature. Curr Colorectal Cancer Rep, 9, 37-
56. 
AHMED, D., EIDE, P. W., EILERTSEN, I. A., DANIELSEN, S. A., EKNAES, M., HEKTOEN, M., LIND, G. E. & 
LOTHE, R. A. 2013. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis, 
2, e71. 
ALBENBERG, L. G. & WU, G. D. 2014. Diet and the intestinal microbiome: associations, functions, and 
implications for health and disease. Gastroenterology, 146, 1564-72. 
ANANTHAKRISHNAN, A. N., CAGAN, A., GAINER, V. S., CAI, T., CHENG, S. C., SAVOVA, G., CHEN, P., 
SZOLOVITS, P., XIA, Z., DE JAGER, P. L., SHAW, S. Y., CHURCHILL, S., KARLSON, E. W., 
KOHANE, I., PLENGE, R. M., MURPHY, S. N. & LIAO, K. P. 2013. Normalization of plasma 25-
hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm 
Bowel Dis, 19, 1921-7. 
ANDERSON, E. C. & WONG, M. H. 2010. Caught in the Akt: regulation of Wnt signaling in the 
intestine. Gastroenterology, 139, 718-22. 
ANDERSON, G. D., HAUSER, S. D., MCGARITY, K. L., BREMER, M. E., ISAKSON, P. C. & GREGORY, S. A. 
1996. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression 
of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest, 97, 2672-9. 
ANTIPOV, D., HARTWICK, N., SHEN, M., RAIKO, M., LAPIDUS, A. & PEVZNER, P. A. 2016. 
plasmidSPAdes: assembling plasmids from whole genome sequencing data. Bioinformatics, 
32, 3380-3387. 
ARMAGHANY, T., WILSON, J. D., CHU, Q. & MILLS, G. 2012. Genetic alterations in colorectal cancer. 
Gastrointest Cancer Res, 5, 19-27. 
ARNOLD, D. & SCHMOLL, H. J. 2005. (Neo-)adjuvant treatments in colorectal cancer. Ann Oncol, 16 
Suppl 2, ii133-40. 
ARNOLD, M., SIERRA, M. S., LAVERSANNE, M., SOERJOMATARAM, I., JEMAL, A. & BRAY, F. 2017. 
Global patterns and trends in colorectal cancer incidence and mortality. Gut, 66, 683-91. 
ARTHUR, J. C. & JOBIN, C. 2011. The struggle within: Microbial influences on colorectal cancer. 
Inflammatory Bowel Diseases, 17, 396-409 10.1002/ibd.21354. 
ARTHUR, J. C., PEREZ-CHANONA, E., MÜHLBAUER, M., TOMKOVICH, S., URONIS, J. M., FAN, T.-J., 
CAMPBELL, B. J., ABUJAMEL, T., DOGAN, B., ROGERS, A. B., RHODES, J. M., STINTZI, A., 
SIMPSON, K. W., HANSEN, J. J., KEKU, T. O., FODOR, A. A. & JOBIN, C. 2012. Intestinal 
Inflammation Targets Cancer-Inducing Activity of the Microbiota. Science, 338, 120-123. 
BACHMANN, B. J. 1972. Pedigrees of some mutant strains of Escherichia coli K-12. Bacteriol Rev, 36, 
525-57. 
BALISH, E. & WARNER, T. 2002. Enterococcus faecalis induces inflammatory bowel disease in 
interleukin-10 knockout mice. Am J Pathol, 160, 2253-7. 
BALMANA, J., BALAGUER, F., CERVANTES, A., ARNOLD, D. & GROUP, E. G. W. 2013. Familial risk-
colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol, 24 Suppl 6, vi73-80. 
BARBAZAN, J., VIEITO, M., ABALO, A., ALONSO-ALCONADA, L., MUINELO-ROMAY, L., ALONSO-
NOCELO, M., LEON, L., CANDAMIO, S., GALLARDO, E., ANIDO, U., DOLL, A., DE LOS ANGELES 
CASARES, M., GOMEZ-TATO, A., ABAL, M. & LOPEZ-LOPEZ, R. 2012. A logistic model for the 
detection of circulating tumour cells in human metastatic colorectal cancer. J Cell Mol Med, 
16, 2342-9. 
224 
 
BARNICH, N., CARVALHO, F. A., GLASSER, A. L., DARCHA, C., JANTSCHEFF, P., ALLEZ, M., PEETERS, H., 
BOMMELAER, G., DESREUMAUX, P., COLOMBEL, J. F. & DARFEUILLE-MICHAUD, A. 2007. 
CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa 
colonization in Crohn disease. J Clin Invest, 117, 1566-74. 
BARON, J. A., COLE, B. F., SANDLER, R. S., HAILE, R. W., AHNEN, D., BRESALIER, R., MCKEOWN-
EYSSEN, G., SUMMERS, R. W., ROTHSTEIN, R., BURKE, C. A., SNOVER, D. C., CHURCH, T. R., 
ALLEN, J. I., BEACH, M., BECK, G. J., BOND, J. H., BYERS, T., GREENBERG, E. R., MANDEL, J. S., 
MARCON, N., MOTT, L. A., PEARSON, L., SAIBIL, F. & VAN STOLK, R. U. 2003. A randomized 
trial of aspirin to prevent colorectal adenomas. N Engl J Med, 348, 891-9. 
BARON, J. A., SANDLER, R. S., BRESALIER, R. S., QUAN, H., RIDDELL, R., LANAS, A., BOLOGNESE, J. A., 
OXENIUS, B., HORGAN, K., LOFTUS, S., MORTON, D. G. & INVESTIGATORS, A. P. T. 2006. A 
randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. 
Gastroenterology, 131, 1674-82. 
BARRILA, J., RADTKE, A. L., CRABBE, A., SARKER, S. F., HERBST-KRALOVETZ, M. M., OTT, C. M. & 
NICKERSON, C. A. 2010. Organotypic 3D cell culture models: using the rotating wall vessel to 
study host-pathogen interactions. Nat Rev Microbiol, 8, 791-801. 
BARTCHEWSKY, W., JR., MARTINI, M. R., MASIERO, M., SQUASSONI, A. C., ALVAREZ, M. C., LADEIRA, 
M. S., SALVATORE, D., TREVISAN, M., PEDRAZZOLI, J., JR. & RIBEIRO, M. L. 2009. Effect of 
Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic 
gastritis and gastric cancer. Scand J Gastroenterol, 44, 153-61. 
BAUER, T. W. & SPITZ, F. R. 1998. Adjuvant and neoadjuvant chemoradiation therapy for primary 
colorectal cancer. Surg Oncol, 7, 175-81. 
BEHRENS, J., VON KRIES, J. P., KUHL, M., BRUHN, L., WEDLICH, D., GROSSCHEDL, R. & BIRCHMEIER, 
W. 1996. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature, 
382, 638-42. 
BELLAMY, C. O., MALCOMSON, R. D., HARRISON, D. J. & WYLLIE, A. H. 1995. Cell death in health and 
disease: the biology and regulation of apoptosis. Semin Cancer Biol, 6, 3-16. 
BERGMANN, S. & STEINERT, M. 2015. From Single Cells to Engineered and Explanted Tissues: New 
Perspectives in Bacterial Infection Biology. Int Rev Cell Mol Biol, 319, 1-44. 
BERSCHNEIDER, B. & KONIGSHOFF, M. 2011. WNT1 inducible signaling pathway protein 1 (WISP1): a 
novel mediator linking development and disease. Int J Biochem Cell Biol, 43, 306-9. 
BERTAGNOLLI, M. M., EAGLE, C. J., ZAUBER, A. G., REDSTON, M., SOLOMON, S. D., KIM, K., TANG, J., 
ROSENSTEIN, R. B., WITTES, J., CORLE, D., HESS, T. M., WOLOJ, G. M., BOISSERIE, F., 
ANDERSON, W. F., VINER, J. L., BAGHERI, D., BURN, J., CHUNG, D. C., DEWAR, T., FOLEY, T. R., 
HOFFMAN, N., MACRAE, F., PRUITT, R. E., SALTZMAN, J. R., SALZBERG, B., SYLWESTROWICZ, 
T., GORDON, G. B., HAWK, E. T. & INVESTIGATORS, A. P. C. S. 2006. Celecoxib for the 
prevention of sporadic colorectal adenomas. N Engl J Med, 355, 873-84. 
BIENZ, M. & CLEVERS, H. 2000. Linking colorectal cancer to Wnt signaling. Cell, 103, 311-20. 
BLAGODATSKI, A., POTERYAEV, D. & KATANAEV, V. L. 2015. Targeting the Wnt pathway for 
therapies. Mol Cell Ther, 2, 28. 
BLUMENTHAL, R. D., HANSEN, H. J. & GOLDENBERG, D. M. 2005. Inhibition of adhesion, invasion, 
and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 
(Carcinoembryonic Antigen). Cancer Res, 65, 8809-17. 
BOLLATI, M., VILLA, R., GOURLAY, L. J., BENEDET, M., DEHO, G., POLISSI, A., BARBIROLI, A., 
MARTORANA, A. M., SPERANDEO, P., BOLOGNESI, M. & NARDINI, M. 2015. Crystal structure 
of LptH, the periplasmic component of the lipopolysaccharide transport machinery from 
Pseudomonas aeruginosa. FEBS J, 282, 1980-97. 
BONGERS, G., PACER, M. E., GERALDINO, T. H., CHEN, L., HE, Z., HASHIMOTO, D., FURTADO, G. C., 
OCHANDO, J., KELLEY, K. A., CLEMENTE, J. C., MERAD, M., VAN BAKEL, H. & LIRA, S. A. 2014. 
Interplay of host microbiota, genetic perturbations, and inflammation promotes local 
development of intestinal neoplasms in mice. J Exp Med, 211, 457-72. 
225 
 
BOTTING, R. M. 2006. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol 
Pharmacol, 57 Suppl 5, 113-24. 
BRINGER, M.-A., BARNICH, N., GLASSER, A.-L., BARDOT, O. & DARFEUILLE-MICHAUD, A. 2005. HtrA 
Stress Protein Is Involved in Intramacrophagic Replication of Adherent and Invasive 
Escherichia coli Strain LF82 Isolated from a Patient with Crohn's Disease. Infection and 
Immunity, 73, 712-721. 
BRINGER, M.-A., ROLHION, N., GLASSER, A.-L. & DARFEUILLE-MICHAUD, A. 2007. The Oxidoreductase 
DsbA Plays a Key Role in the Ability of the Crohn's Disease-Associated Adherent-Invasive 
Escherichia coli Strain LF82 To Resist Macrophage Killing. Journal of Bacteriology, 189, 4860-
4871. 
BROWN, E. M., SADARANGANI, M. & FINLAY, B. B. 2013. The role of the immune system in governing 
host-microbe interactions in the intestine. Nat Immunol, 14, 660-667. 
BROWN, J. R. & DUBOIS, R. N. 2005. COX-2: a molecular target for colorectal cancer prevention. J 
Clin Oncol, 23, 2840-55. 
BURKITT, M. D., DUCKWORTH, C. A., WILLIAMS, J. M. & PRITCHARD, D. M. 2017. Helicobacter pylori-
induced gastric pathology: insights from in vivo and ex vivo models. Dis Model Mech, 10, 89-
104. 
BURKITT, M. D., HANEDI, A. F., DUCKWORTH, C. A., WILLIAMS, J. M., TANG, J. M., O'REILLY, L. A., 
PUTOCZKI, T. L., GERONDAKIS, S., DIMALINE, R., CAAMANO, J. H. & PRITCHARD, D. M. 2015. 
NF-kappaB1, NF-kappaB2 and c-Rel differentially regulate susceptibility to colitis-associated 
adenoma development in C57BL/6 mice. J Pathol, 236, 326-36. 
BUTLER, W. J. & ROBERTS-THOMSON, I. C. 2004. Polymorphisms and risk for sporadic colorectal 
cancer. J Gastroenterol Hepatol, 19, 1215-6. 
CAMPEAU, J. L., SALIM, S. Y., ALBERT, E. J., HOTTE, N. & MADSEN, K. L. 2012. Intestinal epithelial cells 
modulate antigen-presenting cell responses to bacterial DNA. Infect Immun, 80, 2632-44. 
CANE, G., GINOUVES, A., MARCHETTI, S., BUSCA, R., POUYSSEGUR, J., BERRA, E., HOFMAN, P. & 
VOURET-CRAVIARI, V. 2010. HIF-1alpha mediates the induction of IL-8 and VEGF expression 
on infection with Afa/Dr diffusely adhering E. coli and promotes EMT-like behaviour. Cell 
Microbiol, 12, 640-53. 
CANE, G., MOAL, V. L., PAGES, G., SERVIN, A. L., HOFMAN, P. & VOURET-CRAVIARI, V. 2007. Up-
regulation of intestinal vascular endothelial growth factor by Afa/Dr diffusely adhering 
Escherichia coli. PLoS One, 2, e1359. 
CARVALHO, H. M., TEEL, L. D., GOPING, G. & O'BRIEN, A. D. 2005. A three-dimensional tissue culture 
model for the study of attach and efface lesion formation by enteropathogenic and 
enterohaemorrhagic Escherichia coli. Cell Microbiol, 7, 1771-81. 
CASSIDY, J., CLARKE, S., DIAZ-RUBIO, E., SCHEITHAUER, W., FIGER, A., WONG, R., KOSKI, S., 
RITTWEGER, K., GILBERG, F. & SALTZ, L. 2011. XELOX vs FOLFOX-4 as first-line therapy for 
metastatic colorectal cancer: NO16966 updated results. Br J Cancer, 105, 58-64. 
CASSIDY, J., TABERNERO, J., TWELVES, C., BRUNET, R., BUTTS, C., CONROY, T., DEBRAUD, F., FIGER, 
A., GROSSMANN, J., SAWADA, N., SCHOFFSKI, P., SOBRERO, A., VAN CUTSEM, E. & DIAZ-
RUBIO, E. 2004. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients 
with metastatic colorectal cancer. J Clin Oncol, 22, 2084-91. 
CASTELLONE, M. D., TERAMOTO, H., WILLIAMS, B. O., DRUEY, K. M. & GUTKIND, J. S. 2005. 
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin 
signaling axis. Science, 310, 1504-10. 
CHASSAING, B. & DARFEUILLE–MICHAUD, A. 2011. The Commensal Microbiota and Enteropathogens 
in the Pathogenesis of Inflammatory Bowel Diseases. Gastroenterology, 140, 1720-1728.e3. 
CHASSAING, B., ROLHION, N., VALL, XE, E, A., XE, LIE, D., SALIM, S., X, AD, Y., PROROK-HAMON, M., 
NEUT, C., CAMPBELL, B. J., XF, DERHOLM, J. D., HUGOT, J.-P., COLOMBEL, J.-F., XE, XE, RIC & 
DARFEUILLE-MICHAUD, A. 2011. Crohn disease–associated adherent-invasive E. coli bacteria 
226 
 
target mouse and human Peyer’s patches via long polar fimbriae. The Journal of Clinical 
Investigation, 121, 966-975. 
CHEN, W., LIU, F., LING, Z., TONG, X. & XIANG, C. 2012. Human intestinal lumen and mucosa-
associated microbiota in patients with colorectal cancer. PLoS One, 7, e39743. 
CHERVONSKY, A. V. 2010. Influence of microbial environment on autoimmunity. Nat Immunol, 11, 
28-35. 
CHIU, C. H., MCENTEE, M. F. & WHELAN, J. 1997. Sulindac causes rapid regression of preexisting 
tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res, 57, 4267-73. 
CHO, M., GWAK, J., PARK, S., WON, J., KIM, D. E., YEA, S. S., CHA, I. J., KIM, T. K., SHIN, J. G. & OH, S. 
2005. Diclofenac attenuates Wnt/beta-catenin signaling in colon cancer cells by activation of 
NF-kappaB. FEBS Lett, 579, 4213-8. 
CHOI, P. M. & ZELIG, M. P. 1994. Similarity of colorectal cancer in Crohn's disease and ulcerative 
colitis: implications for carcinogenesis and prevention. Gut, 35, 950-4. 
CLARKE, T. B., DAVIS, K. M., LYSENKO, E. S., ZHOU, A. Y., YU, Y. & WEISER, J. N. 2010. Recognition of 
peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med, 
16, 228-31. 
CLEVERS, H. 2016. Modeling Development and Disease with Organoids. Cell, 165, 1586-97. 
COLLIER, P. E., TUROWSKI, P. & DIAMOND, D. L. 1985. Small intestinal adenocarcinoma complicating 
regional enteritis. Cancer, 55, 516-21. 
COMPARE, D. & NARDONE, G. 2011. Contribution of Gut Microbiota to Colonic and Extracolonic 
Cancer Development. Digestive Diseases, 29, 554-561. 
COSTE, I., FREUND, J. N., SPADERNA, S., BRABLETZ, T. & RENNO, T. 2007. Precancerous Lesions Upon 
Sporadic Activation of β-Catenin in Mice. Gastroenterology, 132, 1299-1308. 
COTILLARD, A., KENNEDY, S. P., KONG, L. C., PRIFTI, E., PONS, N., LE CHATELIER, E., ALMEIDA, M., 
QUINQUIS, B., LEVENEZ, F., GALLERON, N., GOUGIS, S., RIZKALLA, S., BATTO, J. M., RENAULT, 
P., CONSORTIUM, A. N. R. M., DORE, J., ZUCKER, J. D., CLEMENT, K. & EHRLICH, S. D. 2013. 
Dietary intervention impact on gut microbial gene richness. Nature, 500, 585-8. 
COUGNOUX, A., DALMASSO, G., MARTINEZ, R., BUC, E., DELMAS, J., GIBOLD, L., SAUVANET, P., 
DARCHA, C., DECHELOTTE, P., BONNET, M., PEZET, D., WODRICH, H., DARFEUILLE-MICHAUD, 
A. & BONNET, R. 2014. Bacterial genotoxin colibactin promotes colon tumour growth by 
inducing a senescence-associated secretory phenotype. Gut, 63, 1932-42. 
COUGNOUX, A., GIBOLD, L., ROBIN, F., DUBOIS, D., PRADEL, N., DARFEUILLE-MICHAUD, A., 
DALMASSO, G., DELMAS, J. & BONNET, R. 2012. Analysis of structure-function relationships 
in the colibactin-maturating enzyme ClbP. J Mol Biol, 424, 203-14. 
COUPER, K. N., BLOUNT, D. G. & RILEY, E. M. 2008. IL-10: the master regulator of immunity to 
infection. J Immunol, 180, 5771-7. 
CROTTI, S., PICCOLI, M., RIZZOLIO, F., GIORDANO, A., NITTI, D. & AGOSTINI, M. 2017. Extracellular 
Matrix and Colorectal Cancer: How Surrounding Microenvironment Affects Cancer Cell 
Behavior? J Cell Physiol, 232, 967-975. 
CUENDET, M., MESECAR, A. D., DEWITT, D. L. & PEZZUTO, J. M. 2006. An ELISA method to measure 
inhibition of the COX enzymes. Nat Protoc, 1, 1915-21. 
CUEVAS-RAMOS, G., PETIT, C. R., MARCQ, I., BOURY, M., OSWALD, E. & NOUGAYREDE, J. P. 2010. 
Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian 
cells. Proc Natl Acad Sci U S A, 107, 11537-42. 
D'HAENS, G. R., VERMEIRE, S., VAN ASSCHE, G., NOMAN, M., AERDEN, I., VAN OLMEN, G. & 
RUTGEERTS, P. 2008. Therapy of metronidazole with azathioprine to prevent postoperative 
recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology, 135, 1123-9. 
DAIGNEAULT, M., PRESTON, J. A., MARRIOTT, H. M., WHYTE, M. K. & DOCKRELL, D. H. 2010. The 
identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and 
monocyte-derived macrophages. PLoS One, 5, e8668. 
227 
 
DALMASSO, G., COUGNOUX, A., DELMAS, J., DARFEUILLE-MICHAUD, A. & BONNET, R. 2014. The 
bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor 
microenvironment. Gut Microbes, 00-00. 
DANNENBERG, A. J., ALTORKI, N. K., BOYLE, J. O., DANG, C., HOWE, L. R., WEKSLER, B. B. & 
SUBBARAMAIAH, K. 2001. Cyclo-oxygenase 2: a pharmacological target for the prevention of 
cancer. Lancet Oncol, 2, 544-51. 
DARFEUILLE-MICHAUD, A. & COLOMBEL, J. F. 2008. Pathogenic Escherichia coli in inflammatory 
bowel diseases Proceedings of the 1st International Meeting on E. coli and IBD, June 2007, 
Lille, France. J Crohns Colitis, 2, 255-62. 
DARFEUILLE-MICHAUD, A., NEUT, C., BARNICH, N., LEDERMAN, E., DI MARTINO, P., DESREUMAUX, 
P., GAMBIEZ, L., JOLY, B., CORTOT, A. & COLOMBEL, J.-F. 1998. Presence of adherent 
Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology, 
115, 1405-1413. 
DAVIES, S. R., DAVIES, M. L., SANDERS, A., PARR, C., TORKINGTON, J. & JIANG, W. G. 2010. 
Differential expression of the CCN family member WISP-1, WISP-2 and WISP-3 in human 
colorectal cancer and the prognostic implications. Int J Oncol, 36, 1129-36. 
DE MATOS, L.L., TRUFELLI, D.C., DE MATOD, M.G.L. & PINHAL, M.A.D.S. 2010. Immunohistochemistry 
as an important tool in biomarker detection and clinical practice. Biomark Insights, 5, 9-20. 
DE REUSE, H., LEVY, S., ZENG, G. & DANCHIN, A. 1989. Genetics of the PTS components in Escherichia 
coli K-12. FEMS Microbiol Rev, 5, 61-7. 
DEXTER, D. L., SPREMULLI, E. N., FLIGIEL, Z., BARBOSA, J. A., VOGEL, R., VANVOORHEES, A. & 
CALABRESI, P. 1981. Heterogeneity of cancer cells from a single human colon carcinoma. Am 
J Med, 71, 949-56. 
DIN, F. V., DUNLOP, M. G. & STARK, L. A. 2004. Evidence for colorectal cancer cell specificity of 
aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer, 91, 381-8. 
DOGAN, B., SCHERL, E., BOSWORTH, B., YANTISS, R., ALTIER, C., MCDONOUGH, P. L., JIANG, Z. D., 
DUPONT, H. L., GARNEAU, P., HAREL, J., RISHNIW, M. & SIMPSON, K. W. 2013. Multidrug 
resistance is common in Escherichia coli associated with ileal Crohn's disease. Inflamm Bowel 
Dis, 19, 141-50. 
DUBOIS, R. N. 2014. Role of inflammation and inflammatory mediators in colorectal cancer. 
Transactions of the American Clinical and Climatological Association, 125, 358-373. 
DUCKWORTH, C. A., ABUDERMAN, A. A., BURKITT, M. D., WILLIAMS, J. M., O'REILLY, L. A. & 
PRITCHARD, D. M. 2015. bak deletion stimulates gastric epithelial proliferation and enhances 
Helicobacter felis-induced gastric atrophy and dysplasia in mice. Am J Physiol Gastrointest 
Liver Physiol, 309, G420-30. 
DULAL, S. & KEKU, T. O. 2014. Gut microbiome and colorectal adenomas. Cancer J, 20, 225-31. 
DUNLOP, M. G., BRITISH SOCIETY FOR, G., ASSOCIATION OF COLOPROCTOLOGY FOR GREAT, B. & 
IRELAND 2002. Guidance on gastrointestinal surveillance for hereditary non-polyposis 
colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers 
syndrome. Gut, 51 Suppl 5, V21-7. 
DUXBURY, M. S., ITO, H., ZINNER, M. J., ASHLEY, S. W. & WHANG, E. E. 2004. CEACAM6 gene 
silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic 
adenocarcinoma cells. Oncogene, 23, 465-73. 
EADEN, J. A., ABRAMS, K. R. & MAYBERRY, J. F. 2001. The risk of colorectal cancer in ulcerative 
colitis: a meta-analysis. Gut, 48, 526-35. 
EADEN, J. A., MAYBERRY, J. F., BRITISH SOCIETY FOR, G., ASSOCIATION OF COLOPROCTOLOGY FOR 
GREAT, B. & IRELAND 2002. Guidelines for screening and surveillance of asymptomatic 
colorectal cancer in patients with inflammatory bowel disease. Gut, 51 Suppl 5, V10-2. 
EKBOM, A., HELMICK, C., ZACK, M. & ADAMI, H. O. 1990a. Increased risk of large-bowel cancer in 
Crohn's disease with colonic involvement. Lancet, 336, 357-9. 
228 
 
EKBOM, A., HELMICK, C., ZACK, M. & ADAMI, H. O. 1990b. Ulcerative colitis and colorectal cancer. A 
population-based study. N Engl J Med, 323, 1228-33. 
ELEWAUT, D., DIDONATO, J. A., KIM, J. M., TRUONG, F., ECKMANN, L. & KAGNOFF, M. F. 1999. NF-
kappa B is a central regulator of the intestinal epithelial cell innate immune response 
induced by infection with enteroinvasive bacteria. J Immunol, 163, 1457-66. 
ELGUETA, R., BENSON, M. J., DE VRIES, V. C., WASIUK, A., GUO, Y. & NOELLE, R. J. 2009. Molecular 
mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev, 
229, 152-72. 
ELLIOTT, N., LEE, T., YOU, L. & YUAN, F. 2011. Proliferation behavior of E. coli in a three-dimensional 
in vitro tumor model. Integrative Biology, 3, 696-705. 
ESCALANTE, A., SALINAS CERVANTES, A., GOSSET, G. & BOLIVAR, F. 2012. Current knowledge of the 
Escherichia coli phosphoenolpyruvate-carbohydrate phosphotransferase system: 
peculiarities of regulation and impact on growth and product formation. Appl Microbiol 
Biotechnol, 94, 1483-94. 
ESCHRICH, S., YANG, I., BLOOM, G., KWONG, K. Y., BOULWARE, D., CANTOR, A., COPPOLA, D., 
KRUHØFFER, M., AALTONEN, L., ORNTOFT, T. F., QUACKENBUSH, J. & YEATMAN, T. J. 2005. 
Molecular Staging for Survival Prediction of Colorectal Cancer Patients. Journal of Clinical 
Oncology, 23, 3526-3535. 
ESSON, D., MATHER, A. E., SCANLAN, E., GUPTA, S., DE VRIES, S. P., BAILEY, D., HARRIS, S. R., 
MCKINLEY, T. J., MERIC, G., BERRY, S. K., MASTROENI, P., SHEPPARD, S. K., CHRISTIE, G., 
THOMSON, N. R., PARKHILL, J., MASKELL, D. J. & GRANT, A. J. 2016. Genomic variations 
leading to alterations in cell morphology of Campylobacter spp. Sci Rep, 6, 38303. 
FANG, X., YU, S. X., LU, Y., BAST, R. C., JR., WOODGETT, J. R. & MILLS, G. B. 2000. Phosphorylation 
and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A, 
97, 11960-5. 
FEARON, E. R. 1995. Molecular genetics of colorectal cancer. Ann N Y Acad Sci, 768, 101-10. 
FERLAY, J., SHIN, H. R., BRAY, F., FORMAN, D., MATHERS, C. & PARKIN, D. M. 2010. Estimates of 
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. 
FLANAGAN, D. J., PHESSE, T. J., BARKER, N., SCHWAB, R. H., AMIN, N., MALATERRE, J., STANGE, D. E., 
NOWELL, C. J., CURRIE, S. A., SAW, J. T., BEUCHERT, E., RAMSAY, R. G., SANSOM, O. J., 
ERNST, M., CLEVERS, H. & VINCAN, E. 2015a. Frizzled7 functions as a Wnt receptor in 
intestinal epithelial Lgr5(+) stem cells. Stem Cell Reports, 4, 759-67. 
FLANAGAN, P. K., CHIEWCHENGCHOL, D., WRIGHT, H. L., EDWARDS, S. W., ALSWIED, A., SATSANGI, 
J., SUBRAMANIAN, S., RHODES, J. M. & CAMPBELL, B. J. 2015b. Killing of Escherichia coli by 
Crohn's Disease Monocyte-derived Macrophages and Its Enhancement by 
Hydroxychloroquine and Vitamin D. Inflamm Bowel Dis, 21, 1499-510. 
FLIS, S. & SPLWINSKI, J. 2009. Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal 
cancer cell survival are synergistically enhanced by sulindac sulfide. Anticancer Res, 29, 435-
41. 
FODDE, R., KUIPERS, J., ROSENBERG, C., SMITS, R., KIELMAN, M., GASPAR, C., VAN ES, J. H., BREUKEL, 
C., WIEGANT, J., GILES, R. H. & CLEVERS, H. 2001. Mutations in the APC tumour suppressor 
gene cause chromosomal instability. Nat Cell Biol, 3, 433-8. 
FREWER, K. A., SANDERS, A. J., OWEN, S., FREWER, N. C., HARGEST, R. & JIANG, W. G. 2013. A role 
for WISP2 in colorectal cancer cell invasion and motility. Cancer Genomics Proteomics, 10, 
187-96. 
GALAMB, O., KALMAR, A., PETERFIA, B., CSABAI, I., BODOR, A., RIBLI, D., KRENACS, T., PATAI, A.D., 
WICHMANN, B., BARTAK, B.K., TOTH, K., VALCZ, G., SPISAK, S., TULASSAY, Z. & MOLNAR, B. 
2016. Epigenetics, 11, 588-602. 
GELLAD, Z. F. & PROVENZALE, D. 2010. Colorectal cancer: national and international perspective on 
the burden of disease and public health impact. Gastroenterology, 138, 2177-90. 
229 
 
GEVERS, D., KUGATHASAN, S., DENSON, L. A., VAZQUEZ-BAEZA, Y., VAN TREUREN, W., REN, B., 
SCHWAGER, E., KNIGHTS, D., SONG, S. J., YASSOUR, M., MORGAN, X. C., KOSTIC, A. D., LUO, 
C., GONZALEZ, A., MCDONALD, D., HABERMAN, Y., WALTERS, T., BAKER, S., ROSH, J., 
STEPHENS, M., HEYMAN, M., MARKOWITZ, J., BALDASSANO, R., GRIFFITHS, A., SYLVESTER, 
F., MACK, D., KIM, S., CRANDALL, W., HYAMS, J., HUTTENHOWER, C., KNIGHT, R. & XAVIER, 
R. J. 2014. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe, 
15, 382-92. 
GOH, T. K., ZHANG, Z. Y., CHEN, A. K., REUVENY, S., CHOOLANI, M., CHAN, J. K. & OH, S. K. 2013. 
Microcarrier culture for efficient expansion and osteogenic differentiation of human fetal 
mesenchymal stem cells. Biores Open Access, 2, 84-97. 
GOODWIN, T. J., JESSUP, J. M. & WOLF, D. A. 1992. Morphologic differentiation of colon carcinoma 
cell lines HT-29 and HT-29KM in rotating-wall vessels. In Vitro Cell Dev Biol, 28A, 47-60. 
GORYSHIN, I. Y., JENDRISAK, J., HOFFMAN, L. M., MEIS, R. & REZNIKOFF, W. S. 2000. Insertional 
transposon mutagenesis by electroporation of released Tn5 transposition complexes. Nat 
Biotechnol, 18, 97-100. 
GRAY, S. G., AL-SARRAF, N., BAIRD, A. M., CATHCART, M. C., MCGOVERN, E. & O'BYRNE, K. J. 2009. 
Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. Eur J 
Cancer, 45, 3087-97. 
GREER, J. B. & O'KEEFE, S. J. 2011. Microbial induction of immunity, inflammation, and cancer. Front 
Physiol, 1, 168. 
GREGORIEFF, A. & CLEVERS, H. 2005. Wnt signaling in the intestinal epithelium: from endoderm to 
cancer. Genes & Development, 19, 877-890. 
GUPTA, R. A. & DUBOIS, R. N. 2001. Colorectal cancer prevention and treatment by inhibition of 
cyclooxygenase-2. Nat Rev Cancer, 1, 11-21. 
HALL, B., LIMAYE, A. & KULKARNI, A. B. 2009. Overview: generation of gene knockout mice. Curr 
Protoc Cell Biol, Chapter 19, Unit 19 12 19 12 1-17. 
HAN, X., GENG, J., ZHANG, L. & LU, T. 2011. The role of Escherichia coli YrbB in the lethal action of 
quinolones. J Antimicrob Chemother, 66, 323-31. 
HANAHAN, D. & WEINBER, R. A. 2011. Hallmarks of cancer: the next generation. Cell, 144, 646-74. 
HANNEMANN, S., GAO, B. & GALAN, J. E. 2013. Salmonella modulation of host cell gene expression 
promotes its intracellular growth. PLoS Pathog, 9, e1003668. 
HERBST-KRALOVETZ, M. M., RADTKE, A. L., LAY, M. K., HJELM, B. E., BOLICK, A. N., SARKER, S. S., 
ATMAR, R. L., KINGSLEY, D. H., ARNTZEN, C. J., ESTES, M. K. & NICKERSON, C. A. 2013. Lack of 
norovirus replication and histo-blood group antigen expression in 3-dimensional intestinal 
epithelial cells. Emerg Infect Dis, 19, 431-8. 
HIRABAYASHI, K., YASUDA, M., KAJIWARA, H., ITOH, J., MIYAZAWA, M., HIRASAWA, T., 
MURAMATSU, T., MURAKAMI, M., MIKAMI, M. & OSAMURA, R. Y. 2008. Alterations in mucin 
expression in ovarian mucinous tumors: immunohistochemical analysis of MUC2, MUC5AC, 
MUC6, and CD10 expression. Acta Histochem Cytochem, 41, 15-21. 
HIRATA, A., UTIKAL, J., YAMASHITA, S., AOKI, H., WATANABE, A., YAMAMOTO, T., OKANO, H., 
BARDEESY, N., KUNISADA, T., USHIJIMA, T., HARA, A., JAENISCH, R., HOCHEDLINGER, K. & 
YAMADA, Y. 2013. Dose-dependent roles for canonical Wnt signalling in de novo crypt 
formation and cell cycle properties of the colonic epithelium. Development, 140, 66-75. 
HOESEL, B. & SCHMID, J. A. 2013. The complexity of NF-kappaB signaling in inflammation and cancer. 
Mol Cancer, 12, 86. 
HOLD, G. L., SMITH, M., GRANGE, C., WATT, E. R., EL-OMAR, E. M. & MUKHOPADHYA, I. 2014. Role of 
the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the 
past 10 years? World J Gastroenterol, 20, 1192-210. 
HOOPER, L. V. 2004. Bacterial contributions to mammalian gut development. Trends Microbiol, 12, 
129-34. 
230 
 
HOOPER, L. V., XU, J., FALK, P. G., MIDTVEDT, T. & GORDON, J. I. 1999. A molecular sensor that 
allows a gut commensal to control its nutrient foundation in a competitive ecosystem. Proc 
Natl Acad Sci U S A, 96, 9833-8. 
HOUSSEAU, F. & SEARS, C. L. 2010. Enterotoxigenic Bacteroides fragilis (ETBF)-mediated colitis in 
Min (Apc+/-) mice: a human commensal-based murine model of colon carcinogenesis. Cell 
Cycle, 9, 3-5. 
HSU, H. C., LIU, Y. S., TSENG, K. C., TAN, B. C., CHEN, S. J. & CHEN, H. C. 2014. LGR5 regulates survival 
through mitochondria-mediated apoptosis and by targeting the Wnt/beta-catenin signaling 
pathway in colorectal cancer cells. Cell Signal, 26, 2333-42. 
HULL, M. A., KO, S. C. & HAWCROFT, G. 2004. Prostaglandin EP receptors: targets for treatment and 
prevention of colorectal cancer? Mol Cancer Ther, 3, 1031-9. 
INOUE, T., ANAI, S., ONISHI, S., MIYAKE, M., TANAKA, N., HIRAYAMA, A., FUJIMOTO, K. & HIRAO, Y. 
2013. Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via 
enhancement of TRAIL in human prostate adenocarcinoma xenograft model. BMC Urol, 13, 
1. 
IYER, S. S. & CHENG, G. 2012. Role of interleukin 10 transcriptional regulation in inflammation and 
autoimmune disease. Crit Rev Immunol, 32, 23-63. 
JACKSTADT, R., SANSOM, O.J 2016. Mouse models of intestinal cancer. J Pathol, 238, 141-151. 
JARRY, A., CREMET, L., CAROFF, N., BOU-HANNA, C., MUSSINI, J. M., REYNAUD, A., SERVIN, A. L., 
MOSNIER, J. F., LIEVIN-LE MOAL, V. & LABOISSE, C. L. 2014. Subversion of human intestinal 
mucosa innate immunity by a Crohn's disease-associated E. coli. Mucosal Immunol. 
JESS, T., GAMBORG, M., MATZEN, P., MUNKHOLM, P. & SORENSEN, T. I. 2005. Increased risk of 
intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am 
J Gastroenterol, 100, 2724-9. 
JESSUP, J. M., FRANTZ, M., SONMEZ-ALPAN, E., LOCKER, J., SKENA, K., WALLER, H., BATTLE, P., 
NACHMAN, A., WEBER, M., THOMAS, D., CURBEAM, R., JR., BAKER, T. & GOODWIN, T. 2000. 
Microgravity culture reduces apoptosis and increases the differentiation of a human 
colorectal carcinoma cell line. In Vitro Cellular & Developmental Biology - Animal, 36, 367-
373. 
JESSUP, J. M., GOODWIN, T. J. & SPAULDING, G. 1993. Prospects for use of microgravity-based 
bioreactors to study three-dimensional host-tumor interactions in human neoplasia. J Cell 
Biochem, 51, 290-300. 
JHO, E.H., ZHANG, T., DOMON, C., JOO, C.K., FREUND, J.N. & COSTANTINI, F. 2002. Wnt/beta-
catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling 
pathway. Mol Cell Biol, 22, 1172-83. 
JOHANSSON, M. E., PHILLIPSON, M., PETERSSON, J., VELCICH, A., HOLM, L. & HANSSON, G. C. 2008. 
The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. 
Proc Natl Acad Sci U S A, 105, 15064-9. 
KADO, S., UCHIDA, K., FUNABASHI, H., IWATA, S., NAGATA, Y., ANDO, M., ONOUE, M., MATSUOKA, 
Y., OHWAKI, M. & MOROTOMI, M. 2001. Intestinal microflora are necessary for 
development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta 
chain and p53 double-knockout mice. Cancer Res, 61, 2395-8. 
KAEFFER, B., BENARD, C., LAHAYE, M., BLOTTIERE, H. M. & CHERBUT, C. 1999. Biological properties 
of ulvan, a new source of green seaweed sulfated polysaccharides, on cultured normal and 
cancerous colonic epithelial cells. Planta Med, 65, 527-31. 
KAEFFER, B., TRUBUIL, A., KERVRANN, C., PARDINI, L. & CHERBUT, C. 2002. Three-dimensional 
binding of epidermal growth factor peptides in colonic tissues produced from rotating 
bioreactor. In Vitro Cell Dev Biol Anim, 38, 436-9. 
KALER, P., AUGENLICHT, L. & KLAMPFER, L. 2012. Activating Mutations in β-Catenin in Colon Cancer 
Cells Alter Their Interaction with Macrophages; the Role of Snail. PLoS ONE, 7, e45462. 
231 
 
KAMADA, N., SEO, S. U., CHEN, G. Y. & NUNEZ, G. 2013. Role of the gut microbiota in immunity and 
inflammatory disease. Nat Rev Immunol, 13, 321-35. 
KAPITANOVIC, S., CACEV, T., ANTICA, M., KRALJ, M., CAVRIC, G., PAVELIC, K. & SPAVENTI, R. 2006. 
Effect of indomethacin on E-cadherin and beta-catenin expression in HT-29 colon cancer 
cells. Exp Mol Pathol, 80, 91-6. 
KARIM, B. O. & HUSO, D. L. 2013. Mouse models for colorectal cancer. Am J Cancer Res, 3, 240-50. 
KARIN, M., LAWRENCE, T. & NIZET, V. 2006. Innate Immunity Gone Awry: Linking Microbial 
Infections to Chronic Inflammation and Cancer. Cell, 124, 823-835. 
KARIN, M., YAMAMOTO, Y. & WANG, Q. M. 2004. The IKK NF-[kappa]B system: a treasure trove for 
drug development. Nat Rev Drug Discov, 3, 17-26. 
KAUFMANN, S. H. & SCHAIBLE, U. E. 2005. Antigen presentation and recognition in bacterial 
infections. Curr Opin Immunol, 17, 79-87. 
KAUR, J. & SANYAL, S. N. 2010. Modulation of inflammatory changes in early stages of colon cancer 
through activation of PPARgamma by diclofenac. Eur J Cancer Prev, 19, 319-27. 
KAUR SAINI, M. & NATH SANYAL, S. 2010. Evaluation of chemopreventive response of two 
cycloxygenase-2 inhibitors, etoricoxib and diclofenac in rat colon cancer using FTIR and NMR 
spectroscopic techniques. Nutr Hosp, 25, 577-85. 
KIM, K. Y., JEON, S. W., PARK, J. G., YU, C. H., JANG, S. Y., LEE, J. K. & HWANG, H. Y. 2014. Regression 
of Colonic Adenomas After Treatment With Sulindac in Familial Adenomatous Polyposis: A 
Case With a 2-Year Follow-up Without a Prophylactic Colectomy. Ann Coloproctol, 30, 201-4. 
KIM, S. S., RUIZ, V. E., CARROLL, J. D. & MOSS, S. F. 2011. Helicobacter pylori in the pathogenesis of 
gastric cancer and gastric lymphoma. Cancer Letters, 305, 228-238. 
KLEMENT, B. J., YOUNG, Q. M., GEORGE, B. J. & NOKKAEW, M. 2004. Skeletal tissue growth, 
differentiation and mineralization in the NASA rotating wall vessel. Bone, 34, 487-98. 
KOBAYASHI, M., HONMA, T., MATSUDA, Y., SUZUKI, Y., NARISAWA, R., AJIOKA, Y. & ASAKURA, H. 
2000. Nuclear translocation of beta-catenin in colorectal cancer. Br J Cancer, 82, 1689-93. 
KUFE, D. W. 2009. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer, 9, 874-85. 
KUHNERT, P., NICOLET, J. & FREY, J. 1995. Rapid and accurate identification of Escherichia coli K-12 
strains. Appl Environ Microbiol, 61, 4135-9. 
KUMAR, R. & SHIMIZU, K. 2010. Metabolic regulation of Escherichia coli and its gdhA, glnL, gltB, D 
mutants under different carbon and nitrogen limitations in the continuous culture. Microb 
Cell Fact, 9, 8. 
LA FERLA, K., SEEGERT, D. & SCHREIBER, S. 2004. Activation of NF-kappaB in intestinal epithelial cells 
by E. coli strains isolated from the colonic mucosa of IBD patients. Int J Colorectal Dis, 19, 
334-42. 
LAFLAMME, N., LACROIX, S. & RIVEST, S. 1999. An essential role of interleukin-1beta in mediating 
NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to 
a systemic and localized inflammation but not during endotoxemia. J Neurosci, 19, 10923-30. 
LAGUINGE, L. M., LIN, S., SAMARA, R. N., SALESIOTIS, A. N. & JESSUP, J. M. 2004. Nitrosative stress in 
rotated three-dimensional colorectal carcinoma cell cultures induces microtubule 
depolymerization and apoptosis. Cancer Res, 64, 2643-8. 
LAWRENCE, T. 2009. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb 
Perspect Biol, 1, a001651. 
LE NEGRATE, G. 2012. Subversion of innate immune responses by bacterial hindrance of NF-kappaB 
pathway. Cell Microbiol, 14, 155-67. 
LEE, S. H., LEE, S. J., KIM, J. H. & PARK, B. J. 2007. Chemical carcinogen, N-methyl-N'-nitro-N-
nitrosoguanidine, is a specific activator of oncogenic Ras. Cell Cycle, 6, 1257-64. 
LEE, S. H., NAM, J. K., PARK, J. K., LEE, J. H., MIN DO, S. & KUH, H. J. 2014. Differential protein 
expression and novel biomarkers related to 5-FU resistance in a 3D colorectal 
adenocarcinoma model. Oncol Rep, 32, 1427-34. 
232 
 
LEIBOVITZ, A., STINSON, J. C., MCCOMBS, W. B., 3RD, MCCOY, C. E., MAZUR, K. C. & MABRY, N. D. 
1976. Classification of human colorectal adenocarcinoma cell lines. Cancer Res, 36, 4562-9. 
LETEURTRE, E., ZERIMECH, F., PIESSEN, G., WACRENIER, A., LEROY, X., COPIN, M. C., MARIETTE, C., 
AUBERT, J. P., PORCHET, N. & BUISINE, M. P. 2006. Relationships between mucinous gastric 
carcinoma, MUC2 expression and survival. World J Gastroenterol, 12, 3324-31. 
LEW, J. I., GUO, Y., KIM, R. K., VARGISH, L., MICHELASSI, F. & ARENAS, R. B. 2002. Reduction of 
intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition 
is additive. J Gastrointest Surg, 6, 563-8. 
LIAO, X., LOCHHEAD, P., NISHIHARA, R., MORIKAWA, T., KUCHIBA, A., YAMAUCHI, M., IMAMURA, Y., 
QIAN, Z. R., BABA, Y., SHIMA, K., SUN, R., NOSHO, K., MEYERHARDT, J. A., GIOVANNUCCI, E., 
FUCHS, C. S., CHAN, A. T. & OGINO, S. 2012. Aspirin use, tumor PIK3CA mutation, and 
colorectal-cancer survival. N Engl J Med, 367, 1596-606. 
LIGGETT, J. L., CHOI, C. K., DONNELL, R. L., KIHM, K. D., KIM, J. S., MIN, K. W., NOEGEL, A. A. & BAEK, 
S. J. 2014. Nonsteroidal anti-inflammatory drug sulindac sulfide suppresses structural 
protein Nesprin-2 expression in colorectal cancer cells. Biochim Biophys Acta, 1840, 322-31. 
LIU, X., LU, R., WU, S. & SUN, J. 2010. Salmonella regulation of intestinal stem cells through the 
Wnt/β-catenin pathway. FEBS Letters, 584, 911-916. 
LU, J., YE, X., FAN, F., XIA, L., BHATTACHARYA, R., BELLISTER, S., TOZZI, F., SCEUSI, E., ZHOU, Y., 
TACHIBANA, I., MARU, D. M., HAWKE, D. H., RAK, J., MANI, S. A., ZWEIDLER-MCKAY, P. & 
ELLIS, L. M. 2013. Endothelial cells promote the colorectal cancer stem cell phenotype 
through a soluble form of Jagged-1. Cancer Cell, 23, 171-85. 
LUCEY, B. P., NELSON-REES, W. A. & HUTCHINS, G. M. 2009. Henrietta Lacks, HeLa cells, and cell 
culture contamination. Arch Pathol Lab Med, 133, 1463-7. 
LUO, F., BROOKS, D. G., YE, H., HAMOUDI, R., POULOGIANNIS, G., PATEK, C. E., WINTON, D. J. & 
ARENDS, M. J. 2009. Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more 
in the large than the small intestines, with synergistic effects between K-ras and Wnt 
pathways. Int J Exp Pathol, 90, 558-74. 
LUO, J. L., MAEDA, S., HSU, L. C., YAGITA, H. & KARIN, M. 2004. Inhibition of NF-kappaB in cancer 
cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-
mediated tumor regression. Cancer Cell, 6, 297-305. 
LUPP, C., ROBERTSON, M. L., WICKHAM, M. E., SEKIROV, I., CHAMPION, O. L., GAYNOR, E. C. & 
FINLAY, B. B. 2007. Host-mediated inflammation disrupts the intestinal microbiota and 
promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe, 2, 204. 
LYSENKO, E. S., CLARKE, T. B., SHCHEPETOV, M., RATNER, A. J., ROPER, D. I., DOWSON, C. G. & 
WEISER, J. N. 2007. Nod1 signaling overcomes resistance of S. pneumoniae to 
opsonophagocytic killing. PLoS Pathog, 3, e118. 
MACDONALD, B. T., TAMAI, K. & HE, X. 2009. Wnt/beta-catenin signaling: components, mechanisms, 
and diseases. Dev Cell, 17, 9-26. 
MAGER, D. L. 2006. Bacteria and cancer: cause, coincidence or cure? A review. Journal of 
Translational Medicine, 4, 1-18. 
MAGRONE, T. & JIRILLO, E. 2013. The interplay between the gut immune system and microbiota in 
health and disease: nutraceutical intervention for restoring intestinal homeostasis. Curr 
Pharm Des, 19, 1329-42. 
MAOUCHE, R., BURGOS, H. L., MY, L., VIALA, J. P., GOURSE, R. L. & BOUVERET, E. 2016. Coexpression 
of Escherichia coli obgE, Encoding the Evolutionarily Conserved Obg GTPase, with Ribosomal 
Proteins L21 and L27. J Bacteriol, 198, 1857-67. 
MARSHMAN, E., BOOTH, C. & POTTEN, C. S. 2002. The intestinal epithelial stem cell. Bioessays, 24, 
91-8. 
MARTIN, H. M., CAMPBELL, B. J., HART, C. A., MPOFU, C., NAYAR, M., SINGH, R., ENGLYST, H., 
WILLIAMS, H. F. & RHODES, J. M. 2004. Enhanced Escherichia coli adherence and invasion in 
Crohn’s disease and colon cancer. Gastroenterology, 127, 80-93. 
233 
 
MARTORANA, A. M., MOTTA, S., DI SILVESTRE, D., FALCHI, F., DEHO, G., MAURI, P., SPERANDEO, P. & 
POLISSI, A. 2014. Dissecting Escherichia coli outer membrane biogenesis using differential 
proteomics. PLoS One, 9, e100941. 
MAY, M. J. & GHOSH, S. 1997. Rel/NF-kappa B and I kappa B proteins: an overview. Semin Cancer 
Biol, 8, 63-73. 
MCCARTY, K. S., JR., SZABO, E., FLOWERS, J. L., COX, E. B., LEIGHT, G. S., MILLER, L., KONRATH, J., 
SOPER, J. T., BUDWIT, D. A., CREASMAN, W. T. & ET AL. 1986. Use of a monoclonal anti-
estrogen receptor antibody in the immunohistochemical evaluation of human tumors. 
Cancer Res, 46, 4244s-4248s. 
MCDONALD, S. L. & SILVER, A. R. 2011. On target? Strategies and progress in the development of 
therapies for colorectal cancer targeted against WNT signalling. Colorectal Dis, 13, 360-9. 
MCGOWIN, C. L., RADTKE, A. L., ABRAHAM, K., MARTIN, D. H. & HERBST-KRALOVETZ, M. 2013. 
Mycoplasma genitalium infection activates cellular host defense and inflammation pathways 
in a 3-dimensional human endocervical epithelial cell model. J Infect Dis, 207, 1857-68. 
MCNALLY, A., OREN, Y., KELLY, D., PASCOE, B., DUNN, S., SREECHARAN, T., VEHKALA, M., VALIMAKI, 
N., PRENTICE, M. B., ASHOUR, A., AVRAM, O., PUPKO, T., DOBRINDT, U., LITERAK, I., 
GUENTHER, S., SCHAUFLER, K., WIELER, L. H., ZHIYONG, Z., SHEPPARD, S. K., MCINERNEY, J. 
O. & CORANDER, J. 2016. Combined Analysis of Variation in Core, Accessory and Regulatory 
Genome Regions Provides a Super-Resolution View into the Evolution of Bacterial 
Populations. PLoS Genet, 12, e1006280. 
MELGAR, S., KARLSSON, A. & MICHAELSSON, E. 2005. Acute colitis induced by dextran sulfate 
sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between 
symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol, 288, G1328-38. 
MENZEL, T., SCHAUBER, J., KRETH, F., KUDLICH, T., MELCHER, R., GOSTNER, A., SCHEPPACH, W. & 
LUHRS, H. 2002. Butyrate and aspirin in combination have an enhanced effect on apoptosis 
in human colorectal cancer cells. Eur J Cancer Prev, 11, 271-81. 
MEREDITH, T. C. & WOODARD, R. W. 2005. Identification of GutQ from Escherichia coli as a D-
arabinose 5-phosphate isomerase. J Bacteriol, 187, 6936-42. 
MERLOS-SUÁREZ, A., BARRIGA, FRANCISCO M., JUNG, P., IGLESIAS, M., CÉSPEDES, MARÍA V., 
ROSSELL, D., SEVILLANO, M., HERNANDO-MOMBLONA, X., DA SILVA-DIZ, V., MUÑOZ, P., 
CLEVERS, H., SANCHO, E., MANGUES, R. & BATLLE, E. The Intestinal Stem Cell Signature 
Identifies Colorectal Cancer Stem Cells and Predicts Disease Relapse. Cell Stem Cell, 8, 511-
524. 
MIYOSHI, J., YAJIMA, T., SHIMAMURA, K., MATSUOKA, K., OKAMOTO, S., HIGUCHI, H., FUNAKOSHI, 
S., TAKAISHI, H. & HIBI, T. 2012. 5-aminosalicylic acid mediates expression of 
cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal 
tumorigenesis. Anticancer Res, 32, 1193-202. 
MORGAN, X. C., TICKLE, T. L., SOKOL, H., GEVERS, D., DEVANEY, K. L., WARD, D. V., REYES, J. A., 
SHAH, S. A., LELEIKO, N., SNAPPER, S. B., BOUSVAROS, A., KORZENIK, J., SANDS, B. E., XAVIER, 
R. J. & HUTTENHOWER, C. 2012. Dysfunction of the intestinal microbiome in inflammatory 
bowel disease and treatment. Genome Biol, 13, R79. 
MORIN, P. J., SPARKS, A. B., KORINEK, V., BARKER, N., CLEVERS, H., VOGELSTEIN, B. & KINZLER, K. W. 
1997. Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or 
APC. Science, 275, 1787-1790. 
MPOFU, C. M., CAMPBELL, B. J., SUBRAMANIAN, S., MARSHALL-CLARKE, S., HART, C. A., CROSS, A., 
ROBERTS, C. L., MCGOLDRICK, A., EDWARDS, S. W. & RHODES, J. M. 2007. Microbial mannan 
inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn's 
disease. Gastroenterology, 133, 1487-98. 
NAGALINGAM, N. A. & LYNCH, S. V. 2012. Role of the microbiota in inflammatory bowel diseases. 
Inflamm Bowel Dis, 18, 968-84. 
234 
 
NAKAMURA, T., KODAMA, N., ARAI, Y., KUMAMOTO, T., HIGUCHI, Y., CHAICHANTIPYUTH, C., 
ISHIKAWA, T., UENO, K. & YANO, S. 2009. Inhibitory effect of oxycoumarins isolated from the 
Thai medicinal plant Clausena guillauminii on the inflammation mediators, iNOS, TNF-alpha, 
and COX-2 expression in mouse macrophage RAW 264.7. J Nat Med, 63, 21-7. 
NATHKE, I. S., ADAMS, C. L., POLAKIS, P., SELLIN, J. H. & NELSON, W. J. 1996. The adenomatous 
polyposis coli tumor suppressor protein localizes to plasma membrane sites involved in 
active cell migration. J Cell Biol, 134, 165-79. 
NEWCOMB, P. A., NORFLEET, R. G., STORER, B. E., SURAWICZ, T. S. & MARCUS, P. M. 1992. Screening 
sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst, 84, 1572-5. 
NEWMAN, J. V., KOSAKA, T., SHEPPARD, B. J., FOX, J. G. & SCHAUER, D. B. 2001. Bacterial infection 
promotes colon tumorigenesis in Apc(Min/+) mice. J Infect Dis, 184, 227-30. 
NG, K., MEYERHARDT, J. A., CHAN, A. T., SATO, K., CHAN, J. A., NIEDZWIECKI, D., SALTZ, L. B., MAYER, 
R. J., BENSON, A. B., 3RD, SCHAEFER, P. L., WHITTOM, R., HANTEL, A., GOLDBERG, R. M., 
VENOOK, A. P., OGINO, S., GIOVANNUCCI, E. L. & FUCHS, C. S. 2015. Aspirin and COX-2 
inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst, 107, 345. 
NILSSON, L., MADSEN, K., TOPCU, S. O., JENSEN, B. L., FROKIAER, J. & NORREGAARD, R. 2012. 
Disruption of cyclooxygenase-2 prevents downregulation of cortical AQP2 and AQP3 in 
response to bilateral ureteral obstruction in the mouse. Am J Physiol Renal Physiol, 302, 
F1430-9. 
NORAT, T., AUNE, D., CHAN, D. & ROMAGUERA, D. 2014. Fruits and vegetables: updating the 
epidemiologic evidence for the WCRF/AICR lifestyle recommendations for cancer 
prevention. Cancer Treat Res, 159, 35-50. 
NORDGAARD, I., HOVE, H., CLAUSEN, M. R. & MORTENSEN, P. B. 1996. Colonic production of 
butyrate in patients with previous colonic cancer during long-term treatment with dietary 
fibre (Plantago ovata seeds). Scand J Gastroenterol, 31, 1011-20. 
NOURSADEGHI, M., TSANG, J., HAUSTEIN, T., MILLER, R. F., CHAIN, B. M. & KATZ, D. R. 2008. 
Quantitative imaging assay for NF-kappaB nuclear translocation in primary human 
macrophages. J Immunol Methods, 329, 194-200. 
OGINO, S., KIRKNER, G. J., NOSHO, K., IRAHARA, N., KURE, S., SHIMA, K., HAZRA, A., CHAN, A. T., 
DEHARI, R., GIOVANNUCCI, E. L. & FUCHS, C. S. 2008. Cyclooxygenase-2 expression is an 
independent predictor of poor prognosis in colon cancer. Clin Cancer Res, 14, 8221-7. 
OGUMA, K., OSHIMA, H., AOKI, M., UCHIO, R., NAKA, K., NAKAMURA, S., HIRAO, A., SAYA, H., 
TAKETO, M. M. & OSHIMA, M. 2008. Activated macrophages promote Wnt signalling 
through tumour necrosis factor-alpha in gastric tumour cells. EMBO J, 27, 1671-81. 
OGURA, Y., OGASAWARA, N., HARRY, E. J. & MORIYA, S. 2003. Increasing the ratio of Soj to Spo0J 
promotes replication initiation in Bacillus subtilis. J Bacteriol, 185, 6316-24. 
OHMAN, U. 1982. Colorectal carcinoma in patients with ulcerative colitis. Am J Surg, 144, 344-9. 
OKADA, K., MINEHIRA, M., ZHU, X., SUZUKI, K., NAKAGAWA, T., MATSUDA, H. & KAWAMUKAI, M. 
1997. The ispB gene encoding octaprenyl diphosphate synthase is essential for growth of 
Escherichia coli. J Bacteriol, 179, 3058-60. 
ONOUE, M., KADO, S., SAKAITANI, Y., UCHIDA, K. & MOROTOMI, M. 1997. Specific species of 
intestinal bacteria influence the induction of aberrant crypt foci by 1,2-dimethylhydrazine in 
rats. Cancer Lett, 113, 179-86. 
OSHIMA, H. & OSHIMA, M. 2010. Mouse models of gastric tumors: Wnt activation and PGE2 
induction. Pathol Int, 60, 599-607. 
OUYANG, W., RUTZ, S., CRELLIN, N. K., VALDEZ, P. A. & HYMOWITZ, S. G. 2011. Regulation and 
functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol, 
29, 71-109. 
PAIK, J., LEE, J. Y. & HWANG, D. 2002. Signaling pathways for TNFa-induced COX-2 expression: 
mediation through MAP kinases and NFkB, and inhibition by certain nonsteroidal anti-
inflammatory drugs. Adv Exp Med Biol, 507, 503-8. 
235 
 
PARASKEVA, C., FINERTY, S. & POWELL, S. 1988. Immortalization of a human colorectal adenoma cell 
line by continuous in vitro passage: possible involvement of chromosome 1 in tumour 
progression. Int J Cancer, 41, 908-12. 
PARASKEVA, C., HAGUE, A., ROONEY, N., WILLIAMS, A. C., HARPER, S. J., HANLON, K. A., ATKINSON, 
R. J. & CORFIELD, A. P. 1992. A single human colonic adenoma cell line can be converted in 
vitro to both a colorectal adenocarcinoma and a mucinous carcinoma. Int J Cancer, 51, 661-
4. 
PENNICA, D., SWANSON, T. A., WELSH, J. W., ROY, M. A., LAWRENCE, D. A., LEE, J., BRUSH, J., 
TANEYHILL, L. A., DEUEL, B., LEW, M., WATANABE, C., COHEN, R. L., MELHEM, M. F., FINLEY, 
G. G., QUIRKE, P., GODDARD, A. D., HILLAN, K. J., GURNEY, A. L., BOTSTEIN, D. & LEVINE, A. J. 
1998. WISP genes are members of the connective tissue growth factor family that are up-
regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc 
Natl Acad Sci U S A, 95, 14717-22. 
PEREZ-CHANONA, E. & JOBIN, C. 2014. From promotion to management: the wide impact of bacteria 
on cancer and its treatment. Bioessays, 36, 658-64. 
PEREZ-CUETO, F. J. & VERBEKE, W. 2012. Consumer implications of the WCRF's permanent update 
on colorectal cancer. Meat Sci, 90, 977-8. 
PETERSON, D. A., FRANK, D. N., PACE, N. R. & GORDON, J. I. 2008. Metagenomic approaches for 
defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe, 3, 417-27. 
PHESSE, T. J., BUCHERT, M., STUART, E., FLANAGAN, D. J., FAUX, M., AFSHAR-STERLE, S., WALKER, F., 
ZHANG, H. H., NOWELL, C. J., JORISSEN, R., TAN, C. W., HIROKAWA, Y., EISSMANN, M. F., 
POH, A. R., MALATERRE, J., PEARSON, H. B., KIRSCH, D. G., PROVERO, P., POLI, V., RAMSAY, 
R. G., SIEBER, O., BURGESS, A. W., HUSZAR, D., VINCAN, E. & ERNST, M. 2014. Partial 
inhibition of gp130-Jak-Stat3 signaling prevents Wnt-beta-catenin-mediated intestinal tumor 
growth and regeneration. Sci Signal, 7, ra92. 
PHESSE, T.J., DURBAN, V.M. & SANSOM, O.J. 2017. Defining key concepts of intestinal and epithelial cancer 
 biology through the use of mouse models. Carcinogenesis, bgx080. 
PLUMBRIDGE, J. 2002. Regulation of gene expression in the PTS in Escherichia coli: the role and 
interactions of Mlc. Curr Opin Microbiol, 5, 187-93. 
POLK, D. B. & PEEK, R. M. 2010. Helicobacter Pylori: gastric cancer and beyond. Nat Rev Cancer, 10, 
593-593. 
POTTEN, C. S. & LOEFFLER, M. 1990. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. 
Lessons for and from the crypt. Development, 110, 1001-20. 
PRADERE, J. P., DAPITO, D. H. & SCHWABE, R. F. 2014. The Yin and Yang of Toll-like receptors in 
cancer. Oncogene, 33, 3485-95. 
PROROK-HAMON, M., FRISWELL, M. K., ALSWIED, A., ROBERTS, C. L., SONG, F., FLANAGAN, P. K., 
KNIGHT, P., CODLING, C., MARCHESI, J. R., WINSTANLEY, C., HALL, N., RHODES, J. M. & 
CAMPBELL, B. J. 2014. Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli 
expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut, 
63, 761-770. 
PUGH, S. & THOMAS, G. A. 1994. Patients with adenomatous polyps and carcinomas have increased 
colonic mucosal prostaglandin E2. Gut, 35, 675-8. 
PUTZE, J., HENNEQUIN, C., NOUGAYREDE, J. P., ZHANG, W., HOMBURG, S., KARCH, H., BRINGER, M. 
A., FAYOLLE, C., CARNIEL, E., RABSCH, W., OELSCHLAEGER, T. A., OSWALD, E., FORESTIER, C., 
HACKER, J. & DOBRINDT, U. 2009. Genetic structure and distribution of the colibactin 
genomic island among members of the family Enterobacteriaceae. Infect Immun, 77, 4696-
703. 
QASIM, B. J., ALI, H. H. & HUSSEIN, A. G. 2013. Immunohistochemical expression of matrix 
metalloproteinase-7 in human colorectal adenomas using specified automated cellular 
image analysis system: a clinicopathological study. Saudi J Gastroenterol, 19, 23-7. 
236 
 
QI, J. & ZHU, Y. Q. 2008. Targeting the most upstream site of Wnt signaling pathway provides a 
strategic advantage for therapy in colorectal cancer. Curr Drug Targets, 9, 548-57. 
QIN, J., LI, R., RAES, J., ARUMUGAM, M., BURGDORF, K. S., MANICHANH, C., NIELSEN, T., PONS, N., 
LEVENEZ, F., YAMADA, T., MENDE, D. R., LI, J., XU, J., LI, S., LI, D., CAO, J., WANG, B., LIANG, 
H., ZHENG, H., XIE, Y., TAP, J., LEPAGE, P., BERTALAN, M., BATTO, J. M., HANSEN, T., LE 
PASLIER, D., LINNEBERG, A., NIELSEN, H. B., PELLETIER, E., RENAULT, P., SICHERITZ-PONTEN, 
T., TURNER, K., ZHU, H., YU, C., LI, S., JIAN, M., ZHOU, Y., LI, Y., ZHANG, X., LI, S., QIN, N., 
YANG, H., WANG, J., BRUNAK, S., DORE, J., GUARNER, F., KRISTIANSEN, K., PEDERSEN, O., 
PARKHILL, J., WEISSENBACH, J., META, H. I. T. C., BORK, P., EHRLICH, S. D. & WANG, J. 2010. 
A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 
464, 59-65. 
RADTKE, A. L., WILSON, J. W., SARKER, S. & NICKERSON, C. A. 2010. Analysis of interactions of 
Salmonella type three secretion mutants with 3-D intestinal epithelial cells. PLoS One, 5, 
e15750. 
RAHMAN, M. M. & MCFADDEN, G. 2011. Modulation of NF-kappaB signalling by microbial 
pathogens. Nat Rev Microbiol, 9, 291-306. 
RAISCH, J., ROLHION, N., DUBOIS, A., DARFEUILLE-MICHAUD, A. & BRINGER, M. A. 2014. Intracellular 
colon cancer-associated Escherichia coli promote protumoral activities of human 
macrophages by inducing sustained COX-2 expression. Lab Invest. 
RAISCH, J., ROLHION, N., DUBOIS, A., DARFEUILLE-MICHAUD, A. & BRINGER, M. A. 2015. Intracellular 
colon cancer-associated Escherichia coli promote protumoral activities of human 
macrophages by inducing sustained COX-2 expression. Lab Invest, 95, 296-307. 
RAKOFF-NAHOUM, S. & MEDZHITOV, R. 2007. Regulation of spontaneous intestinal tumorigenesis 
through the adaptor protein MyD88. Science, 317, 124-7. 
RAKOFF-NAHOUM, S. & MEDZHITOV, R. 2009. Toll-like receptors and cancer. Nat Rev Cancer, 9, 57-
63. 
RAWLS, J. F., MAHOWALD, M. A., LEY, R. E. & GORDON, J. I. 2006. Reciprocal gut microbiota 
transplants from zebrafish and mice to germ-free recipients reveal host habitat selection. 
Cell, 127, 423-33. 
READER, J., HOLT, D. & FULTON, A. 2011. Prostaglandin E2 EP receptors as therapeutic targets in 
breast cancer. Cancer Metastasis Rev, 30, 449-63. 
RECONDO, G. J., DIAZ-CANTON, E., DE LA VEGA, M., GRECO, M., RECONDO, G. S. & VALSECCHI, M. E. 
2014. Advances and new perspectives in the treatment of metastatic colon cancer. World J 
Gastrointest Oncol, 6, 211-24. 
RENZ, B. W., THASLER, W. E., PREISSLER, G., HEIDE, T., KHALIL, P. N., MIKHAILOV, M., JAUCH, K. W., 
KREIS, M. E., RENTSCH, M. & KLEESPIES, A. 2013. Clinical outcome of IBD-associated versus 
sporadic colorectal cancer: a matched-pair analysis. J Gastrointest Surg, 17, 981-90. 
RHEE, K. J., WU, S., WU, X., HUSO, D. L., KARIM, B., FRANCO, A. A., RABIZADEH, S., GOLUB, J. E., 
MATHEWS, L. E., SHIN, J., SARTOR, R. B., GOLENBOCK, D., HAMAD, A. R., GAN, C. M., 
HOUSSEAU, F. & SEARS, C. L. 2009. Induction of persistent colitis by a human commensal, 
enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect Immun, 77, 1708-18. 
RHODES, J. M. & CAMPBELL, B. J. 2002. Inflammation and colorectal cancer: IBD-associated and 
sporadic cancer compared. Trends Mol Med, 8, 10-6. 
RIORDAN, J. T., TIETJEN, J. A., WALSH, C. W., GUSTAFSON, J. E. & WHITTAM, T. S. 2010. Inactivation 
of alternative sigma factor 54 (RpoN) leads to increased acid resistance, and alters locus of 
enterocyte effacement (LEE) expression in Escherichia coli O157 : H7. Microbiology, 156, 
719-30. 
RIZZARDI, A.E., JONSON, A.T., VOGEL, R.I., PAMBUCCIAN, S.E., HENRIKSEN, J., SKUBITZ, A.P.N., 
METZGER, G.J. & SCHMECHEL, S.C. 2012. Quantitative comparison of immunohistochemical 
staining measured by digital image analysis versus pathologist visual scoring. Diag Pathol, 7, 
42. 
237 
 
ROBERTS, C. L., KEITA, A. V., DUNCAN, S. H., O'KENNEDY, N., SODERHOLM, J. D., RHODES, J. M. & 
CAMPBELL, B. J. 2010. Translocation of Crohn's disease Escherichia coli across M-cells: 
contrasting effects of soluble plant fibres and emulsifiers. Gut, 59, 1331-9. 
ROBERTS, C. L., KEITA, A. V., PARSONS, B. N., PROROK-HAMON, M., KNIGHT, P., WINSTANLEY, C., N, 
O. K., SODERHOLM, J. D., RHODES, J. M. & CAMPBELL, B. J. 2013. Soluble plantain fibre 
blocks adhesion and M-cell translocation of intestinal pathogens. J Nutr Biochem, 24, 97-
103. 
ROCHETTE, P. J., BASTIEN, N., LAVOIE, J., GUERIN, S. L. & DROUIN, R. 2005. SW480, a p53 double-
mutant cell line retains proficiency for some p53 functions. J Mol Biol, 352, 44-57. 
ROGLER, G., BRAND, K., VOGL, D., PAGE, S., HOFMEISTER, R., ANDUS, T., KNUECHEL, R., BAEUERLE, P. 
A., SCHOLMERICH, J. & GROSS, V. 1998. Nuclear factor kappaB is activated in macrophages 
and epithelial cells of inflamed intestinal mucosa. Gastroenterology, 115, 357-69. 
RUBINSTEIN, M. R., WANG, X., LIU, W., HAO, Y., CAI, G. & HAN, Y. W. 2013. Fusobacterium 
nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin 
signaling via its FadA adhesin. Cell Host Microbe, 14, 195-206. 
RUNDHAUG, J. E., SIMPER, M. S., SURH, I. & FISCHER, S. M. 2011. The role of the EP receptors for 
prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev, 30, 465-80. 
RUTGEERTS, P., VAN ASSCHE, G., VERMEIRE, S., D'HAENS, G., BAERT, F., NOMAN, M., AERDEN, I., DE 
HERTOGH, G., GEBOES, K., HIELE, M., D'HOORE, A. & PENNINCKX, F. 2005. Ornidazole for 
prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, 
placebo-controlled trial. Gastroenterology, 128, 856-61. 
SADOT, E., CONACCI-SORRELL, M., ZHURINSKY, J., SHNIZER, D., LANDO, Z., ZHARHARY, D., KAM, Z., 
BEN-ZE'EV, A. & GEIGER, B. 2002. Regulation of S33/S37 phosphorylated beta-catenin in 
normal and transformed cells. J Cell Sci, 115, 2771-80. 
SAMUELS, Y., WANG, Z., BARDELLI, A., SILLIMAN, N., PTAK, J., SZABO, S., YAN, H., GAZDAR, A., 
POWELL, S. M., RIGGINS, G. J., WILLSON, J. K., MARKOWITZ, S., KINZLER, K. W., VOGELSTEIN, 
B. & VELCULESCU, V. E. 2004. High frequency of mutations of the PIK3CA gene in human 
cancers. Science, 304, 554. 
SANDLER, R. S., HALABI, S., BARON, J. A., BUDINGER, S., PASKETT, E., KERESZTES, R., PETRELLI, N., 
PIPAS, J. M., KARP, D. D., LOPRINZI, C. L., STEINBACH, G. & SCHILSKY, R. 2003. A randomized 
trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N 
Engl J Med, 348, 883-90. 
SANSOM, O. J., REED, K. R., HAYES, A. J., IRELAND, H., BRINKMANN, H., NEWTON, I. P., BATLLE, E., 
SIMON-ASSMANN, P., CLEVERS, H., NATHKE, I. S., CLARKE, A. R. & WINTON, D. J. 2004. Loss 
of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes 
Dev, 18, 1385-90. 
SANTIAGO, A., LI, D., ZHAO, L. Y., GODSEY, A. & LIAO, D. 2013. p53 SUMOylation promotes its 
nuclear export by facilitating its release from the nuclear export receptor CRM1. Mol Biol 
Cell, 24, 2739-52. 
SAUD, S. M., YOUNG, M. R., JONES-HALL, Y. L., ILEVA, L., EVBUOMWAN, M. O., WISE, J., COLBURN, N. 
H., KIM, Y. S. & BOBE, G. 2013. Chemopreventive activity of plant flavonoid isorhamnetin in 
colorectal cancer is mediated by oncogenic Src and beta-catenin. Cancer Res, 73, 5473-84. 
SAVKOVIC, S. D., KOUTSOURIS, A. & HECHT, G. 1997. Activation of NF-kappaB in intestinal epithelial 
cells by enteropathogenic Escherichia coli. Am J Physiol, 273, C1160-7. 
SCHLAERMANN P., TOELLE B., BERGER H., SCHMIDT S. C., GLANEMANN M., ORDEMANN J., 
BARTFELD S., MOLLENKOPF H. J.& MEYER T.F. 2016. A novel human gastric primary cell 
culture system for modelling Helicobacter pylori infection in vitro. Gut. 65, 202-13. 
SCHEIDEREIT, C. 2006. IkappaB kinase complexes: gateways to NF-kappaB activation and 
transcription. Oncogene, 25, 6685-705. 
238 
 
SCHMIEDERER, M., ARCENAS, R., WIDEN, R., VALKOV, N. & ANDERSON, B. 2001. Intracellular 
induction of the Bartonella henselae virB operon by human endothelial cells. Infect Immun, 
69, 6495-502. 
SCRIBANO, M. L. & PRANTERA, C. 2013. Use of antibiotics in the treatment of Crohn's disease. World 
J Gastroenterol, 19, 648-53. 
SEEMANN, T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics, 30, 2068-9. 
SERAFINO, A., MORONI, N., ZONFRILLO, M., ANDREOLA, F., MERCURI, L., NICOTERA, G., NUNZIATA, 
J., RICCI, R., ANTINORI, A., RASI, G. & PIERIMARCHI, P. 2014. WNT-pathway components as 
predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel 
disease and sporadic colorectal cancer. Oncotarget, 5, 978-92. 
SERMAN, L., MARTIC, T.N., SERMAN, A. & VRANIC, S. 2014. Bosn J Basic Med Sci, 14, 191-4. 
SERVIN, A. L. 2005. Pathogenesis of Afa/Dr diffusely adhering Escherichia coli. Clin Microbiol Rev, 18, 
264-92. 
SHANAHAN, F. 2001. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and 
ecotherapeutics. Gastroenterology, 120, 622-35. 
SHEN, X. J., RAWLS, J. F., RANDALL, T., BURCAL, L., MPANDE, C. N., JENKINS, N., JOVOV, B., ABDO, Z., 
SANDLER, R. S. & KEKU, T. O. 2010. Molecular characterization of mucosal adherent bacteria 
and associations with colorectal adenomas. Gut Microbes, 1, 138-47. 
SIEZEN, R. J. & KLEEREBEZEM, M. 2011. The human gut microbiome: are we our enterotypes? Microb 
Biotechnol, 4, 550-3. 
SINGH, U. P., SINGH, N. P., SINGH, B., HOFSETH, L. J., PRICE, R. L., NAGARKATTI, M. & NAGARKATTI, 
P. S. 2010. Resveratrol (trans-3,5,4'-trihydroxystilbene) induces silent mating type 
information regulation-1 and down-regulates nuclear transcription factor-kappaB activation 
to abrogate dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther, 332, 829-39. 
SIRIWARDANA, P. N., PATHMESWARAN, A., HEWAVISENTHI, J. & DEEN, K. I. 2009. Histopathology 
reporting in colorectal cancer: a proforma improves quality. Colorectal Dis, 11, 849-53. 
SOBHANI, I., TAP, J., ROUDOT-THORAVAL, F., ROPERCH, J. P., LETULLE, S., LANGELLA, P., CORTHIER, 
G., TRAN VAN NHIEU, J. & FURET, J. P. 2011. Microbial dysbiosis in colorectal cancer (CRC) 
patients. PLoS One, 6, e16393. 
SONNENBURG, J. L., XU, J., LEIP, D. D., CHEN, C. H., WESTOVER, B. P., WEATHERFORD, J., BUHLER, J. 
D. & GORDON, J. I. 2005. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. 
Science, 307, 1955-9. 
SOTTORIVA, A., KANG, H., MA, Z., GRAHAM, T.A., SALOMON, M.P., ZHAO, J., MARJORAM, P., 
SIEGMNUD, K., PRESS, M., F., SHIBATA, D. & CURTIS, C. 2015. A Big Bang model of human 
colorectal tumor growth. Nat Genet, 47, 209-16. 
SPERANDEO, P., POZZI, C., DEHO, G. & POLISSI, A. 2006. Non-essential KDO biosynthesis and new 
essential cell envelope biogenesis genes in the Escherichia coli yrbG-yhbG locus. Res 
Microbiol, 157, 547-58. 
STAPPENBECK, T. S., HOOPER, L. V. & GORDON, J. I. 2002. Developmental regulation of intestinal 
angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A, 99, 15451-5. 
SU, L. K., KINZLER, K. W., VOGELSTEIN, B., PREISINGER, A. C., MOSER, A. R., LUONGO, C., GOULD, K. 
A. & DOVE, W. F. 1992. Multiple intestinal neoplasia caused by a mutation in the murine 
homolog of the APC gene. Science, 256, 668-70. 
SUBRAMANIAN, S., ROBERTS, C. L., HART, C. A., MARTIN, H. M., EDWARDS, S. W., RHODES, J. M. & 
CAMPBELL, B. J. 2008. Replication of Colonic Crohn's Disease Mucosal Escherichia coli 
Isolates within Macrophages and Their Susceptibility to Antibiotics. Antimicrob Agents 
Chemother, 52, 427-34. 
SUNDARA RAJAN, S., HORGAN, K., SPEIRS, V. & HANBY, A. M. 2014. External validation of the 
ImmunoRatio image analysis application for ERalpha determination in breast cancer. J Clin 
Pathol, 67, 72-5. 
239 
 
SWIDSINSKI, A., KHILKIN, M., KERJASCHKI, D., SCHREIBER, S., ORTNER, M., WEBER, J. & LOCHS, H. 
1998. Association between intraepithelial Escherichia coli and colorectal cancer. 
Gastroenterology, 115, 281-6. 
SWIDSINSKI, A., LADHOFF, A., PERNTHALER, A., SWIDSINSKI, S., LOENING-BAUCKE, V., ORTNER, M., 
WEBER, J., HOFFMANN, U., SCHREIBER, S., DIETEL, M. & LOCHS, H. 2002. Mucosal flora in 
inflammatory bowel disease. Gastroenterology, 122, 44-54. 
TAK, P. P. & FIRESTEIN, G. S. 2001. NF-κB: a key role in inflammatory diseases. The Journal of Clinical 
Investigation, 107, 7-11. 
TAKIKITA, M., ALTEKRUSE, S., LYNCH, C. F., GOODMAN, M. T., HERNANDEZ, B. Y., GREEN, M., COZEN, 
W., COCKBURN, M., SIBUG SABER, M., TOPOR, M., ZERUTO, C., ABEDI-ARDEKANI, B., 
REICHMAN, M. E. & HEWITT, S. M. 2009. Associations between selected biomarkers and 
prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res, 69, 2950-5. 
TAO, L., ZHANG, J., MERANER, P., TOVAGLIERI, A., WU, X., GERHARD, R., ZHANG, X., STALLCUP, W.B., 
MIAO, J., HE, X., HURDLE, J.G., BREAULT, D.T., BRASS, A.L. & DONG, M. 2016. Frizzled 
proteins are colonic epithelial receptors for C. difficile toxin B. Nature, 538, 350-5. 
TAWFIK, A., FLANAGAN, P. K. & CAMPBELL, B. J. 2014. Escherichia coli-host macrophage interactions 
in the pathogenesis of inflammatory bowel disease. World J Gastroenterol, 20, 8751-63. 
THIERY, J. P., ACLOQUE, H., HUANG, R. Y. & NIETO, M. A. 2009. Epithelial-mesenchymal transitions in 
development and disease. Cell, 139, 871-90. 
TOUGERON, D., SHA, D., MANTHRAVADI, S. & SINICROPE, F. A. 2014. Aspirin and colorectal cancer: 
back to the future. Clin Cancer Res, 20, 1087-94. 
TRAVAGLIONE, S., FABBRI, A. & FIORENTINI, C. 2008. The Rho-activating CNF1 toxin from pathogenic 
E. coli: a risk factor for human cancer development? Infect Agent Cancer, 3, 4. 
TSUCHIYA, S., YAMABE, M., YAMAGUCHI, Y., KOBAYASHI, Y., KONNO, T. & TADA, K. 1980. 
Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). 
Int J Cancer, 26, 171-6. 
TUOMINEN, V. J., RUOTOISTENMAKI, S., VIITANEN, A., JUMPPANEN, M. & ISOLA, J. 2010. 
ImmunoRatio: a publicly available web application for quantitative image analysis of 
estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res, 12, R56. 
TYE, H., KENNED, C.L., NAJDOVSKA, M., MCLEOD, L., MCCORMACK, W., HUGHES, N., DEV, A., 
SIEVERT, W., OOI, C.H., ISHIKAWA, T.O., OSHIMA, H., BHATHAL, P.S., PARKER, A.E., OSIMA, 
M., TAN, P. & JENKINS, B.J. 2012. STAT3-driven upregulation of TLR2 promotes gastric 
tumorigenesis independent of tumor inflammation. Cancer Cell, 22, 466-78. 
URONIS, J. M., MUHLBAUER, M., HERFARTH, H. H., RUBINAS, T. C., JONES, G. S. & JOBIN, C. 2009. 
Modulation of the intestinal microbiota alters colitis-associated colorectal cancer 
susceptibility. PLoS One, 4, e6026. 
URSELL, L. K., METCALF, J. L., PARFREY, L. W. & KNIGHT, R. 2012. Defining the human microbiome. 
Nutr Rev, 70 Suppl 1, S38-44. 
VAN CUTSEM, E., OLIVEIRA, J. & GROUP, E. G. W. 2009a. Advanced colorectal cancer: ESMO clinical 
recommendations for diagnosis, treatment and follow-up. Ann Oncol, 20 Suppl 4, 61-3. 
VAN CUTSEM, E., OLIVEIRA, J. & GROUP, E. G. W. 2009b. Primary colon cancer: ESMO clinical 
recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol, 20 Suppl 4, 
49-50. 
VAN DE WETERING, M., SANCHO, E., VERWEIJ, C., DE LAU, W., OVING, I., HURLSTONE, A., VAN DER 
HORN, K., BATLLE, E., COUDREUSE, D., HARAMIS, A. P., TJON-PON-FONG, M., MOERER, P., 
VAN DEN BORN, M., SOETE, G., PALS, S., EILERS, M., MEDEMA, R. & CLEVERS, H. 2002. The 
beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer 
cells. Cell, 111, 241-50. 
VAN DER FLIER, L. G., SABATES–BELLVER, J., OVING, I., HAEGEBARTH, A., DE PALO, M., ANTI, M., VAN 
GIJN, M. E., SUIJKERBUIJK, S., VAN DE WETERING, M., MARRA, G. & CLEVERS, H. 2007. The 
Intestinal Wnt/TCF Signature. Gastroenterology, 132, 628-632. 
240 
 
VARGHESE, F., BUKHARI, A. B., MALHOTRA, R. & DE, A. 2014. IHC Profiler: an open source plugin for 
the quantitative evaluation and automated scoring of immunohistochemistry images of 
human tissue samples. PLoS One, 9, e96801. 
VERDE, P., CASALINO, L., TALOTTA, F., YANIV, M. & WEITZMAN, J. B. 2007. Deciphering AP-1 function 
in tumorigenesis: fra-ternizing on target promoters. Cell Cycle, 6, 2633-9. 
VIDYASEKAR, P., SHYAMSUNDER, P., ARUN, R., SANTHAKUMAR, R., KAPADIA, N. K., KUMAR, R. & 
VERMA, R. S. 2015. Genome Wide Expression Profiling of Cancer Cell Lines Cultured in 
Microgravity Reveals Significant Dysregulation of Cell Cycle and MicroRNA Gene Networks. 
PLoS One, 10, e0135958. 
VILJOEN, K. S., DAKSHINAMURTHY, A., GOLDBERG, P. & BLACKBURN, J. M. 2015. Quantitative 
profiling of colorectal cancer-associated bacteria reveals associations between 
fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological 
features of colorectal cancer. PLoS One, 10, e0119462. 
VOGELSTEIN, B., FEARON, E. R., HAMILTON, S. R., KERN, S. E., PREISINGER, A. C., LEPPERT, M., 
NAKAMURA, Y., WHITE, R., SMITS, A. M. & BOS, J. L. 1988. Genetic alterations during 
colorectal-tumor development. N Engl J Med, 319, 525-32. 
VORONKOV, A. & KRAUSS, S. 2013. Wnt/beta-catenin signaling and small molecule inhibitors. Curr 
Pharm Des, 19, 634-64. 
WADA, C., IMAI, M. & YURA, T. 1987. Host control of plasmid replication: requirement for the sigma 
factor sigma 32 in transcription of mini-F replication initiator gene. Proc Natl Acad Sci U S A, 
84, 8849-53. 
WALDNER, M. J., WIRTZ, S., JEFREMOW, A., WARNTJEN, M., NEUFERT, C., ATREYA, R., BECKER, C., 
WEIGMANN, B., VIETH, M., ROSE-JOHN, S. & NEURATH, M. F. 2010. VEGF receptor signaling 
links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med, 207, 2855-68. 
WANG, H. M. & ZHANG, G. Y. 2005. Indomethacin suppresses growth of colon cancer via inhibition 
of angiogenesis in vivo. World J Gastroenterol, 11, 340-3. 
WANG, P., ZHANG, L., JIANG, J. M., MA, D., TAO, H. X., YUAN, S. L., WANG, Y. C., WANG, L. C., LIANG, 
H., ZHANG, Z. S. & LIU, C. J. 2012a. Association of NOD1 and NOD2 genes polymorphisms 
with Helicobacter pylori related gastric cancer in a Chinese population. World J 
Gastroenterol, 18, 2112-20. 
WANG, T., CAI, G., QIU, Y., FEI, N., ZHANG, M., PANG, X., JIA, W., CAI, S. & ZHAO, L. 2012b. Structural 
segregation of gut microbiota between colorectal cancer patients and healthy volunteers. 
ISME J, 6, 320-9. 
WANG, X. & HARDWIDGE, P. R. 2012. Enterotoxigenic Escherichia coli prevents host NF-kappaB 
activation by targeting IkappaBalpha polyubiquitination. Infect Immun, 80, 4417-25. 
WANG, X. & HUYCKE, M. M. 2007. Extracellular superoxide production by Enterococcus faecalis 
promotes chromosomal instability in mammalian cells. Gastroenterology, 132, 551-61. 
WANG, X., YANG, Y., MOORE, D. R., NIMMO, S. L., LIGHTFOOT, S. A. & HUYCKE, M. M. 2012c. 4-
hydroxy-2-nonenal mediates genotoxicity and bystander effects caused by Enterococcus 
faecalis-infected macrophages. Gastroenterology, 142, 543-551 e7. 
WANG, Y., YAO, X., GE, J., HU, F. & ZHAO, Y. 2014. Can Vascular Endothelial Growth Factor and 
Microvessel Density Be Used as Prognostic Biomarkers for Colorectal Cancer? A Systematic 
Review and Meta-Analysis. ScientificWorldJournal, 2014, 102736. 
WILLIAMS, A. C., HARPER, S. J. & PARASKEVA, C. 1990. Neoplastic transformation of a human colonic 
epithelial cell line: in vitro evidence for the adenoma to carcinoma sequence. Cancer Res, 50, 
4724-30. 
WILLIAMS, A. R., BALASOORIYA, B. A. & DAY, D. W. 1982. Polyps and cancer of the large bowel: a 
necropsy study in Liverpool. Gut, 23, 835-42. 
WILLIAMS, C. S., GOLDMAN, A. P., SHENG, H., MORROW, J. D. & DUBOIS, R. N. 1999a. Sulindac 
sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia, 1, 170-6. 
241 
 
WILLIAMS, C. S., MANN, M. & DUBOIS, R. N. 1999b. The role of cyclooxygenases in inflammation, 
cancer, and development. Oncogene, 18, 7908-16. 
WILLIAMS, J. G., PULLAN, R. D., HILL, J., HORGAN, P. G., SALMO, E., BUCHANAN, G. N., RASHEED, S., 
MCGEE, S. G., HABOUBI, N., ASSOCIATION OF COLOPROCTOLOGY OF GREAT, B. & IRELAND 
2013. Management of the malignant colorectal polyp: ACPGBI position statement. Colorectal 
Dis, 15 Suppl 2, 1-38. 
WILLIAMS, J. M., DUCKWORTH, C. A., VOWELL, K., BURKITT, M. D. & PRITCHARD, D. M. 2016. 
Intestinal Preparation Techniques for Histological Analysis in the Mouse. Curr Protoc Mouse 
Biol, 6, 148-68. 
WINAWER, S., FLETCHER, R., REX, D., BOND, J., BURT, R., FERRUCCI, J., GANIATS, T., LEVIN, T., 
WOOLF, S., JOHNSON, D., KIRK, L., LITIN, S., SIMMANG, C. & GASTROINTESTINAL 
CONSORTIUM, P. 2003. Colorectal cancer screening and surveillance: clinical guidelines and 
rationale-Update based on new evidence. Gastroenterology, 124, 544-60. 
WINAWER, S. J., FLETCHER, R. H., MILLER, L., GODLEE, F., STOLAR, M. H., MULROW, C. D., WOOLF, S. 
H., GLICK, S. N., GANIATS, T. G., BOND, J. H., ROSEN, L., ZAPKA, J. G., OLSEN, S. J., 
GIARDIELLO, F. M., SISK, J. E., VAN ANTWERP, R., BROWN-DAVIS, C., MARCINIAK, D. A. & 
MAYER, R. J. 1997. Colorectal cancer screening: Clinical guidelines and rationale. 
Gastroenterology, 112, 594-642. 
WIRTZ, S., NEUFERT, C., WEIGMANN, B. & NEURATH, M. F. 2007. Chemically induced mouse models 
of intestinal inflammation. Nat Protoc, 2, 541-6. 
WU, G. D., CHEN, J., HOFFMANN, C., BITTINGER, K., CHEN, Y. Y., KEILBAUGH, S. A., BEWTRA, M., 
KNIGHTS, D., WALTERS, W. A., KNIGHT, R., SINHA, R., GILROY, E., GUPTA, K., BALDASSANO, 
R., NESSEL, L., LI, H., BUSHMAN, F. D. & LEWIS, J. D. 2011. Linking long-term dietary patterns 
with gut microbial enterotypes. Science, 334, 105-8. 
WU, N., YANG, X., ZHANG, R., LI, J., XIAO, X., HU, Y., CHEN, Y., YANG, F., LU, N., WANG, Z., LUAN, C., 
LIU, Y., WANG, B., XIANG, C., WANG, Y., ZHAO, F., GAO, G. F., WANG, S., LI, L., ZHANG, H. & 
ZHU, B. 2013. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb 
Ecol, 66, 462-70. 
WU, S., MORIN, P. J., MAOUYO, D. & SEARS, C. L. 2003. Bacteroides fragilis enterotoxin induces c-
Myc expression and cellular proliferation. Gastroenterology, 124, 392-400. 
XU, M. H. & ZHANG, G. Y. 2005. Effect of indomethacin on cell cycle proteins in colon cancer cell 
lines. World J Gastroenterol, 11, 1693-6. 
XU, Q., DONG, Q. G., SUN, L. P., HE, C. Y. & YUAN, Y. 2013. Expression of serum miR-20a-5p, let-7a, 
and miR-320a and their correlations with pepsinogen in atrophic gastritis and gastric cancer: 
a case-control study. BMC Clin Pathol, 13, 11. 
YANG, J., ZHANG, W., EVANS, P. M., CHEN, X., HE, X. & LIU, C. 2006. Adenomatous polyposis coli 
(APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon 
cancer cells. J Biol Chem, 281, 17751-7. 
YANG, V. W., SHIELDS, J. M., HAMILTON, S. R., SPANNHAKE, E. W., HUBBARD, W. C., HYLIND, L. M., 
ROBINSON, C. R. & GIARDIELLO, F. M. 1998. Size-dependent increase in prostanoid levels in 
adenomas of patients with familial adenomatous polyposis. Cancer Res, 58, 1750-3. 
YEH, C. T., RAO, Y. K., YE, M., WU, W. S., CHANG, T. C., WANG, L. S., WU, C. H., WU, A. T. & TZENG, Y. 
M. 2012. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing 
proliferation and metastasis of colorectal cancer using non-invasive bioluminescence 
imaging. Toxicol Appl Pharmacol, 261, 31-41. 
YONEZAWA, S., GOTO, M., YAMADA, N., HIGASHI, M. & NOMOTO, M. 2008. Expression profiles of 
MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological 
behavior. Proteomics, 8, 3329-41. 
YOUNG, M., ORDONEZ, L. & CLARKE, A. R. 2013. What are the best routes to effectively model 
human colorectal cancer? Mol Oncol, 7, 178-89. 
242 
 
YRLID, U., SVENSSON, M., JOHANSSON, C. & WICK, M. J. 2000. Salmonella infection of bone marrow-
derived macrophages and dendritic cells: influence on antigen presentation and initiating an 
immune response. FEMS Immunol Med Microbiol, 27, 313-20. 
ZACKULAR, J. P., ROGERS, M. A., RUFFIN, M. T. T. & SCHLOSS, P. D. 2014. The Human Gut 
Microbiome as a Screening Tool for Colorectal Cancer. Cancer Prev Res (Phila). 
ZHANG, X. & HAO, J. 2015. Development of anticancer agents targeting the Wnt/beta-catenin 
signaling. Am J Cancer Res, 5, 2344-60. 
ZHU, Q., JIN, Z., WU, W., GAO, R., GUO, B., GAO, Z., YANG, Y. & QIN, H. 2014. Analysis of the 
intestinal lumen microbiota in an animal model of colorectal cancer. PLoS One, 9, e90849. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
243 
 
Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
244 
 
Appendix 1: Nuclear localisation analysis using ImageJ for DAPI/FITC Fluorescence 
Prepare image channels 
1. Download and open ImageJ software 
2. Open image containing DAPI/FITC overlay 
3. Split channels into red/green/blue channels: Image > Color > Split Channels. Channel images 
should now be in greyscale. 
4. Retain blue (DAPI) and green (FITC) channels, discard red channel 
5. Subtract background fluorescence for both image channels: Process > Subtract Background. 
Pixel radius of 50.0 used; ensure all tick options are not selected. 
Define nuclear regions of interest (ROIs) 
6. Duplicate the DAPI image: hover mouse over image > right click > Duplicate 
7. Following background subtraction, use blue (DAPI) channel to define max/min greyscale 
thresholds: Image > Adjust > Thresholds. Image background will default to red; match DAPI-
stained cell nuclei (grey) to those of the unaltered duplicate. Click ‘Apply’ and close 
Threshold adjuster. 
8. Define nuclear regions of interest (ROIs): Edit > Selection > Create Mask 
9. Remove mask outliers: Process > Noise > Remove Outliers. Pixel radius of 2.0, and threshold 
of 10 used to remove dark outliers. 
10. Analyse mask particles: Analyze > Analyze Particles. For dark stained nuclei, use maximum 
pixel size minus ‘Infinity’ (250-Infinity), and include any measure of circularity (0.00-1.00); 
ensure ‘Add to manager’ option is ticked to add nuclear ROIs to ‘ROI manager’ (opens 
automatically). Image mask should now contain numbered nuclear ROIs corresponding to 
ROIs in ROI manager. 
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Define cytoplasmic region of interest 
11. Duplicate the FITC image: hover mouse over image > right click > Duplicate 
12. Threshold the FITC image: Image > Adjust > Thresholds. Image background will default to 
red; match FITC-staining (grey) to that of the unaltered duplicate. Click ‘Apply’ and close 
Threshold adjuster. 
13. Define cytoplasmic region of interest (ROIs): Edit > Selection > Create Mask 
14. Invert image mask: Edit > Invert. FITC staining should now be white. 
15. Remove nuclear staining: Process > Image Calculator. Use this to add (Operation: Add) 
nuclear mask (Image 1: mask) to cytoplasmic mask (Image 2: mask). Create a new window 
for the mask result; any nuclear staining should have been removed in the new window. 
16. Invert result: Edit > Invert. FITC staining should now be black with white background. 
17. Select all cytoplasmic staining: Edit > Selection > Create Selection. This will outline all FITC 
staining in the cytoplasmic mask. 
18. Add cytoplasmic ROI to manager: Edit > Selection > Add to Manager. Cytoplasmic ROI should 
have been added to the bottom of the ROI manager. Rename this ROI as ‘Cytoplasmic’. 
Quantify ROIs 
19. Set required measurements: Analyze > Set Measurements. Set measurements to give a 
‘Mean gray value’, plus any other measurement you may require (e.g. Standard deviation). 
Select to ‘Display label’ alongside you result to distinguish the cytoplasmic ROI. Do not 
redirect measurements (select ‘None’). Select decimal places required. Click ‘OK’. 
20. Select the unaltered FITC image (duplicated in step 11). 
21. Select all the ROIs from ROI manager (‘Show all’). Nuclei and cytoplasm should be outlined. 
22. Quantify staining within ROI Manager: More > Multi Measure. Deselect options for ‘One 
Row Per Slice’ and ‘Append results’. Click ‘OK’. Results table should appear automatically. 
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NOTE: If only one result appears, close this results tab. Highlight all ROIs (nuclear and 
cytoplasmic), deselect and then re-select ‘Show all’ and repeat step 22. 
23. Copy measurements into an Excel file: Edit > Copy. 
24. Save the quantified ROIs. 
Analyse nuclear localisation 
25. Average nuclear ROI data to get a mean nuclear stain. 
26. Obtain a ratio for ‘nuclear:cytoplasmic’ staining by dividing your mean nuclear stain by the 
mean cytoplasmic stain (use result from defined ‘Cytoplasmic’ ROI). 
27. Compare ratios between control and treated cells. Normalise to negative/untreated 
controls. Use an appropriate positive control. 
 
